University Hospitals of North Midlands NHS Trust

AGENDA | Trust Board - Part 1 (in Public)

Meeting held on Wednesday 24th June 2026 at 9.00 am to 10.00 am

Via MS Teams

Time	No.	Agenda Item	Purpose	Lead	Format	BAF Link
09:00	**PROCEDURAL ITEMS**					
5 mins	01	Chair's Welcome, Apologies and Confirmation of Quoracy	Information	Ms J Small	Verbal	
	02	Declarations of Interest	Information	Ms J Small	Verbal	
09:05	**GOVERNANCE**					
5 mins	03	Audit Committee Assurance Report (19-06-26)	Assurance	Mrs M Monckton	Enclosure	
15 mins	04	2025/26 Annual Report and Annual Governance Statement	Approval	Mrs C Cotton	Enclosure	
15 mins	05	2025/26 Annual Accounts, Analytical Review & Certificates	Approval	Mr M Oldham	Enclosure	
5 mins	06	Audit Findings Report and Letter of Representation	Approval	Mr M Oldham	Enclosure	
09:45	**DATE AND TIME OF NEXT MEETING**					
	06	**Wednesday 9th July 2025, 9.30 am, Trust Boardroom, Third Floor, Springfield, Royal Stoke**				

Highlight Report

AUDIT COMMITTEE | 19th June 2026

University Hospitals of North Midlands NHS Trust

Matters of Concern / Key Risks to Escalate	Major Actions Commissioned / Work Underway
• During the update regarding the **accounts and financial statements**, an update was provided on the decision to not consolidate the accounts with the charity accounts. As such an assessment on materiality and presentation was undertaken, including a high-level consolidation exercise which concluded that charity finances remained immaterial. It was noted that external audit had confirmed that they had reviewed the consolidation and were happy with the approach taken. • Section 30 referral issued by **External Audit** due to the deficit position, as anticipated. • The Committee sought assurance regarding the significant impairment recognised on the Community Diagnostic Centre **asset**. It was confirmed that the reduction in value reflected standard valuation methodology, including the impact of build costs exceeding market valuation, the specialist nature of the asset, and the limitation of value due to the lease term. External audit confirmed that, while subject to scrutiny, the valuation remained within an acceptable range and was not considered materially misstated. • The **External Audit Annual Report** and assessment of value for money concluded with the main recommendation focussed on Cost Improvement Programme delivery and financial sustainability, in addition to 3 minor improvement recommendations.	• Updated **Annual Report and accounts** to be provided to the Trust Board for consideration and final approval

Positive Assurances to Provide	Decisions Made
• **Internal audit** progress report highlighted the finalisation of two reports; cost improvement programme which was an advisory review but identified opportunities for improvement, and cyber assessment framework which concluded with **high confidence**. The Committee considered the detail associated with the cyber assessment framework and actions identified for future improvement. • The final **2025/26 Annual Internal Audit report** concluded with **adequate with improvements** informed by 10 internal audit reports; 3 of which received substantial assurance, 3 with reasonable assurance, 1 being an advisory review, two follow up reviews and the review of the Cyber Assessment Framework. • The **External Audit findings** report highlighted an anticipated **unmodified** opinion, in that the accounts represent a true and fair view of the financial position. • The Committee noted that whilst formal assurance ratings had not been applied to the three external audit reports, based on the findings presented and the absence of material misstatements, the Committee concluded that the reports provided **strong assurance** to support approval of the annual accounts.	• The Committee approved the addition of a review around NHS Sexual Safety Charter Assurance Framework within the **Internal Audit Plan** for 2026/27. • The Committee approved the **2025/26 Annual Report**, subject to minor presentational changes being made to the remuneration report, the final version of which would be presented to the Trust Board for final approval. • The Committee approved the **accounts and financial statements** which were subject to final review by External Audit.

Comments on the Effectiveness of the Meeting	Cross Committee Considerations
• Comments on effectiveness were sought via MS Forms.	• It was agreed to track the action arising from the **external audit findings** report regarding a review of the Charity's finances, at the Charity Committee.

Summary Agenda

No.	Agenda Item	BAF Mapping			Purpose	No.	Agenda Item	BAF Mapping			Purpose
		BAF No.	Risk	Assurance				BAF No.	Risk	Assurance	
1.	Internal Audit Progress Report: • Cost Improvement Programme • Cyber Assessment Framework (CAF)	6, 7 4	Various	Advisory High confidence	Assurance	8.	Auditors Findings Report 2025/26 (including Letter of Representation)	6, 7	9 25	Significant Assurance	Approval
2.	Final Annual Internal Audit Report 2025/26	All	Various	Adequate with improvements	Assurance	9.	Auditor's Annual Report 2025/26	6, 7	9 25	Significant Assurance	Assurance
3.	Annual Report and Annual Governance Statement 2025/26	All	Various	Not applicable	Approval	10.	Draft Audit Report (Opinion)	6, 7	9 25	Significant Assurance	Assurance
4.	Audited Accounts and Financial Statements and Analytical Review	6, 7	9 25	Not applicable	Approval	11.	Annual Clinical Audit Programme 2026/27	1	20	Not applicable	Information

Executive Summary
Trust Board | 24th June 2026
Annual Report 2025/2026

NHS
University Hospitals of North Midlands
NHS Trust

Purpose:	**Information**		**Approval**	✓	**Assurance**		**Agenda Item:**	4.
Author:	Nicola Hassall, Deputy Director of Governance							
Executive Lead:	Claire Cotton, Director of Governance & Communications							

Alignment with our Strategic Priorities	
Our People We will create an inclusive environment where everyone learns, thrives and makes a positive difference	✓
Our Patients We will provide timely, innovative and effective services to our patients	✓
Our Population We will tackle inequality and improve the health of our population	✓

Risk Register Mapping		
BAF	Reference to BAF risks is included within the Annual Report, there is no specific risk associated with the report.	

Executive Summary

Situation
Preparation of the Annual Report for 2025/26 is now complete, and the report is being presented to the Trust Board for review and approval, ahead of followed public disclosure in accordance with statutory duties.

Background
Preparation of the Annual Report and Accounts is a statutory requirement, aligned to the NHS Group Accounting Manual, Code of Governance, and reporting expectations of NHS England. The report reflects the Trust's performance during a year of sustained operational, workforce and financial pressure, including continued regulatory oversight, significant access challenges, and delivery of major transformation and capital programmes. The report integrates performance, quality, workforce, financial and governance narratives, alongside the Annual Governance Statement, Board Assurance Framework, Remuneration Report, Staff Report and Financial Statements. The report was approved by the Audit Committee on 19th June 2026.

Assessment
The report has been produced in line with statutory reporting requirements and has been shared in working draft and final draft form with the External Auditors and Audit Committee.

Since the Audit Committee meeting on 19th June, two further changes have been made:

- Page 7 – Non-Executive Director responsibilities updated to incorporate the role of Senior Independent Director, Chair of Quality Access and Outcomes Committee and FTSU Champion.
- Page 31 - 'Change' removed from summary of income table
- Page 32 – Capital table updated.
- Page 75 – presentational amendments made to the remuneration report (changing references of Medical Director to Chief Medical Officer and ensuring the notes regarding Simon Evans and Matthew Lewis were worded consistently.
- Page 77 – Salary and allowances % change, updated following audit.
- Page 80 – Staff costs table updated following audit.

The report will be made available publicly via our website and will be supplemented with a Review of the Year which will be prepared for the Annual General Meeting in September.

Key Recommendations

The Trust Board is asked to review and approve the Annual Report.

University Hospitals of North Midlands NHS Trust

Annual Report & Accounts

DRAFT

2025 / 2026

Kind
Excellent
Together



Contents

Performance Overview	**4 - 19**
Chair and Chief Executive's introduction	5
About us	6
How we are organised – the Trust Board	7
How we provide care	8
Our future	9
Our Strategy 2025-2035: The best joined-up care for *all*	10
Progress in delivering our strategic priorities	11 - 17
Principal risks	18
Going concern	19
Performance Analysis	**20 - 44**
How we measure our performance	21 – 22
Our Key performance indicators (KPIs)	23
Operational performance 2025/26	24 - 25
Quality performance 2025/26	26 – 27
Workforce performance 2025/26	28 - 29
Financial performance 2025/26	30 - 32
Risk profile	33
Social matters and human rights	34
Anti corruption and anti bribery	35
Equality of service delivery	36
Customer satisfaction scores	37
Environmental matters	38 - 42
Emergency preparedness, resilience and response (EPRR)	43
Any important events since year end	44
Corporate Governance Report	**46 - 71**
Directors report	47 – 59
Statement of responsibilities	60
Annual governance statement (AGS)	61 - 69
Speaking up	70
Modern slavery statement	71
Remuneration Report	**72 - 77**
Remuneration policy for directors and senior managers	73 - 74
Remuneration report	75 – 76
Fair pay disclosure & pay ratio	77
Staff Report	**78 - 88**
Our people	79
Staff numbers, cost and composition	80
Sickness absence and turnover	81
NHS staff survey	82
Staff policies applied during the year	83
Equality, diversity and inclusion	84 - 85
Other employee matters	86
Consultancy expenditure and off-payroll engagements	87
Exit packages	88
Financial Statements	**90 - 93**
Annual Accounts 2025/26	**94**

DRAFT

1 Performance Report

DRAFT

Performance Overview

DRAFT

This overview provides a simple summary of what we do, details how we have performed, and considers the main risks and challenges we face.

Chair and Chief Executive's introduction

Welcome to the Annual Report for 2025/26. Over the past year, we have continued to serve a diverse population with increasingly complex healthcare needs, delivering care within a challenging and pressured NHS environment.

During 2025/26, our focus remained on providing safe, high-quality care for our patients, supporting our people, and working collaboratively with partners to improve health outcomes across Staffordshire and Stoke-on-Trent. We strengthened the foundations for future improvement through investment in our services, our estate and our digital capability, alongside a clear focus on our long-term strategic ambitions.

Reflecting on the year, we recognise both the progress achieved and the areas where performance has fallen short of our expectations. Demand for urgent, elective and diagnostic care remained exceptionally high, and workforce and system pressures were sustained throughout the year, particularly during winter. Despite these challenges, we made meaningful improvements in a number of priority areas and continued to prioritise learning, continuous improvement and sustainability as we respond to rising population need. However, we recognise we still have a long way to go to improve things for our population.

Patient safety and quality of care remained central to our priorities. We sustained strong performance in maternity safety, achieving the Clinical Negligence Scheme for Trusts (CNST) Maternity Incentive Scheme standards for a sixth consecutive year, reflecting the professionalism and commitment of our maternity and neonatal teams. We also progressed the implementation of the Patient Safety Incident Response Framework, strengthening our organisational learning and focus on harm prevention.

Access to care continued to present a significant challenge. Urgent and emergency care performance remained below national standards, reflecting system-wide pressures and capacity constraints. At the same time, we made encouraging progress in elective recovery, delivering substantial reductions in the longest waiting times, and improved cancer performance, including achievement of the 28-day Faster Diagnosis Standard. While these improvements are important, further sustained effort is required to improve access and experience for all patients.

Our people remain at the heart of everything we do. We are proud to employ around 13,000 colleagues, representing a wide range of roles and backgrounds, who continue to demonstrate exceptional dedication and resilience.

During the year, we strengthened recruitment and retention, reducing vacancy rates and agency utilisation, while continuing to invest in wellbeing, inclusion and leadership. We recognise that staff engagement and sickness absence remain areas of focus, and we remain committed to creating a supportive and inclusive working environment.

Partnership working has continued to be critical to our progress. As a key provider within the Staffordshire and Stoke-on-Trent Integrated Care System, we worked closely with partners to address shared challenges across access, population health and financial sustainability. Our long-standing relationships with Keele University, the University of Staffordshire and our PFI partners have also supported delivery of major capital programmes, including the Community Diagnostic Centre.

We also made further progress against our environmental commitments, completing significant decarbonisation projects and refreshing our Green Plan to support delivery of our Net Zero ambitions, strengthening both sustainability and resilience.

Looking ahead, our strategy for 2025–2035 sets out a clear long-term vision to provide the best joined-up care for all, underpinned by a sustained focus on our people, our patients and our population. While the challenges facing the NHS remain considerable, we are confident that through strong partnerships, disciplined governance and performance management alongside genuine service transformation, we can continue to make progress for our communities.

We would like to thank our patients, partners and communities for their trust, and, above all, our colleagues for their dedication and professionalism throughout the year. Together, we will continue to work towards improving health outcomes and delivering the best joined-up care for all.



Jackie Small
Chair

Simon Constable
Chief Executive

DRAFT

About us

We are one of the largest teaching trusts in the country, primarily serving patients in Staffordshire and Stoke-on-Trent and acting as a tertiary centre to many more. We are proud to have a growing international reputation for the innovative treatments we provide and pioneer through our research, education and partnerships.

Providing care in modern facilities, we offer a full range of general hospital and specialised services for approximately 3 million people. We employ around 13,000 colleagues and we have around 1,450 inpatient beds across our two sites.

We are one of the largest hospitals in the West Midlands and have one of the busiest emergency departments in the country, with an average of approximately 14,000 patients attending each month across both of our sites. As a Major Trauma Centre, the Trust receives emergency patients from a wide geographical area by both ambulance and helicopter, serving the North Midlands and North Wales.

Our specialised services include cancer diagnosis and treatment, cardiothoracic surgery, neurosurgery, renal and dialysis services, neonatal intensive care, paediatric intensive care, trauma, respiratory conditions, spinal surgery, upper gastro-intestinal surgery, complex orthopaedic surgery and laparoscopic surgery.

Our Partnerships

We work with partners across Staffordshire and Stoke-on-Trent to deliver joined-up care, including the Integrated Care System, local authorities, the voluntary sector and NHS provider partners. We also maintain established relationships with Keele University and the University of Staffordshire to support research, innovation, education and workforce development. Our partnerships help us to improve access, quality and outcomes for patients, and to plan services that meet local needs.



DRAFT

How we are organised – the Trust Board

Non-Executive Directors

Jackie Small
Chair

Louise Bainbridge (to 31/03/26)
Non-Executive Director | Chair of People, Culture & Inclusion Committee

Tanya Bowen
Non-Executive Director | Senior Independent Director (from 01/02/26) | Chair - Finance & Business Performance Committee | Chair - Charity Committee

Professor Gary Crowe (to 31/08/25)
Vice Chair | Non-Executive Director | Chair - Finance & Business Performance Committee | Chair - People, Culture & Inclusion Committee

Professor Andrew Hassell (to 31/01/26)
Senior Independent Director | Associate Non-Executive Director | Chair - Quality, Access & Outcomes Committee | FTSU Champion

Professor Katie Maddock
Non-Executive Director | Chair – Quality, Access & Outcomes Committee (from 01/02/26) | Keele University Nominee

Margaret Monckton
Non-Executive Director | Chair of Audit Committee

Wendy Nicholson MBE
Non-Executive Director (from 01/09/25) | FTSU Champion (from 01/02/26) | Maternity Board Safety Champion

Professor Sunita Toor
Vice Chair (from 01/09/25) | Non-Executive Director | Chair – Risk Management Oversight Committee

Executive Directors

Dr Simon Constable
Chief Executive

Helen Ashley
Deputy Chief Executive | Director of Strategy & Transformation

Claire Cotton
Director of Governance & Communications

Amy Freeman
Chief Digital Information Officer

Jane Haire
Chief People Officer

Dr Diane Adamson
Chief Medical Officer

Mark Oldham
Chief Finance Officer

Ann-Marie Riley
Chief Nurse

Lisa Thomson (to 01/06/25)
Director of Communications & Charity

Katy Thorpe
Interim Chief Operating Officer

Lorraine Whitehead
Director of Estates, Facilities & PFI

Denotes non-voting members

DRAFT

How we provide care

Our organisational structure is made up of two non-clinical divisions and three clinical care groups, following an organisational restructure programme which took place during 2025/26. Each clinical care group is led by a Medical Director, alongside a Director of Operations and Director of Nursing. The non-clinical divisions are led by an Executive Director. We also host the North Midlands and Cheshire Pathology Service, which is a networked service.

DRAFT

Clinical Care Groups

Clinical & Scientific Services

- Acute Care @ Home
- Breast & Bowel Screening
- Child Health
- Children's Assessment Unit
- Community Diagnostic Centre
- Dietetics
- Endoscopy
- Gynaecology
- Imaging
- Maternity
- Neonatal
- Newborn Hearing Screening
- Obstetrics
- Obstetrics Ultrasound
- Outpatient Parenteral Antibiotic Therapy
- Paediatric Community & Critical Care
- Pharmacy
- Speech and Language Therapy
- Staffordshire Children's Hospital
- Therapies
- Transitional Care
- Transfusion Suite
- Virtual Ward

Planned Care

- Abdominal Aortic Aneurysm Screening
- Acute Rehabilitation
- Anaesthetics (incl. cardiac)
- Audiology
- Bariatric
- Breast
- Cardiac Surgery
- Central Treatment Suite
- Colorectal
- Critical Care
- Dermatology
- Ear, Nose & Throat
- Dentistry
- General Surgery
- Hospital Sterilisation & Decontamination Unit
- Interventional Radiology
- Neurosurgery
- Ophthalmology
- Oral Maxillofacial
- Orthopaedics
- Orthoptics
- Paediatric Surgery
- Pain Management
- Plastics
- Prosthetics
- Spines
- Surgical Assessment Unit
- Surgical Special Care Unit
- Theatres (incl. maternity)
- Thoracic Surgery
- Trauma (incl. major)
- Upper Gastrointestinal
- Urology
- Vascular Surgery

Unplanned Care

- Acute Medicine
- Ambulatory Emergency Care/Acute Medical Rapid Assessment Unit
- Bronch / plural
- Cardiac Diagnostic
- Cardiology
- Catheter Labs
- Diabetes
- Dialysis
- Emergency Assessment Unit
- Emergency Department
- Endocrinology
- Frail Elderly Assessment Unit
- Gastroenterology
- General Medicine
- Haematology
- Immunology / Allergy
- Infectious Diseases
- Medical Physics
- Neurology
- Older Adults
- Oncology
- Palliative Care
- Radiotherapy
- Renal
- Respiratory (incl. physiology)
- Surgical Decision Unit
- Stroke
- Targeted Lung Health
- Urgent Treatment Centre

Non-clinical Divisions

Corporate Services

- Chaplains
- Communications
- Complaints & PALS
- Continuous Improvement
- Corporate Governance
- Corporate Nursing
- Digital Services
- Finance
- Infection, Prevention & Control
- Medical Education
- Medical Examiners & Bereavement
- Improvement
- Operations
- People
- Performance & Information
- Quality, Safety & Compliance
- Research & Innovation
- Safeguarding & Mental Health
- Strategy & Planning
- Supplies & Procurement
- Transformation

Estates, Facilities & PFI

- Capital Developments
- Clinical Technology
- Estates Governance, Compliance & Administration
- Estate Operations
- Facilities Management
- Land & Property
- PFI Contract Management
- Sustainability & Transformation

Our future

Our organisational strategy for 2025 – 2035, launched in April 2025, set out our vision to deliver 'the best joined-up care for *all*'. It is underpinned by our core values of Kind, Together and Excellent, and our ambition to lead in health through innovation, investment in our people and improving the wellbeing of our community.

Our long-term ambitions are set out in Our Strategy 2025–2035, underpinned by three strategic priorities: Our People, Our Patients and Our Population. These priorities are being delivered through a series of strategic plans which set out how we will improve performance, transform services and move towards long-term financial sustainability. In addition, our Medium-Term Plan reflects both the scale of the challenges facing us and the actions required over the coming years to deliver sustainable improvement, supported by system partnership and national engagement. We continue to align closely with the national direction towards prevention, digital transformation and care closer to home. This is reflected through a greater emphasis on:

- Prevention – earlier intervention, reducing health inequalities and improving population health.
- Digital – using technology to improve access, safety and productivity.
- Community – delivering more care outside hospital through strengthened system partnerships and integrated pathways.

Together, these approaches support earlier diagnosis, improve patient experience and help ensure the long-term sustainability of services.

Our People

Over the medium term, our focus is on stabilising and reshaping our workforce to support new models of care, improved productivity and service transformation, while continuing to prioritise colleague wellbeing, inclusion and development. Our workforce plans balance targeted growth in priority clinical areas with role redesign, new ways of working and the increased use of digital tools. They also set out actions to reduce reliance on temporary staffing, improve retention and develop flexible career pathways. Continued investment in leadership capability, learning and development is central to ensuring we have the right skills, in the right place, at the right time to deliver safe and effective care over the medium term.

Our Patients

Improving access, experience and outcomes for patients is a core ambition of our Medium-Term Plan, with particular emphasis on urgent and emergency care, planned care waiting times and cancer performance. Our plan sets out clear but challenging improvement trajectories against national standards. While full compliance is not achieved across all standards in the short term, sustained improvement is planned over the medium term through service redesign, improved patient flow, productivity gains and closer working with system partners.

Investment in community diagnostics, urgent treatment centres, elective recovery programmes, digital transformation and new care pathways will support improvements in timeliness and quality of care, recognising that recovery will be incremental and dependent on successful delivery of transformation programmes and capital investment.

Our Population

Improving population health and reducing health inequalities remain central to our medium-term ambitions. Our plans support the national three shifts from hospital to community, analogue to digital, and sickness to prevention. Over the medium term, we will work with partners to strengthen prevention, early intervention and out-of-hospital care, targeting inequalities in access, experience and outcomes. These actions are embedded within place-based and system-wide plans and are designed to deliver care closer to home and improve long-term health outcomes for our population.

Financial Sustainability and Transformation

We continue to operate in a challenging financial environment and forecast an underlying deficit position in the short term. Our Medium-Term Financial Plan sets out a clear improvement trajectory, with a return to recurrent financial balance assumed over the medium term, subject to the successful delivery of cost improvement and transformation programmes and continued system collaboration. This includes a multi-year cost improvement and productivity programme, strengthened financial governance and a renewed focus on value and efficiency. Transformation activity includes service line reviews, workforce optimisation, digital enablement and estate rationalisation, underpinned by robust quality impact assessment to ensure patient safety is maintained.

Partnerships and Collaboration

Delivery of our medium-term ambitions depends on strong system partnerships. We will continue to work closely with the Integrated Care Board, local authorities, voluntary sector organisations and NHS provider partners through provider collaboratives and place-based arrangements. These partnerships are critical to delivering joined-up care, shifting activity out of hospital settings, improving population health and achieving sustainable improvement in performance, quality and financial position across the system.

DRAFT

Our Strategy 2025 - 2035: The best joined-up care for *all*

University Hospitals of North Midlands NHS Trust

Our Priorities

Our People

We will create an **inclusive** workforce where **everyone** learns, thrives, and makes a positive difference

Key Metric:
Staff Engagement Score

Our Patients

We will provide **timely, innovative** and effective services to our **patients**

Key Metric:
Combined Hospital Score

Our Population

We will **tackle inequality,** and improve the health of our population

Key Metric:
Number of Years in Good Health

Our Programmes

Brilliant Basics: Standards & Performance

Addressing the immediate concerns facing our patients

Digitally Enabled Care Transformation

Standardising and redesigning pathways – enabled by a new Electronic Patient Record (EPR)

Our Future Hospital Services

Designing services so they reflect the latest developments in medical knowledge and provide care closer to home

Collaborations & Networks

Working with others to ensure sustainable and joined-up care

Our Strategic Plans

Quality, Access & Performance | People | Population Health | Digital | Research | Innovation | Estates & Facilities

Our Values



DRAFT

Progress in delivering our strategic priorities

This section provides an overview of our performance during 2025/26, including how we have worked towards delivering our priorities for Our People, Our Patients and Our Population.

Our People

During 2025/26, we continued to progress delivery of Our People strategic priority, with a sustained focus on an inclusive and sustainable workforce, leadership, culture and colleague experience. This activity took place against a backdrop of continued operational and financial pressures across the NHS.

The 2025 NHS Staff Survey remained a key source of insight into colleague experience during the year. Results showed that overall engagement and many People Promise themes remained broadly stable compared to 2024, reflecting national trends across the health service in a challenging operating environment. Variation in experience across teams was evident. These findings informed in-year oversight and action planning, with a continued emphasis on strengthening local leadership, communication and targeted improvement activity.

Maintaining a safe and supportive working environment remained a core component of our workforce approach during 2025/26. Regular workforce reporting and establishment reviews, including nursing and Allied Health Professional workforce reviews, have been undertaken to provide assurance on staffing capacity, deployment and emerging pressures, supporting oversight of colleague wellbeing and patient safety.

Learning, development and leadership continued to underpin delivery of our people priorities throughout the year. Professional development programmes, statutory and mandatory training, and leadership development activity were progressed during 2025/26, alongside work to strengthen governance, reporting and assurance on training compliance and quality. Organisational development and leadership interventions remained focused on supporting compassionate and effective leadership in line with Trust values.

Our People

We will create an **inclusive** workforce where **everyone** learns, thrives, and makes a positive difference

Key Metric:
Staff Engagement Score

Staff Engagement Score 2024	Staff Engagement Score 2025
6.84	6.67

During 2025/26, we also continued to progress work relating to culture, safety and inclusion. Oversight was maintained through regular reporting on areas including speaking up, dignity and respect, equality, and sexual safety. These programmes have been subject to ongoing governance and assurance arrangements, recognising that cultural change is incremental and requires sustained focus over time.

Recognising and valuing the contribution of colleagues formed an important part of our people agenda during the year. A Night Full of Stars awards were held in November 2025, celebrating individual and team achievements and reinforcing organisational values, pride and belonging.

During a year which included national industrial action and sustained system pressures, workforce planning and coordination arrangements were implemented to support service continuity and patient safety. Throughout 2025/26, colleagues across the Trust continued to adapt to operational challenges, with governance oversight focused on managing risk, supporting employees and maintaining safe care delivery.

The extract below summarises our people and workforce performance under the NHS Oversight Framework:

People and workforce	Data period	Provider value		Chart
People and workforce domain segment	Q4 2025/26	3	NOF Score	
People and workforce domain score	Q4 2025/26	2.72	NOF Score	

Retention and Culture	Data period	Provider value	Peer average		National value	National value method	Chart
Sickness absence rate score			Q4 2025/26	3	NOF Score	Provider value	
Sickness absence rate (quarter)	To Dec 2025	5.88%	5.44%		5.88%	Provider median	
NHS staff survey engagement theme sub-score score			Q4 2025/26	3	NOF Score	Provider value	
NHS staff survey engagement theme sub-score	2025	6.67	6.54		6.80	Provider median	

DRAFT

Our Patients - Quality

During 2025/26, we continued to deliver against our Our Patients strategic priorities, maintaining a strong focus on safe, effective and patient-centred care, supported by robust quality governance and oversight.

We made good progress in patient safety, achieving all ten safety actions for the 2025/26 CNST Maternity Incentive Scheme, marking the sixth consecutive year of full compliance and resulting in the return of our incentive fund contribution. This reflects the sustained commitment of maternity and neonatal services, supported by effective partnership working across the Local Maternity and Neonatal System. In April 2025, maternity services were rated Good by the Care Quality Commission, and our Director of Midwifery received the Chief Midwifery Officer for England Silver Award.

Maintaining high-quality patient environments remained a priority. Internal assurance processes supported preparation for the 2025 Patient-Led Assessments of the Care Environment (PLACE), with results received in April 2026 confirming performance above the national average across all domains for the third consecutive year. Strong results were achieved across both sites, particularly in cleanliness and condition, maintenance and appearance. Ongoing pressures relating to estate capacity and sustained clinical activity were identified, with targeted improvement actions in progress.

We maintained close oversight of patient safety performance throughout the year, including hospital-acquired pressure damage, infection prevention and control, and medicines optimisation. While improvements were seen in some infection prevention measures, continued operational and financial pressures impacted medicines optimisation and consistency across Care Groups. Strengthening oversight, reducing unwarranted variation and improving assurance in this area have been identified as priorities for 2026/27.

Progress was also made in clinical effectiveness. Care Groups strengthened arrangements for monitoring compliance with NICE guidance, Get It Right First Time (GIRFT) recommendations, clinical audits and accreditation standards, improving visibility of issues and learning. Further work is required to achieve greater consistency in reporting and more robust tracking of actions, which will remain a focus going forward.

Our Patients

We will provide **timely, innovative** and effective services to our **patients**

Key Metric:
Combined Hospital Score

NHS Oversight Framework Average Scores & Ranking			
Q1	Q2	Q3	Q4
2.47 83 / 134	2.43 79 / 134	2.47 71 / 134	2.48 92 / 134

Patient experience and engagement continued to improve, with progress in the timeliness of complaint responses, consistency of Patient Advice and Liaison Service (PALS) handling and engagement with patients and carers. The establishment of the Patient and Carer Leadership Council strengthened the patient voice within quality governance. However, challenges remain, including increased complaint volumes and improving the quality and completeness of data relating to protected characteristics.

Implementation of the Electronic Prescribing and Medicines Administration (EPMA) system progressed, supporting safer and more reliable medicines management. Rollout was temporarily paused during a critical incident to prioritise safe patient care during heightened operational pressures. Once fully embedded, EPMA is expected to strengthen medicines safety, governance and digital workflows.

Further detail on quality governance, assurance processes and data quality is provided in the Accountability Report (pages 59–67). The extract below summarises patient safety, effectiveness and experience performance under the NHS Oversight Framework.

Patient Safety Domain Score	Data period	Provider value	Peer average	National value	National value method	Chart
Patient safety domain segment			Q4 2025/26	3	NOF Score	
Patient safety domain score			Q4 2025/26	2.83	NOF Score	
Patient safety Please note that the MRSA, C-Difficile and E-Coli scores each carry a one third weighting	Data period	Provider value	Peer average	National value	National value method	Chart
NHS Staff Survey - raising concerns sub-score score			Q4 2025/26	3	NOF Score	Provider value
NHS Staff survey - raising concerns sub-score	2025	6.17	6.18	6.32		Provider median
Number of MRSA bacteraemia cases score			Q4 2025/26	4	NOF Score	Provider value
Number of MRSA bacteraemia cases (12 months)	To Mar 2026	9.00	5.00	3.50		Provider median
Proportion of C. difficile infections score			Q4 2025/26	3	NOF Score	Provider value
Proportion of C. difficile infections versus threshold (12 months)	To Mar 2026	1.17	1.11	1.09		Provider median
Proportion of E. coli bacteraemia score			Q4 2025/26	1	NOF Score	Provider value
Proportion of E. coli bacteraemia versus threshold (12 months)	To Mar 2026	1.00	1.18	1.17		Provider median
Effectiveness and experience of care			Data period	Provider value		Chart
Effectiveness and experience of care domain segment			Q4 2025/26	3	NOF Score	
Effectiveness and experience of care domain score			Q4 2025/26	2.22	NOF Score	
Patient experience			Data period	Provider value		Chart
CQC inpatient survey satisfaction rate score			Q4 2025/26	2	NOF Score	
Summary Hospital-level Mortality Indicator score			Q4 2025/26	3	NOF Score	
Effective flow and discharge	Data period	Provider value	Peer average	National value	National value method	Chart
Average number of days from discharge ready date to actual discharge date (including zero days) score			Q4 2025/26	2	NOF Score	Provider value
Average number of days from discharge ready date to actual discharge date (including zero days)	Mar 2026	0.42	1.09	0.80		Provider median

DRAFT

Our Patients - Access

During 2025/26, we continued to experience significant access challenges, particularly across urgent and emergency care, reflecting sustained high demand, workforce pressures and system-wide capacity constraints. These pressures were most acute during winter escalation periods. Following revised enforcement undertakings issued by NHS England in September 2025, we focused delivery on two key areas: Urgent and Emergency Care (UEC) and Elective Recovery. In response, we continued with a comprehensive Urgent and Emergency Care Improvement Plan, developed in collaboration with system partners and informed by national guidance, including engagement with the Urgent and Emergency Care GIRFT programme. Actions throughout the year focused on strengthening operational grip and flow, improving oversight of ambulance handovers and supporting decision-making within the Emergency Department. While overall four-hour performance remained significantly below the national standard (67.0%), improvements were seen in ambulance handover times, with the average handover time reducing compared to the previous year. However, the number of patients waiting over 12 hours in the Emergency Department increased, reflecting continued mismatch between demand and available bed capacity.

In line with our winter plan, cohort wards and bays were opened to support the safe management of patients with influenza and other seasonal pressures, helping to maintain patient flow wherever possible. During periods of extreme operational pressure, corridor care and the use of additional ward spaces were employed as time-limited risk-mitigating measures. We recognise that these arrangements do not reflect the experience we aspire to for our patients and continue to prioritise actions during the year to reduce reliance on them, including improvements to discharge processes, internal flow and escalation practices.

Cancer performance improved during 2025/26. Performance against the 28-day Faster Diagnosis Standard exceeded the national threshold, and we continued to demonstrate incremental improvement against the 62-day pathway. While full compliance with all cancer standards was not consistently achieved, strengthened clinical validation, pathway oversight and governance arrangements were embedded during the year, providing a more robust foundation for continued improvement. Significant progress was made in elective recovery; the number of patients waiting over 78 weeks reduced substantially, falling to six patients by early January 2026. This was achieved through a combination of increased elective activity across theatres and outpatients, utilisation of the County Elective Hub, targeted patient validation, productivity improvements and the use of mutual aid. Progress was not linear, with winter pressures and UEC escalation impacting elective capacity at times; however, by year end we remain on a clear trajectory to eliminate 78-week waits in line with national expectations.

Diagnostic performance, particularly non-obstetric ultrasound, continued to present a material access challenge. Performance against the national diagnostic standard (DM01) remained below target, reflecting sustained workforce shortages, increasing urgent demand and operational pressures across imaging services. A range of mitigating actions were implemented during the year, including pathway reviews, enhanced clinical prioritisation and use of additional capacity. These actions helped reduce the longest waits and stabilise performance, but full recovery will require continued investment in workforce capacity, reporting capability and further pathway redesign.

Throughout 2025/26, we remained subject to enhanced national oversight, including participation in the NHS tiering process, reflecting the scale and complexity of access challenges across urgent, elective and diagnostic pathways. Delivery of the revised UEC and Elective Improvement Plans was overseen through strengthened programme management, regular reporting to NHS England and sustained scrutiny through the Quality, Access and Outcomes Committee and the Trust Board. While significant challenges remain, the progress achieved during the year demonstrates sustained focus on improving access, reducing long waits and delivering safer, timelier care for patients. The extract below summarises our access

DRAFT

Access to Services	Data period	Provider value	Peer average	National value	National value method	Chart
Access to services domain segment			Q4 2025/26	3	NOF Score	
Access to services domain score			Q4 2025/26	2.51	NOF Score	

Elective Care	Data period	Provider value	Peer average	National value	National value method	Chart
Percentage of cases where a patient is waiting 18 weeks or less for elective treatment score			Q4 2025/26	3	NOF Score	Provider value
Percentage of cases where a patient is waiting 18 weeks or less for elective treatment	Mar 2026	64.74%	63.48%		64.83%	Provider median
Difference between planned and actual 18 week performance score			Q4 2025/26	1	NOF Score	Provider value
Difference between planned and actual 18 week performance	Mar 2026	1.95%	-0.36%		0.99%	Provider median
Percentage of patients waiting over 52 weeks for elective treatment score			Q4 2025/26	3	NOF Score	Provider value
Percentage of patients waiting over 52 weeks for elective treatment	Mar 2026	1.82%	1.25%		0.96%	Provider median
Percentage of patients waiting over 52 weeks for community services score			Q4 2025/26	1	NOF Score	Provider value

Cancer Care	Data period	Provider value	Peer average	National value	National value method	Chart
Percentage of patients with cancer diagnosed or ruled out within 28 days of an urgent referral score			Q4 2025/26	2	NOF Score	Provider value
Percentage of patients with cancer diagnosed or ruled out within 28 days of an urgent referral (quarter)	To Mar 2026	78.60%	77.50%		79.34%	Provider median
Percentage of patients treated for cancer within 62 days of referral score			Q4 2025/26	3	NOF Score	Provider value
Percentage of patients treated for cancer within 62 days of referral (quarter)	To Mar 2026	67.02%	67.18%		70.24%	Provider median

Urgent and Emergency Care	Data period	Provider value	Peer average	National value	National value method	Chart
Percentage of emergency department attendances admitted, transferred or discharged within four hours score			Q4 2025/26	4	NOF Score	Provider value
Percentage of emergency department attendances admitted, transferred or discharged within four hours (quarter)	To Mar 2026	64.97%	72.37%		74.01%	Provider median
Percentage of emergency department attendances spending over 12 hours in the department score			Q4 2025/26	3	NOF Score	Provider value
Percentage of emergency department attendances spending over 12 hours in the department (quarter)	To Mar 2026	10.69%	9.44%		8.71%	Provider median

Our Population

During 2025/26, we strengthened our commitment to improving the health and wellbeing of the communities we serve, with a continued focus on tackling inequalities and preventing avoidable ill-health. Our Population strategic priority is rooted in a clear understanding of local need: Stoke-on-Trent and parts of Staffordshire experience some of the highest levels of deprivation nationally, with many residents spending between 16 and 22 years of their lives in poor health. This is particularly stark in Stoke-on-Trent, where 53% of the population lives within the 20% most deprived communities in England.

Many of the illnesses treated within our services are preventable. Physical inactivity, excess weight, smoking and harmful alcohol consumption remain significant contributors to poor health and are closely associated with higher prevalence of cardiovascular disease, respiratory disease, musculoskeletal conditions and cancer. In response, during the year we progressed delivery of our Population Health Strategic Plan, setting the strategic direction for targeted action aligned to the national Core20PLUS5 framework, supported by dedicated public health expertise.

As an anchor institution, we strengthened our strategic commitment to improving community wellbeing, embedding prevention, health equity and Making Every Contact Count as core principles across our Population Health programme. Our system-wide work continued to mature through close collaboration with the Integrated Care Partnership, particularly on shared priorities aimed at reducing inequalities across the life course. Through these actions, we remained focused on our key strategic metric of increasing healthy life expectancy, while ensuring that all communities benefit from timely, high-quality and equitable care.

Our ambition is to prevent sickness wherever possible, enabling people to live more of their lives in good health and ensuring that, when care is needed, outcomes are equitable and consistently high quality. The Population Health and Wellbeing Strategy provides the framework for this work. During 2025/26, we made good progress in establishing the strategic infrastructure, partnerships and governance required to support delivery of our population health ambitions. Over the coming year, our focus will be on consolidating and scaling up these programmes, alongside continued engagement with Integrated Care System partners to expand delivery and impact.

Health Inequalities and Equity

Reducing health inequalities and advancing equity are central to our purpose and align directly with our statutory responsibilities under the Health and Care Act 2022 and the Public Sector Equality Duty. Alongside our overarching population health ambition, we continue to translate our commitment to equity into practical, targeted action to reduce inequalities in access, experience and outcomes across our services.

Our Approach

Our approach is grounded in population health management, using robust data and intelligence to identify unwarranted variation and to target interventions at groups most at risk of poor outcomes. Consideration of health inequalities is increasingly embedded within service planning, pathway design and clinical decision-making, ensuring equity is treated as a core component of quality and safety rather than a separate workstream.

Developing population health analytics and dashboards enable us to segment outcomes by deprivation, ethnicity, geography, age and other protected or inclusion characteristics. This supports proportionate universalism — improving outcomes for all while targeting action where inequalities are greatest.

Targeted Action to Reduce Inequalities

Maternal and Infant Outcomes
Addressing inequalities in maternal and infant outcomes has been a key priority during the year. While local infant mortality rates have improved, they remain above the national average and show persistent deprivation-related inequalities. In response, we have prioritised the development and delivery of a comprehensive Infant Mortality Action Plan, working closely with maternity, obstetric and system partners through the ICS Infant Mortality Steering Group.

Detailed analysis of modifiable risk factors — including smoking at delivery, maternal obesity, premature birth, uptake of antenatal screening and vaccinations, and perinatal mental health — has informed targeted interventions. Bespoke dashboards enable segmentation by ethnicity, deprivation, age, geography and GP practice, supporting focused action and more equitable outcomes for women and babies. While progress has been made, pre-term birth and neonatal mortality rates remain disproportionately high in more deprived populations, reinforcing the importance of sustained system-wide action.

Long-Term Conditions and Prevention
We have continued to focus on prevention and early intervention for people living with long-term conditions, recognising the strong relationship between deprivation, multimorbidity and poorer outcomes. Personalised care and anticipatory approaches have been used to reduce complications and prevent avoidable deterioration, helping to narrow outcome gaps for those experiencing the greatest disadvantage. Evaluation of services such as the Trust Alcohol Care Team has been undertaken using our quality improvement methodology to better understand impact on inequalities and outcomes.

DRAFT

Improving Equity in Cancer and Surgical Outcomes

During the year, we strengthened our focus on inequalities in cancer screening, early diagnosis and survival, aligning with national ambitions to increase stage 1 and 2 diagnosis. This has included work to understand variation in screening uptake, routes to diagnosis and referral quality, alongside action to address unwarranted variation in staging at diagnosis.

In parallel, we have progressed the development of prehabilitation across cancer and elective pathways. Patients from more deprived backgrounds often present with greater complexity and poorer baseline health, contributing to longer lengths of stay, higher complication rates and slower recovery. By focusing on prevention, optimisation and behaviour change ahead of treatment, prehabilitation supports fairer access, improved experience and more equitable clinical outcomes.

Core20PLUS5 and Inclusion Health

Our population health programme is aligned to the Core20PLUS5 national framework. Priority outcomes focus on leading contributors to life expectancy inequalities for populations living in the 20% most deprived communities, including:

- premature mortality from cardiovascular disease.
- cancer survival and early diagnosis.
- respiratory disease.
- infant mortality.
- alcohol-related admissions, mortality and liver disease

In addition, our local population includes several inclusion health (PLUS) groups who experience multiple and overlapping inequalities. Working with Integrated Care System (ICS) partners, we have prioritised targeted action for groups including:

- people with learning disability and/or autism.
- women from ethnic minority communities and those experiencing poverty.
- people at risk of serious violence.
- unpaid carers.
- military veterans.
- asylum seekers and vulnerable migrants.
- older people who are vulnerable or socially isolated.
- people experiencing homelessness

Significant progress has been made to improve data quality, including recording of learning disability, ethnicity and veteran status within clinical systems. This supports identification of need, delivery of reasonable adjustments and more equitable access to screening and outpatient services. Further improvements to recording of protected characteristics are planned in 2026/27 to strengthen our ability to identify inequalities and target action.

Governance, Measurement and Accountability

Delivery of health inequalities priorities is supported through clear governance arrangements within Our Population Health framework. Progress is overseen by the Population Health Steering Group, with assurance reported through the Quality, Access and Outcomes Committee. An outcomes-based framework is being developed with clinical teams and ICS partners to monitor impact and support evaluation. Population health dashboards increasingly provide inequalities-segmented intelligence, enabling evidence-based action and assessment of progress over time.

Anchor Institution Role

As a major employer and economic presence, we act as a key anchor institution, using our assets, employment, investment and influence to support the wider determinants of health. This includes contributing to local economic growth, improving workforce health and wellbeing, supporting skills development, and strengthening social inclusion within underserved communities. During the year, we:

- worked with procurement colleagues to understand and strengthen our contribution to the local economy.
- undertook workforce inequalities analysis to better understand variation in health and wellbeing outcomes.
- collaborated with system partners through ICS prevention, alcohol and early cancer diagnosis programmes.
- invested in population health infrastructure and capability, including analytics and workforce development.

Further work is underway with procurement, estates, sustainability, employment and organisational development teams to better target Core20 communities and workforce groups experiencing inequalities, informed by workforce equality objectives.

Looking Ahead

Population health and reducing inequalities remain a core component of our strategy for 2025/26 and 2026/27. Priorities include strengthening population health intelligence, embedding inequalities plans within care groups, improving data quality for protected characteristics, and further evaluating the impact of interventions on outcomes and experience.



	Number of Years in Good Health	
	Staffordshire & Stoke on Trent	England
Males	61.2 years	60.9 years
Females	60.5 years	61.3 years

DRAFT

Working with Our Partners to Deliver the Joint Forward Plan

During the year we have exercised our functions in full alignment with the Joint Forward Plan (JFP) for the Staffordshire and Stoke-on-Trent Integrated Care Board (ICB) and its partners. The JFP's priorities—including prevention, reducing health inequalities, improving access, and strengthening integrated pathways—were reflected in our refreshed organisational strategy, programme delivery framework and population-health objectives. Our Strategic Plans (2025–2035) explicitly incorporate system priorities, including the ICS "5Ps" life-course model and the system's focus on tackling unwarranted variation and avoidable ill-health.

In accordance with NHS England's latest statement on the use of inequalities information, we continued to strengthen the way we gather, analyse and act on data related to inequalities. This included expanding analytical capacity through OHID-funded population health roles, enhancing intelligence shared through care groups, and undertaking more systematic use of inequalities data to identify priority cohorts and inform pathway redesign.



Developing our Hospitals

We have exercised our capital functions in full accordance with the ICB's capital resource plans. Capital planning and prioritisation were undertaken collaboratively with regional partners and aligned to system-wide capital frameworks, ensuring investment decisions supported agreed system priorities.

Our approved Capital Programme for the year included investment across the following key areas:

- £4.7m Estates Safety Works.
- £2.1m Estates Infrastructure & Property Rationalisation.
- £158k Estates Compliance.
- £100k Net Zero Carbon.
- £516k Charity Funded Initiatives.
- £12.9m Clinical Equipment Replacement.
- £10.5m Digital Enablement.

These investments were prioritised to support system objectives, improve clinical capacity, and ensure our estate and infrastructure are fit for future service models, as set out in the Joint Forward Plan (JFP) and our long-term strategy.

In addition to the core capital programme, we delivered £36.2m of major corporate capital projects during the year to enhance our hospital environments and create better facilities for our people and our patients. Key schemes included:

- £14.4m County Breast Care Unit (construction commenced in 2024/25).
- £29.4m Community Diagnostic Centre (construction commenced in 2024/25).
- £702k Royal Stoke High Voltage Upgrade.
- £4.8m Royal Stoke Urgent Treatment Centre (Phase 1 completed; Phase 2 scheduled for July 2026).

DRAFT

Performance appraisal

Our performance has been assessed against national standards, statutory undertakings and the commitments set out in Our Strategy 2025/26. The summary below highlights where expectations were met, where progress was made but fell short, and where performance remained significantly challenged.

Where our performance met our expectations

Cancer – Faster Diagnosis
- 28-day Faster Diagnosis Standard achieved (83.2% vs 75%)
- Improvement across all cancer pathways year-on-year, including the 62-day standard

Elective Recovery – Long Waiters
- Significant reduction in 52-week and 78-week waits
- Strong trajectory achieved by year end, in line with national expectations

Patient Safety (selected measures)
- Reduction in patient falls and medication incidents
- Improved compliance with sepsis screening across inpatient, ED and children's services
- Significant reduction in serious incident investigations compared to prior year

Workforce – Capacity & Stability
- Vacancy and turnover rates better than target
- Agency utilisation significantly reduced, supporting continuity and productivity

Where progress was made, but our expectations were not fully met

Urgent & Emergency Care
- Four-hour standard remained below national expectation (67.0%)
- Ambulance handover times improved compared to 2024/25
- Sustained pressure during winter escalation limited further improvement

Diagnostics (DM01)
- Material improvement year-on-year (78.2% vs 60.8%)
- Performance remained well below the national standard, driven by workforce shortages

RTT Incomplete Pathways
- Limited improvement in percentage waiting under 18 weeks
- Impacted by winter pressures and prioritisation of urgent care

Finance
- Year-end position delivered, but underlying sustainability and CIP delivery remain challenged.

Where our performance remained challenged

ED Long Waits
- Increase in the number of patients waiting over 12 hours
- Reflects ongoing bed capacity, flow and discharge constraints

Sickness Absence
- Continued to exceed target
- Closely linked to sustained operational pressure and workforce fatigue

Duty of Candour Timeliness
- Improvement year-on-year, but below the 100% standard
- Complexity and timeliness of investigations remained a limiting factor

Key factors impacting delivery

- Sustained high system-wide demand
- Workforce shortages in urgent care, diagnostics and imaging
- Delays to key enabling schemes (e.g. Urgent Treatment Centre)
- Winter escalation impacting both elective recovery and flow

Overall Assessment

2025/26 was a year of mixed but improving performance. We delivered strong progress in several strategic priorities, particularly cancer faster diagnosis, elective recovery for long waits, patient safety and workforce stability. However, urgent and emergency care, diagnostics access and some operational standards did not meet expectations, reflecting ongoing demand, capacity and workforce challenges. These areas remained under enhanced oversight, with clear priorities established for further improvement in 2026/27.

DRAFT

Principal risks

Our Risk Management Policy sets out the framework we use to identify, assess, manage and oversee risk. This includes operational and strategic risks. Operational risks are reported through our Risk Register and strategic risks are reported through the Board Assurance Framework (BAF).

The BAF is updated on a quarterly basis and scrutinised by each of our Committees, each having allocated risks. The Audit Committee is responsible for oversight of the BAF process, and it is also presented to the Trust Board.

A review of strategic risks is undertaken on an annual basis by the Board, considering existing and emerging internal and external factors which might threaten the achievement of our strategic priorities. Each strategic risk is assigned to a designated Executive Director, who is responsible for its quarterly review.

Throughout 2025/26, we managed a total of eight strategic risks, which we assessed as being a threat to our strategic priorities, six of which threatened every priority. In addition, the Board identified three primary issues which also affected the ability to mitigate our strategic risks. The full BAF can be found within our Trust Board papers at https://www.uhnm.nhs.uk/media/huckbrw0/trust-board-part-1-10-06-26.pdf .

Our Risk Management Policy also sets out our Risk Appetite Statement which has been subject to review during the year, alongside the policy. Risk appetite is the amount and type of risk that an organisation is prepared to pursue, retain or take, in pursuit of its strategy, after balancing the potential opportunities and threats a situation presents. As such, when setting target risk scores for the strategic risks contained within our BAF, we have taken into consideration the level of appetite determined in our statement, as well as what level of risk we are prepared to tolerate.

A summary of the strategic risks contained within our BAF during 2025/26 is shown opposite, including the risk level each quarter and the target being worked towards.

Strategic Risk Type	Q1	Q2	Q3	Q4	Target
1. Inability to sustain safe and effective care delivery	Ext 16	Ext 20	Ext 20	Ext 20	High 8
2. Inability to design and deliver services that address local population needs	High 10	High 10	High 10	High 10	High 8
3. Inability to improve workforce sustainability & organisational culture	Ext 15	Ext 15	Ext 15	Ext 15	High 10
4. Inability to delivery digitally enabled care transformation	Ext 16	Ext 16	Ext 16	Ext 16	High 8
5. Inability to deliver investment in estate infrastructure & workforce	High 12	High 12	High 12	High 12	High 12
6. Inability to deliver in-year financial position	Ext 20	Ext 20	High 12	High 9	High 9
7. Inability to deliver financial sustainability	Ext 20	Ext 20	Ext 25	Ext 25	High 12
8. Inability to sustain research and innovation excellence	High 12	High 12	High 12	High 12	High 8

DRAFT

Going concern

After making enquiries, the directors have a reasonable expectation that the services we provide will continue to be provided by the public sector for the foreseeable future.

For this reason, the directors have adopted the going concern basis in preparing the accounts, following the definition of going concern in the public sector adopted by HM Treasury's Financial Reporting Manual.


What does Going Concern mean?

Accounting standards require us to prepare our financial statements on a "going concern" basis. This means we must assume that we will continue to operate for the foreseeable future, unless senior management intends to close the organisation, stop providing services, or has no realistic alternative to doing so.

As part of preparing the accounts, management must consider whether there are any significant events or conditions that could create uncertainty about our ability to continue operating. If any such material uncertainties exist, we are required to clearly explain them in the financial statements. If, in exceptional circumstances, the financial statements were not prepared on a going concern basis, we would have to explain why, outline the alternative basis used, and describe the reasons why the organisation could no longer be considered a going concern.

Assessment Rules

The approach for going concern is based on the requirements of ISA (UK) 570, interpreted as Practice Note 10: Audit of financial statements and regularity of public sector bodies in the United Kingdom (revised 2020) and the National Audit Office's Supplementary Guidance Note 01: Going Concern – Auditors responsibilities for local public bodies.



Performance Analysis

DRAFT

This section provides a summary of how we measure our performance, includes detailed integrated performance analysis and long-term expenditure trend analysis.

How we measure our performance

Our Accountability and Performance Framework outlines our arrangements for monitoring, managing and improving performance across the organisation. This is reviewed and refreshed annually.

Our performance is monitored from ward to board using a variety of key performance metrics including constitutional targets, which spans numerous domains.

The Board receives the Integrated Performance Report (IPR), presented by the relevant Executive Director, which includes a description of performance against expectations, any drivers of under performance, actions being taken and the expected impact of those actions. The Board may request further improvement actions where there is concern with any area of performance.

Data Quality and Statistical Process Control

Data Quality Assurance Indicators are used to assess the reliability and quality of data using the Sign off, Timely and complete, Audit and accuracy, Robust systems and data capture (STAR) Framework. Each domain is rated to indicate the level of assurance.

Statistical Process Control methods are also used to analyse performance data, drawing two main observations together; variation (improvement, decline or no change) and assurance (confidence in meeting targets).

Assurance Grid

An Assurance Grid categorises metrics based on their performance and assurance levels, using icons to indicate whether metrics are consistently meeting targets, showing improvement or requiring attention.

Performance against the NHS Oversight Framework (NOF)

Each Integrated Performance Report includes a summary of performance against the NOF. These include metrics such as access to services, effectiveness and experience, patient safety, people and workforce and finance and productivity.

Our Performance Domains

Performance Domains are aligned with our Strategic Priorities, each with its own set of metrics and dashboards. In summary, these cover:

- **Quality:** focusses on providing safe, effective and caring services. Metrics include patient safety incidents, falls with harm, medication incidents and sepsis management.
- **Access:** ensures efficient and responsive services. Metrics include emergency and elective pathway performance, cancer treatment times and diagnostic wait times.
- **People:** as we aim to create a great place to work. Metrics include employee engagement, sickness absence, vacancy and turnover rates.
- **Finance:** ensures optimal use of resources including employees, assets and finances. Metrics include elective and emergency activity, outpatient appointments and financial performance.

Each domain is also mapped to the strategic risks within the BAF, to support triangulation of performance with strategic risk.

This structured approach enables us to track progress, identify areas for improvement and implement necessary changes to enhance overall performance and patient care.

In addition to the IPR to the Board, our committees scrutinise performance to a greater depth, with more detailed reports provided which are relevant to the respective committee role and responsibilities. These include a range of performance metrics and are presented by Executive Directors.

DRAFT



Performance and Risk Reviews

The performance of our Care Groups is scrutinised through our Performance and Risk Review process. These are bi-monthly reviews, led by the Executive Team and are a key mechanism through which care group leadership teams are held to account.

To support the Performance and Risk Review, a comprehensive data pack is prepared by our Performance and Information Team which, like the IPR, includes a range of performance metrics with supporting narrative provided by the Care Group.

In addition to key performance metrics, these packs include an overview of key risks which are being managed by the Care Group. This aligns with our Risk Management Policy and provides a means through which areas of underperformance can be triangulated with risks. Using a simple methodology, the report flags any risks which require review, do not have actions identified and where there is concern that the level of risk has not reduced over time. Care Groups are asked to pay attention to those risks which have been flagged through this approach and appropriate actions are agreed.

The Performance and Risk Review process is replicated at a lower level, with Care Group Leadership teams following the same approach to hold their leadership teams to account, for performance and risk management across their specialties, wards and departments.

DRAFT

Our Key Performance Indicators (KPIs)

Quality

1. Patient Safety Incidents per 1000 bed days
2. Patient Safety Incidents with moderate harm or above per 1000 bed days
3. Patient falls per 1000 bed days
4. Patient falls with harm per 1000 bed days
5. Medication incidents per 1000 bed days
6. Medication incidents with moderate harm or above (%)
7. Pressure ulcers developed at UHNM per 1000 bed days
8. Pressure ulcers with lapses in care per 1000 bed days
9. Never events reported
10. Patient Safety Incident Investigation instigated
11. Duty of candour verbal
12. Duty of candour written (letter sent within 10 working days)
13. Maternity induction of labour – breach performance
14. Maternity assessment unit triage within 15 minutes
15. Timely observations
16. Venous thromboembolism risk assessment rate (timely)
17. Hospital associated thrombosis rate
18. Sepsis screening – inpatients
19. Sepsis intravenous antibiotics – inpatients
20. Sepsis screening – Emergency Department
21. Sepsis intravenous antibiotics – Emergency Department
22. Sepsis screening – maternity
23. Sepsis intravenous antibiotics – maternity
24. Sepsis screening – children's
25. Sepsis intravenous antibiotics – children's

Outcomes

1. NICE guidance implemented into practice with assurance mechanism identified
2. Participation in national audits / programmes with associated action plans
3. Provision of action plan following GIRFT visit
4. Number of patients who feel that they were involved in decisions made about their care
5. Number of patients receiving a Senior Review within 14 hours of admission
6. Number of patients who had an individualised plan of care
7. Number of GIRFT pathways audited as part of Clinical Audit Programme
8. Number of clinical audits demonstrating significant assurance
9. Compliance with the mandatory completion of questions relating to the never event criteria on the Local Safety Standards for Invasive Procedures (LocSSIP) safety checklist
10. Number of patients who have reported a positive outcome following their hospital admission/procedure

Access

1. Urgent and Emergency Care (UEC) 4-hour performance
2. Urgent and Emergency Care 4-hour performance (aged <18)
3. Over 12 hours in Emergency Department
4. Over 12 hours in Emergency Department (aged <18)
5. Ambulance handover average time
6. Cancer 28-day Faster Diagnosis Standard (FDS)
7. Cancer 31-day combined
8. Cancer 62-day combined
9. Diagnostics DM01 performance
10. Referral to Treatment (RTT) number <18 weeks
11. RTT 52+ weeks (%)
12. RTT % waiting, 1st contact
13. RTT <18 weeks (aged <18)
14. RTT 52+ weeks (%) (aged <18)
15. RTT % waiting 1st contact (aged <18)

Finance

1. Daycase/elective activity
2. Non-elective activity
3. Outpatient first appointment
4. Outpatient follow up
5. Total income (£'000)
6. Expenditure – pay (£'000)
7. Expenditure – non-pay (£'000)

People

1. Staff turnover (rolling 12 month)
2. Staff vacancy rate
3. Sickness absence (in month)
4. Appraisal (Performance Development Review)
5. Agency utilisation
6. Employee engagement

DRAFT

Operational performance 2025/26

The year has been a period of significant challenges and achievements, although despite facing operational pressures and critical incidents, we have made notable progress in various areas, in line with our commitment to ensuring the best joined-up care for all our patients.

Non-Elective Care

During 2025/26, non-elective care performance remained under sustained pressure, reflecting high demand, workforce constraints and system-wide capacity challenges, particularly during winter escalation. Performance against the four-hour Emergency Department standard remained significantly below the national expectation at year end (67%), broadly similar to the previous year. The number of patients waiting over 12 hours increased compared to 2024/25, reinforces the ongoing challenge in achieving timely flow through the urgent and emergency care pathway. There was some improvement in ambulance handover performance over the year, with average handover times reducing compared to 2024/25; however, delays persisted during periods of peak demand. Our established Urgent and Emergency Care improvement programme, supported by external review and system collaboration, will remain a key priority moving into 2026/27.

Elective Care and Diagnostics

Elective care performance was impacted by operational pressures during the year, particularly during winter, as capacity was reprioritised to support urgent and emergency care. Despite this, we made strong progress in addressing long waiting patients. The number of patients waiting over 52 weeks reduced significantly compared to the prior year, and we remain on a clear trajectory to eliminate the longest waits in line with national expectations.

Cancer performance improved over the year, whereby we achieved the 28-day Faster Diagnosis Standard at year end (83.2%), exceeding the national threshold. Performance against the 31-day and 62-day standards also improved compared to 2024/25, although full compliance was not consistently achieved, reflecting complexity of pathways, diagnostic capacity constraints and workforce pressures. Strengthened governance, pathway oversight and clinical validation were embedded during the year to support ongoing improvement.

Diagnostic performance remained a significant challenge, particularly for non-obstetric ultrasound. While performance against the diagnostic standard (DM01) improved materially compared to the previous year (78.2% vs 60.8%), it remained below the national expectation. Targeted recovery actions were implemented, and improvements were seen in some diagnostic modalities; however, full recovery will require sustained investment in workforce capacity and service redesign.

Referral to Treatment (RTT)

RTT performance showed mixed progress during 2025/26. There was a substantial reduction in the number of patients waiting over 52 weeks compared to 2024/25, representing a significant achievement given the operational pressures faced during the year. We successfully eliminated the longest waits, including those over 104 weeks. However, overall RTT performance against the 18-week standard remained below national expectations. Progress was constrained by winter escalation, workforce availability and the need to prioritise urgent care and clinically complex cases.

Key Performance Indicator	Target	2025/26 Performance	2024/25 Performance
UEC 4 hour performance	95%	67.03%	67.92%
UEC 4 hour performance (aged <18)		87.29%	
Over 12 hours in ED		27,982	26,057
Over 12 hours in ED (aged <18)		270	211
Ambulance handover average time		01:07:57	01:17:35
Cancer 28 day faster diagnosis standard	75%	83.24%	73.99%
Cancer 31 day combined	96%	92.96%	92.10%
Cancer 62 day combined	85%	68.66%	65.86%
Diagnostics DM01 performance	99%	78.15%	60.79%
RTT Number <18 weeks		41,126	42,194
RTT 52 weeks+		1,251	1,423
RTT % waiting, 1st contact		75.21%	
RTT <18 weeks (aged <18)		7,717	
RTT 52 weeks+ (%) (aged <18)		2.01%	
RTT % waiting 1st contact (aged <18)		84.23%	

DRAFT


Activity and Utilisation

Non-elective activity continued to increase during the year, although remaining below plan, with growth particularly evident in short-stay activity, including zero-length-of-stay and one-day admissions. Elective activity was variable, reflecting the impact of winter pressures and the requirement to support urgent care escalation. The County Elective Hub continued to increase procedure numbers, contributing positively to overall elective throughput and supporting reductions in long waits.


Future Outlook

Looking ahead, we recognise that urgent and emergency care performance remains the most significant challenge. The revised Urgent and Emergency Care improvement programme, supported by strengthened leadership and recovery oversight, will be central to improvement during 2026/27. Elective and diagnostic recovery plans remain focused on sustaining reductions in long waits and improving pathway resilience, particularly for cancer and diagnostics. Overall, 2025/26 demonstrated resilience in the face of sustained operational pressure. While performance did not meet expectations in all areas, particularly urgent care and diagnostics, we delivered meaningful improvement in cancer faster diagnosis, elective long waits and RTT longest wait reductions. These improvements provide a strong platform on which to build further progress in the coming year.


Ambulance Handover Time



Emergency Department 4-hour performance



Emergency Department 12-hour performance



DRAFT

Quality performance 2025/26

Throughout the year, we have maintained our priority to provide high quality, safe care for all patients, and to learn from our errors and we are committed to driving improvement and a culture of excellence.

During 2025/26, we made measured but tangible progress across a number of quality and patient safety indicators, reflecting sustained focus on harm reduction, early recognition of deterioration and system learning. Overall patient safety incident reporting remained broadly stable compared to 2024/25, with a small reduction in incidents per 1,000 bed days, supporting continued organisational learning and transparency.

There was notable improvement in a number of harm-related measures. Patient falls per 1,000 bed days reduced compared to the previous year, and while falls resulting in harm remained above target, the rate improved year-on-year. Medication incident rates reduced, alongside a further reduction in the proportion of medication incidents resulting in moderate harm or above, demonstrating improved medicines safety and assurance processes. The number of Patient Safety Incident Investigations instigated reduced significantly compared to 2024/25, reflecting both improved prevention and the more proportionate, system-focused approach introduced through the Patient Safety Incident Response Framework (PSIRF).Performance across sepsis pathways remained a relative strength, with sustained high levels of screening and timely administration of intravenous antibiotics for adult inpatients, Emergency Department attendances, maternity services and children. Most sepsis screening indicators exceeded the 90% target at year end, with particularly strong year-on-year improvement seen in Emergency Department and children's pathways. Compliance with timely antibiotic administration improved in several cohorts, although variation remains, particularly within maternity pathways, which continues to be an area of focus.

We continued to embed PSIRF throughout the organisation during the year, strengthening our approach to system-based learning, reducing reliance on high-threshold investigations and improving the quality of insight generated from incidents. This has enabled a clearer focus on learning that supports meaningful improvement rather than process compliance alone.

While progress has been made, performance did not consistently meet expectations across all quality indicators. Overall patient safety incidents with moderate harm or above increased slightly compared to 2024/25, and pressure ulcers developed per 1,000 bed days remained above target, although performance improved year-on-year.

DRAFT

Key Performance Indicator	Target	2025/26 Performance	2024/25 Performance
Patient Safety Incidents per 1000 bed days	50.7	**52.2**	52.8
Patient Safety Incidents with moderate harm or above per 1000 bed days	0.6	**0.7**	0.6
Patient falls per 1000 bed days	5.6	**4.6**	5.0
Patient falls with harm per 1000 bed days	1.5	**1.7**	1.8
Medication incidents per 1000 bed days	6	**5.5**	6.6
Medication incidents with moderate harm or above (%)	5%	**1.4%**	1.6%
Pressure ulcers developed at UHNM per 1000 bed days	1.6	**1.7**	1.8
Pressure ulcers with lapses in care per 1000 bed days	N/A	**0.4**	0.5
Never events reported	0	**4**	9
Patient Safety Incident Investigation instigated	N/A	**14**	31
Duty of candour verbal	100%	**87.7%**	94.9%
Duty of candour written (letter sent within 10 working days)	100%	**83.8%**	76.4%
Maternity induction of labour – breach performance	95%	**99.1%**	98.0%
Maternity assessment unit triage within 15 minutes	85%	**89.2%**	92.9%
Timely observations	90%	**80.0%**	71.5%
Venous thromboembolism risk assessment rate (timely)	95%	**88.1%**	80.5%
Hospital associated thrombosis rate	N/A	**1.04**	0.93
Sepsis screening – inpatients	90%	**98.2%**	95.4%
Sepsis intravenous antibiotics – inpatients	90%	**98.9%**	99.1%
Sepsis screening – Emergency Department	90%	**92.5%**	85.5%
Sepsis intravenous antibiotics – Emergency Department	90%	**85.7%**	81.9%
Sepsis screening – maternity	90%	**91.6%**	78.9%
Sepsis intravenous antibiotics – maternity	90%	**75.0%**	78.7%
Sepsis screening – children's	90%	**98.8%**	87.1%
Sepsis intravenous antibiotics – children	90%	**94.4%**	75.0%

Timely completion of Duty of Candour processes did not achieve the 100% standard, reflecting the complexity and timeliness of incident reviews, although written duty of candour compliance improved compared to the prior year. Compliance with timely observations using our electronic system improved, but remained below target, and venous thromboembolism (VTE) risk assessment performance, while improved year-on-year, did not achieve the 95% standard. Hospital-associated thrombosis rates remain under close review. Never Events reduced compared to 2024/25, but any occurrence remains unacceptable and continues to be a priority for learning and prevention.

We continue to deliver care across multiple clinical and administrative systems. While these systems support day-to-day operations, their limited integration increases reliance on manual processes and reduces end-to-end visibility across patient pathways. This creates additional clinical and operational risk, particularly in relation to continuity of care, timely decision-making and assurance. As such, digital integration and electronic prescribing and medicines administration remain key enablers for further improvements in safety and quality.

12 Month Trend Analysis – Quality KPIs

KPI	Variation	Assurance
HSMR (Rolling 12-months)		
PSI per 1000 bed days		
PSI with moderate harm or above per 1000 bed days		
Patient Falls per 1000 bed days		
Patient falls with harm per 1000 bed days		
Medication incidents per 1000 bed days		
Medication incidents with moderate harm or above (%)		
Never Events reported		
PSIIs instigated		
Duty of Candour verbal		
Duty of Candour written (letter sent within 10 working days)		
Pressure Ulcers developed at uhnm per 1000 bed days		
Pressure ulcers with lapses in care per 1000 bed days		
Trust Apportioned Infections		
Avoidable cases of MRSA Bacteraemia		
HAI and COHA cases of C.Diff toxin		
HAI E.Coli Bacteraemia Cases		
Sepsis Screening - Inpatients		
Sepsis IVAB - Inpatients		
Sepsis Screening - ED		
Sepsis IVAB - ED		

KPI	Variation	Assurance
Sepsis Screening - Maternity		
Sepsis IVAB - Maternity		
Sepsis Screening - Childrens		
Sepsis IVAB - Childrens		
VTE Risk assessment Rate (timely) - data from Tendable		
Hospital Associated Thrombosis Rate		
Care hours per patient day (safe staffing)		
Timely Observations		
UHNM Inpatients - Friends & Family Test (% recommending)		
UHNM A&E - Friends & Family Test (% recommending)		
UHNM Maternity - Friends & Family Test (% recommending)		
Complaints - % closed within 25/40/60 working day target		
Written complaints rate per 10,000 spells		
Mixed Sex Accommodation Breaches Reported		
Maternity Induction of Labour - Breach performance		
Maternity Assessment Unit Triage within 15 minutes		
3rd/4th degree tears		
Neonatal deaths		

During 2025/26, our outcomes assurance continued to strengthen, with high performance in several indicators that reflect safe, person-centred care. We embedded a large proportion of applicable NICE guidance into practice with defined assurance mechanisms (83%) and maintained strong compliance with Local Safety Standards for Invasive Procedures checks (94%). Patient-reported measures remained a relative strength, with most respondents reporting involvement in decisions about their care (96%) and having an individualised plan of care (95%); a snapshot audit also demonstrated a high rate of senior review within 14 hours of admission (96%). Alongside this progress, further work is required to improve the timeliness and completeness of action planning arising from national audits and GIRFT and strengthening the proportion of clinical audits demonstrating significant assurance (55%), supported by continued improvement in clinical effectiveness governance and reporting.

Key Performance Indicator	2025/26 Performance
NICE guidance implemented into practice with assurance mechanism identified (including Health Technology Appraisals)	94 / 113 (83%)
Participation in national audits / programmes with associated action plans	68 (action plans to be developed once published)
Provision of action plan following GIRFT visit	5 / 6
Number of patients who feel that they were involved in decisions made about their care	280 / 291 (96%) (for patient experience questionnaires sent)
Number of patients receiving a Senior Review within 14 hours of admission	96% (snapshot audit)
Number of patients who had an individualised plan of care	276 / 291 (95%)
Number of GIRFT pathways audited as part of Clinical Audit Programme	Data not available
Number of clinical audits demonstrating significant assurance	66 / 120 (55%)
Compliance with the mandatory completion of questions relating to the never event criteria on the Local Safety Standards for Invasive Procedures (LocSSIP) safety checklist	94%
Number of patients who have reported a positive outcome following their hospital admission/procedure	Data not available

Future Outlook

Looking ahead, we remain committed to delivering high-quality, safe and compassionate care in the context of ongoing operational pressure and rising demand. Priorities for 2026/27 include further reducing harm from falls and pressure ulcers, improving compliance with timely observations, strengthening Duty of Candour timeliness, and addressing areas of variation within sepsis pathways. Through continued embedding of PSIRF, investment in digital transformation, and sustained focus on workforce wellbeing and engagement, we will continue to strengthen our safety culture and learning systems. This will support our ambition to reduce avoidable harm, improve patient outcomes and deliver consistently high-quality care for all patients.

DRAFT

Workforce performance 2025/26

Throughout the year, we have remained focused on supporting our workforce, recognising that engaged, healthy and supported colleagues are critical to delivering safe, high-quality care and driving continuous improvement.

Staff Engagement

Our staff engagement score for 2025/26 was 6.67, a slight deterioration compared to 6.84 in 2024/25 and below the ambition of 7.2. This reflected ongoing operational pressures, workforce fatigue and sustained demand across services. Alongside the National NHS Staff Survey, insights from the quarterly Staff Voice Survey have been considered throughout the year, informing targeted actions to address themes such as workload, wellbeing, inclusion and psychological safety. While engagement initiatives continued to develop, it is recognised that sustained improvement in engagement is closely linked to addressing sickness absence, staffing pressure and workload sustainability.

Sickness Absence

Sickness absence remained above our expected standard with an in-month rate of 5.4% in 2025/26, broadly consistent with the prior year. The primary drivers continued to be anxiety, stress and depression, followed by musculoskeletal conditions. The clear relationship between wellbeing, workload pressures and operational demand and sickness absence is recognised and seasonal variation remained evident, including reductions in respiratory-related illness towards the end of winter; however, overall sickness absence remained a key challenge requiring continued focus.

Turnover Rate and Vacancy Rates

Turnover remained stable at 7.5%, well below the 10% target, demonstrating continued success in retention despite the challenging operating environment. Turnover of registered nursing staff and midwives achieved upper quartile performance (7 out of 205 organisations for registered nurses; 24th out of 141 organisations for midwives).

Vacancy rates reduced significantly to 4.4%, compared to 8.3% in 2024/25. This improvement reflected sustained recruitment activity across Registered Nursing, support to clinical employees and infrastructure roles, alongside focused retention efforts. However, these gains have been partially offset by increases in budgeted establishment and continued workforce pressures within specific employee groups, particularly medical staffing.

Agency Utilisation

Agency utilisation reduced further during the year to 1.0%, remaining well below the NHS England threshold of 3.2% and representing a significant improvement compared to 2024/25. This reflected sustained scrutiny and while short-term increases in agency usage occurred during periods of peak pressure, overall utilisation remained tightly controlled, supporting financial sustainability and workforce stability.

Appraisal Rate

Performance Development Review (PDR) completion remained below the Trust's 95% target, with year-end performance at 81.8%, a deterioration compared to the previous year. The consistency of appraisal completion continues to be a focus, given the recognition of its importance for colleague development, engagement and performance. Care Groups continue to maintain active oversight of PDR compliance, with additional support and monitoring introduced during the year to improve performance.

Employee Engagement Initiatives

During 2025/26, we strengthened our approach to workforce culture and engagement through a more structured, evidence-led focus aligned to the NHS People Promise. Initiatives progressed during the year included the expansion of the People Promise Exemplar Programme (Cohort 2), enhanced wellbeing offers, and the transition of Employee Support Advisors into Freedom to Speak Up Champion roles to strengthen local engagement and psychological safety. These initiatives were supported by ongoing People Promise-aligned engagement campaigns and targeted interventions addressing mental health, inclusion and resilience.

Key Performance Indicator	Target	2025/26 Performance	2024/25 Performance
Staff turnover	10%	7.5%	7.5%
Staff vacancy rate	8%	4.4%	8.3%
Sickness absence (in month)	3.40%	5.4%	5.3%
Appraisal (performance development review)	95%	81.8%	86.3%
Agency utilisation	3.20%	1.0%	2.8%
Employee engagement	7.2	6.67	6.84


DRAFT

Future Outlook


Looking ahead, we will continue to prioritise employee engagement, wellbeing and workforce sustainability as critical enablers of high-quality patient care. Reducing sickness absence, improving PDR completion and strengthening engagement scores remain key priorities for 2026/27. Recruitment and retention activity will continue to focus on priority roles, alongside efforts to maintain low turnover and vacancy rates.

We will also continue to scrutinise agency usage, with a sustained focus on converting agency roles to bank or substantive positions where possible. Through these actions, and continued partnership working with the Integrated Care System and local universities, we aim to create a supportive, inclusive and engaged workforce capable of delivering the best joined-up care for *all*.


Vacancy Rate



Employee Engagement



In month sickness absence



DRAFT

Financial performance 2025/26

Throughout the year, we have remained focused on effective stewardship of our resources, underpinned by strong financial governance and a continued commitment to efficiency and sustainability.

Use of Resources and Financial Performance

Our resources are managed within a financial governance framework that incorporates systems of financial control, budgetary control and the financial responsibilities for individuals outlined within our corporate governance policies and procedures. Financial and quality governance arrangements incorporate benchmarking activities and an internal audit function to ensure probity, accuracy and the economic, efficient and effective use of resources, include value for money. Financial performance is reported into the non-executive led Finance and Business Performance Committee which meets monthly. Standing items on the agenda include the monthly financial position, cost improvement schemes, capital schemes and cost pressure analysis to ensure regular review of any financial challenges and implementation of recovery measures. We have a policy and governance framework in place to guide staff on the appropriate use of resources and are designed to ensure that our financial transactions are carried out in accordance with the law and with Government policy, through our Standing Orders, Standing Financial Instructions and Scheme of Delegation. In addition, there is a robust system for developing and routinely developing policies and procedures and staff are regularly updated and guided or trained on their application.

2025/26 Outturn

We ended the 2025/26 financial year with a deficit of £13.201 million against a planned £6.900 surplus. After statutory adjustments, a surplus for breakeven duty purposes was achieved of £2.226 million and the adjusted financial performance deficit was £4.739 million against a breakeven plan. The position was supported by non-recurrent measures, and we recognise the need to strengthen recurrent efficiency and cost control to support long-term financial sustainability. We have a range of key financial policies in place, which are designed to ensure that our financial transactions are carried out in accordance with the law and with Government policy in order to achieve probity, accuracy, economy, efficiency and effectiveness; these remained in place throughout the year. Our services are organised into 3 Care Groups, Corporate and Estates Divisions plus the North Staffordshire and Cheshire Pathology Network as a hosted function within UHNM's governance structure, these are managed through a devolved structure, which is governed by our Scheme of Delegation, defining all key roles and responsibilities. Each area has dedicated financial and human resources input to support delivery of their plans. We maintain a strong focus on performance management, as a means by which our services are held to account for the delivery of financial and other performance targets. Performance is monitored through our monthly performance management review process, which is chaired by an Executive Director.

Financial Assurance and Audit

During 2025/26, our Internal Auditors have reviewed our key financial systems and controls in relation to expenditure and concluded with 'reasonable assurance with minor improvements required'. A number of recommendations were made, which will remain a focus throughout 2026/27.

Our external auditors give an expert and independent opinion on whether our financial statements are a true and fair view of our financial position at the end of the financial year. They also provide an expert and independent opinion on whether the financial statements comply with relevant laws. In carrying out their audit, they must have regard to aspects of corporate governance and securing economy, efficiency and effective use of resources.

Cumulative Financial Position

Due to the continued cumulative deficit and the expectation that expenditure will exceed income for the foreseeable future, the External Auditors issued a Section 30 referral to the Secretary of State for Health on 28 May 2025. This follows earlier referrals in 2017 and 2021.

We recognise that this position is set within the context of a wider sustainability gap across the local health and social care economy. To address this challenge, work remains on-going with our system partners.

Financial Performance 2025/26

Key Performance Indicator	2025/26 Performance	2024/25 Performance
Total income (£'000)	1,271,227	1,292,878
Expenditure - pay (£'000)	849,092	787,322
Expenditure -non-pay (£'000)	515,057	484,501
Daycase / elective activity	125,899	125,108
Non-elective activity	102,777	130,452
First outpatients	307,913	316,711
Follow up outpatients	414,762	391,944
Non face to face outpatients	218,200	210,483

DRAFT

Statement of Comprehensive Income Account for the year ended 31 March 2026

	2025/26	2024/25
	£'000	£'000
Revenue from patient care activities	1,271,227	1,186,037
Other operating revenue	109,088	106,840
Total revenue	**1,380,315**	**1,292,878**
Operating expenses	(1,364,149)	(1,271,731)
Operating surplus	**16,166**	**21,147**
Other gains and losses	137	70
Surplus before interest	**16,303**	**21,217**
Investment revenue	5,185	6,054
Finance costs	(30,144)	(35,422)
Deficit for the financial year	**(8,656)**	**(8,151)**
Public dividend capital dividends payable	(4,545)	(3,530)
Retained deficit for the year	**(13,201)**	**(11,681)**

Performance against breakeven duty

	2025/26	2024/25
	£'000	£'000
Deficit for the period	(13,201)	(11,681)
Impairments not scoring to Department of Health limit	18,183	268
I&E impact of capital grants and donations	(2,756)	(4,293)
Impact of IFRS 16 on IFRIC 12 schemes	(6,965)	(2,442)
Net impact of DHSC provided inventories for Covid response	0	92
Adjusted financial performance surplus	**(4,739)**	**(18,056)**

Revenue Income

Income in 2025/26 totalled £1,380.3m. The majority of our income (£1,245.6m, 90%) was delivered from Integrated Care Boards and NHS England in relation to healthcare services provided to patients during the year. Other operating revenue relates to services provided to other Trusts, training and education and miscellaneous fees and charges.

Summary of Total Income

	2025/26	2024/25
	£m	£m
Integrated Care Boards and NHS England (patient care)	1,252.4	1,167.9
Other patient care income	18.8	18.1
Education, training and R&D income	48.3	47.0
Non patient care services to other NHS bodies	44.2	40.9
Other	16.6	19.071
Total revenue	**1,380.3**	**1,292.9**

Summary of Income from ICBs and NHSE

	2025/26		2024/25	
	£m	%	£m	%
Specialised commissioning / NHS England	191.7	15%	188.6	15%
Stafford & Stoke ICB	952.9	77%	883.6	70%
Cheshire ICB	48.9	4%	46.7	4%
Other	51.3	4%	152.3	12%
Total revenue from patient care	**1,244.8**	**100%**	**1,271.2**	**100%**

	2025/26	2024/25	% Change
	£m	£m	%
Revenue from patient care activities	**1,271.2**	**1,186.0**	**7%**
Other revenue:			
Medical school (SIFT)	8.9	8.6	4%
Junior doctor training (MADEL)	26.9	24.5	10%
WDD funding	1.9	6.8	(72%)
Research and development	3.8	3.2	19%
Non patient care services to other NHS bodies	44.2	36.1	22%
Other income	23.4	27.7	(16%)
Total other revenue	**109.1**	**106.9**	**2%**
Total revenue	**1380.3**	**1292.9**	**7%**


DRAFT

Operating Expenditure

Staff costs at £846.5m represent 62.1 per cent of our operating expenditure with clinical supplies and services non pay costs at £276.5m representing a further 20.3 per cent. A summary of operating expenditure is shown in the table below:

	2025/26	2024/25	% Change
	£m	£m	%
Staff costs	849.1	787.3	8%
Other costs	106.3	114.5	(7%)
Clinical supplies and services	276.5	260.8	6%
Depreciation	41.7	39.7	5%
Premises costs	43.7	43.2	1%
Clinical negligence	28.8	26.0	11%
Total operating expenditure before impairments	**1,345.9**	**1,271.4**	**6%**
Impairments	18.2	0.3	
Total operating expenditure	**1,364.1**	**1,271.7**	**7%**

The extract below summarises our finance and productivity performance under the NHS Oversight Framework:



Finance and productivity						Data period	Provider value		Chart
Finance and productivity domain segment						Q4 2025/26	3	NOF Score	
Finance and productivity domain score						Q4 2025/26	2.2	NOF Score	
Finance Please note that only the combined finance score contributes to the domain score	Data period	Provider value		Peer average	National value	National value method	Chart		
Combined finance score				Q4 2025/26	1	NOF Score	Provider value		
Planned surplus/deficit score				Q4 2025/26	1	NOF Score	Provider value		
Planned surplus/deficit	Q4 2025/26	0.00%		-0.48%	0.00%	Provider median			
Variance year-to-date to financial plan score				Q4 2025/26	2	NOF Score	Provider value		
Variance year-to-date to financial plan	Mar 2026	-0.34		-1.78	0.35	Provider median			
Productivity Please note: In Q1 2025/26, the implied productivity metric for ICBs applied only to acute trusts. This was later expanded to all trust types, so Q1 figures are not directly comparable with later quarters.	Data period	Provider value		Peer average	National value	National value method	Chart		
Implied productivity level score				Q4 2025/26	3	NOF Score	Provider value		
Implied productivity level	Dec 2025	0.58%		0.44%	2.57%	Provider median			

Capital

Of the capital funding in 2025/26, £19.3m was generated internally from the depreciation of assets and use of the Trust's cash reserves and this is predominantly allocated to the replacement of medical equipment, ICT systems and the refurbishment of the Trust's buildings and estate. In addition, the Trust was awarded central capital funding totalling £40.6m for a number of investments including the funding of imaging and diagnostic equipment, ICT projects including the development of an Electronic Patient Record system, developments at the County site, replacement boilers and continuing work on a Community Diagnostic Centre. The main areas of capital expenditure are as set out opposite:

	2025/26
	£'000
Medical Assets:	
CDC - equipment	2,517
Third surgical robot	1,989
CT scanner replacement	1,104
MRI scanner replacement	1,029
Spinal robot	840
Haemodialysis machines	756
Daycase theatre equipment	735
Other schemes under £500,000	6,206
Total medical assets	**15,175**
ICT Schemes:	
IT devices	1,515
Frontline digitalisation	1,478
LIMS	1,323
Digital pathology scanners	685
Printing lease replacement	593
Other schemes under £500,000	1,666
Total ICT schemes	**7,260**
Estates and General Works:	
Community Diagnostic Centre (CDC)	22,738
Breast unit	9,459
IFRS16 adjustments	2,501
Stoke and County UTC	2,259
Stoke LTHW remediation	968
150 acella baxter beds	758
Chiller replacement	757
High voltage upgrade - RS	660
Other schemes under £500,000	6,096
Total Estates and PFI schemes	**46,194**
PFI	
PFI MES	3,736
PFI lifecycle	2,474
Total PFI	**6,210**
Total	**74,839**

DRAFT

Risk profile

As part of the Board Assurance Framework, key strategic risks are identified and linked to our three Strategic Priorities as part of our strategy, 'The best joined-up care for *all*'.

Our risk profile during 2025/26 reflected sustained operational, financial and system pressures across the Trust. Throughout the year, the Board Assurance Framework comprised eight strategic risks that, in combination, could affect delivery of our strategic priorities. By year end, these included two risks rated as Extreme (financial sustainability at 25 and responsive patient care at 20), one risk rated at 16 (digital transformation), one risk rated at 15 (workforce sustainability) and four risks rated at 12, relating to population health, estate infrastructure, research and innovation. The highest-scoring risks related to our ability to deliver responsive patient care, particularly within urgent and emergency care pathways, and to achieve sustainable financial recovery.

These risks had a direct impact on performance and delivery during the year. Sustained pressures across urgent and emergency care, elective recovery, workforce capacity, digital resilience and medium-term financial sustainability constrained progress against national standards and slowed delivery of some planned transformation. In response, we prioritised patient safety, operational resilience and financial grip and control where required, particularly during periods of peak demand.

A range of mitigating actions were implemented during 2025/26, including formal recovery programmes, strengthened Executive and Board oversight, enhanced system working, tighter financial controls, and targeted workforce interventions. While these actions reduced immediate likelihood and consequence in-year, many relied on short-term or resource-intensive measures and did not yet provide sufficient assurance of sustained risk reduction. This reinforced the need for continued focus on structural solutions, including workforce sustainability, digital and cyber resilience, estate investment and large-scale service redesign.

By the end of the year, the risk to delivering the in-year financial position had reduced to its target score of 9, reflecting improved grip and control and delivery of the agreed 2025/26 revenue plan. However, the risk to financial sustainability remained Extreme at 25, reflecting reliance on non-recurrent measures, the scale of the recurrent efficiency challenge and the need for sustained multi-year transformation. Risks relating to responsive patient care and digital transformation also remained above target. The risk relating to population health remained unchanged at 10, reflecting early progress but the need for sustained delivery at scale.

The year also saw continued emergence and escalation of interdependencies across risks, including increased reliance on digital systems, cyber resilience, regulatory and information governance requirements, specialist workforce pressures and the interaction between operational performance and financial sustainability. These risks were actively monitored through the Board Assurance Framework and operational risk registers.

Looking ahead, persistent demand pressures, workforce constraints, financial limitations and dependencies on digital and estate infrastructure may continue to limit the pace of improvement if not addressed through sustained, long-term solutions. We will therefore continue to prioritise proactive risk management, focused on reducing underlying risk exposure rather than reliance on short-term mitigations. The principal risks set out in page 18 and within the Annual Governance Statement (pages 59-67) remain appropriate and will be reviewed for 2026/27. We continue to apply our Risk Appetite Statement, as part of the Risk Management Policy, to guide decision-making and support a balanced approach to managing risk while delivering strategic objectives.



DRAFT

Social matters and human rights

We have continued to strengthen our commitment to social value and human rights, placing the wellbeing, dignity and rights of our people, patients and population at the heart of everything we do.

Social Matters

Workforce Experience, Inclusion, Culture and Wellbeing
During 2025/26, progress has been made in delivering agreed priorities relating to workforce experience, inclusion, culture and wellbeing. This included strengthened engagement with employee networks, continued oversight of Freedom to Speak Up arrangements, and further opportunities for colleagues to influence organisational development through formal engagement routes. There has also been a sustained focus on colleague health and wellbeing and maintaining openness during a period of significant operational pressure.

Across the year, employee-focused communications and engagement activity supported transparency around organisational change and shared learning from employee feedback, including early engagement with NHS Staff Survey themes ahead of formal publication. Awareness-raising activity linked to recognised campaigns, including Race Equality Week, LGBT History Month and National Apprenticeship Week, was progressed and supported through committee oversight. Together, these activities reflect our continued commitment to fostering an inclusive, positive and respectful working environment.

Recognising sustained operational pressures during 2025/26, we prioritised wellbeing through coordinated mental, physical and psychological support arrangements. A Health and Wellbeing Action Plan for 2025/26 has been developed, supported by improved triangulation of wellbeing data, including sickness absence trends, employee feedback and usage of support services. This enabled a more targeted approach to support for services and groups experiencing heightened pressure.

Support available during the year included access to Staff Support and Counselling services, Occupational Health, Staff Physiotherapy, and pastoral support for colleagues involved in formal people processes. Targeted wellbeing interventions for high-pressure services were put in place, including urgent and emergency care and critical care. There has also been progress in rolling out evidence-based approaches such as Stress First Aid, Critical Incident Stress Management (CISM) and RESPOND training, alongside wellbeing events, drop-in support and leadership coaching to strengthen psychological safety.

Progress was also made during the year to address physical working environments and “brilliant basics”, including rest space provision, hydration and access to appropriate facilities, recognising their contribution to colleague wellbeing. Work also remained ongoing on sexual safety, violence and aggression, smoking cessation and health promotion, reinforcing our focus on maintaining safe and supportive workplaces.

Supporting Equality and Tackling Health Inequalities
Work on social matters during 2025/26 aligned with statutory duties under the Equality Act 2010 and our commitment to reducing inequalities in workforce experience. Wellbeing and support arrangements were delivered in an inclusive manner, with targeted interventions reported to address differing needs across employee groups and services. Further detail on Equality Act responsibilities, including workforce policies, reasonable adjustments and equality of service delivery, is set out within the Equality, Diversity and Inclusion section of this report.

Community Engagement and Social Partnership Working
During the year, we continued to contribute to social value through engagement with local partners. This included collaboration with local colleges to support T-Level students, strengthening education pathways and future workforce capacity. This activity supports our wider role as an anchor organisation within its local community.

Human Rights

Throughout 2025/26, we upheld our responsibilities under the Human Rights Act 1998, with human rights principles embedded within policies, procedures and day-to-day practice. We continued to apply the FREDA principles—Fairness, Respect, Equality, Dignity and Autonomy—to inform policy development, organisational decision-making and Quality Impact Assessments during the year. These arrangements support an environment in which colleagues feel able to raise concerns, are treated with respect, and are supported during periods of organisational pressure.

DRAFT

Anti corruption and anti bribery

We are committed to maintaining the highest standards of honesty, integrity and accountability in all areas of our work. As a public body, we have a duty to safeguard public resources and ensure that our systems, processes and culture actively prevent fraud, bribery and corruption.

DRAFT

We have a clear and firmly embedded zero-tolerance approach to fraud, bribery and corruption, and we remain committed to taking all necessary steps to prevent, detect and respond to any such activity. This commitment underpins our responsibility to maintain an honest, transparent and open organisational culture, enabling us to fulfil our objectives and uphold the wider expectations of the NHS.

As part of this commitment, we continue to adhere to the NHS Counter Fraud Authority (NHSCFA) Standards for Providers, alongside the full suite of national directions, procedures and the NHSCFA Anti-Fraud Manual. These standards inform our local policies, training and assurance processes, ensuring that our counter-fraud arrangements remain robust and aligned with national expectations.

All allegations or suspicions of fraud, bribery or corruption are assessed and investigated proportionately, with appropriate action taken in line with Trust policy and relevant legislation. This includes, where appropriate, disciplinary action, pursuit of financial recovery and referral for criminal investigation.
We maintain a number of established policies to support strong internal controls and prevent fraud or corruption, including the:

- Standards of Business Conduct.
- Standing Financial Instructions.
- Anti-Bribery and Anti-Fraud.
- Scheme of Reservation and Delegation.

These policies reinforce expected standards of behaviour, clarify responsibilities, and provide clear routes for raising concerns.

We have an appointed Local Counter Fraud Specialist (LCFS) who provides expert advice on all fraud-related matters and acts as the primary point of contact for reporting concerns. The LCFS undertakes both proactive and reactive work, including awareness-raising, investigations and targeted thematic reviews. Regular counter-fraud reports are provided to the Audit Committee, ensuring appropriate oversight and scrutiny. The LCFS service is provided by RSM UK Risk Assurance Services LLP and operates independently of the internal audit function.

The Chief Finance Officer is the Trust's Accountable Officer for Anti-Fraud and is responsible for ensuring effective counter-fraud arrangements are in place. During 2025/26, 25 referrals were made to the LCFS; each was reviewed and investigated in line with Trust policy.

The LCFS workplan for 2025/26, including a comprehensive fraud risk assessment, was aligned to Government Functional Standards and was formally approved by the Audit Committee. Oversight of this programme supports the identification and mitigation of emerging fraud risks, ensures learning is embedded, and helps maintain a responsive and proportionate counter-fraud approach.

During the year, we also undertook a gap analysis to assess readiness for the requirements introduced under the Economic Crime and Corporate Transparency Act (ECCTA). This work included reviewing existing controls, policies and assurance arrangements relating to fraud prevention and detection. Areas for further strengthening were identified, and an action plan has been established, supported by the LCFS and internal auditors, to address these gaps and enhance organisational awareness of the expanded legislative obligations. This work forms part of our broader commitment to robust financial stewardship, protection of public funds, and upholding the highest standards of accountability and transparency.

Equality of service delivery

As a public sector organisation, we are required to demonstrate how we meet the Public Sector Equality Duty as outlined in section 149 of the Equality Act 2010.

As a public sector organisation, we are required to demonstrate compliance with the Public Sector Equality Duty (PSED) under section 149 of the Equality Act 2010. Our approach is guided by our Equality, Diversity and Inclusion (EDI) Strategy and our refreshed 2025–2035 organisational strategy, both of which reaffirm our commitment to equitable access, inclusive service design and targeted action to reduce health inequalities.

We continue to prioritise equality of access and outcomes for Our Patients, Our People and Our Population. Equality Impact Assessments (EIAs) are undertaken for all proposed service changes to identify and mitigate any disproportionate effects on protected or underserved groups. These are complemented by Quality Impact Assessments to ensure that service developments promote fairness, safety and improved outcomes.

Inclusive patient feedback mechanisms ensure that service redesign is informed by diverse lived experiences. Engagement is strengthened through our Lived Experience Champions and our Patient Involvement and Engagement Coordinator, who work with service-specific groups and undertake targeted outreach with under-represented communities to ensure services reflect the needs, preferences and experiences of the people we serve.

We work closely with community, advocacy and voluntary sector partners to identify local health challenges, remove barriers to accessing care and reduce inequalities in patient experience and outcomes. This partnership approach helps identify structural barriers and informs targeted improvement activity across clinical and non-clinical services.

Our statutory obligations are met through publication of the annual EDI Report, Workforce Race Equality Standard (WRES), Workforce Disability Equality Standard (WDES), and Gender Pay Gap reports. These datasets provide transparency on access, experience and outcomes, and enable use to demonstrate due regard to eliminating discrimination, advancing equality and fostering good relations in line with the PSED.

We also meet our legal duty to have due regard to the Armed Forces Covenant. Our accreditation from the Veterans Covenant Healthcare Alliance reflects our commitment to ensuring that serving personnel, veterans and their families do not face disadvantage when accessing services.



DRAFT

Customer satisfaction scores

The National Adult Inpatient Survey has been an annual requirement since 2002 by the Care Quality Commission, which looks at the experiences of adults that have been an inpatient with us.

We use national patient surveys to obtain detailed feedback on the standards of service and care experienced by patients. This feedback supports the identification of priorities for improvement and provides a key source of intelligence used by the Care Quality Commission (CQC) to measure, monitor and inform their inspection activity.

The most recent CQC Adult Inpatient Survey was published in 2025 and relates to the experiences of patients discharged from UHNM in November 2024. Fieldwork took place between January and April 2025, with responses received from 511 patients. A report on the findings was considered by the Quality Access and Outcomes Committee in February 2025, and the full benchmark report is publicly available on the CQC website.

Survey Participation and Respondent Profile

We achieved a 42% response rate, in line with the national average, and an increase from the previous year, providing a robust basis for understanding inpatient experience across Trust services.

The demographic profile of respondents, was as follows:

- 95% were White, 2% were Asian or Asian British, and 2% were not known.
- 49% were male and 51% were female.
- 83% of respondents reported having a physical or mental health condition, disability or illness lasting, or expected to last, 12 months or more.

Equality and Protected Characteristics

While the survey collects demographic information to support interpretation of results, the CQC benchmark report does not provide statistically reliable breakdowns of experience scores by protected characteristic. As such, conclusions regarding differences in experience by ethnicity, sex, disability or other protected groups cannot be drawn from the national survey alone.

To address this, we triangulate national survey findings with other sources of patient experience intelligence, including complaints, PALS contacts, local surveys and targeted engagement activity. This approach supports the identification of any potential inequalities in experience and informs proportionate, targeted improvement actions.

Key Findings

Overall, the survey demonstrated that patients continued to report positive experiences of care. Performance was stable overall, with improvements seen in a number of key areas, and we did not score worse than expected in any question compared with other trusts or the previous survey.

Key areas of strength identified through the survey included:

- Respect, dignity and privacy.
- Kindness and compassion demonstrated by colleagues.
- Communication with doctors and nurses, including being listened to and receiving clear explanations.
- Consideration of patients' individual needs, including language and religious or cultural requirements.

Consistent improvements over the previous two years were particularly noted in communication from nursing employees, supported by our focus on health literacy within employee induction and training programmes.

The survey also identified areas where experience scores, while improving, remain relatively lower and continue to be a focus for improvement. These include aspects of involvement of patients, families and carers in discharge planning, and the clarity and consistency of information provided at discharge, including information about medicines. Free-text comments submitted as part of the survey broadly reinforced the quantitative findings, with many patients highlighting the professionalism, commitment and compassion of Trust colleagues.

Using Patient Feedback to Drive Improvement

We have plans in place to continuously improve the experience of all patients, aligned with refreshed quality priorities. Actions arising from the Adult Inpatient Survey are monitored through regular reporting to the Quality, Access and Outcomes Committee, alongside other patient experience and quality metrics. We remain committed to using patient feedback to inform service improvement, ensuring that learning from national and local sources supports safer, more responsive and more equitable care for all patients.

DRAFT

Environmental matters

Climate change poses a major threat to our health as well as our planet. The environment is changing, that change is accelerating, and this has direct and immediate consequences for our patients, our population and the NHS.

We recognise that climate change poses a major risk to the health of the population directly through heatwaves, flooding, air pollution and disease and indirectly through threatening NHS infrastructure and its ability to maintain service continuity, employee safety, and patient care.

Healthcare provision contributes a significant amount of greenhouse gas emissions; approximately 5% of the UK's carbon footprint is directly related to the NHS. In 2022 the NHS announced targets to become the world's first carbon neutral healthcare service by 2045, and the Delivering a Net Zero National Health Service report is now issued as statutory guidance.

Looking after our environment has many benefits for health and wellbeing, through cleaner air, improved access to green spaces, healthier food as well as the ability to protect vulnerable members of the community from the effects of extreme weather. Therefore, we are fully committed to supporting the NHS ambition to be a Net Zero health service.

Task Force on Climate Related Financial Disclosures (TCFD)

The TCFD is a global framework to help organisations disclose climate-related risks and opportunities. It provides positive assurance that NHS Trusts will strengthen governance, risk assessment processes, and long-term planning by embedding climate-related risks into existing oversight and decision-making structures. This includes demonstrating clear Board-level oversight, integration of climate risk into existing risk management processes, and alignment with wider sustainability commitments set out in our Green Plan.

For 2025/26 we have reported against the TCFD pillars on a 'comply or explain' basis. We are fully compliant with the Governance and Metrics & Targets requirements. Work is underway to implement formal processes for climate-related risk identification, assessment and management; therefore, full compliance with the Risk Management pillar will be achieved from 2026/27. In addition, disclosures in the Strategy pillar will be strengthened once the new risk assessment framework is fully embedded.


TCFD Pillar 1: Governance

Sustainability Performance and Risk Management Oversight

In October 2025, we published our refreshed Green Plan which covers 2025/26-2028/29. The Green Plan sets out the actions we have agreed to achieve our Net Zero targets, and how we will measure and report on these.

We have the following established programme of sustainability reporting, which monitors delivery of the Green Plan, risks and trajectory toward achieving Net Zero Carbon by 2040:

- Monthly operational Sustainability Working Groups (Energy and Water, Procurement, Travel and Transport and Waste).
- Monthly reporting to the Estates, Facilities and PFI Services Board.
- Bi-annual performance reporting to the Trust Sustainable Development Steering Group.
- Bi-annual performance reporting to the Finance and Business Performance Committee.



We recognise that we cannot deliver a Net Zero Carbon zero health service without support and collaboration across the NHS and with partner organisations.

DRAFT

The Sustainability team support the work of the Staffordshire and Stoke-on-Trent ICS Sustainability Programme Board and the delivery of the ICS Green Plan which comprises national, regional and local priorities. The bi-monthly ICS 'Greener Delivery Group' which comprises attendance from each member organisation.

The structure and terms of reference of the Sustainable Development Steering Group (SDSG) is being updated to strengthen accountability and senior decision-making, with the Group being split into a Strategic SDSG (chaired by the Executive Lead for Net Zero and attended by executive level clinical and operational decision-makers) and a quarterly Operational SDSG. The revised SDSG structure to be implemented at the start of 2026/27 aims to:

- Strengthen leadership and oversight of delivery of Net Zero targets and Green Plan objectives.
- Formally set strategic direction, approve priorities, policies and major business cases, and ensure appropriate resourcing.
- Provide a framework for effective evaluation of risks, particularly relating to climate change and the attainment of net zero targets.
- Track outcomes, risks and escalations, removing structural blockers where required.

The revised structure will ensure we comply with the TCFD requirement to ensure climate-related risks are identified, monitored and escalated to Trust Board. Climate related risks will be included within the bi-annual Sustainability report and embedded into the risk register.

Sustainability Roles and Responsibilities

We have a Board Level Net Zero Executive Lead (Lorraine Whitehead) and a Net Zero Clinical Lead (Dr Andrew Bennett, Specialty Doctor in Emergency Medicine).

We also have a dedicated Transformation and Sustainability team that is in place to specifically assess and manage sustainability and climate related issues. The team lead the monthly operational Sustainability Working Groups and develop initiatives, in partnership with stakeholders, that respond to areas where focus is required to improve sustainability performance and mitigate risks. The team provide all required sustainability performance reporting, in line with Trust governance outlined above.

TCFD Pillar 2: Risk Management

We do not currently have a formal process for identifying, assessing or managing climate-related risks, however there are plans to address this in 2026/27 so that we will be compliant with the requirements to disclose robust risk management processes in future reporting periods.

This means ensuring that climate related risks, such as heatwave related disruptions, energy cost volatility, and infrastructure resilience, are assessed using robust, evidence-based methodologies. Green Plans must be refreshed every three years and aligned with TCFD expectations, providing a clear roadmap for carbon reduction and climate adaptation. Strengthening internal capability to report on relevant emissions and risk exposures will be essential to achieving full compliance.

We also operate a Severe Weather Policy, led by the Emergency Preparedness, Resilience and Response (EPRR) team, which defines organisational responsibilities, escalation pathways and operational triggers during periods of adverse weather. This policy forms a core element of our business continuity arrangements and aligns with wider system governance through the Local Resilience Forum.

As this work progresses, engagement with EPRR will be essential to ensure that climate related risks, operational dependencies and weather-related service pressures are fully reflected within emergency planning and continuity frameworks.

As part of this work, we are also collaborating closely with the wider ICS and system partners to develop a coordinated system level response to TCFD, ensuring that climate related risk assessment, governance expectations, and reporting processes are aligned across organisations.

TCFD Pillar 3: Strategy

Climate change poses a major threat to our health as well as our planet. The environment is changing, that change is accelerating, and this has direct and immediate consequences for our patients, our services and our population. We recognise climate change as a risk to operational service delivery and that it also poses significant financial risk.

We are currently going through the process of identifying and quantifying material climate change risks so that they can be managed and reported through the formal Trust Risk Management procedure.


TCFD Pillar 4: Metrics and Targets

National Net Zero Target

The national target set by NHS England is for all NHS Trusts to achieve Net Zero by 2040 for emissions that we directly control, with an ambition for an 80% reduction (compared with a 1990 baseline) by 2028 to 2032. These include emissions from our buildings, energy and water usage, anaesthetic gases, waste and business travel and are known as 'Scope 1 and 2'.

DRAFT

Our trajectory against our NZC target is provided below:



The main carbon savings will be delivered by:

- Estates decarbonisation through the Public Sector Decarbonisation Scheme (PSDS) delivered in 2024/25: Reducing annual emissions by 941 tCO2e.
- Expansion of solar panelling across the Trust: Reducing annual emissions by 296 tCO2e.
- Potential connection to the Stoke-on-Trent District Heat Network: Reducing annual emissions by 3,298 tCO2e in 2030/31 and 5,433 in 2031/32 and 8,731 tCO2e in subsequent years.
- Decommissioning nitrous oxide piped supply: Reducing annual emissions by 350 tCO2e.

Our Green Plan targets

Our obligations to deliver the national Net Zero Carbon targets and related deliverables set out in the NHS Standard Contract (Service Condition 18: Green NHS and Sustainability) are outlined in our Green Plan. Actions to achieve these requirements, along with the regional target to reduce emissions from anaesthetic gases and further internal targets, are also detailed in the Green Plan. Additionally, data is routinely reported through the National Greener NHS Dashboard and the annual Estates Return Information Collection (ERIC).

Progress against all targets is reported monthly to the Estates, Facilities and PFI Board and biannually to the SDSG and the Finance and Business Performance Committee.

2025/26 Highlights

Our Net Zero Carbon Vision: Our Sustainable Future

During 2025/26, we refreshed our Green Plan for 2025/26 - 2028/29, setting out our next three-year strategic approach to achieving Net Zero Carbon and building climate resilient healthcare services. The plan was developed with strong clinical and operational stakeholder engagement with input from Local Authority and Keele University partners.


The new Green Plan strengthens ambitions and places greater emphasis on:


- Clinical transformation.
- Colleague development and sustainability training.
- Digital innovation as an enabler of low-carbon care.
- Strengthening organisational climate resilience.
- Embedding carbon reduction into everyday decision-making.

Low Carbon Care Framework: Inspiring Sustainability in Care

Launched in September 2025, the Low Carbon Care Framework (LCCF) plays a pivotal role in engaging a wider range of colleagues on sustainability and climate change. It supports colleagues to take practical, evidence-based action to make small but meaningful changes that improve sustainability, reduce waste and support high quality patient care across clinical and non-clinical services. The LCCF sets out three achievement levels, Bronze, Silver and Gold. It has been very well received and participation is growing, with 28 teams currently involved. These teams are progressing through evidence submission and independent audits.

A 'Green' Award has been added to the 2026 annual Staff Awards to recognise and celebrate teams and individuals who have gone above and beyond to embed sustainability into their working practice. Some recent clinical case studies are listed below:





DRAFT

Accessing UHNM: Greener Travel

February 2026 saw the completion of the Travel Survey, launched as part of the development of new site-wide Travel Plans. The surveys are critical to understanding colleague travel needs, barriers and ensuring that future investment is informed by meaningful colleague engagement.

The new Travel Plans will set out a structured approach to improving sustainable travel options across both Royal Stoke and County Hospital, such as improved cycling infrastructure, enhancements to public transport connectivity, car share support, EV charging expansion, and other sustainable commuting initiatives. Each scheme will undergo site wide feasibility assessment to understand operational impacts, demand, costs, carbon benefits and alignment with wider Trust infrastructure plans. To ensure the Travel Plans integrate with regional and national direction, development work will also consider the wider transport landscape including:

- Local Authority Bus Service Improvement Plans (BSIPs).
- County and City Council Electric Vehicle Infrastructure Strategies.
- ICS active travel and mobility initiatives.
- Regional strategic transport and decarbonisation plans.


Taking this coordinated approach ensures that we prioritise investment where it will have the greatest environmental, social, operational and financial benefit, while supporting a healthier, more accessible and more sustainable commute for employees.

Achieving Net Zero Carbon: Investment

We recognise that the net zero agenda must be prioritised and resourced if it is to succeed. In addition, efforts to mitigate and adapt to climate change also produce opportunities such as resource efficiency and cost savings. In 2025/26 significant investment was put into reducing cost and carbon emissions related to energy use.

- £26k was spent on replacing faulty and end of life heat meters as part of a wider sub metering project, ensuring accurate energy monitoring and supporting ongoing work to reduce energy consumption and carbon emissions.
- £110k was used to fund detailed design works for optimisation of the Heat Network at Royal Stoke. The optimisation works will deliver a step-change in system efficiency and enable connection to the proposed city-wide District Energy Network (DEN). Once these works are complete energy costs will be reduced by around £260k per year and carbon dioxide equivalent emissions will be reduced by around 9,150 tonnes of through the lifetime of the equipment.

Public Sector Decarbonisation Scheme (PSDS)



2025/26 saw the successful completion of a major heat and energy decarbonisation scheme at Royal Stoke Hospital. Overall, £6.8m investment was put into Air Source Heat Pumps, LED lighting and Solar PV panels across the estate to reduce direct CO2 emissions from our buildings. £5.4m was awarded through the Department for Energy Security and Net Zero (DESNZ) Public Sector Decarbonisation Scheme, with the Trust contributing a further £1.38m.

Overall Impact:

- Year 1: reduction of 91 tonnes CO2 equivalent emissions (tCO2e).
- Year 2: expected reduction of 723 tCO2e.
- Ongoing annual reduction of 941 tCO2e.
- Replacement of end-of-life boilers (backlog improvement).
- Major site risks removed (steam distribution).

LED Rollout

Our 5-year lighting upgrade programme continues across both sites, replacing outdated lighting with energy efficient LEDs. It is delivering reduced electricity consumption, reduced carbon emissions, financial benefits and creating brighter, safer spaces for patients and colleagues. This scheme demonstrates how small changes across the estate can make a big impact.

District Energy Network (DEN)

Stoke on Trent is building a new heating network that will deliver cleaner and cheaper heat and hot water to buildings through insulated underground pipes. This new system could reduce carbon emissions by up to 75% in places that connect to it. The City Council has partnered with SSE Energy Solutions to develop this network as part of a wider plan to make the city greener and more energy efficient. We are currently undertaking a robust due-diligence exercise regarding the connectivity of Royal Stoke University Hospital to the network.

Together that City Council and SSE have agreed to work on projects that help Stoke on Trent move towards net zero, such as exploring more renewable power from solar and wind, developing new low carbon heat solutions, and even looking at more electric vehicle charging points around the city. Nationally, heat networks are expected to play a major role in decarbonising heating.

DRAFT

Energy Procurement Partnership

We are now beginning engagement with Stoke on Trent City Council and the EIC Partnership to potentially extend our existing energy contracts by a further year or negotiate new contracts from April 2027. This early engagement aims to ensure continuity of value, support long term energy resilience, and explore opportunities for locally produced sustainable energy to be delivered to our sites.

Achieving Net Zero Carbon: Reducing Harmful Gas Emissions

Nitrous Oxide

Nitrous oxide (N2O) is a potent greenhouse gas, almost 300 times more harmful than carbon dioxide. It is traditionally delivered via a piped supply, however 70-95% of gas is lost within the pipeline system. 2025/26 saw the successful delivery of NHS England grant funding, awarded to significantly reduce N2O emissions across the Trust.

In a major transformational project seeing collaboration between clinical and operational colleagues across the Trust all clinical areas have fully switched to using small portable cylinders for pure N2O, allowing the pipeline systems to be decommissioned. This is estimated to save approximately 350 tonnes CO2 equivalent emissions per annum.

Penthrox

Penthrox, also known as the 'Green Whistle' which has a carbon impact of 117.7 times less than Entonox is now routinely used in both Emergency Departments as pain relief for most manipulations in patients attending with dislocations and minor fractures. We have become one of the first Trusts to expand the use of Penthrox in children aged 5 and over, following licencing of this drug for use in this age group.

We are also aligned with the regional ambition to reduce anaesthetic gas emissions by 19% for pure Nitrous Oxide and 5% for Entonox compared to 2024/25 levels, demonstrating its commitment to collaborative sustainability across the NHS.

UHNM Community Energy Scheme: Keep Warm, Keep Well



Fuel poverty remains a major issue in Staffordshire, particularly in Stoke-on-Trent, where more than half of residents live in the most deprived areas nationally.

The longstanding Keep Warm, Keep Well (KWKW) scheme delivered in partnership between UHNM and Staffordshire Community Energy and Staffordshire fuel poverty charity 'Beat the Cold' demonstrates how an innovative partnership between health, community energy and third sector can improve the health outcomes of those affected. KWKW works by surplus income from Staffordshire Community Energy's community-owned solar panels hosted in our buildings being ringfenced to fund local fuel poverty support, delivered by Beat the Cold.

KWKW has been in in operation for 9 years, and in February 2026 a significant development of the scheme was launched. Face to face patient referrals have now been replaced by the One Health and Care digital shared care record to proactively identify and refer a clinical patient cohort who are known to reside in fuel poverty and deprivation across Staffordshire and Stoke on Trent. It is hoped that this approach will strengthen the outcomes of the scheme, preventing the exacerbation of conditions and emergency hospital admissions as a consequence of residing in a cold, damp home.



DRAFT

Emergency preparedness, resilience and response (EPRR)

We are required to respond to business continuity, critical and major incidents arising from a range of causes. We maintain comprehensive plans to ensure that critical functions can continue to be delivered during incidents and emergencies, in line with the NHS Emergency Preparedness, Resilience and Response (EPRR) framework.

We operate in a complex and evolving risk environment, including failures of utilities or information technology, severe weather, system-wide capacity pressures, major incidents involving large numbers of casualties, hazardous materials incidents and new and emerging infectious diseases. As an acute provider, we are a Category 1 responder under the Civil Contingencies Act 2004, with statutory duties under the Health and Social Care Act 2022 and the NHS England EPRR Framework 2023.

Our responsibilities include assessing emergency risks, maintaining emergency and business continuity plans, ensuring effective arrangements to warn and inform the public, and working closely with partner organisations to support coordinated responses.

EPRR assurance 2025/26

Compliance with these duties is assessed annually through the NHS England EPRR Core Standards Assurance process, as assessed below:

Full compliance	Fully compliant against 100% of the relevant EPRR core standards (62 out of 62)
Substantial compliance	Fully compliant against 89-99% of the relevant EPRR core standards (55 – 61 out of 62)
Partial compliance	Fully compliant against 77-88% of the relevant EPRR core standards (47 – 54 out of 62)
Non-Compliance	Fully compliant against up to 76% of the relevant EPRR core standards (46 or less, out of 62)

During 2025/26, we completed a comprehensive self-assessment against 62 EPRR Core Standards and self-declared as 'Partially Compliant', achieving 49 out of 62 Core Standards (79%), representing a modest improvement on the previous year and reflecting strengthened assurance and reduced challenge from system partners.

Areas of partial compliance relate primarily to complex system-dependent requirements, including aspects of business continuity management, pandemic planning, mass casualty arrangements and on-call resilience, with action plans in place for further improvement.

Training, exercising and incidents

A comprehensive programme of training and exercising has been delivered throughout the year in line with NHS England Minimum Occupational Standards, including training for strategic and tactical on-call managers, business continuity impact analysis training, specialist legal training and the continued development of trained loggists. We have also participated in a range of multi-agency and live exercises, including HazMat and CBRN scenarios.

During 2025/26, we responded to a range of critical incidents and business continuity challenges, including severe capacity pressures, IT outages, infrastructure failures, severe weather events, fire and flooding incidents and hazardous materials-related risks. Effective command and coordination arrangements were maintained throughout, working closely with system partners to minimise disruption and maintain patient safety.

We remain committed to continuous improvement in emergency preparedness, resilience and response, supported by ongoing Board oversight and assurance.

Clarification of prior year reporting

Our 2024/25 Annual Report stated that our EPRR Core Standards position had been independently validated by the ICB and NHS England. It should be noted that this wording was inaccurate, as the annual confirm and challenge process with system partners had not yet formally concluded. While we had completed our self-assessment and were progressing through the assurance process at the time, the final agreed position had not been confirmed at that the point of writing the Annual Report.

DRAFT

Any important events since year end

There were no events after the reporting period that require disclosure.

DRAFT

Dr Simon Constable
Chief Executive
DATE



2 Accountability Report

DRAFT

Corporate Governance Report

Setting out how the Trust Board provides leadership, oversight and assurance to support effective governance, accountability and decision-making.

DRAFT

Directors report

Between 1 April 2025 and 31 March 2026, there were 15 meetings of the Board. In compliance with the requirements of the Health and Social Care Act 2012, the Board holds part of its meetings in public, followed by a private business session.

Meetings of the Board

Meetings of the Board are held bi-monthly, with separate Board development sessions held periodically throughout the year. Agendas for each meeting are set in line with agreed business cycles and discussed with the Chair. Where possible, Board meetings take place in person. Guest speakers and members of the public are able to attend either in person or via Microsoft Teams, supporting transparency, accessibility and public accountability.

Role of the Board and Decision-Making Responsibilities

The Board has overall responsibility for the strategic direction, leadership and control of the Trust. Its role is to set strategy, establish our values and culture, oversee organisational performance and ensure accountability to stakeholders in an open and effective manner. The Board is responsible for setting our strategy and objectives; overseeing quality, performance, finance and risk; maintaining effective systems of governance and internal control; appointing and appraising the Chief Executive; and ensuring compliance with statutory, regulatory and constitutional requirements.

To support effective decision-making and assurance, the Board operates in accordance with a Scheme of Reservation and Delegation, which clearly sets out:

- Matters reserved to the Board, including strategy, annual plans, budgets, major capital investment, and key governance and risk decisions.
- Matters delegated to Board committees for detailed scrutiny and assurance.
- Matters delegated to the executive management team for day-to-day operational management.

Board Committees and Executive Delegation

During 2025/26, a number of committees were in place to support the Board in discharging its responsibilities (page 48). Each committee operates under formally approved Terms of Reference, is chaired by a Non-Executive Director (with the exception of the Nominations and Remuneration Committee, which is chaired by the Trust Chair), and provides regular assurance reports to the Board. Terms of Reference set attendance rules for each Committee, including those invited to attend.

The Board delegates responsibility for the day-to-day management and operational delivery to the Chief Executive and Executive Directors. Executive management is accountable to the Board for performance and delivery within the parameters set by the Board and its committees.

Board Composition, Balance and Independence

The composition of the Board is reviewed periodically, and whenever vacancies arise, to ensure that it remains balanced, complete and appropriate to our size, complexity and strategic challenges. The Board comprises a mix of Executive and Non-Executive Directors, as determined by our Establishment Order, bringing together a broad range of skills, experience and professional backgrounds to support effective leadership and decision-making.

The Board considers its Non-Executive Directors to be independent in character and judgement. Independence is assessed with reference to the NHS Code of Governance and includes consideration of the absence of any material business or financial relationship with the Trust, independence from our day-to-day management and the ability to provide objective challenge and scrutiny. During the year, all serving Non-Executive Directors were considered by the Board to meet these independence criteria.

Board Effectiveness Evaluation

During the year, we undertook an annual evaluation of Board effectiveness, supported by the Deputy Director of Governance. The evaluation was conducted internally and included Board self-assessment questionnaires, and collective reflection on Board effectiveness. No external evaluator was appointed during the year and, as such, there was no external contact with the Board, its Committees or individual Directors as part of the evaluation process.

The evaluation confirmed strong levels of engagement, constructive challenge and effective working relationships between Executive and Non-Executive Directors, while also identifying areas for continued development. Actions arising have been incorporated into the Board development programme, including a continued focus on strategic discussion, succession planning and skills mix.

DRAFT

Committees of the Board - Attendance

In line with the Code of Governance, this section sets out the number of meetings held by the Trust Board and its Committees during the year, together with director attendance.

Member	Trust Board (Private) (n=15)	Trust Board Public (n=6)	Audit (n=5)	Finance & Business Performance (n=13)	Nomination & Remuneration (n=9)	People, Culture & Inclusion (n=6)	Quality, Access & Outcomes (n=13)
Jackie Small, Chair	⦸⦸●●●○●●●●○●●●●	⦸●●●○●	N/A	N/A	⦸●●●●●●●	N/A	N/A
Louise Bainbridge, Non-Executive Director	●●●●○○○○●●○○●○	●●●○●●	⦸⦸⦸●●	●●●●●●●●●●●●	○○○○○●●○○	⦸●●●●⦸	N/A
Tanya Bowen, Non-Executive Director	●●●○●●●●●●●●●●	●●●●●●	●●●●●	●●●●●●●●●●●●	●●●○●●●●○	N/A	N/A
Prof Katie Maddock, Non-Executive Director	●●○●●○○●●●○○●●	●○●●●●	⦸⦸⦸⦸●	N/A	○○○○○○○○○	●●●●●●	●●●●●○○●●●●●●
Margaret Monckton, Non-Executive Director	●○●○●●●○○●●●○●●	●○●●●○	●●●●●	●●●●●●●●●●●●	●●●○●●●○○●	N/A	N/A
Wendy Nicholson, Non-Executive Director	●●●●●●●●●●●●●●	●●●●●●	N/A	N/A	●●○○●○○○○	●○○●●●	●●●●●○●●●●●●○
Prof Sunita Toor, Non-Executive Director	●●●●●●○●○●●●○●○	●●●●●○	N/A	N/A	○●○●○○○○●	●○●●●●	●○●●●○●●●●●●●
Dr Simon Constable, Chief Executive	●●●●●●●●●●●●●●	●●○●●●	N/A	N/A	●●●●●●●●	N/A	N/A
Dr Di Adamson, Chief Medical Officer	⦸●●●●●●●○●●●●●●	●●●●●●	N/A	⦸⦸●●●●●●●●●●	N/A	○●●●●●	●●●●●●●●●●●●●
Helen Ashley, Director of Strategy	●●●●●●●●●●●●●●	●○●●●●	N/A	●●●●●●●●●●●●	N/A	N/A	N/A
Claire Cotton, Director of Governance & Communications	●●●●●●●●●●●●●●	●●●●●●	●●●●●	●○●●●●●●●●●●	●●●●●●●●	●●●●●●	●●●●●●●●●●●●
Amy Freeman, Chief Digital Information Officer	●●●●●●●●●●●●●●	○●●●●●	N/A	N/A	N/A	N/A	N/A
Jane Haire, Chief People Officer	●●●●●●●●●●●●●●	●●●●●●	N/A	N/A	●●●●●●●●	●●●●●●	N/A
Mark Oldham, Chief Finance Officer	●●●●●●●●●●●●●●	●●●●●●	●●●●●	●●●●●●●●●●●●	N/A	N/A	N/A
Ann-Marie Riley, Chief Nurse	●●●●○●●●●●●●●●	●●●●●●	N/A	N/A	N/A	●●●●●●	●●●●●●●●●●●●
Katy Thorpe, Chief Operating Officer	●●●●●●●●●●●●●●	●●●●●●	N/A	●●●○○●○●●●●○	N/A	N/A	●●●○○●●○●●●●○
Lorraine Whitehead, Director of Estates, Facilities & PFI	●●●●●●●●●●●●●●	●●●●●●	N/A	N/A	N/A	N/A	N/A

DRAFT

NB. In February 2025 to March 2026, a time limited Risk Management Oversight Committee was established to provide focused oversight and direct assurance to the Trust Board in relation to organisational risk and actions relating to confidential operations.

Key: ⦸ Not in post ● Attended ○ Did not attend ● Represented by a deputy

Audit Committee

The Audit Committee is required to report annually to the Board outlining the work it has undertaken during the year and where necessary, highlighting any areas of concern.

The Audit Committee is responsible, on behalf of the Trust Board, for providing independent oversight of the arrangements for integrated governance, risk management, internal control and assurance. While the Committee has a particular focus on financial reporting and audit, its remit extends across our wider governance framework in support of the delivery of strategic objectives.

During 2025/26, the Committee comprised a minimum of four Non-Executive Directors, with a quorum of two, and met on five occasions. The Committee was chaired by Margaret Monckton, with membership during the year including Tanya Bowen, Louise Bainbridge, Andrew Hassell (to November 2025) and Katie Maddock (from February 2026). The Chair of the Trust was not a member of the Audit Committee, in line with best practice. The Committee's membership collectively provided the required balance of skills, experience and recent and relevant financial expertise.

Regular attendees included Grant Thornton (External Auditor), RSM (Internal Auditor and Local Counter Fraud Specialist), the Chief Finance Officer, and the Director of Governance, with additional executive attendance for specific items where required.

Significant issues relating to the financial statements

In reviewing the 2025/26 Annual Accounts, the Audit Committee considered the key judgements, estimates and risks relevant to the preparation of the financial statements. This included scrutiny of:

- The going concern assessment, including understanding the statutory context in which NHS trusts operate and the implications of our deficit position.
- Significant accounting judgements and estimates, including asset valuations.
- The adequacy of the control environment supporting financial reporting.

Having received assurance from management, internal audit and external audit, the Committee concluded that the financial statements were properly prepared on a going concern basis and recommended them to the Trust Board for approval.

Internal audit and assurance

During 2025/26, the Committee approved the Internal Audit Plan and received regular progress reports on delivery against the plan. Internal audit work during the year focused on areas of strategic and operational risk aligned to the Trust's Board Assurance Framework and priority risk areas. Audit coverage during the year included:

- Transformation and major change project management, including follow-up on the implementation of agreed actions.
- Key financial controls and cost improvement arrangements.
- Workforce and payroll processes, including HR record keeping and the DBS checking process.
- Clinical governance arrangements, including pathology service governance.
- Cyber security and information governance, including a Cyber Assessment Framework-aligned Data Security and Protection Toolkit independent assessment.
- Risk management arrangements and the operation of the Board Assurance Framework.

The Committee also considered the Annual Internal Audit Opinion for the year ended 31 March 2026. The Head of Internal Audit issued an opinion that the Trust has an adequate and effective framework of risk management, governance and internal control, while identifying further enhancements required to ensure the framework remains effective.

In reviewing internal audit findings across the year, the Committee noted recurring themes, particularly in relation to governance arrangements, compliance with policies and procedures, and the timely completion of agreed management actions. The Committee sought assurance that these issues were being addressed through agreed management action plans, strengthened action-tracking arrangements and targeted follow-up audits. Progress against internal audit recommendations was monitored through the Audit Action Tracker, including the introduction of a more structured approach to managing delayed, problematic and superseded actions. Where required, executive leads were invited to attend the Committee to provide additional assurance on the delivery of high- and medium-priority actions and learning from internal audit work was used to inform audit planning and ongoing assurance activity.

DRAFT

Audit Committee (continued)

External audit: independence, effectiveness and appointment

The Audit Committee is responsible for overseeing the relationship with the external auditor and for assessing independence, objectivity and effectiveness.

During the year, the Committee:

- Reviewed and approved the External Audit Plan and associated fees.
- Considered the Auditor's Annual Report, Audit Findings Report and Letter of Representation.
- Undertook an annual assessment of external audit effectiveness, which concluded that the external auditor had operated effectively and independently.

Grant Thornton is our external auditor and were reappointed in November 2025 following a formal process, recognising the limited availability of audit providers within the NHS audit market. The Committee keeps auditor tenure under review and will provide advance notice of any future retendering in line with regulatory requirements.

Where the external auditor provides non-audit services, these are subject to prior approval by the Audit Committee. Such work is limited in scope and value and is assessed to ensure that it does not compromise auditor independence or objectivity. The Committee was satisfied that appropriate safeguards were in place throughout the year.

Counter fraud, governance and risk oversight

The Committee received regular reports from the Local Counter Fraud Specialist, including progress against the Counter Fraud Work Plan, outcomes of proactive exercises and investigations, and assurance on compliance with national functional standards. During the year, the Committee also considered our preparedness in relation to the Economic Crime and Corporate Transparency Act, including a gap analysis and agreed actions.

The Committee reviewed the Board Assurance Framework on a quarterly basis, providing challenge on risk articulation, risk tolerance and assurance gaps, and seeking continuous improvement in the clarity and usability of the framework.

The Committee also received regular assurance in relation to:

- Declarations of interest, gifts and hospitality.
- Policy compliance and overdue policies.
- Cyber security risks, including shadow IT and information governance.
- Losses and special payments, Single Tender Waivers and Standing Financial Instruction breaches.

Effectiveness and business cycle

The Audit Committee undertook an annual effectiveness review during the year, which considered its performance, membership, Terms of Reference and delivery against its annual business cycle. The Terms of Reference are aligned with the HFMA Audit Committee Handbook.

The review concluded that the Committee was operating effectively and in line with best practice, while identifying opportunities to strengthen its focus on cross-cutting assurance themes, prioritisation and clarity of assurance, and targeted executive engagement where additional challenge or assurance was required.



DRAFT

Chair and Chief Executive



Jackie Small
Chair (Voting)

Jackie was appointed Chair in June 2025. Jackie is the Interim Joint Chair between Midlands Partnership Foundation NHS Trust (MPFT) and UHNM, a role which is integral to ensuring closer collaboration across acute, community, mental health, and social care – helping to deliver more joined-up, patient first services.

Jackie has worked in a range of senior Public Health management and executive level roles within the NHS and local government in London, Birmingham, and Staffordshire. She joined MPFT from the Royal Wolverhampton NHS Trust where she had served as a Non-Executive Director since 2017, bringing her extensive experience and skills in the fields of commissioning, partnership working, community-based health improvement and wellbeing services. Initially qualifying as a Registered Nurse and Midwife, Jackie later took a BA in Social Policy and a MSc in Health Promotion.

Jackie is Chair of the:

- Trust Board.
- Nominations and Remuneration Committee.
- Corporate Trustee for UHNM Charity.



Dr Simon Constable
Chief Executive (Voting)

Simon was appointed Chief Executive in September 2024. A consultant physician and clinical pharmacologist by background, Simon joined us from Warrington and Halton NHS Foundation Trust (WHH) where he had been Chief Executive since November 2019. Prior to that he held the position of Executive Medical Director at WHH since February 2015.

Prior to taking up the post at WHH, he worked with the NHS Leadership Academy, Harvard University and the Institute for Healthcare Improvement on clinical leadership, employee engagement and transformational change within the NHS.

Simon has also held several clinical leadership roles at the Royal Liverpool and Broadgreen University Hospitals and is a visiting professor at the University of Chester. He studied medicine at Guy's and St Thomas' Hospitals in London, before undertaking postgraduate training in the UK and New Zealand.

Simon is a member of the Charity Committee and attends the Nominations and Remuneration Committee.

DRAFT

Non-Executive Directors



Prof Sunita Toor
Vice-Chair (Voting)

Sunita is currently serving her third term at UHNM, having joined initially as an Associate Non-Executive Director in September 2022. She is Professor of Human Rights and Gender Justice Practice at the world leading Helena Kennedy Centre for International Justice, Sheffield Hallam University. She is an award-winning academic, activist and advocate who is passionate about combatting gender-based violence, advancing women and girls rights across the world and shaping justice sector reform and architecture to promote human rights for all. She is a cutting-edge thought leader who champions rights, equality, diversity, and inclusion.

Sunita became Vice-Chair in September 2025. She is a member of the Nominations and Remuneration, People, Culture and Inclusion and Quality Access and Outcomes Committees. Sunita was our Maternity Board Safety Champion until September 2025.



Louise Bainbridge
(Voting)

Louise joined UHNM in November 2024 following retirement from her role as Chief Executive at Nottingham CityCare, a community interest company providing NHS and Local Authority community services.

Louise is an experienced finance professional, previously holding senior finance positions in NHS commissioning organisations. She is currently a trustee for 2 East Midlands based charities.

Louise became Chair of the People, Culture & Inclusion Committee in September 2025 and is a member of the Audit, Nominations and Remuneration, Finance and Business Performance and Charity Committees. Louise is our Wellbeing Guardian.



Tanya Bowen
(Voting)

Tanya is currently serving her third term at UHNM, having joined us in June 2021. She is a data and digital specialist from the retail technology sector, having been on tech corporate boards driving areas of innovation and governance. She has worked in strategy and execution for both retailers and software providers and her main focus is on new technologies that improve customer experience and employee engagement, and on open systems that allow greater collaboration between partners.

Tanya became Senior Independent Director in February 2026 and is Chair of the Finance and Business Performance and Charity Committees. She is also a member of the Audit and Nominations and Remuneration Committees.

DRAFT

Non-Executive Directors



Prof Katie Maddock (Voting)

Katie is currently serving her third term as Keele University Non-Executive Director, having initially joined us in April 2021. She has been Head of School at the School of Pharmacy and Bioengineering, Keele University, since 2018 and a Reader in Clinical Pharmacy since 2016, having previously been the MPharm Course Director and Associate Dean for Education for the Faculty of Medicine and Health Sciences. Her research interests lie within the field of pharmacy education, particularly technology enhanced learning, augmented reality simulation, and interprofessional education.

Prior to her career in academia, Katie was a hospital pharmacist working extensively across the Black Country.

Katie is a member of the Nomination and Remuneration, People, Culture and Inclusion and Quality, Access and Outcomes Committees. Katie is our Security Management Champion.



Margaret Monckton (Voting)

Margaret joined UHNM in October 2024 and is a qualified chartered accountant with a breadth of experience across the private and public sector. She is currently Chief Finance Officer at Great Ormond Street Hospital and before that, she spent 8 years as Chief Financial Officer at the University of Nottingham. As well as finance she has led teams across all of the resource areas including estates and information technology. She has been an executive leader for the past 15 years as well a variety of non-executive roles. In addition to being a Non-Executive Director at UHNM, she is also Chair of the Nova Education Trust.

Margaret is Chair of Audit Committee and is a member of the Nominations and Remuneration and Finance and Business Performance Committees.



Wendy Nicholson MBE (Voting since Sept 25)

Wendy initially joined UHNM in October 2024 as Associate Non-Executive Director, before becoming a Non-Executive Director in September 2025. She is a registered nurse (adult and child) and educator, who previously held the position as Deputy Chief Nurse and Head of the WHO Collaborating Centre for public health nurses and midwives within the Office of Health Improvement and Disparities at the Department of Health and Social Care and Public Health England. Wendy has led numerous national programmes and policy developments including the modernisation of the Healthy Child Programme, the implementation of one of the first Sure Start programmes in England and the Teenage Pregnancy Programme for the North-West.

Wendy is a member of the Nominations and Remuneration, People, Culture and Inclusion and Quality, Access and Outcomes Committees. Wendy is our Maternity Board Safety Champion and Freedom to Speak Up Non-Executive Director Champion.

DRAFT

Executive Directors



Dr Diane Adamson
Chief Medical Officer (Voting)

Diane became Interim Chief Medical Officer in April 2025, before becoming substantive Chief Medical Officer in October 2025. She began her NHS career in nursing before joining Royal Stoke University Hospital as part of the first cohort of clinical training at Keele University, through the Manchester–Keele Collaboration.

She completed her postgraduate medical training across the West Midlands and in Wales, specialising in General and Vascular Surgery. Following an accident that resulted in a long term disability, Diane switched to Emergency Medicine and Major Trauma. Diane previously served as a Consultant in Emergency Medicine and Major Trauma, taking on several senior leadership roles, including Clinical Lead for Emergency Medicine and Divisional Medical Director for Women's, Children's and Clinical Support Services.

Diane is member of the Finance and Business Performance, People, Culture and Inclusion and Quality, Access and Outcomes Committees.



Helen Ashley
Deputy CEO/Director of Strategy (Non-Voting)

Helen joined UHNM in 2016 following nearly seven years as Chief Executive at neighbouring Burton Hospitals NHS Foundation Trust. Helen has a strong finance background and is leading on the transformational aspects of finances at UHNM.

Helen is a member of the Finance and Business Performance Committee.



Claire Cotton
Director of Governance & Communications (Non-Voting)

Claire has 25 years NHS experience with UHNM, starting out administration and progressing through her career in a range of governance, assurance and risk management related roles. Claire has driven many improvements within UHNM and is passionate about ensuring that governance is welcomed as an enabler and not a barrier, through continuous improvement and an agile and responsive approach. Using her coaching skills and engaging style of teaching, she provides leadership development up to Board level and as a risk management practitioner, has led the organisation through significant improvements in risk management policy and practice. Her portfolio beyond Corporate Governance extends to Legal Services, Health and Safety and Speaking Up. In addition, she became responsible for the Communications portfolio from August 2025.

Claire is a member of all Committees, in addition to attending the Audit and Nominations and Remuneration Committees, in the role of Company Secretary, providing advice to the Board.

DRAFT

Executive Directors



Amy Freeman
Chief Digital Information Officer (Non-Voting)

Amy joined UHNM in August 2021 and has worked in the field of information technology (IT) support and digital since 1998, joining the NHS in 2002. She has held senior IT and digital leadership roles at NHS Connecting for Health (now NHS Digital), NHS Commissioning Board (now NHS England), Staffordshire and Stoke-on-Trent Partnership NHS Trust (now Midlands Partnership NHS Foundation Trust) and Mid Cheshire Hospitals NHS Foundation Trust.

Amy moved to work for NHS provider organisations to be closer to frontline care (community and acute) to help make a difference to the safety and quality of care provided to patients. This has included the delivery of a range of clinical systems most notably electronic patient record systems, patient portals and a virtual clinic solutions.



Jane Haire
Chief People Officer (Non-Voting

Jane joined the Board in January 2023 as Chief People Officer. She has more than 35 years' experience in the NHS, starting out in administration and as a people professional since 1998. She has worked in both Staffordshire and Cheshire health and social care systems including Cheshire and Merseyside Strategic Health Authority, East Cheshire NHS Trust, Cheshire HR Services, Staffordshire and Stoke on Trent NHS Partnership Trust. In her previous role at UHNM as Deputy Chief People Officer she led on strategic and operational HR, transforming people practices, workforce development, workforce planning and playing a lead role in the workforce response to the Covid-19 pandemic.

Jane has an MSc from Manchester Business School in Leadership and is a Fellow of the Chartered Institute of Personnel and Development.

Jane is a member of the People, Culture and Inclusion Committee and attends the Nominations and Remuneration Committee.



Mark Oldham
Chief Finance Officer (Voting)

Mark joined UHNM in June 2019 having moved from Mid Cheshire Hospitals NHS Foundation Trust where he served 10 years as their Finance Director.

Originally joining the NHS from Local Government in 1990 Mark has 30 over years' experience in both the acute and community sector in a wide range of finance roles.

Mark is a member of the Finance and Business Performance Committee and also attends the Audit Committee.

DRAFT

Executive Directors



Ann-Marie Riley OBE
Chief Nurse (Voting)

Ann-Marie joined UHNM in July 2021. She became a registered nurse in the early 1990's and has a clinical background in critical care nursing. She has held a number of nursing leadership roles, including Deputy Chief Nurse at Nottingham University Hospitals where she supported the organisation to attain both internationally accredited Pathway to Excellence and Magnet Designations, and Director of Nursing at Walsall Healthcare NHS Trust.

She is passionate about creating positive practice environments, supported by collective leadership approaches and patient co-design, to positively impact on patient outcomes, patient experience and employee experience.

Ann-Marie is a member of the People, Culture and Inclusion and Quality, Access and Outcomes Committee.



Katy Thorpe
Chief Operating Officer (Voting)

Katy was appointed as Interim Chief Operating Officer in September 2024. She has nearly two decades of experience in healthcare, having held significant roles in various NHS trusts. She has a proven record of leading and transforming services, with key skills in leadership, service improvement and emergency preparedness.

She is committed to personal and professional development and completed the Oxford Executive Leadership Programme and the NHS Leadership Academy's Nye Bevan programme and holds and MSc in Leadership for Health Service Improvement from Birmingham University. Throughout her career Katy has achieved significant milestones including leading UHNM through elective and non-elective recovery, service reconfiguration and Covid-19 response.

Katy is a member of the Finance and Business Performance and Quality, Access and Outcomes Committee.



Lorraine Whitehead
Director of Estates, Facilities & PFI (Non-Voting)

Lorraine commenced as Director of Estates, Facilities & PFI in 2017, and has worked for UHNM for over 30 years commencing as an admin trainee in Trust Headquarters in 1985. Exposure to the executive agenda gave her an appetite to pursue senior management in the NHS as a career path and Lorraine subsequently worked in various managerial roles at all levels across the organisation and has a MSc in Facilities Management from Reading University.

Lorraine is passionate about the development of Estates, Facilities and PFI services recognising the vital role these services play in supporting and enhancing patient care and colleague experience at UHNM.

DRAFT

Former Board Members

David Wakefield
Previous Chair

David left UHNM in May 2025 at the end of this third term. Until this time, David was Chair of the Trust Board (attended 1 / 1 meeting), Nominations and Remuneration Committee (attended 1 / 1 meeting) and the Corporate Trustee for UHNM Charity.

Declarations of Interest: Director of Pewterspear Green Trust (Charitable Trust).

Lisa Thomson
Previous Director of Communications & Charity

Lisa left her role as Director of Communications in June 2025 before becoming the Director of UHNM Charity. Lisa was a member of the People, Culture and Inclusion (attended 1 / 1 meeting). She continues to be a member of the Charity Committee.

Declarations of Interest: Nothing to declare

Professor Gary Crowe
Previous Vice-Chair / Non-Executive Director

Gary left UHNM in August 2025 at the end of this fourth term. Until this time, in addition to being Vice-Chair, Gary was Chair of the Finance and Business Performance (attended 4 / 5 meetings), and People, Culture & Inclusion Committees (attended 2 / 2 meetings). Gary was also a member of the Nominations and Remuneration Committee (attended 1 / 2 meetings) and was our Security Management Champion.

Declarations of Interest: Deputy Chair and Non-Executive Director of The Dudley Group NHS Foundation Trust; Independent Member & Non-Executive Director of The Human Tissue Authority and Independent Governor Reaseheath College and University Centre.

Professor Andrew Hassell
Previous Senior Independent Director / Non-Executive Director

Andrew left UHNM at the end of January 2026, having initially joined us as Keele University Non-Executive Director in April 2017, before moving into an Associate role in July 2022. Andrew was the Chair of the Quality, Access and Outcomes Committee (attended 9 / 10 meetings) and a member of the Audit (attended 3 / 5 meetings) and Nominations and Remuneration (attended 7 / 8 meetings). Andrew was also our Freedom to Speak Up Champion and Doctors Disciplinary Champion.

Declarations of Interest: Non-Executive Director, Countess of Chester NHS Foundation Trust. 20-01-2024 to 20-01-2027

DRAFT

Declaration of interests

In line with Trust policy and NHS England guidance, Board members are responsible for declaring any actual or potential conflicts of interest in a timely manner. All declarations of interest are published on our website.

Member	Declaration
Jackie Small	1) Chair of Board and Council of Governors, Midlands Partnership University NHS FT. December 2018 to date, 12 days per month 2) Partner is a GP in Worcestershire 3) Member of Seacole Group (Network of BAME NEDs in NHS), December 2019 to date, 4) Member of NHS Chair and CEO Ethnic Minority Network, February 2024 to date
Louise Bainbridge	1) Trustee – Active Partners Trust. From March 2020 2) Nottingham CityCare Community Charity. From June 2024
Tanya Bowen	1) Parish Councillor, Newcastle On Clun Parish Council, Shropshire. May 2025 to May 2029. Meetings 6x/year. 2) Director of Sprucepoint Limited. Joint directorship with Jonathan Bowen, partner. Tech consultancy. Thus far in retail and tech sectors. From 08/02/2021. 1 day a quarter, some quarters 0 days
Prof Katie Maddock	1) Trustee of the North Staffordshire Medical Institute. August 2019 – present. One meeting per month 2) Professor of Pharmacy Education at Keele University. August 2007 - present. Full time role
Margaret Monckton	1) Chair of Nova Education Trust. From 2020. 1 day a month. 2) Chief Financial Officer, Great Ormond Street Hospital Foundation Trust. From 1st Jan 2025. Full time. 3) Husband is a Director at Nottingham University Hospitals. From 2022.
Wendy Nicholson	1) Non-Executive Director and Maternity & Neonatal Safety Champion at Shrewsbury & Telford Hospital. From 1st Nov 2023. 2-3 days per month.
Prof Sunita Toor	1) Non-Executive Director - Nottingham University Hospitals. June 2023 - current. 2 days a month 2) Professor at Sheffield Hallam University. March 2026 – current. Full time. 3) Director of own company Luna-V Ltd. From 7th June 2006. Company no. 05840231

Member	Declaration
Dr Simon Constable	1) Visiting Professor, University of Chester (2015 onwards) 2) General Medical Council Responsible Officer & Designated Body is Dr Elizabeth O'Grady and Liverpool University Hospitals NHS Foundation Trust (2019 onwards) 3) Lay Member, Keele University Council (April 2025) 4) Chair, West Midland Imaging Network (2024 onwards)
Dr Diane Adamson	1) Director Voutech Ltd. 18/04/2018 - 22/09/2022 2) Director Rinkitinks. 21/04/2018 - 30/03/2021 3) CMO BETA. 2022 to date. 4) Husband is director of Sim4Med and VueTech which have previously and support trust Sim Suite at County and MITA. 2020 to date.
Helen Ashley	1) Member of DCHS (Derbyshire Community Health Services FT). 2011 - ongoing.
Claire Cotton	1) I have two sisters working as senior nurses within UHNM.
Amy Freeman	1) Director of Bridge Farm Court Management Company LTD. Company number 04045494. From 23rd Jan 2017.
Jane Haire	Nothing to declare
Mark Oldham	1) Trustee of North Staffs Post Grad Education Centre. 01/01/2025 - ongoing.
Ann-Marie Riley	Nothing to declare
Katy Thorpe	1) Sales of skin care products (Tropic Ambassador). Family members only. From 03/10/25. Pay/Benefits : reduced price skincare products.
Lorraine Whitehead	1) Member of Orchard Community Trust, Schools Academy Trust, based in Stoke-on-Trent. From Jul 2022 on-going. 5-10 hours per annum. 2) Son is a Mechanical and Engineering Apprentice with Sodexo Estates, at Royal Stoke. being appointed to the role following a competitive interview process. From Jan 2021 to Jan 2026.

Additional Significant Appointments

In accordance with the Code of Governance, the Chair and Chief Executive has reviewed all external appointments held by Directors during the year. Where Board members have taken on additional significant appointments, these have been permitted only where:

- The role supports the Director's professional development and brings relevant skills, experience or system-level insight back into UHNM.
- The appointment does not conflict with the Director's duties.
- The time commitment does not adversely affect their ability to discharge their responsibilities.
- Any potential conflicts of interest have been declared and managed in line with Trust policy.

The Board is satisfied that all external appointments declared in this report meet these criteria.

Directors Released to Serve Elsewhere

Where Directors have been released to undertake duties for external organisations (for example, roles within professional bodies), this has been approved in line with our governance arrangements. For each case:

- The time commitment has been assessed to ensure it does not impact their UHNM responsibilities.
- Appropriate arrangements have been put in place to ensure continuity of leadership within the Trust.
- Directors have confirmed whether any remuneration associated with these duties is retained personally or returned to the Trust, in accordance with their contractual terms and Trust policy.

All such arrangements are recorded within individual declarations and monitored through the declarations process.

DRAFT

Code of Governance

The Code of Governance describes numerous requirements which are to be disclosed within our annual report. We have assessed our position against the Code of Governance on a comply or explain basis and review this on an annual basis.

Comply or Explain Assessment

In our 2024/25 Annual Report, we described two requirements which we had determined as requiring an explanation. The two requirements remain requiring explanation as we do not have plans to introduce a policy for performance related pay and the structure of remuneration for our first level of senior management is not considered by the Nominations and Remuneration Committee as their Terms and Conditions are in line with Agenda for Change.

Disclosure Requirements

Disclosure requirements stipulated within the Code of Governance are addressed throughout this report. For ease of identification, these can be cross referenced as follows:

- How opportunities and risks to future sustainability have been considered and addressed and how our ongoing governance is contributing to the delivery of our strategy (pages 9, 18, 33 and 61-69).
- The Board's activities and any action taken, and our approach to investing in, rewarding and promoting the wellbeing of our workforce (pages 11, 28-29, 34, 64 and 68).
- How the interests of stakeholders, including system and place-based partners have been considered in our discussions and decision making, and our key partnerships for collaboration with other providers into which we have entered (pages 5 - 6, 9, 14-16, 34, 38-42 and 63).
- Each non-executive director we consider to be independent (pages 7, 46-47, 49-52).
- The number of times the board and its committees have met, and individual director attendance (pages 46-48).
- Any reasons for permitting additional significant appointments for Board members (page 58).
- Schedule of matters or a summary statement of how the board of directors operate, including a summary of the types of decisions to be taken by the board, board committees and the types of decisions that are delegated to the executive management of the board of directors (pages 46, 65).
- A description of each directors' skills, expertise and experience along with a statement about the board's balance, completeness and appropriateness to our requirements (pages 49-55).
- How the chair has acted on the results of the annual evaluation of the Board, by recognising the strengths and addressing any weaknesses (pages 46).
- The external reviewer of the Well Led Framework and a statement made about any connection with the Trust or individual directors (pages 62).
- The work of the Nominations and Remuneration Committee (pages 71-72).
- The significant issues relating to the financial statements that the audit committee considered and how these issues were addressed, an explanation of how the audit committee has assessed the independence and effectiveness of the external audit process and its approach to the appointment or reappointment of the external auditor; length of tenure of the current audit firm, when a tender was last conducted and advance notice of any retendering plans and an explanation of how auditor independence and objectivity are safeguarded if the external auditor provides non-audit services (pages 48-50, 67 and 90+).
- Directors' responsibility for preparing the annual report and accounts and that they consider taken as a whole is fair, balanced and understandable and provides the information necessary for stakeholders to assess our performance, business model and strategy (pages 58 & 60).
- A robust assessment of emerging and principal risks (pages 18, 33, 61, 64-65).
- Internal control through the Annual Governance Statement (pages 59-67).
- That the Board has considered it appropriate to adopt the going concern basis of accounting when preparing them and identify any material uncertainties to going concern (pages 19).
- A statement about any director released to serve elsewhere, including as to whether or not they will retain such earnings (pages 58).

DRAFT



Statement of Accountable Officer's responsibilities

Directors have confirmed that they know of no information which would be relevant to the auditors for the purpose of their audit report and of which the auditors are not aware. Directors have taken all the steps they ought to have taken to make themselves aware of any such information and to establish that the authors are aware of it.

Statement of Accountable Officers Responsibilities

The Chief Executive of NHS England has designated that the Chief Executive should be the Accountable Officer of the Trust. The relevant responsibilities of Accountable Officers are set out within the NHS Trust Accountable Officer Memorandum. These including ensuring that:

- There are effective management systems in place to safeguard public funds and assist in the implementation of corporate governance.
- Value for money is achieved from the resources available to the Trust.
- The expenditure and income of the Trust has been applied to the purposes intended by Parliament and conform to the authorities which govern them.
- Effective and sound financial management systems are in place.
- Annual statutory accounts are prepared in a format directed by the Secretary of State to give a true and fair view of the state of affairs as at the end of the financial year and the income and expenditure, other items of comprehensive income and cash flows for the year.

As far as I am aware, there is no relevant audit information of which the Trust's auditors are unaware, and I have taken all the steps that I ought to have taken to make myself aware of any relevant audit information and to establish that the entity's auditors are aware of that information.

To the best of my knowledge and belief, I have properly discharged the responsibilities set out in my letter of appointment as an Accountable Officer

Dr Simon Constable
Chief Executive
DATE



Statement of Director's Responsibilities in Respect of the Accounts

The directors are required under the National Health Service Act 2006 to prepare accounts for each financial year. The Secretary of State, with the approval of HM Treasury, directs that these accounts give a true and fair view of the state of affairs of the Trust and of the income and expenditure, other items of comprehensive income and cash flows for the year. In preparing those accounts, the directors are required to:

- Apply on a consistent basis accounting policies laid down by the Secretary of State with the approval of the Treasury.
- Make judgements and estimates which are reasonable and prudent.
- State whether applicable accounting standards have been followed, subject to any material departures disclosed and explained in the accounts.
- Prepare the financial statements on a going concern basis and disclose any material uncertainties over going concern.

The directors are responsible for keeping proper accounting records which disclose with reasonable accuracy at any time the financial position of the Trust and to enable them to ensure that the accounts comply with requirements outlined in the above-mentioned direction of the Secretary of State. They are also responsible for safeguarding the assets of the Trust and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

The directors confirm to the best of their knowledge and belief they have complied with the above requirements in preparing the accounts. The directors confirm that the annual report and accounts, taken as a whole, is fair, balanced and understandable and provides the information necessary for patients, regulators and stakeholders to assess the NHS trust's performance, business model and strategy
By order of the Board.

Dr Simon Constable
Chief Executive
DATE



Mark Oldham
Chief Finance Officer
DATE



DRAFT

Annual Governance Statement (AGS)

The Annual Governance Statement summarises our governance framework, outlining how we manage risk, maintain effective internal controls and ensure compliance with statutory and regulatory requirements. It provides assurance that the organisation is well-led and focused on delivering safe, high-quality care.

Scope of Responsibility

As Accountable Officer, I have responsibility for maintaining a sound system of internal control that supports the achievement of the NHS trust's policies, aims and objectives, whilst safeguarding the public funds and departmental assets for which I am personally responsible, in accordance with the responsibilities assigned to me. I am also responsible for ensuring that the NHS trust is administered prudently and economically and that resources are applied efficiently and effectively. I also acknowledge my responsibilities as set out in the NHS Trust Accountable Officer Memorandum.

The Purpose of the System of Internal Control

The system of internal control is designed to manage risk to a reasonable level rather than to eliminate all risk of failure to achieve policies, aims and objectives; it can therefore only provide reasonable and not absolute assurance of effectiveness. The system of internal control is based on an ongoing process designed to identify and prioritise the risks to the achievement of the policies, aims and objectives of our Trust, to evaluate the likelihood of those risks being realised and the impact should they be realised, and to manage them efficiently, effectively and economically. The system of internal control has been in place in our Trust for the year ended 31 March 2026 and up to the date of approval of the annual report and accounts.

Capacity to Handle Risk

As Accounting Officer, and with the support of the Board, I hold overall responsibility for the direction and effectiveness of our risk management systems and processes. Operational responsibility for the development, review and monitoring of our Risk Management Policy is delegated to the Director of Governance & Communications, who also oversees the provision of training, expert guidance and the facilitation of risk reporting across the organisation.

We maintain a strong and embedded leadership framework that provides a clear line of sight from the Board through to Executive Groups, Care Groups/Divisions and frontline teams. The Risk Management Policy establishes the principles and expectations for identifying, assessing, escalating and reviewing risks, ensuring that all colleagues operate within a consistent and robust governance structure.

Risk management capability is supported through a comprehensive training offer, including mandatory e-learning, guidance materials and face-to-face sessions. This ensures colleagues understand their responsibilities, can assess and manage risks effectively, and escalate concerns when required.

We promote a culture of continuous learning and improvement. Reporting to Executive Groups highlights risks from Divisions and Care Groups, identifies trends, and strengthens controls. Learning from internal audits, external reviews and incident reporting informs policy updates and enhances control measures, ensuring our processes remain evidence-based and aligned with good governance practice.

Executive leadership and oversight are delivered through formal governance mechanisms. The BAF provides quarterly scrutiny of strategic risks, enabling the Board and its committees to monitor, challenge and gain assurance on the effectiveness of controls. Executive Groups and Care Group Leadership Boards oversee operational and divisional risks, escalating issues where necessary. These structures ensure proportionate risk management and early identification of emerging concerns. Operational risks are aligned to the BAF and reviewed through divisional and care group governance, with escalation through Executive Groups, Board Committees and ultimately the Trust Board.

The Quality, Access & Outcomes Committee oversees risks related to quality, clinical governance, operational delivery and population health. The Finance & Business Performance Committee provides assurance on financial, estates, digital and research-related risks. The People, Culture and Inclusion Committee oversees workforce, culture and employee wellbeing risks. The Audit Committee provides overarching scrutiny of the risk management system, including an annual internal audit of the BAF and assurance from Board Committee Chairs and internal/external audit findings on the effectiveness of controls for all strategic risks.

In 2025/26, the Board Assurance Framework received a Significant Assurance rating, reflecting the maturity and effectiveness of our risk management arrangements.

DRAFT

The Risk and Control Framework

Our Risk Management Policy provides a Trust-wide framework for managing risk and ensuring that risk assessment is integral to our clinical, managerial, digital and financial processes. It outlines how risks are identified, evaluated, transferred and controlled, and clarifies the responsibilities of the Board, its committees, managers and colleagues. This structured and systematic approach ensures that risks are consistently managed, escalated and aligned with our strategic objectives through the Board Assurance Framework.

Identification of risk is undertaken through both proactive and reactive means, drawing on incident reporting, audit findings, clinical governance reviews, colleague feedback, and horizon scanning for emerging strategic risks:

- Proactive risk identification focusses on our objectives and the consideration of any risks which may threaten their achievement – this approach is used when developing the Board Assurance Framework.
- Reactive risk identification is undertaken following an adverse event or ongoing issue which presents a further risk for the future – this approach is used within our risk register.

Evaluation of risk is undertaken using our Risk Scoring Matrix, which is based on national NHS methodology and has been adapted to incorporate data security risks, ensuring alignment with the Cyber Assessment Framework.

Transfer of risk is a type of risk control and is defined as risk passing over to a third party, who bears or shares the impact. Other types of risk control include **termination** of risk, where it is completely eliminated, **treatment** of risk where it is either contained or a contingent is introduced or **tolerated**, where a risk is accepted subject to monitoring. These control types are applied proportionately, and each risk record sets out the existing controls, assurances, and further mitigating actions required to achieve the target risk score.

Our Risk Appetite Statement, reviewed and updated during the year, supports consistent decision-making by setting the level of risk we are willing to accept in pursuit of its strategic objectives. It informs the setting of target risk scores and guides the introduction of additional controls where required.

We use a simple 'alarm bell' approach within our reporting to highlight any risks that have not been reviewed in line with policy requirements or may require further action. This mechanism helps ensure timely oversight and escalations where risks are not progressing as expected.

Quality Governance Arrangements

Our quality governance arrangements are jointly led by the Chief Nurse and Chief Medical Officer and form part of our 'ward-to-board' corporate governance structure. This includes Quality, Access and Outcomes Committee, Executive Quality and Outcomes Group, Specialist Corporate Quality Groups and Care Group Quality Governance Groups.

Assurance on compliance with CQC registration requirements is obtained routinely through this structure and includes the regular review of findings from our internal ward accreditation programme, the Care Excellence Framework (CEF). The CEF provides structured assurance through a programme of visits to all wards and departments, using a methodology aligned to the CQC's key lines of enquiry. The CEF has been strengthened during 2025/26 to provide more consistent and robust assurance and recent improvements include a stronger requirement for services to maintain up-to-date risk registers with regular review and escalation of significant issues, ensuring clearer visibility of risks to quality at care group and corporate levels. The framework incorporates enhanced triangulation of quality information, drawing on incident reviews, thematic learning and focused quality improvement work, particularly in services where targeted regulatory attention has been required. Where CEF outcomes identify areas requiring improvement, enhanced escalation and support arrangements now involve more frequent meetings with the Chief Nurse or Deputy Chief Nurse, supported by a patient representative, until sustained improvement is achieved. These changes ensure that concerns are acted upon promptly, support is targeted where most needed, and improvements are delivered in line with CQC expectations

Assessing the Quality of Performance Information

The quality of performance information is assessed through internal validation processes tailored to each indicator, alongside reviews undertaken by Internal Audit as part of their annual programme. In 2025/26, we have continued to use the STAR assurance model, developed in collaboration with NHS data quality teams, NHS Digital and Academic Health Science Networks. STAR assesses data quality across four domains:

- S – Sign-off and validation.
- T – Timely and complete.
- A – Audit and accuracy.
- R – Robust systems and data capture.

This framework provides a consistent, structured approach to evidencing data quality and supporting continual improvement. While governance arrangements for data quality are well established, underlying challenges remain. Reliance on multiple systems and manual data handling increases the risk of inconsistency and reduces opportunities for automation. Addressing data quality therefore requires both continued assurance and progress in digital integration to reduce manual processes across clinical and operational pathways.

DRAFT

Risks to Data Security

Our Data Protection, Security and Confidentiality Policy provides the framework for safeguarding information and information systems, ensuring confidentiality, integrity and availability. Risks to data security are managed in line with our Risk Management Policy, with risks scoring 12 or above escalated to the Executive Digital and Data Security and Protection Group, chaired by the Senior Information Risk Officer (SIRO).

Data security breaches are treated as adverse incidents under our Incident Reporting Policy and are escalated to the Executive Digital and Data Security and Protection Group for oversight of corrective actions and learning. The Group also monitors compliance with the Cyber Assurance Framework, which is subject to annual internal audit review. During 2025/26, our internal auditors undertook their annual review of data security and protection arrangements confirming a medium risk rating across all five CAF objectives and a high confidence level of the independent assessor in the veracity of the self-assessment.

Major Risks

Our major risks are set out within the BAF. During 2025/26, we managed eight significant in-year risks that affected the achievement of our strategic priorities. These related to our ability to:

- Sustain safe and effective care delivery.
- Design and deliver services that address local population needs.
- Improve workforce sustainability and organisational culture.
- Deliver digitally enabled care transformation.
- Deliver investment in estate infrastructure and workforce.
- Deliver in-year financial position.
- Deliver financial sustainability.
- Sustain research and innovation excellence.

Each strategic risk is overseen by an Executive Director, with mitigations monitored quarterly through the BAF and triangulated with quality, workforce and performance data. Outcomes are assessed through Board and Committee scrutiny, internal audit findings and progress against agreed action plans, enabling assurance on whether controls remain effective and whether further intervention is required.

Of those risks, the most significant as we reached the end of the year were in relation to the following, these remain similar to the risks we faced at the end of 2024/25:

Risk		How we manage the risk	How we assess the outcome of actions
Financial sustainability	Ext 25	• Financial plan • Policies and procedures • Cost improvement programme	• Financial reporting • Performance and risk reviews • Internal and external audit
Safe and effective care delivery	Ext 20	• Strategies and plans • Policies and procedures • Risk assessment	• Incident reporting • Delivery of quality indicators/metrics • Internal audit • Performance and risk reviews
Digitally enabled care transformation	Ext 16	• Investment • Training • Policies and procedures • Continuity planning	• Internal audit • Digital maturity assessments • Incident reporting

During 2025/26, the Board reviewed and refreshed the BAF to ensure it continued to reflect the most significant risks to delivering our strategy. The Board agreed that the three principal underlying causes of strategic risk identified in 2025/26 remained relevant for 2026/27, and that the overall subject matter of the strategic risks continued to represent those most likely to impact delivery. Refinements were agreed to improve clarity, including updates to risk wording and clearer alignment with Committee oversight, and the separation of operational performance risk in light of our medium-term plan.

The Board also recognised that, in some areas, existing actions had not been sufficient to materially reduce risk. As a result, the approach for 2026/27 will place greater emphasis on aligning strategic programmes directly to the BAF risks, ensuring actions are of sufficient scale and impact to drive meaningful risk reduction. This includes clearer mapping between major strategic programmes, such as Our Future Hospitals, and the risks they are intended to mitigate.

Further information on our principal risks is listed on page 18.

DRAFT

Well-led framework

The NHS Well-Led Framework supports the Board in assessing the effectiveness of leadership, governance, culture and improvement across the Trust. This section summarises the outcomes of our 2025/26 Well-Led self-assessment and the key areas of focus for continued improvement.

Our last CQC well-led inspection was undertaken in 2021, whereby we were rated as 'Good'. During 2024/25 we commissioned an independent well-led review which was undertaken by Deloitte. Their findings, which were presented to the Board were consistent with those of the CQC and formed the basis of our development plan throughout the year.

During 2025, we undertook an internal comprehensive self-assessment against the NHS Well-Led Framework to evaluate the effectiveness of leadership, culture, governance and improvement capability across the organisation. The assessment was informed by a triangulated review of Board and Committee assurance, external intelligence and system feedback, including the Provider Capability Assessment and a Board-to-Board discussion with NHS England. This approach enabled the Board to take an honest and evidence-based view of where we are performing well and where further development is required.

The self-assessment confirmed that we have strong strategic foundations, including a clear and refreshed vision, values and strategy, robust governance and risk management arrangements, improving openness through Freedom to Speak Up, and established frameworks for equality, sustainability and quality improvement. These provide the Board with clear line of sight from strategy to delivery and assurance. However, the assessment also highlighted that leadership behaviours, consistency of culture, and the pace of delivery remain key binding constraints. In particular, we must further embed accountability following organisational restructure, improve data maturity and triangulation at Care Group level, and strengthen the translation of strategy and improvement plans into measurable outcomes for our people, patients and the population.

As a result of the 2025 self-assessment, the Board agreed a focused set of priorities for the next phase of improvement. These include strengthening leadership capability and line management confidence, embedding governance and assurance at Care Group level, ensuring improvement and partnership working deliver demonstrable impact, and moving from policy and process compliance to evidenced outcomes in areas such as equality, inclusion and culture. Progress against these priorities is overseen through an integrated Well-Led and Provider Capability action plan, aligned to the Board Assurance Framework and the Board Development Programme, ensuring sustained Board-level focus on becoming consistently and demonstrably well-led.



DRAFT

Enforcement Undertakings

Following the enforcement undertakings issued by NHS England in October 2023, substantial progress was made across several regulatory domains. NHS England's formal review in late 2024 confirmed that we had demonstrated sufficient evidence of compliance for undertakings relating to:

- Quality Improvement – Maternity.
- Staff Survey.
- Cancer performance.
- Governance requirements.

A Compliance Certificate was issued on 14 July 2025, confirming these areas were fully met. Given this progress, NHS England subsequently issued revised enforcement undertakings in September 2025, superseding the original 2023 undertakings.

Due to continuing challenges in Urgent and Emergency Care (UEC) and Elective Recovery, we received updated operational performance undertakings. These included the requirement to develop:

- A robust UEC Improvement Plan, addressing ambulance handover delays, A&E waiting times, leadership and management issues, culture, risks, milestones, KPIs and system-partner collaboration.
- A comprehensive Elective Improvement Plan, setting out elective care recovery trajectories, long-term service redesign, governance arrangements and ten-year vision alignment.

Both plans are reported monthly to NHS England in addition to ad-hoc updates.

Provider Capability Assessment

During 2025, we completed a comprehensive Provider Capability Self-Assessment, which confirmed strengthened governance, strategic alignment and quality oversight across the organisation. The assessment noted that our strategy was well aligned with the wider Integrated Care System strategy and Joint Forward Plan, with clear supporting plans in place for financial, digital and operational delivery. Improvements were also recognised in our governance and accountability structures, with revised performance reviews, clearer Care Group responsibilities and enhanced oversight through Board committees and Executive Groups. Areas requiring continued focus include embedding clinical effectiveness, strengthening programme management capacity, improving mortality assurance, and progressing organisational development and colleague experience initiatives. Following submission to NHS England, we received the rating of Amber-Red.

Governance

Our governance structure supports the Board's overarching responsibility to ensure openness, transparency and candour in relation to our people, our patients and our population. The Board actively promotes a culture that encourages open, constructive debate from both Executive and Non-Executive Directors, with both also conducting regular visits to wards and departments, enabling direct engagement and visibility of operational reality.

Aligned to the Provider Licence, the effectiveness of our governance arrangements is reviewed annually, with all Board members participating in structured effectiveness reviews. Findings inform updates to committee structures, terms of reference and membership, ensuring governance remains fit for purpose.

Board committees are chaired by Non-Executive Directors, providing independent challenge and assurance. The Audit Committee, also chaired by a Non-Executive Director, provides statutory oversight of internal control, risk management and governance. Executive Groups, chaired by Executive Directors, provide the operational leadership and decision-making needed to progress workstreams and manage risks. These groups report directly into Board committees, strengthening clarity of reporting lines and accountability.

We have strengthened our mechanisms for ensuring timely, accurate and validated information flows. Improvements to performance reporting, triangulation of intelligence and risk escalation processes—highlighted positively in CQC feedback—have reduced variability and increased confidence in the reliability of information used by the Board for assurance and decision-making.

Board oversight is reinforced through a clear line of sight from ward to Board, structured reporting cycles and regular triangulation of quality, performance, workforce and financial data. The Board maintains rigorous challenge over organisational performance, scrutinising trends, testing the robustness of controls and seeking further assurance where required. The Board's leadership role is further demonstrated through development sessions, oversight of improvements in operational and quality performance, and active involvement in addressing risks to service quality, culture and workforce sustainability.

Committee Highlight reports are submitted to the Board routinely, providing timely insight into areas of assurance, and escalation. This ensures the Board receives accurate and reliable information to assess risks to compliance with licence conditions and to act swiftly where additional scrutiny is required.

DRAFT

Embedding Risk Management

Risk management is a core part of how we operate as a Trust and is embedded into everyday clinical, operational and corporate activity. It supports safer care, better outcomes and consistent decision-making by ensuring that risks are identified early, assessed proportionately and managed within agreed tolerances.

We embed risk management across the organisation in several ways, including:

- Open incident reporting, which is actively encouraged to support continual learning and improvement. All incidents are captured within our reporting system, reviewed through our governance structure and used to inform improvements in practice, policy and training.
- Equality Impact Assessments (EIAs), which form an integral part of policy development. EIAs help us identify potential discriminatory effects and ensure mitigating actions are built into core business processes.
- Integration into day-to-day operations, including clinical care delivery, operational and workforce planning, complaint and claim handling, financial and investment decisions, strategic planning, procurement processes, audit prioritisation, accreditation and regulatory preparedness.
- Routine governance oversight, where risks are reviewed through governance meetings, Executive Groups and Board Committees, ensuring alignment with the Board Assurance Framework and consistent escalation of issues requiring senior attention.

Through these embedded processes, risk management is not a standalone activity but a continuous, organisation-wide discipline that informs how we plan, deliver and improve services.

Workforce Sustainability

We apply the Developing Workforce Safeguards to ensure safe, effective and sustainable staffing. In line with National Quality Board guidance, we deploy sufficient, suitably qualified colleagues, use a systematic approach to determining staffing requirements, and ensure all decisions reflect current legislation and best practice.

Safe staffing is supported through a range of established mechanisms. Digital rostering systems are used across clinical professions to ensure equitable staffing and rapid response to pressures. Daily operational oversight by senior nurses and matrons, supported by real-time dashboards, enables timely escalation and redeployment. Temporary staffing is managed through dedicated bank and agency teams, with central rota systems in place for doctors. Additional digital tools support administrative redeployment and systematic management of unplanned absence.

Medium-term workforce sustainability is strengthened through annual workforce planning, aligned to financial and activity planning cycles and scrutinised by the People, Culture and Inclusion Committee. Workforce reporting to Executive Groups and Board committees provides visibility of vacancy trends, staffing risks and mitigation actions. Nursing and midwifery establishments are reviewed annually and monitored throughout the year, while our Medical Workforce Group oversees job planning, locum usage and workforce supply.

Long-term workforce priorities are set out within our refreshed People Plan, aligned to national workforce strategies and covering future workforce growth, leadership development, colleague wellbeing, inclusion and skills development.

Assurance on the effectiveness of staffing processes is provided through internal audits of recruitment, payroll and rostering, and through Board oversight of key workforce indicators within the Board Assurance Framework and Integrated Performance Report.



DRAFT

Care Quality Commission

We are fully compliant with the registration requirements of the Care Quality Commission with an overall rating of Requires Improvement and Good for Well Led.

Conflicts of Interest

We have published on our website an up-to-date register of interests, including gifts and hospitality, for decision-making colleagues within the past twelve months, as required by the 'Managing Conflicts of Interest in the NHS' guidance.

NHS Pensions Scheme

As an employer with colleagues entitled to membership of the NHS Pension Scheme, control measures are in place to ensure all employer obligations contained within the Scheme regulations are complied with. This includes ensuring that deductions from salary, employers' contributions and payments into the Scheme are in accordance with the Scheme rules, and that member Pension Scheme records are accurately updated in accordance with the timescales detailed in the Regulations.

Equality, Diversity and Human Rights

Control measures are in place to ensure that all the organisations' obligations under equality, diversity and human rights legislation are complied with.

Sustainability

We have undertaken risk assessments on the effects of climate change and severe weather and have developed a Green Plan following the guidance of the Greener NHS Programme. We ensure that our obligations under the Climate Change Act and the Adaptation Reporting Requirements are complied with.

Review of Economy, Efficiency and the Effectiveness of the Use of Resources

We have established performance management and financial control processes to ensure that resources are used economically, efficiently and effectively. The Chief Finance Officer reports regularly to the Finance and Business Performance Committee, which scrutinises financial performance, challenges variance, and provides assurance to the Board on the stewardship and deployment of resources.

Our policy and governance framework—including Standing Orders, Standing Financial Instructions and the Scheme of Reservation and Delegation—provides clear guidance on the proper use of public funds. Policies and procedures are subject to routine review, with updates communicated through organisational governance structures to ensure employees understand their responsibilities in managing resources appropriately.

Operational accountability is supported through our devolved structure, in which Care Groups operate within defined delegations and receive dedicated financial and human resources support. Executive-led performance and risk review arrangements enable systematic challenge of financial delivery, workforce usage, productivity, and progress against efficiency requirements.

Independent assurance is provided through our internal audit programme, which tests the effectiveness of key financial systems, internal controls, data quality and value-for-money arrangements. Counter fraud activity further supports the safeguarding of public funds. Findings are reported to the Audit Committee, enabling the Board to form an independent view of financial governance and resource use. Additional assurance is obtained from external audit and NHS England through regulatory oversight, triangulation of performance information and external review of key processes. Together, these allocated arrangements provide the Board with a clear line of sight over how resources are planned, and used, ensuring that we remain focused on achieving value for money and delivering high-quality, sustainable services.

Information Governance

Information governance and cyber security continue to be overseen through established executive and Board-level governance arrangements. Assurance activity during the year indicates strengthening capability in a number of control areas, although maturity remains variable as improvements are embedded across a complex digital estate. Cyber resilience is increasingly recognised as a patient safety and service continuity issue, rather than solely a compliance requirement. Disruption to digital services has the potential to directly impact clinical care delivery, and this risk is actively managed through a combination of technical controls, incident response planning and organisational preparedness.

Organisations with access to NHS patient information must provide assurance that robust data security and protection measures are in place. We complete the Cyber Assessment Framework (CAF) annually, demonstrating our compliance with national information governance data, security and protection standards. During 2025/26, our internal auditors undertook their annual review of data security and protection arrangements confirming a medium risk rating across all five CAF objectives and a high confidence level of the independent assessor in the veracity of the self-assessment.

All data security and protection incidents are reported through our incident management system. The Data Security and Protection Team reviews each incident to ensure appropriate investigation, including root cause analysis and implementation of remedial actions and learning where required. Serious incidents are notified to the Information Commissioner's Office (ICO) through the Data Security Incident Reporting Tool. In 2025/26, one personal data related incidents was formally reported to the ICO. The ICO was satisfied with the remedial steps taken and no further actions were required.

DRAFT

Data Quality and Governance

We have a comprehensive Data Quality Assurance Framework, overseen by our Data Quality Assurance Group, which ensures that appropriate systems and controls are in place to maintain accurate, timely and reliable data. The framework includes our Data Quality Policy, Data Quality Strategy and an annual programme of internal audits, all of which sit within the wider Data Security and Protection Framework.

All colleagues involved in recording or processing data—clinicians, administrative teams and operational services—are responsible for ensuring adherence to national and local data standards, and for maintaining data that is accurate, valid, reliable and timely. The Data Quality Policy clearly sets out expectations, including the requirement to report any data quality issues or concerns to managers or the Data Quality Team for investigation.

Elective Waiting Time Data

We have a range of controls in place to ensure the accuracy, completeness and reliability of elective waiting time data. Our corporate validation team undertakes daily validations, focusing on pathway records with data-quality flags that indicate potential inaccuracies. Care Group management teams also carry out routine validation work, tracking patients through pathway milestones to ensure correct application of RTT rules and accurate pathway status.

Elective waiting time data quality is further supported through our Data Quality Team, who monitor key indicators and trends. These are reviewed monthly at Operational Data Quality Groups, with cross-cutting risks and recurring issues escalated to the Data Quality Assurance Group for system-wide action.

Training is provided to all employees responsible for recording patient pathway data, including structured programmes on RTT rules, validation processes and correct completion of clinic outcome forms, with tailored support made available for colleagues requiring more detailed knowledge.

All externally reported data is subject to executive sign-off, and internal audit provides independent assurance on the robustness of our controls. Whilst no internal audits were undertaken in this respect during 2025/26, this will be considered for 2026/27 with any recommendations monitored by the Audit Committee.

DRAFT



Review of Effectiveness

As Accountable Officer, I have responsibility for reviewing the effectiveness of the system of internal control. My review of the effectiveness of the system of internal control is informed by the work of the internal auditors, clinical audit and the executive managers and clinical leads within the Trust who have responsibility for the development and maintenance of the internal control framework. I have drawn on the information provided in this annual report and other performance information available to me. My review is also informed by comments made by the external auditors in their management letter and other reports. I have been advised on the implications of the result of my review of the effectiveness of the system of internal control by the Board and the Audit Committee and a plan to address weaknesses and ensure continuous improvement of the system is in place.

Trust Board: maintains oversight of the effectiveness of the internal control system through regular review of the BAF. The BAF provides a comprehensive overview of our internal control environment and sets out the controls, assurances and gaps relating to the principal risks to achieving our strategic priorities. The Board reviews these assurances routinely, ensuring that risks are effectively identified, managed and escalated.

Audit Committee: provides independent scrutiny of the internal control framework. It reviews the adequacy and effectiveness of internal controls through delivery of the annual internal audit plan, consideration of internal audit reports, counter fraud updates, follow-up of recommendations, and thematic assurance work. The Committee uses a structured mapping process to ensure audit coverage is targeted and risk-based, with findings and actions reported at each meeting and formally recorded in its minutes.

Clinical Audit: is an integral component of our internal control and quality assurance framework. An annual clinical audit programme is developed with all care groups and prioritised based on clinical risk, regulatory requirements, national audit participation and local quality priorities. Findings from clinical audits support assurance on compliance with clinical standards and inform quality improvement activity.

Internal Audit: RSM provides an independent and objective internal audit service. Internal audit reviews are aligned to our key risks, governance processes and areas of material change in the risk profile and are subject to approval by the Audit Committee. Detailed reports, including follow-up audits to assess progress in implementing agreed actions, are presented to each meeting of the Audit Committee. The Head of Internal Audit Opinion for the year ended 31 March 2026 concluded that we have an adequate and effective framework of risk management, governance and internal control, while identifying areas where enhancements are required in order to maintain the effectiveness of that framework.

External Audit: provides independent assurance on our Annual Report, Annual Governance Statement and financial accounts. Their findings offer further validation of the effectiveness of internal controls and the robustness of governance arrangements.

Quality and Clinical Governance Structures: The Quality and Outcomes Group, led by the Chief Nurse and Chief Medical Officer, provides oversight of quality, safety and clinical governance controls. The Group receives assurance reports, undertakes thematic reviews, and provides regular escalation and annual summaries to the Quality, Access and Outcomes Committee. Clinical governance processes—such as incident management, clinical audit, patient experience reporting and regulatory readiness—are embedded within Care Groups, enabling risks to be managed at source.

Risk Management Oversight: The Director of Governance & Communications holds executive responsibility for risk management. Directors and senior managers are accountable for identifying, assessing and managing risks within their portfolios, supported by training, guidance and risk management tools. The BAF and risk register processes ensure visibility of organisational risk and enable systematic review of controls and assurance levels across the Trust.


Other Review and Assurance Mechanisms: We also use targeted reviews, performance and accountability meetings, data quality audits, and external regulatory assessments to inform our view of internal control effectiveness. Findings and recommendations from these mechanisms feed into Board and Committee assurance processes.

Addressing Control Gaps: Where internal or external reviews identify gaps in control, action plans are developed, monitored and reviewed by the relevant committee, or Executive Group. During the year, targeted improvement plans have been put in place in areas requiring further strengthening, including operational performance, data quality, and aspects of clinical governance, with progress monitored through established governance routes.

Conclusion

In preparing this statement I have considered the corporate, quality and clinical governance infrastructure, functionality and effectiveness in place. The Board remain committed to continuous improvements and enhancement of the systems of internal control. In line with the guidance on the definition of no significant control issues, I have no significant control issues to declare within this year's statement. My review confirms that University Hospitals of North Midlands NHS Trust has a good system of governance and stewardship that supports the achievement of its policies, aims and objectives.

Dr Simon Constable
Chief Executive
DATE



DRAFT

Speaking Up

We encourage and welcome speaking up and we are committed to listening to those who do. Our colleagues understand that by speaking up they are playing a vital role in helping us to continuously improve.

Speaking up is fundamental to creating a safe, inclusive and supportive culture. We are committed to ensuring that all colleagues feel able to raise concerns wherever they work, including those who may be harder to reach or who belong to groups with protected characteristics. We continue to take active steps to promote psychological safety, visibility of support, and equitable access to speaking up channels.

Our Board has a nominated Non-Executive Director for Speaking Up, and our Freedom to Speak Up (FTSU) Guardian provides a comprehensive biannual report to the People, Culture and Inclusion Committee, with a summary submitted to the Trust Board. These confidential reports offer trend analysis, thematic learning, insights into cultural issues, and assurance on the development and impact of the service. Themes are triangulated with other intelligence where possible, including HR data, staff survey results and incident reporting to identify early indicators of concern.

We maintain a Speaking Up Policy that aligns with the National Guardian's Office (NGO) model policy, and it is publicly accessible on our website. During the year we continued to implement recommendations from our Internal Audit review, strengthening the consistency, governance and responsiveness of the service. Our FTSU Accountability Framework sets clear expectations for Care Groups around leadership behaviours, escalation, learning and feedback, with FTSU Champions providing local points of contact across clinical and non-clinical areas.

During 2025/26, we significantly expanded our network of Freedom to Speak Up Champions, increasing the number of active Champions across the Trust to strengthen visibility, reach and cultural influence. Champions now represent a wider range of professional groups, departments and employee networks, ensuring that colleagues have accessible, local points of contact regardless of shift pattern, work location or role. Champions support the Guardian by promoting Speaking Up, signposting colleagues, escalating concerns appropriately, and reinforcing our expectation that all colleagues act with openness, honesty and transparency. The expansion of this network has greatly enhanced our ability to provide early support, detect emerging themes and embed a culture where speaking up is normalised and supported across all levels of the organisation.

A total of 405 concerns were raised via the Freedom to Speak Up Guardian in 2025/26, an increase from 275 in 2024/25. This rise potentially reflects greater visibility, trust and confidence in the service. However, the 2025 staff survey results indicated a decline across all Freedom to Speak Up (FTSU) measures compared to 2024. While a majority of respondents continue to report feeling able to raise concerns, the reductions suggest reduced confidence in organisational response and psychological safety, which is an important area for continued focus. These findings align with wider cultural and engagement challenges reported nationally and will continue to inform our approach to culture, leadership development and Freedom to Speak Up arrangements during 2026/27.

Speaking up support is reinforced by regular walkabouts by senior leaders and Non-Executive Directors, enhanced communication routes such as "Time to Talk" sessions, and accessible digital and face-to-face contact options. All concerns are handled confidentially and independently and learning from Speaking Up informs ongoing improvements across leadership, culture and team behaviours.



DRAFT

Modern Slavery Statement

The Modern Slavery Bill was introduced into Parliament on 10 June 2014 and passed into UK law on 26 March 2025. The Modern Slavery Act is an act to make provision about slavery, servitude and forced or compulsory labour and about human trafficking, including the provision for the protection of victims.

A person commits an offence if:

- The person holds another person in slavery or servitude, and the circumstances are such that the person knows or ought to know that the other person is held in slavery or servitude.
- The person requires another person to perform forced or compulsory labour, and the circumstances are such that the person knows or ought to know that the other person is being required to perform forced or compulsory labour.

We are fully aware of the responsibilities we bear towards Our People, Our Patients and Our Population and as such, have a strict set of ethical values that we use as guidance regarding our commercial activities. We therefore expect that all our suppliers adhere to the same ethical principles.

We have a non-pay annual budget of £506m (inclusive of drugs at approximately £55m) of which more than £367m per annum is spent on goods and services.

It is important to ensure that our suppliers have in place robust systems to ensure that their own colleagues, and organisations within their own supply chain are fully compliant with the requirements of the Modern Slavery Act 2015.

In compliance with the consolidation of offences relating to trafficking and slavery within the Modern Slavery Act 2015, we have an ongoing process of reviewing our supply chains with a view to confirming that such behaviour is not taking place.

DRAFT

The standard NHS Terms and Conditions of Contract which form the basis of all orders and contracts with suppliers have a specific clause contained within them relating to modern slavery that determine that suppliers (and their sub-contractors) will:

- Comply with the Modern Slavery Act 2015.
- Implement due diligence policies for its sub-contractors.
- Respond promptly to all slavery and trafficking due diligence questionnaires.
- At our request, prepare and deliver an annual slavery and trafficking and report setting out steps to ensure slavery and trafficking is not taking place within its own supply chain.
- Implement a system for all employees to ensure compliance with the Act.

As part of our commitment to ensuring that we do not trade with organisations who do not meet the requirements of the act, suppliers will be required to provide a copy of their annual Modern Slavery Act Statutory Statement detailing actions undertaken to ensure they meet and enforce the requirements of the Act.

This will only apply to a supplier defined as a ‘commercial organisation’; in accordance with the Act if it:

- Supplies goods and services.
- Has a turnover of no less than £36m.

Our Procurement Team is committed to raising awareness with all suppliers by ensuring that all suppliers we trade with are aware of our commitment to ensure compliance with the Act. As part of our procurement processes, when trading with new suppliers, and prior to establishing the supplier on our systems, the supplier will be requested to confirm in writing that they are compliant with the Act.

Remuneration Report

Setting out our approach to senior pay, reward and transparency, and how remuneration decisions are governed and assured.

DRAFT

Remuneration policy for directors and senior managers

The Board delegates responsibility to its Nominations and Remuneration Committee to determine the appointment, remuneration and terms of service for Executive Directors, including the Chief Executive

Role and scope of the Committee

The Nomination and Remuneration Committee provides oversight of our pay and reward arrangements and is responsible for determining remuneration, contractual terms and conditions of service for Executive Directors and Very Senior Managers (VSMs) who are not covered by the NHS Agenda for Change (AfC) pay framework. The majority of our workforce, including the first tier of management below Board level, is remunerated in accordance with AfC arrangements and therefore falls outside the Committee's direct remit.

The Committee also has responsibility for overseeing senior appointments, succession planning and compliance with the Fit and Proper Persons Regulations, providing assurance to the Trust Board that robust processes are in place.

Appointments and succession planning

The Committee oversees the process for the appointment of Executive Directors and supports the Trust Board in ensuring that appointments are made through open, fair and transparent processes, aligned to national guidance and best practice, with advice sought from NHS England and external assessors included on selection panels. Where vacancies arise in established Executive Director roles, the Committee's expectation is to appoint substantively wherever possible, recognising that Executive Directors are typically subject to a six-month contractual notice period. Non-Executive Directors are appointed through NHS England as public appointees, on a fixed term-of-office basis and in line with the NHS Code of Governance. Once appointed, induction programmes are set for new directors, with Non-Executive Directors attending specific NHS Providers induction training. We also maintain appropriate insurance/indemnity arrangements for directors in line with usual practice.

Succession planning is considered on a regular basis as part of the Committee's annual work programme. This includes reviewing the balance of skills, knowledge, experience and capacity across the Board, identifying future leadership requirements, and supporting the development of a diverse and sustainable pipeline for senior leadership roles. These arrangements are intended to support both continuity of leadership and longer-term organisational resilience.

Remuneration policy and performance

The Committee monitors and evaluates the annual performance of individual Executive Directors, taking account of advice from the Chief Executive in relation to other Executive Directors. Performance assessments inform decisions relating to remuneration, contractual variations and reward, ensuring that pay outcomes are evidence-based and linked to delivery and behaviours.

During the year, the Committee operated an annual work programme that included benchmarking of Executive Director remuneration against national lower and upper quartile benchmarks. This ensures that remuneration levels remain fair, competitive and aligned with sector standards. Any proposed changes to Executive Director pay are considered by the Committee on receipt of updated benchmarking information.

Compliance with the NHS Very Senior Manager Pay Framework

The NHS Very Senior Manager Pay Framework, published by the Department of Health and Social Care and NHS England, applies to all NHS trusts and foundation trusts. We confirm that we have complied with the requirements of the NHS Very Senior Manager Pay Framework during 2025/26.

Where the Framework required national approval for pay cases during the reporting year, we confirm that approval was sought and received in accordance with the Framework. Any decisions taken during the year were made within the parameters of national guidance.

There were no departures from the NHS Very Senior Manager Pay Framework during 2025/26. Should any future departure be required, this would be explicitly disclosed and explained within the remuneration report for the relevant reporting year.

DRAFT

Remuneration policy for directors and senior managers

The Board delegates responsibility to its Nominations and Remuneration Committee to determine the appointment, remuneration and terms of service for Executive Directors, including the Chief Executive

Severance and compensation arrangements

Compensation for the early termination of Executive Directors is limited to payment in lieu of notice, except in cases of summary dismissal. Any severance proposals outside contractual provisions must be calculated in line with national guidance. Payments falling outside these guidelines require formal approval from HM Treasury via NHS England.

The Committee considered severance and redundancy matters during the year in line with its delegated authority and thresholds, ensuring appropriate scrutiny, compliance with national requirements and value-for-money considerations.

Mutually Agreed Resignation Scheme (MARS)

During 2025/26, the Nomination and Remuneration Committee considered and approved matters relating to our Mutually Agreed Resignation Scheme (MARS) as part of its oversight of workforce change, affordability and value for money. The Committee approved the introduction and operation of the MARS scheme in line with national guidance, recognising its role as a voluntary workforce measure intended to support organisational change and cost control, while mitigating the need for compulsory redundancy wherever possible.

The Committee received assurance that the scheme was applied consistently, transparently and within the agreed parameters, and that each case was subject to appropriate scrutiny. Individual MARS applications brought forward by management, including assurance on eligibility, affordability, payback periods and anticipated recurrent savings. Particular attention was given to ensuring that decisions were supported by clear rationale, that service impact and quality considerations were appropriately assessed, and that proposals represented value for money.

Throughout the year, the Committee monitored the overall operation of the scheme, noting that conversion rates from application to approval reflected our lean management structure and the limited ability to release posts without adverse operational impact. The Committee concluded that the MARS scheme had been implemented in a controlled and compliant manner during 2025/26, with appropriate governance oversight and alignment to our financial recovery and workforce strategies.

Committee activity during 2025/26

During the period 1 April 2025 to 31 March 2026, the Nomination and Remuneration Committee met on eight occasions, including extraordinary meetings convened where required to enable timely consideration of urgent or high-risk matters.

During the year, the Committee considered and approved matters including:
processes for the appointment of senior Executive roles;

- Remuneration and contractual arrangements for Executive Directors and Very Senior Managers.
- Matters relating to the application of the NHS Very Senior Manager Pay Framework.

These activities supported effective governance, leadership stability and assurance to the Trust Board on senior pay and appointments.



DRAFT

Remuneration report - single total figure (subject to audit)

Name and Job Title	2025/26					2024/25				
	Salary	Pension Recycling Payment (Taxable)	Expense payments (taxable) total to nearest £100	All pension related benefits	TOTAL	Salary	Pension Recycling Payment (Taxable)	Expense payments (taxable) total to nearest £100	All pension related benefits	TOTAL
	(bands of £5,000) £000	(bands of £5,000) £000	£	(bands of £2,500) £000	(bands of £5,000) £000	(bands of £5,000) £000	(bands of £5,000) £000	£	(bands of £2,500) £000	(bands of £5,000) £000
Trust Board Members as at 31 March 2026:										
Dr Simon Constable, Chief Executive (from 01/09/24)	260-265			297.5-300	**555-560**	145-150			295-297.5	**440-445**
Dr Diane Adamson, Chief Medical Officer (from 16/04/25)"	215-220			40-42.5	**255-260**					
Helen Ashley, Deputy CEO / Director of Strategy *	190-195	20-25			**215-220**	190-195	20-25			**215-220**
Claire Cotton, Director of Governance & Communications*	120-125				**120-125**	110-115				**110-115**
Amy Freeman, Chief Digital Information Officer	155-160		100	77.5-80	**230-235**	145-150			45-47.5	**190-195**
Jane Haire, Chief People Officer	155-160			27.5-30	**180-185**	145-150			15-17.5	**160-165**
Mark Oldham, Chief Financial Officer*	205-210	25-30			**230-235**	200-205	20-25			**225-230**
Ann-Marie Riley, Chief Nurse	170-175			60-62.5	**230-235**	160-165			25-27.5	**190-195**
Katy Thorpe, Interim Chief Operating Officer (from 02/09/24)	165-170			120-122.5	**285-290**	90-95			65-67.5	**155-160**
Lorraine Whitehead, Director of Estates, Facilities & PFI	150-155			85-87.5	**240-245**	145-150			0v	**145-150**
Simon Evans, Chief Operating Officer (on secondment from 30/08/24)*~						75-80	5-10			**85-90**
Jackie Small, Chair (from 01/06/25)	50-55				**50-55**					
Louise Bainbridge, Non-Executive Director (from 04/11/24)	10-15				**10-15**	5-10				**5-10**
Tanya Bowen, Non-Executive Director	15-20		800		**15-20**	10-15		600		**15-20**
Prof Katie Maddock, Non-Executive Director	10-15				**10-15**	10-15				**10-15**
Margaret Monckton, Non-Executive Director (from 07/10/24)	15-20				**15-20**	5-10				**5-10**
Wendy Nicholson, Non-Executive Director (from 01/09/25, Associate to 31/08/25)	10-15				**10-15**	5-10				**5-10**
Prof Sunita Toor, Non-Executive Director	10-15		900		**10-15**	10-15		900		**10-15**
Previous Board Members:										
Tracy Bullock, Chief Executive (to 30/06/24)*						60-65	5-10			**65-70**
Dr Matthew Lewis, Chief Medical Officer (to 31/03/25) ^						225-230			65-67.5	**290-295**
Lisa Thomson, Director of Communications (to 01/06/25)	20-25			0v	**20-25**	125-130			20-22.5	**145-150**
Prof Gary Crowe, Non-Executive Director (to 31/08/25)	5-10		300		**5-10**	15-20		200		**15-20**
Arvinda Gohil, Non-Executive Director (to 31/10/24)						0-5				**0-5**
Leigh Griffin, Non-Executive Director (to 31/08/24)						5-10		200		**5-10**
Prof Andrew Hassell, Associate Non-Executive Director (to 31/01/26)	10-15				**10-15**	15-20				**15-20**
Alison Rodwell, Non-Executive Director (to 31/10/24)						5-10		200		**5-10**
David Wakefield, Chair (to 31/05/25)	10-15				**10-15**	60-65				**60-65**

DRAFT

There has been no performance pay or bonuses paid to any of the Directors in either financial year.

Pension recycling payments have been made to directors who have exited the pension scheme. These are non contractual payments and subject to annual review.

The value of pension benefits accrued during the year is calculated as the real increase in pension multiplied by 20, less the contributions made by the individual. The real increase excludes increases due to inflation or any increase or decrease due to a transfer of pension rights. This value does not represent an amount that will be received by the individual. It is a calculation that is intended to convey to the reader of the accounts an estimation of the benefit that being that being a member of the pension scheme could provide.

All taxable expenses paid during the year were in relation to home to work mileage claims.

*Board member is not a member of the NHS Pension scheme and so there are no pension benefits to report.

" Dr Diane Adamson was appointed to the role of Chief Medical Officer in an acting capacity on 16/04/25 and was appointed to the post permanently on 01/10/25. The figures shown in the table above reflects her remuneration from 16/04/25 to 31/03/26.

~ Simon Evans was on secondment at NHS England for the period 01/04/25 to 31/03/26. His total benefit figure for the year is in the band £210,000-£215,000 (2024/25 £205,000-£210,000).

^ Dr Matthew Lewis was on secondment at NHS Birmingham & Solihull ICB for the period 01/04/25 to 31/03/26. His total benefit figure for the year is in the band £320,000-£325,000 (2024/25 £290,000-£295,000)

v Where pension benefits result in a negative figure they have been substituted with "0" in accordance with the DHSC Group Accounting Manual.

Remuneration report – pension benefits (subject to audit)

Name and Job Title	2025/26						
	Real increase in pension at pension age	Real increase in pension lump sum at pension age	Total accrued pension at pension age at 31 March 2026	Lump sum at pension age related to accrued pension at 31 March 2026	Cash equivalent transfer value at 1 April 2026	Real increase in cash equivalent transfer value	Cash equivalent transfer value at 31 March 2026
	(bands of £2,500) £000	(bands of £2,500) £000	(bands of £5,000) £000	(bands of £5,000) £000	£000	£000	£000
Simon Constable, Chief Executive (from 01/09/24)	15-17.5	30-32.5	70-75	180-185	1,324	308	1,685
Diane Adamson, Chief Medical Officer (Interim from 16/04/25 to 30/09/25)	2.5-5	0-2.5	30-35	70-75	636	40	703
Helen Ashley, Deputy CEO / Director of Strategy							
Claire Cotton, Director of Governance & Communications					0		
Amy Freeman, Chief Digital Information Officer	2.5-5	5-7.5	45-50	100-105	793	70	894
Jane Haire, Chief People Officer	0-2.5	0	50-55	130-135	1,168	35	1,241
Mark Oldham, Chief Financial Officer							
Ann-Marie Riley, Chief Nurse	2.5-5	0-2.5	55-60	130-135	1,251	71	1,364
Katy Thorpe, Interim Chief Operating Officer	5-7.5	0	35-40	0	429	83	538
Lorraine Whitehead, Director of Estates, Facilities & PFI	2.5-5	5-7.5	60-65	150-155	1,297	97	1,435
Simon Evans, Chief Operating Officer (from 16/06/23 to 30/08/24) - on secondment at NHSE							

DRAFT

As non-executive directors do not receive pensionable remuneration, there will be no entries in respect of pensions for non-executive directors. The pensions information disclosed has been subject to audit.

Cash Equivalent Transfer Value (CETV)

A Cash Equivalent Transfer Value (CETV) is the actuarially assessed capital value of the pension scheme benefits accrued by a member at a particular point in time. The benefits valued are the member's accrued benefits and any contingent spouse's pension payable from the scheme. A CETV is a payment made by a pension scheme or arrangement to secure pension benefits in another pension scheme or arrangement when the member leaves a scheme and chooses to transfer the benefits accrued in their former scheme. The pension figures shown relate to the benefits that the individual has accrued as a consequence of their total membership of the pension scheme, not just their service in a senior capacity to which disclosure applies.

The CETV figures and the other pension details include the value of any pension benefits in another scheme or arrangement which the individual has transferred to the NHS pension scheme. They also include any additional pension benefit accrued to the member as a result of their purchasing additional years of pension service in the scheme at their own cost. CETVs are calculated within the guidelines and framework prescribed by the Institute and Faculty of Actuaries.

Real Increase in CETV reflects the increase in CETV effectively funded by the employer. This calculation does not take account of any increase due to inflation or contributions paid by the employee.


Fair pay disclosure and pay ratio (subject to audit)

We are required to disclose for each single total figure table (page 72), the percentage change from the previous year in respect of the highest paid director and the average percentage change from the previous financial year in respect of employees taken as a whole.

Percentage changes for the current and prior year are shown below for salary and allowances. Changes for the highest-paid director are calculated using the midpoint of the relevant pay band. Employee averages exclude the highest-paid director and are based on annualised full-time equivalent (FTE) remuneration. As we do not operate a performance-related pay or bonus scheme, no percentage changes are reported for this component.

	2025/26		2024/25	
	Highest paid director % change	All employees (average) % change	Highest paid director % change	All employees (average) % change
Salary and allowances	3.96%	5.49%	4.12%	3.01%

Changes in remuneration may vary between years due to factors such as national pay awards, incremental progression within bands, recruitment or departure of senior directors, changes in bonus arrangements, or organisational restructuring. Differences between director and employee averages may reflect the structure of director contracts, performance-related elements, and the distribution of pay across the wider workforce.



We are required to disclose information on the range of employee remuneration and the ratio between the remuneration of the highest-paid director and employee remuneration at the 25th percentile, median and 75th percentile. Pension benefits are excluded from the calculation of the remuneration range. These ratios are based on annualised full-time equivalent (FTE) remuneration for all employees, including temporary and agency employees, as at the reporting date. The ratios are calculated using the mid-point of the banded remuneration of the highest-paid director.

The banded remuneration of the highest paid director in the Trust in the financial year 2025/26 was £260,000 to £265,000 (2024/25: £250,000 to £255,000). The relationship to the remuneration of the organisation's workforce is disclosed in the below table opposite.

	2025/26	2024/25
25th percentile ratio	8.59:1	8.84:1
Median ratio	6.37:1	6.53:1
75th percentile ratio	4.80:1	4.78:1

The highest paid director's salary range mid-point was £262.500 (2024/25: £252,500). This is an increase of 3.96% (2024/25: 4.12%). The overall average remuneration of the organisation increased from £53,533 in 2024/25 to £56,471 in 2025/26. This represents a percentage increase of 5.49% (2024/25: 3.01%).

Based on annualised, full-time remuneration the 25th percentile of pay at 31st March 2026 was £30,555, the median was £41,198 and the 75th percentile was £54,710.

In 2025/26, 21 employees (2024/25 17 employees) received remuneration in excess of the highest paid director. The range of staff remuneration during 2025/26 was £10,000 - £15,000 to £485,000 - £490,000 (2024/25 £10,000-£15,000 to £420,000- £425,000).

Please note that previous year's disclosures have been calculated including Non-Executive Directors salaries. For 2025/26 NED salaries have been removed.

Total remuneration includes salary, non-consolidated performance-related pay and benefits-in-kind. It does not include employer pension contributions, the cash equivalent transfer value of pensions or severance payments.

DRAFT

Staff Report

DRAFT

Providing an overview of our workforce, how we support, develop and engage our people, and how we meet our responsibilities as a fair and inclusive employer.

Our People

We employ more than 12,500 colleagues comprising more than 70 nationalities. Most of our colleagues are employed and paid under national pay arrangements established under Agenda for Change or medical and dental provisions.

A small number of colleagues, comprising the Trust Board and very senior managers, are employed under local pay and terms and conditions of service, which are determined by the Trust Board's Nomination and Remuneration Committee. This ensures appropriate governance, transparency and consistency with national guidance.

All colleagues are employed subject to meeting NHS Standards on Employment Checks. These include identity, right-to-work, professional registration, references, health checks and Disclosure and Barring Service (DBS) requirements. These checks provide assurance that individuals are suitable for employment and legally entitled to work within the organisation before commencing their role.

Our values and behaviours, refreshed and relaunched in April 2025, are embedded across the organisation and underpin how we work together and deliver care. We expect all colleagues to uphold these standards, and they are integral to our recruitment, induction and ongoing performance processes.

We adopt national pay, terms and conditions of service wherever applicable. This provides assurance that employees are treated fairly and consistently and that we comply with employment legislation, including payment of at least the National Living Wage. We also have a comprehensive suite of employment policies and procedures in place to support colleagues and managers and to ensure compliance with employment law. All policies are subject to equality impact assessment to ensure they promote fairness, inclusion and accessibility.

Robust safeguarding arrangements are in place to protect children and vulnerable adults. Colleagues are supported through an extensive training and development programme, including mandatory and role-specific training. Individual training needs are identified through annual performance development reviews, supported by personal development plans.

We have a dedicated Equality, Diversity and Inclusion (EDI) lead within the Organisational Development Team. We actively support local and national awareness-raising events and initiatives, including those focused on disability inclusion, anti-racism and the LGBT+ community.

Our People Plan

Our workforce is central to delivering our vision of providing the best joined-up care for all. By valuing our people, investing in their development and creating the right conditions for excellent care, we aim to be an organisation where people want to work and where patients want to receive care.

Launched alongside Our Strategy in April 2025, the People Plan sets out our priorities for the next ten years. It reflects our commitment to building a sustainable, skilled and inclusive workforce and to supporting colleagues at all stages of their careers, regardless of role, background, nationality or contract type.

We recognise the importance of our wider and indirect workforce, including volunteers, contractors and agency colleagues, and remain committed to working in partnership with them to deliver safe and effective services.

We continue to invest in the safety, health and wellbeing of our people and to promote equality of opportunity. Our bespoke training and development offer is designed to build values-led leadership capability, strengthen inclusion and equip our workforce to meet current and future challenges.

As an anchor institution, we are committed to providing opportunities across our local population, including school leavers, graduates, members of the armed forces community, retirees and volunteers. We will continue to develop our wellbeing offer and employee networks to support our people to thrive.

We recognise that workforce challenges cannot be addressed in isolation. As a lead employing organisation within our Integrated Care System, we work closely with system partners to deliver shared priorities for people, culture and inclusion, supporting a sustainable workforce for the communities we serve.

DRAFT

Staff numbers, cost and composition (subject to audit)

On 31 March 2026, we had a workforce of 11,961 whole time equivalents (WTE). This excludes bank workers, honorary contracts and colleagues out on secondment. Our workforce is made up of a variety of roles and pay scales and below provides an analysis of average employee numbers and costs.

Senior Managers

	Headcount		WTE	
	Female	Male	Female	Male
Band 8a	365	120	332.3	114.5
Band 8b	88	45	78.2	43.8
Band 8c	41	19	37.9	18.2
Band 8d	9	14	8.8	14.0
Band 9	13	4	12.9	4.0
Director	7	4	6.8	4.0
Total	**523**	**206**	**476.9**	**198.6**

Average Number of Employees (WTE basis) (audited)

	2025/26			2024/25
	Permanent	Other	Total	Total
Medical and dental	794	863	**1,657**	1,597
Ambulance staff	-	-	**-**	-
Administration and estates	2,473	115	**2,588**	2,588
Healthcare assistants and other support staff	2,293	71	**2,365**	2,469
Nursing, midwifery and health visiting staff	3,781	60	**3,841**	3,649
Nursing, midwifery and health visiting learners	19	10	**29**	26
Scientific, therapeutic and technical staff	1058	26	**1084**	1,017
Healthcare science staff	389	7	**397**	389
Social care staff	-	-	**-**	-
Other	-	-	**-**	-
Total average numbers	**10,809**	**1,152**	**11,961**	**11,735**
Of which:				
Number of employees (WTE) engaged on capital projects				**27**

Staff Costs

	2025/26			2024/25
	Permanent	Other	Total	Total
	£000	£000	£000	£000
Salaries and wages	578,340	57,570	**635,910**	599,809
Social security costs	71,809	7,778	**78,787**	58,598
Apprenticeship levy	3,142	-	**3,142**	2,899
Employer's contributions to NHS pension scheme	114,698	5,523	**120,221**	108,750
Pension cost - other	98	8	**106**	128
Temporary staff	-	13,513	**13,513**	18,655
Total staff costs	**767,287**	**84,392**	**851,679**	788,849
Of which:				
Costs capitalised as part of assets	2,587	-	**2,587**	1,527
Total employee benefits excluding capitalised costs	**764,700**	**84,392**	**849,092**	787,322

Staff Composition

	Part Time		Full Time		Total
	Female	Male	Female	Male	
Director	0	1	4	6	**11**
Senior Managers (Band 8a - 9 & senior manager)	15	103	180	367	**665**
Other employees	552	3729	2365	4639	**11286**
Total	**567**	**3833**	**2549**	**5012**	**11961**

DRAFT

Sickness absence and turnover

Sickness Absence

We have a clear and robust framework within which managers are supported to address the issues of attendance and sickness with a consistent, supportive and fair approach through our Attendance Policy. There is a strong focus on workforce health and wellbeing across our organisation, as set out within our People Strategy.

Initiatives such as health and wellbeing drop in events have successfully been held, with targeted approaches for those areas with higher sickness absence rates and signposting to appropriate support. Our appraisal framework is also designed to focus on the health and wellbeing of individuals.

These preventative measures support our workforce to remain healthy in the workplace.

The sickness rate on 31 March 2026 (cumulative for the 12 months from 1 April 2025 to 31 March 2026) was 5.38% (5.29% on 31 March 2025).

Turnover

We have seen a reduction in turnover when compared to last year, which is a positive outcome of our focus on colleague wellbeing and personal development. We continue to support individuals to return to the workplace following retirement, recognising their invaluable skills and experience.

We support employees to achieve a work/life balance by offering both flexible and agile working arrangements. Individuals and line managers are encouraged to reflect upon the flexibility of roles and are supported to do so through dedicated policies and toolkits.

The turnover rate on 31 March 2026 (cumulative for the 12 months from 1 April 2025 to 31 March 2026) was 7.5% (7.08% on 31 March 2025). This excludes junior doctors on rotation.



DRAFT


NHS staff survey

Staff engagement is measured through the annual NHS Staff Survey. As at March 2026, our staff engagement score for 2025 was 6.67, slightly lower than the average of 6.74 for acute and acute and community trusts.

The 2025 NHS Staff Survey remained a key source of insight into colleague experience during the year. Results showed a slight deterioration in overall engagement and across a number of People Promise themes compared to 2024, with performance sitting just below the peer average. This position reflects wider national trends across the NHS in a challenging operating environment. Variation in experience across teams was evident. These findings have informed in-year oversight and action planning, with a continued focus on strengthening local leadership, communication and targeted improvement activity to improve colleague experience, recognising its importance in delivering high-quality patient care.

Our staff engagement score decreased slightly from 6.84 in 2024 to 6.67 in 2025. Staff Morale also slightly declined from 5.97 in 2024 to 5.86 in 2025, which remains just above the benchmarking group for acute and acute and community trusts of 5.84.

The benchmarked findings are show in the graph here:



	We are compassionate and inclusive	We are recognised and rewarded	We each have a voice that counts	We are safe and healthy	We are always learning	We work flexibly	We are a team	Staff Engagement	Morale
Your org	7.12	5.64	6.48	6.04	5.41	6.05	6.46	6.67	5.86
Best result	7.71	6.34	7.12	6.58	6.21	6.74	7.14	7.36	6.42
Average result	7.28	5.87	6.60	6.07	5.57	6.22	6.75	6.74	5.84
Worst result	6.71	5.27	5.93	5.51	4.98	5.69	6.29	5.92	5.06
Responses	5371	5369	5299	5328	5108	5325	5360	5362	5368



DRAFT

Staff policies applied during the financial year

Our People Plan outlines how we will make UHNM a great place to work and set out our aims to provide a positive work environment that promotes an open, supportive and fair culture which helps our colleagues to do their job to the best of their ability and ensure delivery of high-quality care.

We have a comprehensive suite of policies in place to ensure compliance with equality, diversity and human rights legislation and to promote fair and inclusive employment practices. We are committed to creating an environment where all colleagues are supported to perform to the highest standards and where people are treated with dignity, respect and fairness.

Recruitment and employment of disabled people

We are committed to giving full and fair consideration to applications for employment from disabled people, having regard to their particular aptitudes and abilities. Our Recruitment and Selection Policy requires applicants to be assessed solely against objective, job-related criteria and their ability to undertake the role, with no unlawful discrimination. Reasonable adjustments are offered throughout the recruitment process to ensure disabled applicants are not disadvantaged. Members of Appointments Advisory Committees recruiting to consultant posts are required to have received training in equality and diversity.

Retention and support of colleagues who become disabled

We are committed to supporting employees who become disabled during their employment with us. Our Occupational Health Policy provides access to professional advice to support colleagues and managers in identifying appropriate workplace adjustments, redeployment opportunities where necessary, and support to enable individuals to continue in employment wherever possible. Adjustments are made in line with the Equality Act 2010, and employees are supported through occupational health referrals, management support and, where appropriate, phased returns to work.

Training, development and career progression

We are committed to supporting the training, career development and promotion of disabled employees. Equality, diversity and inclusion principles are embedded within corporate and local induction programmes and reinforced through statutory and mandatory training. Individual training and development needs, including any adjustments required to support learning or career progression, are identified through annual performance development reviews and personal development plans. Training records are maintained electronically to support assurance and monitoring.

Policies, safeguarding and culture

All employment policies are equality impact assessed to ensure they promote inclusion and accessibility. We have specific policies in place to safeguard children and vulnerable adults and to support a culture of positive behaviours. Our Resolution Policy supports early and constructive resolution of workplace issues, helping to maintain positive employment relationships and a supportive working environment.

We also have a dedicated Equality, Diversity and Inclusion lead within the Organisational Development Team and supports local and national awareness-raising initiatives, including those focused on disability inclusion, anti-racism and the LGBT+ community.



DRAFT

Equality, diversity and inclusion (EDI)

As referenced earlier within this report, we have developed a comprehensive strategy which sets out our longer-term ambitions for Equality, Diversity and Inclusion.

Equality, Diversity and Inclusion (Workforce)

Creating an inclusive, fair and equitable workplace remains central to our People Strategy and to our long-term ambition to build a workforce that reflects the communities we serve and supports all colleagues to thrive. Our approach is underpinned by our EDI Strategy, delivery plan and EDI Policy, which together set clear expectations for inclusive practice, fair treatment and full compliance with statutory duties. A new Lead Educator role for nursing, midwifery and allied health professionals ensures that equity and inclusion are embedded in workforce development and clinical practice, supporting our ongoing focus on tackling health inequalities, anti-racism and accessibility.

Policies and Governance

Our EDI Policy ensures that equality, diversity and inclusion are consistently embedded across the organisation. This includes the fair and equitable application of all employment policies, access to EDI-related learning for all colleagues, and the active promotion of a strong speaking-up culture where colleagues feel supported and confident to raise concerns.

Our well-established Diversity Employee Networks—covering ethnicity, disability and long-term conditions, LGBTQ+, and the armed forces—play an essential role in shaping an inclusive and compassionate workplace and informing organisational priorities. The Men's and Women's Health Groups also contribute to our workforce wellbeing strategy.

An annual programme of inclusion events—including Black History Month, Race Equality Week, Pride Month, Disability History Month and key religious and cultural celebrations—strengthens organisational culture, enhances cultural competence and amplifies marginalised voices. These activities reinforce our commitment to being an inclusive, values-led Trust.

Progress and Workforce Performance in 2025/26

During 2025/26 we achieved progress across several key indicators, including increased ethnic diversity in senior roles, improved access to workplace adjustments and a continued narrowing of the Gender Pay Gap. To strengthen accountability and alignment with Board priorities, we introduced the EDI Assurance Framework.

To support transparency and fulfil our responsibilities under the Public Sector Equality Duty, we publish an annual EDI Report alongside our Workforce Race Equality Standard (WRES), Workforce Disability Equality Standard (WDES) and Gender Pay Gap reports. This year we voluntarily extended reporting to include ethnicity and disability pay gaps.

Commitment to Anti Racism

We remain committed to creating an environment free from racism and discrimination. Guided by our Anti-Racism Statement and supported by the Ethnic Diversity Employee Network, we continue to address bias in policy, process and culture. A Race Equality Task and Finish Group is driving this work through lived-experience insights and best practice, focusing on:

- Debiasing recruitment and selection.
- Improving equity in career development and promotion.
- Tackling harassment, bullying and abuse.

In October 2025, we marked our progress by hosting our first Anti-Racism Conference as part of Black History Month. Our We're People Too campaign, co-designed by colleagues, further raises awareness of the impact of racism and abuse on colleagues and supports our wider anti-racism ambitions.

Identified Barriers and Targeted Action

Despite improvements, challenges remain in relation to senior-level representation of global majority colleagues and women, disparities in recruitment outcomes, and poorer workplace experiences reported by disabled and global majority colleagues. Disability and ethnicity pay gap analyses highlight structural factors linked to representation across pay quartiles.

To address these issues, we have strengthened our approach through the Race Equality Task and Finish Group, a refreshed Reasonable Adjustments Policy, enhanced employee networks with executive sponsorship, development of EDI dashboards and targeted leadership development and inclusive recruitment initiatives.

Oversight of this work is provided through the People, Culture and Inclusion Committee and the Trust Board.

DRAFT

Board and senior leadership ethnic diversity (WRES Indicator 9)

We monitor the ethnic diversity of the Board and senior leadership in comparison with our wider workforce and local communities. While workforce ethnicity increased to 29.2% in 2025, senior representation does not yet reflect this position. Addressing this gap remains a priority and is being progressed through targeted succession planning, inclusive recruitment practices, leadership development and executive sponsorship of employee networks, with assurance provided through the People, Culture and Inclusion Committee and the Trust Board.

Workforce composition and trends

We undertake an annual analysis of workforce demographics, published in our EDI Annual Report. This includes year-on-year trend data across ethnicity, disability, gender and pay band. At 31 March 2025, Black, Asian and Minority Ethnic colleagues represented 29.2% of the workforce, with higher representation in clinical and medical roles and lower representation in senior non-clinical roles. This remains a priority area for improvement.

Looking ahead

While progress continues, key challenges remain—particularly under-representation of marginalised groups at senior levels, recruitment disparities and poorer experiences reported by disabled and global majority colleagues. We will continue to embed equity and inclusion across all areas of the organisation, centring the voices of patients, colleagues and communities through the Hospital User Group, Patient Leaders and Employee Networks.

Guided by our new UHNM Strategy and the NHS Equality, Diversity and Inclusion Improvement Plan's six high-impact actions, we will deliver measurable improvements for our people, patients and population. Progress will be tracked through robust KPIs, including patient satisfaction, the National Staff Survey, WRES/WDES outcomes and equity metrics such as pay gaps.

DRAFT



Other Employee Matters

This section provides a high-level overview of other employee-related matters, reflecting how we engage with colleagues and supports a safe, inclusive and sustainable working environment, in line with statutory reporting requirements.



We engage with colleagues and their representatives on matters affecting the workforce, including organisational change, workforce planning, health and safety, wellbeing and equality. This engagement supports employee participation, constructive dialogue and informed decision-making on issues that impact colleagues.

Health and safety at work is supported through established governance arrangements, statutory training and risk management processes, with appropriate involvement of employee representatives where required.

Our approach to employee engagement and employee relations forms part of a broader focus on human capital management, including workforce sustainability, development, wellbeing and inclusion. These priorities are embedded within our People Plan and workforce strategies, supporting colleague engagement, retention and a safe, respectful and inclusive working environment.

Consultancy expenditure and off-payroll engagements

Consultancy

Expenditure on consultancy services for the year 2025/26 was £1,904m, compared to £1.206m in 2024/25.

Off Payroll Engagements

As part of the Treasury's Annual Reporting Guidance, Government Departments are required to report information relating to off-payroll engagements. Therefore, NHS bodies are required to include information on any such engagements allowing for consolidation.

The table here shows all off-payroll engagements as of 31 March 2026, for more than £245 per day:

	Number
Number of existing engagements as of 31 March 2026	2
Of which, the number that have existed:	
for less than one year at the time of reporting	2
for between one and two years at the time of reporting	0
for between 2 and 3 years at the time of reporting	0
for between 3 and 4 years at the time of reporting	0
for 4 or more years at the time of reporting	0

For all off-payroll engagements between 1 April 2025 and 31 March 2026, for more than £245 per day:

	Number
Number of temporary off-payroll workers engaged between 1 April 2025 and 31 March 2026	4
Of which:	
number not subject to off-payroll legislation	0
number subject to off-payroll legislation and determined as in-scope of IR35	1
number subject to off-payroll legislation and determined as out of scope of IR35	3
the number of engagements reassessed for compliance or assurance purposes during the year	0
of which, number of engagements that saw a change to IR35 status following review	0

All existing off-payroll engagements have at some point been subject to a risk- based assessment as to whether assurance is required that the individual is paying the right amount of tax and where necessary, that assurance has been sought.

For any off-payroll engagements of board members, and/or senior officials with significant financial responsibility, between 1 April 2025 and 31 March 2026:

	Number
Number of off-payroll engagements of board members, and/or senior officers with significant financial responsibility during the financial year	0
Total number of individuals on payroll and off-payroll that have been deemed 'board members', and/or senior officials with significant financial responsibility during the financial year. This figure must include both on payroll and off payroll engagements.	0



DRAFT

Exit packages (subject to audit)

Exit Packages 2025/26

Exit package cost band (including any special payment element)	2025/26						2024/25					
	No. of compulsory redundancies	Cost of compulsory redundancies £000	No. of other departures agreed	Cost of other departures agreed £000	Total no. of exit packages	Total cost of exit packages £000	No. of compulsory redundancies	Cost of compulsory redundancies £000	No. of other departures agreed	Cost of other departures agreed £000	Total no. of exit packages	Total cost of exit packages £000
Less than £10,000			57	240	57	**240**	0	0	31	95	31	95
£10,000 - £25,000			10	181	10	**181**	0	0	3	37	3	37
£25,001 - £50,000	1	27	6	226	7	**253**	0	0	0	0	0	0
£50,001 - £100,000	1	93	1	57	2	**150**	0	0	0	0	0	0
£100,001 - £150,000			0	0	0	**0**	0	0	0	0	0	0
£150,001 - £200,000			0	0	0	**0**	0	0	0	0	0	0
>£200,000			0	0	0	**0**	0	0	0	0	0	0
Total	**2**	**120**	**74**	**704**	**76**	**824**	**0**	**0**	**34**	**132**	**34**	**132**

- Redundancy and other departure costs have been paid in accordance with standard NHS terms and conditions.
- This disclosure reports the number and value of exit packages agreed with colleagues during the year.
- The remuneration information disclosed in the tables above have been subject to audit.

During the year the Trust offered a Mutually Agreed Resignation Scheme (MARS). The number and value of agreed schemes is shown in the table below. The costs of this scheme were not met by the NHS Pension Scheme.

Exit Packages: other departure payments

Type of departures	Agreements	Total value of agreements
	Number	£000s
Voluntary redundancies including early retirement contractual costs		
Mutually agreed resignations (MARS) contractual costs	17	386
Early retirements in the efficiency of the service contractual costs		
Contractual payments in lieu of notice	56	308
Exit payments following Employment Tribunals or court orders		
Non-contractual payments requiring HMT approval	1	10
Total	**74**	**704**

DRAFT



Dr Simon Constable
Chief Executive
DATE

3 Financial Statements

DRAFT

Summary Financial Statements

A commentary on our financial position is included earlier in this report. The following pages are our Summary Financial Statements.

The Statement of Comprehensive Income shows how much money we earned and how we spent it. The main source of our income is from ICS, with which we have agreements to provide services for their patients.

Our biggest expense is on the salaries and wages of our staff. On average during this year, we employed the equivalent of 11,961 full-time staff (11,459 24/25). The actual number of people working for the Trust is more because some staff work part-time (therefore, the full-time equivalent is less).

We buy clinical and general supplies, maintain our premises, some of the costs of which are payable to our PFI partner, and pay for gas and electricity, rent and rates. We also allow for depreciation, the wearing out of buildings and equipment which need to be replaced.

Our Statement of Financial Position summarises our assets and liabilities. It tells us the value of the land, buildings and equipment we own and of supplies we hold in stock for the day to day running of the hospital. It also shows money owed to us and the money we owe to others, mainly for goods and services received but not yet paid for. Under International Financial Reporting Standards, it also shows buildings and equipment that are legally owned by our PFI partner and related borrowings which will be settled through the unitary payments we make over the term of the PFI contracts.

The Trust's valuation approach is to have a full valuation including a full site inspection every 5 years with interim "desk top" valuations on an annual basis. A full valuation was undertaken as at 31st March 2022, which included site valuations to provide assurance that the value of land and building assets within the accounts are not materially misstated at the balance sheet date. An interim valuation was undertaken as at 31st March 2026 as well as a site visit at the Clinical Diagnostic Centre and County Breast Unit as these were significant capital schemes that were completed during the year and would impact the valuation.

The net book value of the Trust's estate as at 31st March 2026 is £640.580 million. If the Trust's management had not revalued the estate, at 31st March 2026 the value would have been £657.042 million.

The Trust obtains valuations for its land, buildings and dwellings from a qualified independent valuer. These valuations are performed at a point in time and take into account conditions and circumstances relevant to that date. In future years, conditions may change resulting in uplifts or impairments being required to the value of land, buildings and dwellings. The valuation has been completed based on the depreciated replacement cost and the remaining useful economic life of the assets.

The Better Payment Practice Code shows how quickly we pay our bills.

DRAFT

Summary Financial Statements

Statement of Comprehensive Income for the year ended 31 March 2026

	2025/26	2024/25
	£000	£000
Operating income from patient care activities	1,271,227	1,186,037
Other operating income	109,088	106,840
Operating expenses	(1,364,149)	(1,271,731)
Operating surplus from continuing operations	**16,166**	**21,147**
Finance income	5,185	6,054
Finance expenses	(30,144)	(35,422)
PDC dividends payable	(4,545)	(3,530)
Net finance costs	**(29,504)**	**(32,898)**
Other gains	137	70
Surplus for the year	**(13,201)**	**(11,681)**
Other comprehensive income		
Impairments	(7,960)	(8,095)
Revaluations	6,013	11,724
Total comprehensive income/(expense) for the period	**(15,148)**	**(8,052)**

Financial Performance for the year

	2025/26	2024/25
	£000	£000
Surplus for the year	**(13,201)**	**(11,681)**
Remove net impairments not scoring to the departmental expenditure limit	18,183	268
Remove I&E impact of capital grants and donations	(2,756)	(4,293)
Remove impact of IFRS 16 on IFRIC 12 schemes	(6,965)	(2,442)
Remove net impact of DHSC provided inventories for Covid response	0	92
Reported NHS financial performance position	**(4,739)**	**(18,056)**

Statement of Financial Position as at 31 March 2026

	Note	2025/26	2024/25
		£000	£000
Non-current assets			
Property, plant and equipment		734,232	715,699
Intangible assets		14,615	15,985
Right of use assets		22,062	23,087
Trade and other receivables		1,018	1,105
Total non-current assets		**771,927**	**755,876**
Current assets			
Inventories		21,429	19,219
Trade and other receivables		51,579	43,518
Non-current assets held for sale		7,700	10,900
Cash and cash equivalents		88,083	84,186
Total current assets		**168,776**	**157,823**
Total assets		**940,704**	**913,699**
Current liabilities			
Trade and other payables		(137,226)	(129,415)
Provisions		(1,054)	(8,469)
Borrowings		(28,792)	(20,286)
Total current liabilities		**(167,072)**	**(158,170)**
Total assets less current liabilities		**773,632**	**755,529**
Non-current liabilities			
Provisions		(3,407)	(2,783)
Borrowings		(482,248)	(490,255)
Total non-current liabilities		**(485,655)**	**(493,038)**
Total assets employed		**287,977**	**262,491**
Financed by			
Public dividend capital		775,578	734,943
Revaluation reserve		(691,911)	(680,749)
Income and expenditure reserve		204,310	208,297
Total taxpayers' equity		**287,977**	**262,491**

DRAFT

Summary Financial Statements

Statement of cash flows for the year ended 31 March 2026

	2025/26	2024/25
	£000	£000
Cash flows from operating activities		
Operating surplus	16,166	21,055
Non-cash income and expense:		
Depreciation and amortisation	47,771	39,720
Net impairments / (reversal of impairments)	18,183	360
Income recognised in respect of capital donations	(4,809)	(6,047)
(Increase)/decrease in inventories	(2,210)	(1,504)
(Increase)/decrease in receivables and other assets	(6,314)	(1,010)
Increase/(decrease) in payables and other liabilities	5,377	4,173
Increase/(decrease) in provisions	(6,830)	3,258
Net cash generated from / (used in) operating activities	**61,334**	**60,005**
Cash flows from investing activities		
Interest received	5,185	6,054
Purchase of intangible assets	(3,226)	(6,266)
Purchase of property, plant and equipment	(68,741)	(63,650)
Sales of property, plant and equipment	137	88
Receipt of capital donations to purchase capital assets	7,032	3,823
Net cash inflow/(outflow) from investing activities	**(59,613)**	**(59,951)**
Cash flows from financing activities		
Public dividend capital received	40,635	41,042
Capital element of finance lease rental payments	(4,457)	(4,001)
Capital element of PFI	(15,533)	(21,964)
Other interest	(7)	(1)
Interest paid on finance lease liabilities	(528)	(286)
Interest paid on PFI	(12,909)	(13,011)
PDC dividend (paid)/refunded	(5,040)	329
Net cash generated from / (used in) financing activities	**2,161**	**2,108**
Increase/(decrease) in cash and cash equivalents	**3,882**	**2,162**
Cash and cash equivalents at 1 April - brought forward	**84,186**	**82,024**
Cash and cash equivalents at 31 March	**88,068**	**84,186**

Statement of changes in Taxpayers Equity for the year ended 31 March 2026

	Public dividend capital	Revaluation reserve	Income and expenditure reserve	Total
	£000	£000	£000	£000
Taxpayers' and others' equity at 1 April 2025 - brought forward	**734,943**	**208,297**	**(680,750)**	**262,490**
Withdrawal of revaluation model for intangible assets on 1 April 2025	0	(2,040)	2,040	**0**
Surplus for the year	0	0	(13,201)	**(13,201)**
Impairments	0	(7,960)	0	**(7,960)**
Revaluations	0	6,013	0	**6,013**
Public dividend capital received	40,635	0	0	**40,635**
Taxpayers' and others' equity at 31 March 2026	**775,578**	**204,310**	**(691,911)**	**287,977**

Note 35 Better Payments Practice Code

Measure of compliance	2025/26		2024/25	
	Number	£000	Number	£000
Total non-NHS trade invoices paid in the year	124,713	722,221	129,880	714,550
Total non-NHS trade invoices paid within target	122,554	712,867	127,660	700,695
Percentage of non-NHS trade invoices paid within target	**98.3%**	**98.7%**	**98.3%**	**98.1%**
Total NHS trade invoices paid in the year	2,937	48,196	2,756	44,377
Total NHS trade invoices paid within target	2,557	39,400	2,458	38,564
Percentage of NHS trade invoices paid within target	**87.1%**	**81.7%**	**89.2%**	**86.9%**

The Better Payments Practice Code requires us to aim to pay all undisputed invoices by the due date or within 30 days of receipt of goods or a valid invoice, whichever is later. We have not signed up to the Prompt Payments Code.

DRAFT

Summary Financial Statements

Cumulative Breakeven Position

Year	Turnover	Surplus/(deficit)
	£000	£000
1997/1998	152,393	(1,199)
1998/1999	165,535	(1,246)
1999/2000	182,744	1,279
2000/2001	193,823	1,225
2001/2002	212,576	18
2002/2003	235,801	4
2003/2004	257,641	3
2004/2005	295,327	41
2005/2006	299,619	(15,059)
2006/2007	333,855	311
2007/2008	393,915	3,990
2008/2009	371,299	3,008
2009/2010	408,938	5,312
2010/2011	418,078	4,141
2011/2012	426,319	1,050
2012/2013	473,558	235
2013/2014	475,330	(19,301)
2014/2015	623,395	3,782
2015/2016	702,917	(26,936)
2016/2017	739,279	(27,773)
2017/2018	696,630	(69,717)
2018/2019	713,838	(63,607)
2019/2020	840,636	5,231
2020/2021	915,076	7,085
2021/2022	980,348	9,126
2022/2023	1,064,132	47
2023/2024	1,151,805	(8,375)
2024/2025	1,292,878	(15,614)
2025/2026	1,380,315	2,226
Cumulative breakeven position		**(200,713)**

We have a statutory duty to break even on a cumulative basis. Due to the continued cumulative deficit and the expectation that expenditure will exceed income for the foreseeable future, the External Auditors issued a Section 30 referral to the Secretary of State for Health on 28 May 2025. This follows earlier referrals in 2017 and 2021.

Our External Auditor

To demonstrate that we are running our Trust properly we are required to publish a number of statements which are signed by our Chief Executive on behalf of our Trust Board. These statements cover our financial affairs as well as a number of other aspects of managing our Trust.

Our external auditor also checks our accounts and other aspects of our work, and we are required to publish statements from them confirming that they are satisfied with what we have done. These formal statements are reproduced on these pages.

Our accounts are externally audited by Grant Thornton UK LLP to meet the statutory requirements of the Department of Health. They receive fees of £318k (inc VAT)

Pension Costs

Past and present employees are covered by the provisions of the NHS Pension Scheme. The scheme is an unfunded defined benefit scheme that covers NHS employers, general practices and other bodies, allowed under the direction of the secretary of State, in England and Wales. As a consequence, it is not possible for our Trust to identify our share of the underlying scheme assets and liabilities. Therefore, the scheme is accounted for as a defined contribution scheme and the cost of the scheme is equal to the contributions payable to the scheme for the accounting period.

Full Accounts

A full set of audited accounts for University Hospitals of North Midlands NHS Trust is available on request or can be viewed and downloaded on our website www.uhnm.nhs.uk .

Dr Simon Constable
Chief Executive Officer
DATE

Mr Mark Oldham
Chief Finance Officer

DRAFT

4

Annual Accounts 2025/26

DRAFT

Executive Summary
Trust Board | 24th June 2026
Audited Accounts and Financial Statements

University Hospitals of North Midlands NHS Trust

Purpose:	**Information**		**Approval**	✓	**Assurance**		**Agenda Item:**	5.
Author:	Nick Sone, Deputy Director of Finance – Financial Controller							
Executive Lead:	Mark Oldham, Chief Financial Officer							
Alignment with our Strategic Priorities								
	Our People We will create an inclusive environment where everyone learns, thrives and makes a positive difference							✓
	Our Patients We will provide timely, innovative and effective services to our patients							✓
	Our Population We will tackle inequality and improve the health of our population							✓

Executive Summary

Situation

- This report gives an update on the Trust's final Accounts following the external audit of the Accounts and presentation of the Annual Report; Accounts; Audit Findings Report; and Annual Audit Report to the Audit Committee on 19th June.
- It also sets out the Trust's performance against key statutory duties and an overview of the main movements in the primary financial statements from the prior year. This is intended to give sufficient assurance over the financial statements to enable the Trust Board to approve the accounts.
- The audit of the accounts is substantially complete and all audit adjustments required to the Accounts and Annual Report have been made by the Trust and have been checked by the auditors.
- There are a number of items that require signature by the Chief Executive and Chief Financial Officer on behalf of the Trust Board as part of the accounts approval and submission process, as detailed in section 7.

Background

- The Trust's key statutory duties are:
  - Achievement of breakeven in-year and cumulatively.
  - Not to overshoot the Capital Resource Limit (CRL) or Capital Departmental Expenditure Limit (CDEL)
  - Compliance with the Better Payment Practice Code (BPPC) i.e. payment of 95% of undisputed invoices by the due date or within 30 days of receipt of goods / services

The Trust previously had an additional statutory duty - the External Financing Limit (EFL), which has now been removed by NHS England

Assessment

- Financial performance for the year is a deficit of £13.201 million and the Trust remains in a cumulative deficit position.
- The Trust underspent against its CRL target of £70.530 million by £0.500 million.
- The Trust complied with the BPPC requirements and paid 95% of its invoices within 30 days.

Key Recommendations

- The Trust Board is asked to note the report; approve the accounts and approve the signing of the following items:
  - TAC Confirmation Schedule
  - Statement of Accounting / Accountable Officer's Responsibilities
  - Annual report - Performance Report
  - Annual report - Accountability Report (incorporates Corporate Governance Report, remuneration and Staff Report, and Parliamentary Accountability Report (if applicable))
  - Annual Governance Statement
  - Statement of Financial Position
  - Letter of Representation
  - Statement of Directors' Responsibilities

University Hospitals of North Midlands NHS Trust

Overview of 2025/26 Financial Statements

24th June 2026

1. Introduction

The report sets out the Trust's performance against key statutory duties and gives an overview of movements from the prior year in the key financial statements.

The items below should be read in conjunction with the Trust's annual accounts which are included in Appendix 1.

2. The Trust's Statutory Financial Duties

The Trust's financial statutory duties are:

- Achievement of breakeven in-year and cumulatively
- Not to overshoot the Capital Resource Limit (CRL) or Capital Departmental Expenditure Limit (CDEL)
- Compliance with the Better Payment Practice Code (BPPC) i.e. payment of 95% of undisputed invoices by the due date or within 30 days of receipt of goods / services

3. Breakeven in year and cumulative position

The Trust achieved a deficit of £13.201 million in 2025/26 as shown in Table 1, and the Trust remains in a cumulative deficit position. The Trust's deficit is adjusted for reporting to NHS England on a control total basis which is the primary mechanism for financial control. The adjusted deficit of £4.739 million reported to NHS England reflects the Trust's actual financial performance in accordance with NHS England financial measures.

Table 1 – Adjusted Financial Performance

	2025/26 £000	2024/25 £000
Deficit for the period per SOCI	(13,201)	(11,681)
Remove net impairments not scoring to the departmental expenditure limit	18,183	268
Remove I&E impact of capital grants and donations	(2,756)	(4,293)
IFRIC 12 breakeven adjustment*: Remove I&E impact of IFRIC 12 schemes on an IFRS 16 basis	75,739	75,937
IFRIC 12 breakeven adjustment*: Add back I&E impact of IFRIC 12 schemes on former UK GAAP basis	(82,704)	(78,379)
Remove net impact of DHSC centrally procured inventories	-	92
Adjusted financial performance deficit	**(4,739)**	**(18,056)**

The financial deficit for the year of £4.739 million is further adjusted to report against our breakeven duty in-year performance as shown in Table 2, which shows a £2.226 million 'breakeven duty' surplus for the year.

Table 2 – Breakeven duty financial performance

	2025/26 £000	2024/25 £000
Adjusted financial performance deficit	(4,739)	(18,056)
*IFRIC 12 breakeven adjustment	6,965	2,442
Breakeven duty financial performance surplus	**2,226**	**(15,614)**

Our breakeven performance for the last three years is shown in Table 3 and shows that we currently have a £200.713 million cumulative deficit.

Table 3 – Cumulative breakeven performance

	2023/24 £000	2024/25 £000	2025/26 £000
Breakeven duty in-year financial performance	(8,375)	(15,614)	2,226
Breakeven duty cumulative position	(187,325)	(202,939)	(200,713)
Operating income	1,151,805	1,292,878	1,380,315
Cumulative breakeven position as a percentage of operating income	**(16.3%)**	**(15.7%)**	**(14.5%)**

The Trust's auditors have issued a section 30 referral to the Secretary of State for Health each year since 2016/17, reporting that the Trust's expenditure is likely to continue to exceed income for the foreseeable future. A further referral will be made by the auditors for 2025/26.

4. Capital Resource Limit (CRL) and Capital Departmental Expenditure Limit (CDEL)

The Trust underspent by £0.500 million against its Capital Resource Limit (CRL) of £70.530 million as shown in Table 4.

Table 4 – Cumulative breakeven performance

	2025/26 £000	2024/25 £000
Gross capital expenditure	74,839	81,396
Less: Disposals	-	(18)
Less: Donated and granted capital additions	(4,809)	(6,047)
Charge against Capital Resource Limit	**70,030**	**75,331**
Capital Resource Limit	70,530	90,982
Under / (over) spend against CRL	**500**	**15,651**

DRAFT

5. Better Payment Practice Code (BPPC)

The Trust met the target of paying 95% of invoices within 30 days of the receipt of goods / services.

Table 5 – BPPC performance 2025/26

Total Payables	2025/26 Number	2025/26 £000	2024/25 Number	2024/25 £000
Total trade invoices paid in the year	127,650	770,417	132,636	758,927
Total trade invoices paid within target	125,111	752,267	130,118	739,259
Percentage of non-NHS trade invoices paid within target	**98.0%**	**97.6%**	**98.1%**	**97.4%**

6. Accounts and analytical review

The Trust's Accounts are included in Appendix 1. Key points from the accounts are as follows:

- The adjusted I&E surplus of £4.739 million compared to plan of £0 (breakeven), comprises the following:
  - income of £1,380.315 million;
  - pay expenditure of (£846.548) million;
  - non-pay expenditure (£517,601) million;
  - non-operating items of (£29.367) million;
  - adjustments of £2.159 million (Table 1).

- Capital expenditure of £27.185 million was achieved against our system allocation (including IFRS16 lease costs of £4.985 million) and we also incurred spend on PDC funded schemes of £40.635 million.

- Efficiency savings of £48.146 million were achieved.

A detailed analytical review has been included in Appendix 2 which explains the movements between 2024/25 and 2025/26 in relation to the main elements that comprise the Trust's income expenditure account and balance sheet.

A further report is provided in Appendix 3 outlining the rationale for the Trust not to consolidate its charity accounts with the Trust's accounts in order to form a group set of accounts. The auditors have concluded that such consolidation is not necessary for 2025/26.

7. Audit completion and accounts submission requirements

All audit adjustments that the Trust has agreed to make have been amended in the accounts in Appendix 1. All amendments required within the Annual Report have also been made. These have all been checked by the auditors and we have no outstanding amendments to make on either document.

As part of the process of approving the accounts there are a number of statements and documents that require signing by the Chief Executive and Chief Financial Officer. Following this meeting we need to provide the Auditors with the following:

1) Full signed set of financial statements and TACS.
2) Full version of Annual Report and Accounts
3) Signed Letter of Representation

The following sign offs are required:

DRAFT

Detail	Signature required
TAC Confirmation Schedule	Accountable Officer / Chief Exec
Statement of Accounting / Accountable Officer's Responsibilities	Accountable Officer / Chief Exec
Annual report - Performance Report	Accountable Officer / Chief Exec
Annual report - Accountability Report (incorporates Corporate Governance Report, remuneration and Staff Report, and Parliamentary Accountability Report (if applicable))	Accountable Officer / Chief Exec
Annual Governance Statement	Accountable Officer / Chief Exec
Statement of Financial Position	Accountable Officer / Chief Exec
Letter of Representation	Accountable Officer / Chief Exec on behalf of "those responsible for the preparation of the financial statements"
Statement of Directors' Responsibilities	Chief Exec ***AND*** Chief Financial Officer

Following the receipt of the required information, the auditors will provide us with their signed Audit Opinion, which we will need to be able to submit the Accounts by the deadline on Friday 26th June.

8. Conclusions

- The Trust's annual accounts have been prepared and include the required reporting of the Trust's performance against its statutory financial duties.
- The audit is substantially complete and the Accounts have been amended for all agreed amendments and have been checked by audit.
- The Trust Board is now able to approve the accounts.

9. Recommendations

- The Trust Board is asked to note the report; approve the accounts and approve the signing of the following items:
    - TAC Confirmation Schedule
    - Statement of Accounting / Accountable Officer's Responsibilities
    - Annual report - Performance Report
    - Annual report - Accountability Report (incorporates Corporate Governance Report, remuneration and Staff Report, and Parliamentary Accountability Report (if applicable))
    - Annual Governance Statement
    - Statement of Financial Position
    - Letter of Representation
    - Statement of Directors' Responsibilities

DRAFT

University Hospitals of North Midlands NHS Trust

Annual accounts for the year ended 31 March 2026

DRAFT

Statement of Comprehensive Income

	Note	2025/26 £000	2024/25 £000
Operating income from patient care activities	3	1,271,227	1,186,037
Other operating income	4	109,088	106,840
Operating expenses	7,9	(1,364,149)	(1,271,731)
Operating surplus		**16,166**	**21,147**
Finance income	11	5,185	6,054
Finance expenses	12	(30,144)	(35,422)
PDC dividends payable		(4,545)	(3,530)
Net finance costs		**(29,504)**	**(32,898)**
Other gains	13	137	70
Deficit for the year		**(13,201)**	**(11,681)**
The operating surplus and deficit for the year are from continuing operations			
Other comprehensive income			
Will not be reclassified to income and expenditure:			
Impairments	8	(7,960)	(8,095)
Revaluations	15,18	6,013	11,724
Total other comprehensive income for the period		**(1,947)**	**3,629**
Total comprehensive expense for the period		**(15,148)**	**(8,052)**

The note below does not form part of the primary statement of accounts. It is included here to show that the deficit for the year of £13.201 million is adjusted for reporting against the breakeven duty and also adjusted for reporting to NHS England on a control total basis which is the primary mechanism for financial control. The adjusted deficit reported to NHS England reflects the Trust's actual financial performance in accordance with NHS England financial measures. Details of the adjustments are provided in notes 36 and 37.

Breakeven duty and adjusted financial performance	**Note**	**2025/26 £000**	**2024/25 £000**
Breakeven duty financial performance surplus/(deficit)	36,37	2,226	(15,614)
Adjusted financial performance (control total basis) deficit	36,37	(4,739)	(18,056)

DRAFT

Statement of Financial Position

	Note	31 March 2026 £000	31 March 2025 £000
Non-current assets			
Intangible assets	14	14,615	15,985
Property, plant and equipment	15	734,232	715,699
Right of use assets	18	22,062	23,087
Receivables	20	1,018	1,105
Total non-current assets		**771,928**	**755,877**
Current assets			
Inventories	19	21,429	19,219
Receivables	20	49,737	43,518
Non-current assets for sale and assets in disposal groups	22	7,700	10,900
Cash and cash equivalents	23	88,068	84,186
Total current assets		**166,934**	**157,823**
Current liabilities			
Trade and other payables	24	(114,647)	(108,614)
Borrowings	26	(28,792)	(20,286)
Provisions	27	(1,054)	(8,469)
Other liabilities	25	(20,737)	(20,801)
Total current liabilities		**(165,230)**	**(158,170)**
Total assets less current liabilities		**773,631**	**755,530**
Non-current liabilities			
Borrowings	26	(482,248)	(490,255)
Provisions	27	(3,407)	(2,783)
Total non-current liabilities		**(485,655)**	**(493,038)**
Total assets employed		**287,977**	**262,491**
Financed by			
Public dividend capital		775,578	734,943
Revaluation reserve		204,310	208,297
Income and expenditure reserve		(691,911)	(680,749)
Total taxpayers' equity		**287,977**	**262,491**

The notes on pages 6 to 50 form part of these accounts.

Name
Position
Date

DRAFT

Statement of Changes in Taxpayers' Equity for the year ended 31 March 2026

	Public dividend capital	Revaluation reserve	Income and expenditure reserve	Total
	£000	£000	£000	£000
Taxpayers' equity at 1 April 2025 - brought forward	**734,943**	**208,297**	**(680,749)**	**262,491**
Withdrawal of revaluation model for intangible assets on 1 April 2025	-	(2,040)	2,040	**-**
Deficit for the year	-	-	(13,201)	**(13,201)**
Impairments	-	(7,960)	-	**(7,960)**
Revaluations	-	6,013	-	**6,013**
Public dividend capital received	40,635	-	-	**40,635**
Taxpayers' equity at 31 March 2026	**775,578**	**204,310**	**(691,911)**	**287,977**

Public Dividend Capital of £40.635 million was received in 2025/26 for a number of capital schemes, including:

£18.172 million Community Diagnostic Centres funding: CDC phase 1 (Including £0.072 million CDC Pathways)
£4.000 million System Capital Support PDC
£2.340 million Constitutional Standards: Urgent Treatment Centre
£4.767 million Estates Safety funding
£3.000 million Elective Recovery/Targeted Investment Fund: County Breast care unit completion
£2,583 million Constitutional Standards: Imaging and Diagnostic
£0.874 million Diagnostics funding
£1.628 million Pathology: LIMS
£0.839 million Constitutional Standards : Elective
£0.828 million Digital Pathology
£0.590 million Constitutional Standards: Equipment for Physiological Science

DRAFT

Statement of Changes in Taxpayers' Equity for the year ended 31 March 2025

	Public dividend capital	Revaluation reserve	Income and expenditure reserve	Total
	£000	£000	£000	£000
Taxpayers' equity at 1 April 2024 - brought forward	**693,901**	**204,668**	**(669,068)**	**229,501**
Surplus deficit for the year	-	-	(11,681)	**(11,681)**
Impairments	-	(8,095)	-	**(8,095)**
Revaluations	-	11,724	-	**11,724**
Public dividend capital received	41,042	-	-	**41,042**
Taxpayers' equity at 31 March 2025	**734,943**	**208,297**	**(680,749)**	**262,491**

Information on reserves

Public dividend capital
Public dividend capital (PDC) is a type of public sector equity finance based on the excess of assets over liabilities at the time of establishment of the predecessor NHS organisation. Additional PDC may also be issued to Trusts by the Department of Health and Social Care. A charge, reflecting the cost of capital utilised by the Trust, is payable to the Department of Health as the public dividend capital dividend.

Revaluation reserve
Increases in asset values arising from revaluations are recognised in the revaluation reserve, except where, and to the extent that, they reverse impairments previously recognised in operating expenses, in which case they are recognised in operating income. Subsequent downward movements in asset valuations are charged to the revaluation reserve to the extent that a previous gain was recognised unless the downward movement represents a clear consumption of economic benefit or a reduction in service potential.

Income and expenditure reserve
The balance of this reserve is the accumulated surpluses and deficits of the Trust.

Statement of Cash Flows

	Note	2025/26 £000	2024/25 £000
Cash flows from operating activities			
Operating surplus		16,166	21,147
Non-cash income and expense:			
Depreciation and amortisation	7.1	41,771	39,720
Net impairments	8	18,183	268
Income recognised in respect of capital donations	4	(4,809)	(6,047)
Increase in receivables and other assets		(4,472)	(1,010)
Increase in inventories		(2,210)	(1,504)
Increase in payables and other liabilities		3,535	4,173
Increase / (decrease) in provisions		(6,830)	3,258
Net cash flows from operating activities		**61,334**	**60,005**
Cash flows from investing activities			
Interest received		5,185	6,054
Purchase of intangible assets		(3,226)	(6,266)
Purchase of PPE		(68,741)	(63,650)
Sales of PPE		137	88
Receipt of cash donations to purchase assets		7,032	3,823
Net cash flows used in investing activities		**(59,613)**	**(59,951)**
Cash flows from financing activities			
Public dividend capital received		40,635	41,042
Capital element of lease rental payments		(4,457)	(4,001)
Capital element of PFI		(15,533)	(21,964)
Other interest		(7)	(1)
Interest paid on lease liability repayments		(528)	(286)
Interest paid on PFI		(12,909)	(13,011)
PDC dividend (paid) / refunded		(5,040)	329
Net cash flows from financing activities		**2,161**	**2,108**
Increase in cash and cash equivalents		**3,882**	**2,162**
Cash and cash equivalents at 1 April - brought forward		**84,186**	**82,024**
Cash and cash equivalents at 31 March	23	**88,068**	**84,186**

DRAFT

Notes to the Accounts

Note 1 Accounting policies and other information

Note 1.1 Basis of preparation

The Department of Health and Social Care has directed that the financial statements of the Trust shall meet the accounting requirements of the Department of Health and Social Care Group Accounting Manual (GAM), which shall be agreed with HM Treasury. Consequently, the following financial statements have been prepared in accordance with the GAM 2025/26 issued by the Department of Health and Social Care. The accounting policies contained in the GAM follow International Financial Reporting Standards to the extent that they are meaningful and appropriate to the NHS, as determined by HM Treasury, which is advised by the Financial Reporting Advisory Board. Where the GAM permits a choice of accounting policy, the accounting policy that is judged to be most appropriate to the particular circumstances of the Trust for the purpose of giving a true and fair view has been selected. The particular policies adopted are described below. These have been applied consistently in dealing with items considered material in relation to the accounts.

Accounting convention

These accounts have been prepared under the historical cost convention modified to account for the revaluation of property, plant and equipment, intangible assets, inventories and certain financial assets and financial liabilities.

Note 1.2 Going concern

These accounts have been prepared on a going concern basis. Non-trading entities in the public sector are assumed to be going concerns where the continued provision of a service in the future is anticipated, as evidenced by inclusion of financial provision for that service in published documents. The directors have a reasonable expectation that this will continue to be the case.

Note 1.3 Interests in other entities

Under the provisions of IFRS 10 Consolidated Financial Statements, those Charitable Funds that fall under common control with NHS bodies should be consolidated within the entity's financial statements. The Trust has a Charitable Fund, the 'UHNM Charity' that falls under the definition of common control. Common control is defined within IFRS 10 as "the power to govern the financial and operational policies of an entity so as to obtain benefits from its activities". Control is presumed to exist where a parent owns directly or indirectly more than half of the voting power of an entity, including where a body acts as a Corporate Trustee.

The Trustees of the Charitable Fund are all members of the Trust Board. The purpose of an NHS Charity is to assist NHS patients, and HM Treasury view this as the "benefit" link as per the IFRS 10 guidance. The Trust has reviewed the financial statements of the 'UHNM Charity' and it is deemed that the income, expenditure, assets and liabilities of the Charitable Fund are not material. IAS 1 Presentation of Financial Statements states that specific disclosure requirements set out in individual standards or interpretations need not be satisfied if the information is not material. The consolidation of the Charitable Fund would not have a material impact on the financial statements of the Trust and has therefore not been consolidated into the Trust's financial statements.

DRAFT

Note 1.4 Revenue from contracts with customers

Where income is derived from contracts with customers, it is accounted for under IFRS 15. The GAM expands the definition of a contract to include legislation and regulations which enables an entity to receive cash or another financial asset that is not classified as a tax by the Office of National Statistics (ONS).

Revenue in respect of goods/services provided is recognised when (or as) performance obligations are satisfied by transferring promised goods/services to the customer and is measured at the amount of the transaction price allocated to those performance obligations. At the year end, the Trust accrues income relating to performance obligations satisfied in that year. Where the Trust's entitlement to consideration for those goods or services is unconditional a contract receivable will be recognised. Where entitlement to consideration is conditional on a further factor other than the passage of time, a contract asset will be recognised. Where consideration received or receivable relates to a performance obligation that is to be satisfied in a future period, the income is deferred and recognised as a contract liability.

The Trust applies standard NHS terms and conditions of 30 day payment terms for all invoices raised to customers and does not offer any further credit terms. Payment is expected once the performance obligations are satisfied and within 30 days of the invoice being raised.

Revenue from NHS contracts

The Trust's main source of income is contracts with commissioners for the provision of NHS funded healthcare services. For 2025/26, funding envelopes are set at Integrated Care System (ICS) level, and the majority of the Trust's NHS income is earned under the 2025/26 NHS Payment Scheme (NHSPS), which governs the rules determining payments for secondary healthcare services.

Aligned Payment and Incentive (API) contracts remain the primary payment mechanism for NHS providers in 2025/26. API is a blended model comprising a fixed element and a variable element, as set out in the NHSPS.

Under the variable element, providers earn income for specific activity categories defined in the NHSPS, including:

- elective inpatient and day case activity
- outpatient procedures
- first outpatient attendances
- diagnostic imaging and nuclear medicine
- chemotherapy delivery

Income is earned at NHSPS unit prices based on actual activity delivered. The fixed element covers all other services included within the NHSPS and is based on an agreed level of activity. "Fixed" in this context means that payment does not vary with activity volumes, although commissioners and providers are required to review fixed payments annually in line with NHSPS guidance. For relationships where activity is expected to be low, the NHSPS mandates Low Volume Activity (LVA) block payments. For 2025/26, LVA applies where the expected annual value of activity is £1.5 million or less, and providers receive an annual fixed payment determined in accordance with NHSPS rules. This threshold replaces the lower thresholds used in earlier years.

Elective Recovery Funding (ERF) continues to be allocated to integrated care boards to support the commissioning of elective activity within their systems. Trusts do not receive ERF directly; instead, they earn income for activity delivered under API variable element rules. The Trust's activity levels contribute to overall system performance, which in turn influences the level of ERF available to commissioners.

Pay award adjustments for 2025/26 have been incorporated into the NHSPS prices through the updated pay award prices workbook, which applies from 1 April 2025. These updated prices reflect the revised cost uplift for the year and must be used in all contract values and payment schedules.

Revenue from research contracts

Where research contracts fall under IFRS 15, revenue is recognised as and when performance obligations are satisfied. For some contracts, it is assessed that the revenue project constitutes one performance obligation over the course of the multi-year contract. In these cases it is assessed that the Trust's interim performance does not create an asset with alternative use for the Trust, and the Trust has an enforceable right to payment for the performance completed to date. It is therefore considered that the performance obligation is satisfied over time, and the Trust recognises revenue each year over the course of the contract. Some research income alternatively falls within the provisions of IAS 20 for government grants.

DRAFT

NHS injury cost recovery scheme

The Trust receives income under the NHS Injury Cost Recovery (ICR) scheme, designed to reclaim the cost of treating injured individuals to whom personal injury compensation has subsequently been paid, for instance by an insurer. The Trust recognises the income when performance obligations are satisfied. In practical terms this means that treatment has been given, it receives notification from the Department of Work and Pension's Compensation Recovery Unit, has completed the NHS2 form and confirmed there are no discrepancies with the treatment. The income is measured at the agreed tariff for the treatments provided to the injured individual, less an allowance for unsuccessful compensation claims and doubtful debts in line with IFRS 9 requirements of measuring expected credit losses over the lifetime of the asset.

Education and Training

The Trust receives income from Health Education England (HEE) in relation to medical and non medical trainees. Revenue is in respect of training provided and is recognised when performance obligations are satisfied when training has been performed. All performance obligations are undertaken within the financial year and is agreed and invoiced to HEE. Where training occurs across financial years the income is deferred to match the expenditure.

High cost devices

High cost drugs and devices excluded from the calculation of national prices are reimbursed by NHS England based on actual usage or at a fixed baseline in addition to the price of the related service.

Note 1.5 Other forms of income

Grants and donations

Government grants are grants from government bodies other than income from commissioners or trusts for the provision of services. Where a grant is used to fund revenue expenditure it is taken to the Statement of Comprehensive Income to match that expenditure. Where the grants is used to fund capital expenditure, it is credited to the Statement of Comprehensive Income once conditions attached to the grant have been met. Donations are treated in the same way as government grants.

Apprenticeship service income

The value of the benefit received when accessing funds from the Government's apprenticeship service is recognised as income at the point of receipt of the training service. Where these funds are paid directly to an accredited training provider from the Trust's apprenticeship service account held by the Department for Education, the corresponding notional expense is also recognised at the point of recognition for the benefit.

Note 1.6 Expenditure on employee benefits

Short-term employee benefits

Salaries, wages and employment-related payments such as social security costs and the apprenticeship levy are recognised in the period in which the service is received from employees. The cost of annual leave entitlement earned but not taken by employees at the end of the period is recognised in the financial statements to the extent that employees are permitted to carry-forward leave into the following period.

Pension costs

NHS Pension Scheme

Past and present employees are covered by the provisions of the two NHS Pension Schemes. Both These schemes are unfunded, defined benefit schemes that cover NHS employers, general practices and other bodies, allowed under the direction of Secretary of State for Health and Social Care in England and Wales. The schemes are is not designed in a way that would enable NHS Bodies employers to identify their share of the underlying scheme assets and liabilities. Therefore, the schemes is are accounted for as though they were it is a defined contribution schemes: the cost to the Trust of participating in a scheme is taken as equal to the employer's pension contributions payable to the scheme for the accounting period. The contributions are charged to operating expenses as and when they become due.

Additional pension liabilities arising from early retirements are not funded by the schemes except where the retirement is due to ill-health. The full amount of the liability for the additional costs is charged to the operating expenses at the time the trust commits itself to the retirement, regardless of the method of payment.

Note 1.7 Expenditure on other goods and services

Expenditure on goods and services is recognised when, and to the extent that they have been received, and is measured at the fair value of those goods and services. Expenditure is recognised in operating expenses except where it results in the creation of a non-current asset such as property, plant and equipment.

Note 1.8 Value added tax

Most of the Trust's activities are outside the scope of value added tax (VAT). Irrecoverable VAT is charged to the relevant expenditure category or included in the capitalised purchase cost of non-current assets. Where output tax is charged or input VAT is recoverable, the amounts are stated net of VAT. Entities for which the above is not appropriate should specify an alternative policy

DRAFT

Note 1.9 Property, plant and equipment

Recognition

Property, plant and equipment is capitalised where:

• it is held for use in delivering services or for administrative purposes
• it is probable that future economic benefits will flow to, or service potential be provided to, the trust
• it is expected to be used for more than one financial year
• the cost of the item can be measured reliably
• the item has cost of at least £5,000, or
• collectively, a number of items have a cost of at least £5,000 and individually have cost of more than £250, where the assets are functionally interdependent, had broadly simultaneous purchase dates, are anticipated to have similar disposal dates and are under single managerial control.

Where a large asset, for example a building, includes a number of components with significantly different asset lives, eg, plant and equipment, then these components are treated as separate assets and depreciated over their own useful lives.

Subsequent expenditure

Subsequent expenditure relating to an item of property, plant and equipment is recognised as an increase in the carrying amount of the asset when it is probable that additional future economic benefits or service potential deriving from the cost incurred to replace a component of such item will flow to the enterprise and the cost of the item can be determined reliably. Where a component of an asset is replaced, the cost of the replacement is capitalised if it meets the criteria for recognition above. The carrying amount of the part replaced is de-recognised. Other expenditure that does not generate additional future economic benefits or service potential, such as repairs and maintenance, is charged to the Statement of Comprehensive Income in the period in which it is incurred.

Measurement

Valuation

All property, plant and equipment assets are measured initially at cost, representing the costs directly attributable to acquiring or constructing the asset and bringing it to the location and condition necessary for it to be capable of operating in the manner intended by management.

Assets are measured subsequently at valuation. Assets which are held for their service potential and are in use (ie operational assets used to deliver either front line services or back office functions) are measured at their current value in existing use. Assets that were most recently held for their service potential but are surplus with no plan to bring them back into use are measured at fair value where there are no restrictions on sale at the reporting date and where they do not meet the definitions of investment properties or assets held for sale.

Revaluations of property, plant and equipment are performed with sufficient regularity to ensure that carrying values are not materially different from those that would be determined at the end of the reporting period. Current values in existing use are determined as follows:

- Land and non-specialised buildings – market value for existing use
- Specialised buildings – depreciated replacement cost on a modern equivalent asset basis.

For specialised assets, current value in existing use is interpreted as the present value of the asset's remaining service potential, which is assumed to be at least equal to the cost of replacing that service potential. Specialised assets are therefore valued at their depreciated replacement cost (DRC) on a modern equivalent asset (MEA) basis. An MEA basis assumes that the asset will be replaced with a modern asset of equivalent capacity and meeting the location requirements of the services being provided. Assets held at depreciated replacement cost have been valued on an alternative site basis where this would meet the location requirements.

DRAFT

Valuation guidance issued by the Royal Institute of Chartered Surveyors states that valuations are performed net of VAT where the VAT is recoverable by the entity. This basis has been applied to the trust's Private Finance Initiative (PFI) scheme where the construction is completed by a special purpose vehicle and the costs have recoverable VAT for the trust.

Properties in the course of construction for service or administration purposes are carried at cost, less any impairment loss. Cost includes professional fees and, where capitalised in accordance with IAS 23, borrowings costs. Assets are revalued and depreciation commences when the assets are brought into use.

IT equipment, transport equipment, furniture and fittings, and plant and machinery that are held for operational use are valued at depreciated historic cost where these assets have short useful lives or low values or both, as this is not considered to be materially different from current value in existing use.

All land (including surplus land) and buildings, are valued at fair value using independent professional valuations in accordance with IAS16 at least every five years, with interim revaluations carried out annually also by independent professional valuers. The full asset valuation includes a full site inspection by the professional valuer whilst interim valuations only include a site inspection where deemed necessary due to significant changes in the year. A full asset valuation was undertaken as at 31st March 2022 and the next full valuation is due in 2027.

Depreciation

Items of property, plant and equipment are depreciated over their remaining useful lives in a manner consistent with the consumption of economic or service delivery benefits. Freehold land is considered to have an infinite life and is not depreciated.

Property, plant and equipment which has been reclassified as 'held for sale' cease to be depreciated upon the reclassification. Assets in the course of construction and residual interests in off-Statement of Financial Position PFI contract assets are not depreciated until the asset is brought into use or reverts to the Trust, respectively.

Otherwise, depreciation or amortisation is charged to write off the costs or valuation of property, plant and equipment and intangible assets, less any residual value, on a straight line basis over their estimated useful lives. The estimated useful life of an asset is the period over which The Trust expects to obtain economic benefits or service potential from the asset. This is specific to the Trust and may be shorter than the physical life of the asset itself. Estimated useful lives and residual values are reviewed each year end, with the effect of any changes recognised on a prospective basis.

Assets held under finance leases are depreciated over the shorter of the lease term and the estimated useful life, unless the Trust expects to acquire the asset at the end of the lease term, in which case the asset is depreciated in the same manner as for owned assets.

Revaluation gains and losses

Revaluation gains are recognised in the revaluation reserve, except where, and to the extent that, they reverse a revaluation decrease that has previously been recognised in operating expenses, in which case they are recognised in operating expenditure.

Revaluation losses are charged to the revaluation reserve to the extent that there is an available balance for the asset concerned, and thereafter are charged to operating expenses.

Gains and losses recognised in the revaluation reserve are reported in the Statement of Comprehensive Income as an item of 'other comprehensive income'.

DRAFT

Impairments

In accordance with the GAM, impairments that arise from a clear consumption of economic benefits or of service potential in the asset are charged to operating expenses. A compensating transfer is made from the revaluation reserve to the income and expenditure reserve of an amount equal to the lower of (i) the impairment charged to operating expenses; and (ii) the balance in the revaluation reserve attributable to that asset before the impairment.

An impairment that arises from a clear consumption of economic benefit or of service potential is reversed when, and to the extent that, the circumstances that gave rise to the loss is reversed. Reversals are recognised in operating expenditure to the extent that the asset is restored to the carrying amount it would have had if the impairment had never been recognised. Any remaining reversal is recognised in the revaluation reserve. Where, at the time of the original impairment, a transfer was made from the revaluation reserve to the income and expenditure reserve, an amount is transferred back to the revaluation reserve when the impairment reversal is recognised. Other impairments are treated as revaluation losses. Reversals of 'other impairments' are treated as revaluation gains.

De-recognition

Assets intended for disposal are reclassified as 'held for sale' once the criteria in IFRS 5 are met. The sale must be highly probable and the asset available for immediate sale in its present condition.

Following reclassification, the assets are measured at the lower of their existing carrying amount and their 'fair value less costs to sell'. Depreciation ceases to be charged and the assets are not revalued, except where the 'fair value less costs to sell' falls below the carrying amount. Assets are de-recognised when all material sale contract conditions have been met.

Property, plant and equipment which is to be scrapped or demolished does not qualify for recognition as 'held for sale' and instead is retained as an operational asset and the asset's useful life is adjusted. The asset is de-recognised when scrapping or demolition occurs.

Donated and grant funded assets

Donated and grant funded property, plant and equipment assets are capitalised at their fair value on receipt. The donation/grant is credited to income at the same time, unless the donor has imposed a condition that the future economic benefits embodied in the grant are to be consumed in a manner specified by the donor, in which case, the donation/grant is deferred within liabilities and is carried forward to future financial years to the extent that the condition has not yet been met.

The donated and grant funded assets are subsequently accounted for in the same manner as other items of property, plant and equipment.

They are valued, depreciated and impaired as described above for purchased assets. Gains and losses on revaluations, impairments and sales are treated in the same way as for purchased assets. Deferred income is recognised only where conditions attached to the donation preclude immediate recognition of the gain.

Government grant funded assets are capitalised at current value in existing use, if they will be held for their service potential, or otherwise at fair value on receipt, with a matching credit to income. Deferred income is recognised only where conditions attached to the grant preclude immediate recognition of the gain.

DRAFT

Private Finance Initiative (PFI) transactions

PFI transactions which meet the IFRIC 12 definition of a service concession, as interpreted in HM Treasury's FReM, are accounted for as 'on-Statement of Financial Position' by the Trust. The underlying assets are recognised as property, plant and equipment, together with an equivalent PFI liability measured in alignment with the principles of IFRS 16.

The annual unitary payment is separated into the following component parts, using appropriate estimation techniques where necessary:
• payment for the fair value of services received
• repayment of the PFI liability, including finance costs, and
• payment for the replacement of components of the asset during the contract 'lifecycle replacement'.

Services received
The cost of services received in the year is recorded under the relevant expenditure headings within 'operating expenses'.

PFI assets, liabilities and finance costs

The PFI assets are initially measured using the principles of IFRS 16. Subsequently, the assets are measured at current value in existing use per the policies applied under IAS 16.

A PFI liability equal to the capital value of the contract is recognised at the same time as the PFI assets are recognised. This does not include service elements and interest charges within the PFI contract which are expensed in accordance with IFRIC 12 as adapted and interpreted by the FReM and as detailed below.

An annual finance cost is calculated by applying the implicit interest rate in the contract to the opening PFI liability for the period, and is charged to 'Finance Costs' within the Statement of Comprehensive [Income / Net Expenditure].

An element of the annual unitary payment is therefore allocated as a financing cost when repaying the PFI liability over the life of the contract.

Where there is a change in future lease payments resulting from a change in an index or a rate used to determine those payments, including for example a change to reflect changes in market rental rates following a market rent review. The entity remeasures the PFI liability to reflect those revised payments only when there is a change in the cash flows (i.e. when the adjustment to the payments takes effect). The entity shall determine the revised payments for the remainder of the PFI arrangement based on the revised contractual payments. As subsequent measurement of the PFI asset is per IAS 16 than IFRS 16, the opposite entry to adjustment of the PFI liability for such remeasurements is charged to Finance Costs.

Initial recognition

In accordance with HM Treasury's FReM, the underlying assets are recognised as property, plant and equipment, together with an equivalent liability. Initial measurement of the asset and liability are in accordance with the initial measurement principles of IFRS 16 (see leases accounting policy).

Subsequent measurement

Assets are subsequently accounted for as property, plant and equipment and/or intangible assets as appropriate.

The liability is subsequently reduced by the portion of the unitary charge allocated as payment for the asset and increased by the annual finance cost. The finance cost is calculated by applying the implicit interest rate to the opening liability and is charged to finance costs in the Statement of Comprehensive Income. The element of the unitary charge allocated as payment for the asset is split between payment of the finance cost and repayment of the net liability.

Where there are changes in future payments for the asset resulting from indexation of the unitary charge, the Trust remeasures the PFI liability by determining the revised payments for the remainder of the contract once the change in cash flows takes effect. The remeasurement adjustment is charged to finance costs in the Statement of Comprehensive Income.

The service charge is recognised in operating expenses in the Statement of Comprehensive Income.

DRAFT

Lifecycle replacement

Components of the asset replaced by the operator during the contract ('lifecycle replacement') are capitalised where they meet the NHS Trust's criteria for capital expenditure. They are capitalised at the time they are provided by the operator and are measured initially at their fair value.

The element of the annual unitary payment allocated to lifecycle replacement is pre-determined for each year of the contract from the operator's planned programme of lifecycle replacement. Where the lifecycle component is provided earlier or later than expected, a short-term accrual or prepayment is recognised respectively.

Where the fair value of the lifecycle component is less than the amount determined in the contract, the difference is recognised as an expense when the replacement is provided. If the fair value is greater than the amount determined in the contract, the difference is treated as a 'free' asset and a deferred income balance is recognised. The deferred income is released to operating income over the shorter of the remaining contract period or the useful economic life of the replacement component.

Assets contributed by the NHS Trust to the operator for use in the scheme

Assets contributed for use in the scheme continue to be recognised as items of property, plant and equipment in the NHS Trust's Statement of Financial Position.

Other assets contributed by the NHS Trust to the operator

Assets contributed (e.g. cash payments, surplus property) by the NHS Trust to the operator before the asset is brought into use, which are intended to defray the operator's capital costs, are recognised initially as prepayments during the construction phase of the contract. Subsequently, when the asset is made available to the NHS Trust, the prepayment is treated as an initial payment towards the finance lease liability and is set against the carrying value of the liability.

Useful lives of property, plant and equipment

Useful lives reflect the total life of an asset and not the remaining life of an asset. The range of useful lives are shown in the table below:

	Min life Years	**Max life Years**
Buildings, excluding dwellings	15	80
Plant & machinery	5	20
Transport equipment	4	7
Information technology	2	10
Furniture & fittings	5	16

DRAFT

Note 1.10 Intangible assets

Recognition

Intangible assets are non-monetary assets without physical substance controlled by the Trust. They are capable of being sold separately from the rest of the trust's business or arise from contractual or other legal rights. Intangible assets are recognised only where it is probable that future economic benefits will flow to, or service potential be provided to, the trust and where the cost of the asset can be measured reliably.

Internally generated intangible assets

Internally generated goodwill, brands, mastheads, publishing titles, customer lists and similar items are not capitalised as intangible assets.

Expenditure on research is not capitalised. Expenditure on development is capitalised where it meets the requirements set out in IAS 38.

Software

Software which is integral to the operation of hardware, eg an operating system, is capitalised as part of the relevant item of property, plant and equipment. Software which is not integral to the operation of hardware, eg application software, is capitalised as an intangible asset where it meets recognition criteria.

Measurement

From 1 April 2025, intangible assets are carried at cost. Where intangible assets have historically been revalued, the carrying net amount at 31 March 2026 is treated as deemed historic cost.

Subsequently intangible assets are measured at current value in existing use. Where no active market exists, intangible assets are valued at the lower of depreciated replacement cost and the value in use where the asset is income generating. Revaluations gains and losses and impairments are treated in the same manner as for property, plant and equipment. An intangible asset which is surplus with no plan to bring it back into use is valued at fair value where there are no restrictions on sale at the reporting date and where they do not meet the definitions of investment properties or assets held for sale.

Intangible assets held for sale are measured at the lower of their carrying amount or fair value less costs to sell.

Amortisation

Intangible assets are amortised over their expected useful lives in a manner consistent with the consumption of economic or service delivery benefits.

Useful lives of intangible assets

Useful lives reflect the total life of an asset and not the remaining life of an asset. The range of useful lives are shown in the table below:

	Min life Years	**Max life Years**
Software licences	2	15

DRAFT

Note 1.11 Inventories

Inventories are valued at the lower of cost and net realisable value. The cost of inventories is measured using the first in, first out (FIFO) method. This is considered to be a reasonable approximation to the fair value due to the high turnover of stocks.

Note 1.12 Cash and cash equivalents

Cash is cash in hand and deposits with any financial institution repayable without penalty on notice of not more than 24 hours. Cash equivalents are investments that mature in three months or less from the date of acquisition and that are readily convertible to known amounts of cash with insignificant risk of change in value.

In the Statement of Cash Flows, cash and cash equivalents are shown net of bank overdrafts that are repayable on demand and that form an integral part of the Trust's cash management. Cash, bank and overdraft balances are recorded at current values.

Note 1.13 Financial assets and financial liabilities

Recognition

Financial assets and financial liabilities arise where the Trust is party to the contractual provisions of a financial instrument, and as a result has a legal right to receive or a legal obligation to pay cash or another financial instrument. The GAM expands the definition of a contract to include legislation and regulations which give rise to arrangements that in all other respects would be a financial instrument and do not give rise to transactions classified as a tax by ONS.

This includes the purchase or sale of non-financial items (such as goods or services), which are entered into in accordance with the Trust's normal purchase, sale or usage requirements and are recognised when, and to the extent which, performance occurs, ie, when receipt or delivery of the goods or services is made.

Classification and measurement

Financial assets and financial liabilities are initially measured at fair value plus or minus directly attributable transaction costs except where the asset or liability is not measured at fair value through income and expenditure. Fair value is taken as the transaction price, or otherwise determined by reference to quoted market prices or valuation techniques.

Financial assets or financial liabilities in respect of assets acquired or disposed of through leasing arrangements are recognised and measured in accordance with the accounting policy for leases described below.

Financial assets are classified as subsequently measured at amortised cost.

Financial liabilities classified as subsequently measured at amortised cost.

DRAFT

Financial assets and financial liabilities at amortised cost

Financial assets and financial liabilities at amortised cost are those held with the objective of collecting contractual cash flows and where cash flows are solely payments of principal and interest. This includes cash equivalents, contract and other receivables, trade and other payables, rights and obligations under lease arrangements and loans receivable and payable.

After initial recognition, these financial assets and financial liabilities are measured at amortised cost using the effective interest method less any impairment (for financial assets). The effective interest rate is the rate that exactly discounts estimated future cash payments or receipts through the expected life of the financial asset or financial liability to the gross carrying amount of a financial asset or to the amortised cost of a financial liability.

Interest revenue or expense is calculated by applying the effective interest rate to the gross carrying amount of a financial asset or amortised cost of a financial liability and recognised in the Statement of Comprehensive Income and a financing income or expense.

Impairment of financial assets

For all financial assets measured at amortised cost including lease receivables, contract receivables and contract assets or assets measured at fair value through other comprehensive income, the Trust recognises an allowance for expected credit losses.

The Trust adopts the simplified approach to impairment for contract and other receivables, contract assets and lease receivables, measuring expected losses as at an amount equal to lifetime expected losses. For other financial assets, the loss allowance is initially measured at an amount equal to 12-month expected credit losses (stage 1) and subsequently at an amount equal to lifetime expected credit losses if the credit risk assessed for the financial asset significantly increases (stage 2).

For financial assets that have become credit impaired since initial recognition (stage 3), expected credit losses at the reporting date are measured as the difference between the asset's gross carrying amount and the present value of estimated future cash flows discounted at the financial asset's original effective interest rate.

Expected losses are charged to operating expenditure within the Statement of Comprehensive Income and reduce the net carrying value of the financial asset in the Statement of Financial Position.

Derecognition

Financial assets are de-recognised when the contractual rights to receive cash flows from the assets have expired or the Trust has transferred substantially all the risks and rewards of ownership.

Financial liabilities are de-recognised when the obligation is discharged, cancelled or expires.

DRAFT

Note 1.14 Leases

A lease is a contract or part of a contract that conveys the right to use an asset for a period of time in exchange for consideration. HM Treasury have adapted the public sector approach to IFRS 16 which impacts on the identification and measurement of leasing arrangements that will be accounted for under IFRS 16.

The Trust is required to apply IFRS 16 to lease like arrangements entered into in which consideration exchanged is nil or nominal, therefore significantly below market value. These arrangements are described as peppercorn leases. Such arrangements are again required to meet the definition of a lease in every other respect prior to inclusion in the scope of IFRS 16. The accounting for peppercorn arrangements aligns to that identified for donated assets. Peppercorn leases are different in substance to arrangements in which consideration is below market value but not significantly below market value.

The Trust determines the term of the lease term with reference to the non-cancellable period and any options to extend or terminate the lease which the Trust is reasonably certain to exercise.

The Trust as a lessee

Recognition and initial measurement

At the commencement date of the lease, being when the asset is made available for use, the Trust recognises a right of use asset and a lease liability. The right of use asset is recognised at cost comprising the lease liability, any lease payments made before or at commencement, any direct costs incurred by the lessee, less any cash lease incentives received. It also includes any estimate of costs to be incurred restoring the site or underlying asset on completion of the lease term.

The lease liability is initially measured at the present value of future lease payments discounted at the interest rate implicit in the lease. Lease payments includes fixed lease payments, variable lease payments dependent on an index or rate and amounts payable under residual value guarantees. It also includes amounts payable for purchase options and termination penalties where these options are reasonably certain to be exercised.

Where an implicit rate cannot be readily determined, the Trust's incremental borrowing rate is applied. This rate is determined by HM Treasury annually for each calendar year. A nominal rate of 4.81% applied to new leases commencing in 2025 and 5.32% to new leases commencing in 2026.

The Trust does not apply the above recognition requirements to leases with a term of 12 months or less or to leases where the value of the underlying asset is below £5,000, excluding any irrecoverable VAT. Lease payments associated with these leases are expensed on a straight-line basis over the lease term. Irrecoverable VAT on lease payments is expensed as it falls due.

Subsequent measurement

As required by a HM Treasury interpretation of the accounting standard for the public sector, the Trust employs a revaluation model for subsequent measurement of right of use assets, unless the cost model is considered to be an appropriate proxy for current value in existing use or fair value, in line with the accounting policy for owned assets. Where consideration exchanged is identified as significantly below market value, the cost model is not considered to be an appropriate proxy for the value of the right of use asset.

The Trust subsequently measures the lease liability by increasing the carrying amount for interest arising which is also charged to expenditure as a finance cost and reducing the carrying amount for lease payments made. The liability is also remeasured for changes in assessments impacting the lease term, lease modifications or to reflect actual changes in lease payments. Such remeasurements are also reflected in the cost of the right of use asset. Where there is a change in the lease term or option to purchase the underlying asset, an updated discount rate is applied to the remaining lease payments.

The Trust as a lessor

The Trust assesses each of its leases and classifies them as either a finance lease or an operating lease. Leases are classified as finance leases when substantially all the risks and rewards of ownership are transferred to the lessee. All other leases are classified as operating leases. Where the Trust is an intermediate lessor, classification of the sublease is determined with reference to the right of use asset arising from the headlease.

Finance leases

Amounts due from lessees under finance leases are recorded as receivables at the amount of the Trust's net investment in the leases. Finance lease income is allocated to accounting periods to reflect a constant periodic rate of return on the Trust's net investment outstanding in respect of the leases.

Operating leases

Income from operating leases is recognised on a straight-line basis or another systematic basis over the term of the lease. Initial direct costs incurred in negotiating and arranging an operating lease are added to the carrying amount of the leased asset and recognised as an expense on a straight-line basis over the lease term.

DRAFT

Note 1.15 Provisions

The Trust recognises a provision where it has a present legal or constructive obligation of uncertain timing or amount; for which it is probable that there will be a future outflow of cash or other resources; and a reliable estimate can be made of the amount. The amount recognised in the Statement of Financial Position is the best estimate of the resources required to settle the obligation. Where the effect of the time value of money is significant, the estimated risk-adjusted cash flows are discounted using HM Treasury's discount rates effective as at 31 March 2026:

		Nominal rate	Prior year rate
Short-term	Up to 5 years	3.64%	4.03%
Medium-term	After 5 years up to 10 years	4.22%	4.07%
Long-term	After 10 years up to 40 years	5.32%	4.81%
Very long-term	Exceeding 40 years	5.07%	4.55%

HM Treasury provides discount rates for general provisions on a nominal rate basis. Expected future cash flows are therefore adjusted for the impact of inflation before discounting using nominal rates. The following inflation rates are set by HM Treasury, effective as at 31 March 2026:

	Inflation rate	Prior year rate
Year 1	2.50%	2.60%
Year 2	2.00%	2.30%
Into perpetuity	2.00%	2.00%

Early retirement provisions and injury benefit provisions both use the HM Treasury's post-employment benefits discount rate of 2.95% in real terms (prior year: 2.40%).

Clinical negligence costs

NHS Resolution operates a risk pooling scheme under which the Trust pays an annual contribution to NHS Resolution, which, in return, settles all clinical negligence claims. Although NHS Resolution is administratively responsible for all clinical negligence cases, the legal liability remains with the Trust. The total value of clinical negligence provisions carried by NHS Resolution on behalf of the trust is disclosed at Note 27.1 but is not recognised in the Trust's accounts.

Non-clinical risk pooling

The trust participates in the Property Expenses Scheme and the Liabilities to Third Parties Scheme. Both are risk pooling schemes under which the trust pays an annual contribution to NHS Resolution and in return receives assistance with the costs of claims arising. The annual membership contributions, and any excesses payable in respect of particular claims are charged to operating expenses when the liability arises.

Note 1.16 Contingencies

Contingent assets (that is, assets arising from past events whose existence will only be confirmed by one or more future events not wholly within the entity's control) are not recognised as assets, but are disclosed in Note 28 where an inflow of economic benefits is probable.

Contingent liabilities are not recognised, but are disclosed in Note 28, unless the probability of a transfer of economic benefits is remote.

Contingent liabilities are defined as:

• possible obligations arising from past events whose existence will be confirmed only by the occurrence of one or more uncertain future events not wholly within the entity's control; or

• present obligations arising from past events but for which it is not probable that a transfer of economic benefits will arise or for which the amount of the obligation cannot be measured with sufficient reliability.

DRAFT

Note 1.17 Public dividend capital

Public dividend capital (PDC) is a type of public sector equity finance based on the excess of assets over liabilities at the time of establishment of the predecessor NHS organisation. HM Treasury has determined that PDC is not a financial instrument within the meaning of IAS 32.

The Secretary of State can issue new PDC to, and require repayments of PDC from, the Trust. PDC is recorded at the value received.

A charge, reflecting the cost of capital utilised by the trust, is payable as public dividend capital dividend. The charge is calculated at the rate set by HM Treasury (currently 3.5%) on the average relevant net assets of the trust during the financial year. Relevant net assets are calculated as the value of all assets less the value of all liabilities, with certain additions and deductions as defined by the Department of Health and Social Care.

This policy is available at
https://www.gov.uk/government/publications/guidance-on-financing-available-to-nhs-trusts-and-

In accordance with the requirements laid down by the Department of Health and Social Care (as the issuer of PDC), the dividend for the year is calculated on the actual average relevant net assets as set out in the "pre-audit" version of the annual accounts. The dividend calculated is not revised should any adjustment to net assets occur as a result the audit of the annual accounts.

Note 1.18 Value added tax

Most of the activities of the trust are outside the scope of VAT and, in general, output tax does not apply and input tax on purchases is not recoverable. Irrecoverable VAT is charged to the relevant expenditure category or included in the capitalised purchase cost of fixed assets. Where output tax is charged or input VAT is recoverable, the amounts are stated net of VAT.

Note 1.19 Third party assets

Assets belonging to third parties in which the Trust has no beneficial interest (such as money held on behalf of patients) are not recognised in the accounts. However, they are disclosed in a separate note to the accounts in accordance with the requirements of HM Treasury's *FReM*.

Note 1.20 Losses and special payments

Losses and special payments are items that Parliament would not have contemplated when it agreed funds for the health service or passed legislation. By their nature they are items that ideally should not arise. They are therefore subject to special control procedures compared with the generality of payments. They are divided into different categories, which govern the way that individual cases are handled. Losses and special payments are charged to the relevant functional headings in expenditure on an accruals basis.

The losses and special payments note is compiled directly from the losses and compensations register which reports on an accrual basis with the exception of provisions for future losses.

Note 1.21 Gifts

Gifts are items that are voluntarily donated, with no preconditions and without the expectation of any return. Gifts include all transactions economically equivalent to free and unremunerated transfers, such as the loan of an asset for its expected useful life, and the sale or lease of assets at below market value.

Note 1.22 IFRS 17

The entity applies IFRS 17 Insurance Contracts from 1 April 2025. The standard applies to contracts that transfer significant insurance risk. Where no such contracts exist, the entity has assessed and concluded that IFRS 17 does not apply.

DRAFT

Note 1.23 Early adoption of standards, amendments and interpretations

No new accounting standards or revisions to existing standards have been early adopted in 2025/26.

Note 1.24 Standards, amendments and interpretations in issue but not yet effective or adopted

IFRS18 Presentation and Disclosure in Financial Statements - The Standard is effective for accounting periods beginning on or after 1 January 2027. The Standard is not yet UK endorsed and not yet adopted by the FReM. Early adoption is not permitted.

IFRS19 Subsidiaries without Public Accountability: Disclosures -The Standard is effective for accounting periods beginning on or after 1 January 2027. The Standard is not yet UK endorsed and not yet adopted by the FReM. Early adoption is not permitted.

Changes to non-investment asset valuation – Following a thematic review of non-current asset valuations for financial reporting in the public sector, HM Treasury has made a number of changes to valuation frequency, valuation methodology and classification which are effective in the public sector from 1 April 2025 with a 5 year transition period. NHS bodies are adopting these changes to an alternative timeline.

Changes to subsequent measurement of intangible assets and PPE classification / terminology to be implemented for NHS bodies from 1 April 2025:

• Withdrawal of the revaluation model for intangible assets. Carrying values of existing intangible assets measured under a previous revaluation will be taken forward as deemed historic cost.

• Removal of the distinction between specialised and non-specialised assets held for their service potential. Assets will be classified according to whether they are held for their operational capacity.
These changes are not expected to have a material impact on these financial statements.

Changes to valuation cycles and methodology to be implemented for NHS bodies in later periods:

• A mandated quinquennial revaluation frequency (or rolling programme) supplemented by annual indexation in the intervening years.

• Removal of the alternative site assumption for buildings valued at depreciated replacement cost on a modern equivalent asset basis. The approach for land has not yet been finalised by HM Treasury.

The impact of applying these changes in future periods has not yet been assessed. PPE and right of use assets currently subject to revaluation have a total book value of £645.876 million as at 31 March 2026. Assets valued on an alternative site basis have a total book value of £640.580 million at 31 March 2026.

Although the impact has not been quantified, the revised valuation assumption may have a material or significant impact on PPE measurement in future periods.

Note 1.25 Critical judgements in applying accounting policies

The following are the judgements, apart from those involving estimations (see below) that management has made in the process of applying the Trust accounting policies and that have the most significant effect on the amounts recognised in the financial statements:

PFI Assets

The Trust's PFI scheme is deemed under International Financial Reporting Standards to be classed as on Statement of Financial Position on the basis that the asset is under the control of the Trust and all risks and rewards sit with the Trust. This is deemed to be a critical judgement that impacts on the financial statements.

The Trust's PFI assets have been valued using the Modern Equivalent Asset (MEA) method at depreciated replacement cost excluding VAT. By excluding VAT the Trust is accurately reflecting the depreciated replacement cost of the PFI assets. Our judgement based on the assumption that any replacement assets would be funded by PFI provider which is a requirement under the PFI project contract agreement. In these circumstances, by the nature of the contract, VAT would be recoverable by the Trust.

DRAFT

Practical Expedients Applied (IFRS 15)

As permitted by IFRS 15 and the DHSC Group Accounting Manual, the Trust has elected to apply the practical expedient in paragraph 121(a) of the standard. Consequently, the Trust does not disclose information regarding the transaction price allocated to remaining performance obligations for contracts that have an expected original duration of one year or less.

Significant Judgements in Applying IFRS 15

In applying IFRS 15, the Trust makes the following significant judgements regarding the timing and measurement of revenue:

Timing of Satisfaction: Revenue from patient care activities and education contracts is recognised over time, as the customer simultaneously receives and consumes the benefits provided by the Trust's performance.

Variable Consideration: Income subject to performance targets or activity variances is only recognized when it is highly probable that a significant revenue reversal will not occur in future periods

Note 1.26 Sources of estimation uncertainty

The following are assumptions about the future and other major sources of estimation uncertainty that have a significant risk of resulting in a material adjustment to the carrying amounts of assets and liabilities within the next financial year:

Estate Valuation

The Trust’s valuation approach is to have a full valuation including a full site inspection every 5 years with interim “desk top” valuations on an annual basis. A full valuation was undertaken as at 31st March 2022, which included site valuations to provide assurance that the value of land and building assets within the accounts are not materially misstated at the balance sheet date. An interim valuation was undertaken as at 31st March 2026 as well as a site visit at the Clinical Diagnostic Centre and County Breast Unit as these were significant capital schemes that were completed during the year and would impact the valuation.

The net book value of the Trust's estate as at 31st March 2026 is £640.580 million. If the Trust's management had not revalued the estate, at 31st March 2026 the value would have been £657.042 million.

The Trust's valuation adopts the MEA approach for its depreciated replacement cost DRC valuations rather than the identical replacement method. The MEA approach used to value the property is based on the cost of a modern equivalent asset that has the same service potential as the existing asset and then adjusted to take account of functional obsolescence. Functional obsolescence examines a building’s design or specification and whether it may no longer fulfil the function for which it was originally designed or whether it may be much more basic than the MEA. The asset will still be capable of use but at a lower level of efficiency than the MEA, or may be capable of modification to bring it up to a current specification. Other common causes of functional obsolescence include advances in technology or legislative change. The obsolescence adjustment will reflect either the cost of upgrading, or if this is not possible, the financial consequences of the reduced efficiency compared with the modern equivalent.

The Trust has made the judgement that the modern equivalent asset would be based around the use of an "optimised alternative site" in that all services would be based at a single site at Royal Stoke. The overall size of the modern equivalent asset includes an examination of building design or specification and makes assumptions around efficiencies. The resulting judgement is that under this approach a number of clinical and administrative areas would be combined into a "notional building" and would result in efficiencies in the overall footprint of the site. As a result the overall footprint provided to the valuer is lower than it would have been on a direct replacement basis.

The Trust obtains valuations for its land, buildings and dwellings from a qualified independent valuer. These valuations are performed at a point in time and take into account conditions and circumstances relevant to that date. In future years, conditions may change resulting in uplifts or impairments being required to the value of land, buildings and dwellings. The valuation has been completed based on the depreciated replacement cost and the remaining useful economic life of the assets.

DRAFT

Note 1.26 sets out the key judgements that impact on the estate valuation provided by the external valuer. Within the external valuation provided by the valuer the major sources of estimation uncertainty are around building indices and the location factor which form part of the overall valuation of assets.

A 1% movement in the BCIS cost indices or location factor for Staffordshire would have an impact of increasing or reducing the valuation of the Trusts estate by £6.406 million based on an overall valuation of building assets of £640.580 million.

PFI

The Trust uses appropriate estimations to allocate the annual unitary payment into the relevant component parts. The Trust obtained professional advice at the beginning of the PFI contract to review and allocate the payments appropriately as set out in note 29.

Note 2 Operating Segments

The Trust operates in a single segment, which is healthcare.

DRAFT

Note 3 Operating income from patient care activities

All income from patient care activities relates to contract income recognised in line with accounting policy 1.

Note 3.1 Income from patient care activities (by nature)	2025/26	2024/25
	£000	£000
Acute services		
Income from commissioners under API contracts - variable element*	255,927	228,253
Income from commissioners under API contracts - fixed element*	847,581	795,681
High cost drugs income from commissioners	110,816	107,133
Other NHS clinical income	7,389	7,248
All services		
Private patient income	1,535	1,722
National pay award central funding**	-	2,352
Additional pension contribution central funding***	47,979	43,647
Total income from activities	**1,271,227**	**1,186,037**

*Aligned payment and incentive contracts are the main form of contracting between NHS providers and their commissioners. More information can be found in the 2025/26 NHS Payment Scheme documentation.

https://www.england.nhs.uk/pay-syst/nhs-payment-scheme/

**Additional funding was made available directly to providers by NHS England in 2024/25 only.

***Increases to the employer contribution rate for NHS pensions since 1 April 2019 have been funded by NHS England. NHS providers continue to pay at the former rate of 14.38% with the additional amount being paid over by NHS England on providers' behalf. The full cost of employer contributions (23.7%) and related NHS England funding (9.4%) have been recognised in these accounts.

DRAFT

Note 3.2 Income from patient care activities (by source)	2025/26	2024/25
Income from patient care activities received from:	**£000**	**£000**
NHS England	191,661	188,626
Integrated care boards	1,060,753	979,240
Department of Health and Social Care	55	53
Other NHS providers	243	12
Non-NHS: private patients	1,535	1,722
Non-NHS: overseas patients (chargeable to patient)	3,163	4,342
Injury cost recovery scheme	3,932	2,842
Non NHS: other	9,886	9,201
Total income from activities	**1,271,227**	**1,186,037**
Of which:		
Related to continuing operations	1,271,227	1,186,037

Non NHS: Other mainly relates to income received from NHS bodies within Wales which are classified as non NHS as such bodies are outside NHS England.

During 2025/26, the Trust recognised £5.034m of income in relation to prior years. This mainly related to £1.3m relating to contract finalisation of patient activity, £2.4m release relating to High Cost Devices and £1.2m for High Cost Drugs.

Note 3.3 Overseas visitors (relating to patients charged directly by the provider)

	2025/26	2024/25
	£000	£000
Income recognised this year	3,163	4,342
Cash payments received in-year	614	215
Amounts added to provision for impairment of receivables	2,415	4,422
Amounts written off in-year	809	1,359

The Trust wrote off £0.809 million of overseas debt where a number of separate debts were deemed irrecoverable after all forms of debt recovery had become exhausted.

Note 4 Other operating income

	2025/26			2024/25		
	Contract income	Non-contract income	Total	Contract income	Non-contract income	Total
	£000	£000	£000	£000	£000	£000
Research and development	4,175	-	**4,175**	3,200	-	**3,200**
Education and training	44,169	2,039	**46,209**	42,052	1,715	**43,767**
Non-patient care services to other bodies	44,245	-	**44,245**	40,862	-	**40,862**
Receipt of capital grants and donations and peppercorn leases	-	4,809	**4,809**	-	6,047	**6,047**
Charitable and other contributions to expenditure	-	446	**446**	-	404	**404**
Revenue from operating leases	-	913	**913**	-	901	**901**
Other income	8,291	-	**8,291**	11,660	-	**11,660**
Total other operating income	**100,881**	**8,207**	**109,088**	**97,774**	**9,067**	**106,840**
Of which:						
Related to continuing operations			109,088			106,840

Note 4.1 Analysis of Other Income

	2025/26	2024/25
	£000	£000
Car Parking charges	4,317	3,730
Catering	229	236
Clinical Excellence Awards	432	426
External contribution to Community Diagnostic Centre landlord works*	-	2,433
Pharmacy sales	361	405
Pharmacy services	864	794
Staff accommodation rental	692	576
Other income not identified above	1,396	3,060
Total other contract income	**8,291**	**11,660**

**2024/25 only*

DRAFT

Note 4.2 Contract Balances

	2025/26
	£000
Opening Contract Liabilities (1 April 2025)	20,801
Closing Contract Liabilities (31 March 2026)	20,737
Revenue recognised in the reporting period	11,225

Of the contract liability balance outstanding at 1 April 2025, £11,225k was recognised as operating revenue during the 2025/26 financial year. This represents the satisfaction of performance obligations linked to deferred income for areas including high cost devices and research grants.

Note 5 Fees and charges

The following disclosure is of income from charges for car parking to service users as the full cost of providing that service exceeds £1.000 million and is presented as the aggregate of such income. The cost associated with car parking that generated the income is also disclosed.

	2025/26	2024/25
	£000	£000
Income	4,399	3,806
Full cost	(4,930)	(4,590)
Deficit	**(531)**	**(784)**

Note 6 Operating leases - University Hospitals of North Midlands NHS Trust as lessor

This note discloses income generated in operating lease agreements where University Hospitals of North Midlands NHS Trust is the lessor.

The Trust receives rental income from commercial retail outlets within the Hospital reception areas and from rental of buildings owned by the Trust.

Note 6.1 Operating lease income

	2025/26	2024/25
	£000	£000
Lease receipts recognised as income in year:		
Minimum lease receipts	913	901
Total in-year operating lease income	**913**	**901**

Note 6.2 Future lease receipts

	31 March 2026	31 March 2025
	£000	£000
Future minimum lease receipts due in:		
- not later than one year	325	327
- later than one year and not later than two years	161	332
- later than two years and not later than three years	144	168
- later than three years and not later than four years	126	150
- later than four years and not later than five years	132	133
- later than five years	935	1,010
Total	**1,823**	**2,120**

DRAFT

Note 7.1 Operating expenses

	2025/26	2024/25
	£000	£000
Purchase of healthcare from NHS and DHSC bodies	13,392	13,537
Purchase of healthcare from non-NHS and non-DHSC bodies	12,286	20,675
Staff and executive directors costs	844,930	783,504
Remuneration of non-executive directors	179	178
Supplies and services - clinical (excluding drugs costs)	134,026	123,979
Supplies and services - general	10,078	9,891
Drug costs (drugs inventory consumed and purchase of non-inventory drugs)	142,284	136,775
Inventories written down	746	745
Consultancy costs	1,904	1,206
Establishment	6,094	5,172
Premises	43,667	43,159
Transport (including patient travel)	5,970	6,030
Depreciation on property, plant and equipment	37,193	34,800
Amortisation on intangible assets	4,578	4,920
Net impairments	18,183	268
Movement in credit loss allowance: contract receivables / contract assets	2,633	4,033
Increase / (decrease) in other provisions	(1,525)	3,469
Change in provisions discount rate(s)	(46)	6
Fees payable to the external auditor: audit services- statutory audit	318	198
Internal audit costs	221	169
Clinical negligence	28,823	26,042
Legal fees	127	131
Insurance (as a policy holder)	138	97
Research and development	3,656	3,818
Education and training	4,797	4,511
Expenditure on short term leases	-	316
Redundancy	506	-
Charges to operating expenditure for on-SoFP IFRIC 12 PFI scheme	46,224	41,444
Car parking & security	1,178	833
Hospitality	159	138
Losses, ex gratia & special payments	15	38
Other services, eg external payroll	819	761
Other	595	888
Total	**1,364,149**	**1,271,731**
Of which:		
Related to continuing operations	1,364,149	1,271,731

[1]Staff and executive directors costs include £47.979 million (2024/25: £43.647 million) in respect of central funding of additional pension contributions.

[2]The fees payable to the external auditor are inclusive of VAT, and the net fee is £265k.

DRAFT

Note 7.2 Limitation on auditor's liability

The limitation on auditor's liability for external audit work is £2.000 million (2024/25: £2.000 million).

Note 8 Impairment of assets

	2025/26	2024/25
	£000	£000
Net impairments charged to operating surplus / deficit resulting from:		
Unforeseen obsolescence	-	425
Changes in market price	18,183	(157)
Total net impairments charged to operating surplus	**18,183**	**268**
Impairments charged to the revaluation reserve	7,960	8,095
Total net impairments	**26,143**	**8,363**

Impairments in the above table represent a reduction in the value of individual assets following the valuations of the Trust's land and building assets as at 31st March 2026.

Impairments charged to the revaluation reserve of £7.960 million and this mainly relates to the Modern Equivalent Asset.

Impairments charged to the operating surplus include £15.645 million relating to the Clinical Diagnostic Centre; £3.200 million relating to the reduction in value of the surplus land at the former Royal Infirmary and COPD sites (included in note 22 as Assets Held for Sale) ; less a reversal of impairments on the PFI DTC.

Note 9 Employee benefits

	2025/26	2024/25
	Total	Total
	£000	£000
Salaries and wages	635,910	599,809
Social security costs	78,787	58,598
Apprenticeship levy	3,142	2,899
Employer's contributions to NHS pensions	120,221	108,750
Pension cost - other	106	128
Temporary staff (including agency)	13,513	18,665
Total gross staff costs	**851,679**	**788,849**
Total staff costs	**851,679**	**788,849**
Of which		
Costs capitalised as part of assets	2,587	1,527

The £851.679 million total staff costs less the capitalised costs of £2.587 million is £849.092 million. This compares to the total of the staff and executive directors costs; redundancy costs; and research and development costs in Note 7.1.

Costs in the above table relating to salaries and wages, social security costs and employer's contribution to NHS Pensions have increased due to the impact of the staff pay award.

Note 9.1 Retirements due to ill-health

During 2025/26 there were 14 early retirements from the trust agreed on the grounds of ill-health (5 in the year ended 31 March 2025). The estimated additional pension liabilities of these ill-health retirements is £1.093 million (£0.392 million in 2024/25).

These estimated costs are calculated on an average basis and will be borne by the NHS Pension Scheme.

DRAFT

Note 10 Pension costs

Past and present employees are covered by the provisions of the NHS Pension Schemes. Details of the benefits payable and rules of the schemes can be found on the NHS Pensions website at www.nhsbsa.nhs.uk/pensions. Both the 1995/2008 and 2015 schemes are accounted for, and the scheme liability valued, as a single combined scheme. Both are unfunded defined benefit schemes that cover NHS employers, GP practices and other bodies, allowed under the direction of the Secretary of State for Health and Social Care in England and Wales. They are not designed to be run in a way that would enable NHS bodies to identify their share of the underlying scheme assets and liabilities. Therefore, each scheme is accounted for as if it were a defined contribution scheme: the cost to the NHS body of participating in each scheme is taken as equal to the contributions payable to that scheme for the accounting period.

In order that the defined benefit obligations recognised in the financial statements do not differ materially from those that would be determined at the reporting date by a formal actuarial valuation, the FReM requires that "the period between formal valuations shall be four years, with approximate assessments in intervening years". An outline of these follows:

a) Accounting valuation

A valuation of scheme liability is carried out annually by the scheme actuary (currently the Government Actuary's Department) as at the end of the reporting period. This utilises an actuarial assessment for the previous accounting period in conjunction with updated membership and financial data for the current reporting period, and is accepted as providing suitably robust figures for financial reporting purposes. The valuation of the scheme liability as at 31 March 2026, is based on valuation data as at 31 March 2024, updated to 31 March 2026 with summary global member and accounting data. In undertaking this actuarial assessment, the methodology prescribed in IAS 19, relevant FReM interpretations, and the discount rate prescribed by HM Treasury have also been used.

The latest assessment of the liabilities of the scheme is contained in the Statement by the Actuary, which forms part of the annual NHS Pension Scheme Annual Report and Accounts. These accounts can be viewed on the NHS Pensions website and are published annually. Copies can also be obtained from The Stationery Office.

b) Full actuarial (funding) valuation

The purpose of this valuation is to assess the level of liability in respect of the benefits due under the schemes (considering recent demographic experience), and to recommend the contribution rate payable by employers.

The latest actuarial valuation undertaken for the NHS Pension Scheme was completed as at 31 March 2020. The results of this valuation set the employer contribution rate payable from 1 April 2024 at 23.7% of pensionable pay. The core cost cap cost of the scheme was calculated to be outside of the 3% cost cap corridor as at 31 March 2020. However, when the wider economic situation was taken into account through the economic cost cap cost of the scheme, the cost cap corridor was not similarly breached. As a result, there was no impact on the member benefit structure or contribution rates.

The 2024 actuarial valuation is currently being prepared and will be published before new contribution rates are implemented from April 2027

Additional defined contribution scheme

The Trust offers an additional defined contribution workplace pension scheme - the National Employment Savings Scheme (NEST). This is not material.

DRAFT

Note 11 Finance income

Finance income represents interest received on assets and investments in the period.

	2025/26	2024/25
	£000	£000
Interest on bank accounts	5,185	6,054
Total finance income	**5,185**	**6,054**

Note 12.1 Finance expenditure

Finance expenditure represents interest and other charges involved in the borrowing of money or asset financing.

	2025/26	2024/25
	£000	£000
Interest expense:		
Interest on lease obligations	528	286
Interest on late payment of commercial debt	7	1
Finance costs on PFI arrangements:		
Main finance costs	12,909	13,011
Remeasurement of the liability resulting from change in index or rate	16,662	22,093
Total interest expense	**30,106**	**35,391**
Unwinding of discount on provisions	38	31
Total finance costs	**30,144**	**35,422**

[1]The PFI lease liability remeasurement is based on the RPI indexation applicable to the PFI unitary payment each year and is applied to the opening liability. The RPI applicable to the unitary payment in 2025/26 was 3.4% (4.5% in 2024/25).

Note 12.2 The late payment of commercial debts (interest) Act 1998

	2025/26	2024/25
	£000	£000
Amounts included within interest payable arising from claims made under this legislation	7	1

Note 13 Other gains

	2025/26	2024/25
	£000	£000
Gains on disposal of assets	137	70
Total gains on disposal of assets	**137**	**70**
Total other gains	**137**	**70**

DRAFT

Note 14.1 Intangible assets - 2025/26

	Software licences	Intangible assets under construction	Total
	£000	£000	£000
Cost at 1 April 2025 - brought forward *	**54,541**	**1,509**	**56,050**
Additions	1,777	1,449	**3,226**
Reclassifications	472	(490)	**(18)**
Disposals / derecognition	(3,283)	-	**(3,283)**
Cost at 31 March 2026	**53,507**	**2,468**	**55,975**
Amortisation at 1 April 2025 - brought forward	**40,065**	**-**	**40,065**
Provided during the year	4,578	-	**4,578**
Disposals / derecognition	(3,283)	-	**(3,283)**
Amortisation at 31 March 2026	**41,360**	**-**	**41,360**
Net book value at 31 March 2026	**12,147**	**2,468**	**14,615**
Net book value at 1 April 2025	**14,476**	**1,509**	**15,985**

* From 1 April 2025, the option to apply the revaluation model in IAS 38 to intangible assets has been withdrawn prospectively. Where assets were previously revalued, the carrying value at the transition date was carried forward as 'deemed cost'.

Note 14.2 Intangible assets - 2024/25

	Software licences	Intangible assets under construction	Total
	£000	£000	£000
Valuation / gross cost at 1 April 2024	**52,846**	**1,067**	**53,913**
Additions	3,670	977	**4,647**
Reclassifications	535	(535)	**-**
Disposals / derecognition	(2,510)	-	**(2,510)**
Valuation / gross cost at 31 March 2025	**54,541**	**1,509**	**56,050**
Amortisation at 1 April 2024	**37,655**	**-**	**37,655**
Provided during the year	4,920	-	**4,920**
Disposals / derecognition	(2,510)	-	**(2,510)**
Amortisation at 31 March 2025	**40,065**	**-**	**40,065**
Net book value at 31 March 2025	**14,476**	**1,509**	**15,985**
Net book value at 1 April 2024	**15,191**	**1,067**	**16,258**

DRAFT

Note 15.1 Property, plant and equipment - 2025/26

	Land	Buildings excluding dwellings	Assets under construction	Plant & machinery	Transport equipment	Information technology	Furniture & fittings	Total
	£000	£000	£000	£000	£000	£000	£000	£000
Valuation/gross cost at 1 April 2025 - brought forward	**15,497**	**604,187**	**20,637**	**136,717**	**28**	**30,041**	**7,424**	**814,531**
Additions	-	9,461	37,745	16,872	-	3,571	137	**67,786**
Impairments	-	(30,407)	-	-	-	-	-	**(30,407)**
Reversals of impairments	-	(120)	-	-	-	-	-	**(120)**
Revaluations	-	(2,430)	-	-	-	-	-	**(2,430)**
Reclassifications	-	44,391	(52,742)	7,486	-	878	5	**18**
Disposals / derecognition	-	-	-	(7,117)	(28)	(1,271)	(1,777)	**(10,193)**
Valuation/gross cost at 31 March 2026	**15,497**	**625,082**	**5,640**	**153,958**	**-**	**33,219**	**5,789**	**839,185**
Accumulated depreciation at 1 April 2025 - brought forward	**-**	**-**	**-**	**78,171**	**28**	**14,420**	**6,213**	**98,832**
Provided during the year	-	16,495	-	11,874	-	4,180	260	**32,809**
Impairments	-	(7,309)	-	-	-	-	-	**(7,309)**
Reversals of impairments	-	(968)	-	-	-	-	-	**(968)**
Revaluations	-	(8,218)	-	-	-	-	-	**(8,218)**
Disposals / derecognition	-	-	-	(7,117)	(28)	(1,271)	(1,777)	**(10,193)**
Accumulated depreciation at 31 March 2026	**-**	**-**	**-**	**82,928**	**-**	**17,329**	**4,696**	**104,953**
Net book value at 31 March 2026	**15,497**	**625,082**	**5,640**	**71,030**	**-**	**15,890**	**1,093**	**734,232**
Net book value at 1 April 2025	**15,497**	**604,187**	**20,637**	**58,546**	**-**	**15,621**	**1,211**	**715,699**

DRAFT

Note 15.2 Property, plant and equipment - 2024/25

	Land	Buildings excluding dwellings	Assets under construction	Plant & machinery	Transport equipment	Information technology	Furniture & fittings	Total
	£000	£000	£000	£000	£000	£000	£000	£000
Valuation / gross cost at 1 April 2024	**26,567**	**576,140**	**17,630**	**134,610**	**28**	**23,268**	**7,376**	**785,619**
Additions	-	23,354	20,925	14,322	-	8,963	133	**67,697**
Impairments	(175)	(17,646)	-	(376)	-	(925)	-	**(19,122)**
Reversals of impairments	5	1,264	-	-	-	-	-	**1,269**
Revaluations	-	4,210	-	-	-	-	-	**4,210**
Reclassifications	-	16,865	(17,918)	774	-	200	79	**-**
Transfers to / from assets held for sale	(10,900)	-	-	-	-	-	-	**(10,900)**
Disposals / derecognition	-	-	-	(12,613)	-	(1,465)	(164)	**(14,242)**
Valuation/gross cost at 31 March 2025	**15,497**	**604,187**	**20,637**	**136,717**	**28**	**30,041**	**7,424**	**814,531**
Accumulated depreciation at 1 April 2024	**-**	**-**	**-**	**79,811**	**28**	**13,526**	**6,003**	**99,368**
Provided during the year	-	15,994	-	11,132	-	3,058	374	**30,558**
Impairments	-	(7,259)	-	(177)	-	(699)	-	**(8,135)**
Reversals of impairments	-	(1,355)	-	-	-	-	-	**(1,355)**
Revaluations	-	(7,380)	-	-	-	-	-	**(7,380)**
Disposals / derecognition	-	-	-	(12,595)	-	(1,465)	(164)	**(14,224)**
Accumulated depreciation at 31 March 2025	**-**	**-**	**-**	**78,171**	**28**	**14,420**	**6,213**	**98,832**
Net book value at 31 March 2025	**15,497**	**604,187**	**20,637**	**58,546**	**-**	**15,621**	**1,211**	**715,699**
Net book value at 1 April 2024	**26,567**	**576,140**	**17,630**	**54,799**	**-**	**9,742**	**1,373**	**686,251**

DRAFT

Note 15.3 Property, plant and equipment financing - 31 March 2026

	Land	Buildings excluding dwellings	Assets under construction	Plant & machinery	Information technology	Furniture & fittings	Total
	£000	£000	£000	£000	£000	£000	£000
Owned - purchased	15,497	370,304	5,450	52,111	13,233	1,051	**457,646**
On-SoFP PFI contracts and other service concession arrangements	-	249,763	-	9,217	2,558	-	**261,538**
Owned - donated/granted	-	5,015	190	9,702	99	42	**15,048**
Total net book value at 31 March 2026	**15,497**	**625,082**	**5,640**	**71,030**	**15,890**	**1,093**	**734,232**

Note 15.4 Property, plant and equipment financing - 31 March 2025

	Land	Buildings excluding dwellings	Assets under construction	Plant & machinery	Information technology	Furniture & fittings	Total
	£000	£000	£000	£000	£000	£000	£000
Owned - purchased	15,497	351,799	20,623	43,651	12,759	1,178	**445,507**
On-SoFP PFI contracts and other service concession arrangements	-	247,481	-	7,960	2,684	-	**258,125**
Owned - donated/granted	-	4,907	14	6,935	178	33	**12,067**
Total net book value at 31 March 2025	**15,497**	**604,187**	**20,637**	**58,546**	**15,621**	**1,211**	**715,699**

DRAFT

Note 16 Donations of property, plant and equipment

The UHNM Charity donated £4.809 million to the Trust (2024/25: £3.520 million) in respect of assets acquired in the financial year. The Trust acquired no Government Granted assets in 2025/26 (2024/25: £2.527 million).

Note 17 Revaluations of property, plant and equipment

Valuations are carried out by professionally qualified valuers in accordance with the Royal Institute of Chartered Surveyors (RICS) Appraisal and Valuation Manual. The valuation as at 31st March 2026 in relation to our operational land and buildings was carried out by a qualified independent valuer from the District Valuation Service.

Valuation approach
As set out in the accounting policies the Department of Health has adopted the Modern Equivalent Asset (MEA) approach for its Depreciated Replacement Cost (DRC) valuations rather than the previous identical replacement method. The MEA approach used to value the property will normally be based on the cost of a modern equivalent asset that has the same service potential as the existing asset and then adjusted to take account of obsolescence.

The MEA approach incorporates the Building Cost Information Service Index to determine an increase or decrease in building costs which impact on the asset valuation. The Trust's land and building valuation was carried out by the Trust's current valuer (District Valuer), on a MEA "Optimised Alternative Site" method valuation.

The valuation has been undertaken having regard to IFRS as applied to the UK public sector and in accordance with HM Treasury guidance.

All land and buildings are restated to current value using independent professional valuations in accordance with IAS16 and in accordance with the Royal Institute of Chartered Surveyors (RICS) Appraisal and Valuation Manual. At least every five years, with interim revaluations carried out annually also by independent professional valuers. The full asset valuation includes a full site inspection by the professional valuer whilst interim valuations only include a site inspection where deemed necessary due to significant changes in the year. An interim valuation was undertaken of our operational land and buildings as at 31st March 2026. The last full valuation of these assets was as at 31st March 2022.

The value of land and buildings assets provided by the District Valuer at 31st March 2026 was £640.580 million (2024/25: £619.684 million), the valuation is reflected in note 15.1 and reflects an increase of £20.896 million from the previous valuation at 31 March 2025 of which £15.110 relates to tenant improvement works on the Community Diagnostic Centre.

The carrying values of PPE are reviewed for impairment in periods if events or changes in circumstances indicate the carrying value may not be recoverable. Further information is provided in Note 7 to explain the impairments resulting from the valuation.

The asset lives relating to buildings and dwellings are provided as part of the independent valuation of the Trusts assets by the external valuer.

Asset lives for dwellings are no longer disclosed as all of the Trust's dwellings are leased and have been reclassified as Right of Use (RoU) assets.

DRAFT

Note 18 Right of use assets - 2025/26

	Property (land and buildings)	Plant & machinery	Transport equipment	Information technology	Total	Of which: leased from DHSC group bodies
	£000	£000	£000	£000	£000	£000
Valuation / gross cost at 1 April 2025 - brought forward	**17,299**	**12,118**	**471**	**5,147**	**35,035**	**5,394**
Additions	148	898	177	593	**1,816**	-
Remeasurements of the lease liability	847	1,162	2	-	**2,011**	(10)
Impairments	(741)	-	-	-	**(741)**	-
Revaluations	137	-	-	-	**137**	137
Disposals / derecognition	(462)	(841)	(163)	(1,625)	**(3,091)**	-
Valuation/gross cost at 31 March 2026	**17,228**	**13,337**	**487**	**4,115**	**35,167**	**5,521**
Accumulated depreciation at 1 April 2025 - brought forward	**3,111**	**6,768**	**256**	**1,813**	**11,948**	**537**
Provided during the year	1,554	1,657	158	1,015	**4,384**	349
Impairments	(48)	-	-	-	**(48)**	-
Revaluations	(88)	-	-	-	**(88)**	(88)
Disposals / derecognition	(462)	(841)	(163)	(1,625)	**(3,091)**	-
Accumulated depreciation at 31 March 2026	**4,067**	**7,584**	**251**	**1,203**	**13,105**	**798**
Net book value at 31 March 2026	**13,161**	**5,753**	**236**	**2,912**	**22,062**	**4,723**
Net book value at 1 April 2025	**14,188**	**5,350**	**215**	**3,334**	**23,087**	**4,857**

Net book value of right of use assets leased from other NHS providers	2,616
Net book value of right of use assets leased from other DHSC group bodies	2,107

DRAFT

Note 18.1 Right of use assets - 2024/25

	Property (land and buildings)	Plant & machinery	Transport equipment	Information technology	Total	Of which: leased from DHSC group bodies
	£000	£000	£000	£000	£000	£000
Valuation / gross cost at 1 April 2024 - brought forward	**13,266**	**12,148**	**427**	**1,799**	**27,640**	**2,746**
Additions	4,655	220	56	2,885	**7,816**	572
Remeasurements of the lease liability	48	711	-	477	**1,236**	(55)
Revaluations	(4)	-	-	-	**(4)**	(4)
Reclassifications	-	-	-	-	**-**	2,135
Disposals / derecognition	(666)	(961)	(12)	(14)	**(1,653)**	-
Valuation/gross cost at 31 March 2025	**17,299**	**12,118**	**471**	**5,147**	**35,035**	**5,394**
Accumulated depreciation at 1 April 2024 - brought forward	**2,048**	**6,074**	**127**	**1,248**	**9,497**	**5**
Provided during the year	1,867	1,655	141	579	**4,242**	292
Revaluations	(138)	-	-	-	**(138)**	(91)
Reclassifications	-	-	-	-	**-**	331
Disposals / derecognition	(666)	(961)	(12)	(14)	**(1,653)**	-
Accumulated depreciation at 31 March 2025	**3,111**	**6,768**	**256**	**1,813**	**11,948**	**537**
Net book value at 31 March 2025	**14,188**	**5,350**	**215**	**3,334**	**23,087**	**4,857**
Net book value at 1 April 2024	**11,218**	**6,074**	**300**	**551**	**18,143**	**2,741**

Net book value of right of use assets leased from other NHS providers	2,490
Net book value of right of use assets leased from other DHSC group bodies	2,367

DRAFT

Note 18.2 Revaluations of right of use assets

The Trust has applied the revaluation model in IAS 16 and revalued several right of use assets in 2025/26.
The revaluation of right of use dwellings resulted in a £0.693 million impairment to the revaluation reserve and the revaluation of peppercorn leases resulted in an increase of £0.225 million to the revaluation reserve.

Note 18.3 Reconciliation of the carrying value of lease liabilities

Lease liabilities are included within borrowings in the statement of financial position. A breakdown of borrowings is disclosed in note 26.1.

	2025/26	2024/25
	£000	£000
Carrying value at 1 April	**18,234**	**13,183**
Lease additions	1,816	7,816
Lease liability remeasurements	2,011	1,236
Interest charge arising in year	528	286
Lease payments (cash outflows)	(4,985)	(4,287)
Carrying value at 31 March	**17,604**	**18,234**

Lease payments for short term leases, leases of low value underlying assets and variable lease payments not dependent on an index or rate are recognised in operating expenditure.

These payments are disclosed in Note 7.1. Cash outflows in respect of leases recognised on-SoFP are disclosed in the reconciliation above.

Note 18.4 Maturity analysis of future lease payments

	Total	Of which leased from DHSC group bodies:	Total	Of which leased from DHSC group bodies:
	31 March 2026	31 March 2026	31 March 2025	31 March 2025
	£000	£000	£000	£000
Undiscounted future lease payments payable in:				
- not later than one year;	5,745	271	5,672	213
- later than one year and not later than five years;	9,341	1,041	9,072	1,140
- later than five years.	4,485	954	5,684	1,202
Total gross future lease payments	**19,571**	**2,266**	**20,428**	**2,555**
Finance charges allocated to future periods	(1,967)	(137)	(2,194)	(181)
Net lease liabilities at 31 March 2026	**17,604**	**2,129**	**18,234**	**2,374**
Of which:				
Leased from other NHS providers		14		26
Leased from other DHSC group bodies		2,115		2,348

DRAFT

Note 19 Inventories

	31 March 2026	31 March 2025
	£000	£000
Drugs	5,905	5,952
Consumables	15,316	13,114
Energy	208	153
Total inventories	**21,429**	**19,219**

Inventories recognised in expenses for the year were £280.612 million (2024/25: £264.234 million). Write-down of inventories recognised as expenses for the year were £0.746 million (2024/25: £0.745 million).

Note 20 Receivables

	31 March 2026	31 March 2025
	£000	£000
Current		
Contract receivables	43,680	34,343
Capital receivables[1]	-	2,224
Allowance for impaired contract receivables / assets	(11,708)	(9,995)
Prepayments (non-PFI)	9,762	12,837
PFI lifecycle prepayments	3,566	177
PDC dividend receivable	588	93
VAT receivable	3,818	3,804
Other receivables[2]	31	35
Total current receivables	**49,737**	**43,518**
Non-current		
Other receivables[2]	1,018	1,105
Total non-current receivables	**1,018**	**1,105**
Of which receivable from NHS and DHSC group bodies:		
Current	15,627	11,770
Non-current	1,018	1,105

[1]Capital receivables in 2024/25 of £2.224 million relate to grant monies owed to the Trust in relation to the Public Sector Decarbonisation Scheme and relate to that year only.

[2]Current and non current Other receivables relate to the clinician pension tax provision reimbursement funding receivable from NHS England.

DRAFT

Note 20.1 Allowances for credit losses

	2025/26	2024/25
	Contract receivables and contract assets	Contract receivables and contract assets
	£000	£000
Allowances as at 1 April - brought forward	**9,995**	**7,187**
New allowances arising	4,015	4,091
Changes in existing allowances	16	480
Reversals of allowances	(1,398)	(538)
Utilisation of allowances (write offs)	(920)	(1,225)
Allowances as at 31 Mar 2026	**11,708**	**9,995**

In line with IFRS 9 the Trust has reviewed the likelihood of the non-receipt of income for overseas patients, private patients, payroll reclaims and other commercial income and has agreed the probability to use for the recognition of doubtful debts. For RTA accruals the Trust has used the prescribed rate of 24.62% (2024/25: 24.45%). The Trust's management considers that this is a reasonable estimate of the value of asset.

The increase or decrease for allowance for credit losses is reviewed on a monthly basis and increased or decreased dependent upon the Trust's view of receivables deemed to be potentially at risk of being collected in full.

Note 20.2 Exposure to credit risk

Because the majority of the Trust's revenue comes from contracts with other public sector bodies, the Trust has low exposure to credit risk. The maximum exposure as at 31 March 2026 are in receivables from customers, as disclosed in the trade and other receivables note.

Credit risk arises principally from the Trust's receivables balances. The Trust does not apply external credit ratings to counterparties; instead, credit risk is assessed using an ageing analysis and a simplified provision matrix in accordance with IFRS 9.

The table below shows the gross carrying amounts of financial assets analysed by ageing, which the Trust considers to be an appropriate equivalent to credit risk grading for NHS bodies. This excludes RTA debt where a prescribed % rate is applied.

	Overseas patients	All other receivables	Total receivables
Ageing category - gross carrying amount as at 31 March 2026	**£'000**	**£'000**	**£'000**
Less than 180 days	1,078	2,050	3,128
More than 180 days	6,602	1,859	8,461
Total	**7,680**	**3,909**	**11,589**
Loss allowance by ageing category as at 31 March 2026			
Less than 180 days	(1,078)	0	(1,078)
More than 180 days	(6,602)	(1,492)	(8,094)
Total	**(7,680)**	**(1,492)**	**(9,172)**

Note 21 Finance leases (University Hospitals of North Midlands NHS Trust as a lessor)

The Trust has no finance leases where it acts as lessor.

DRAFT

Note 22 Non-current assets held for sale and assets in disposal groups

	2025/26	2024/25
	£000	£000
NBV of non-current assets for sale and assets in disposal groups at 1 April	**10,900**	-
Assets classified as available for sale in the year	-	10,900
Impairment of assets held for sale	(3,200)	-
NBV of non-current assets for sale and assets in disposal groups at 31 March	**7,700**	**10,900**

At 31st March 2026 the surplus land at the Royal Infirmary and COPD sites continue to meet the IFRS 5 “held for sale” criteria first satisfied in 2024/25. At that point the fair value of the asset held for sale was determined by an independent valuer using the market approach. This technique utilises observable market prices for comparable commercial land and property transactions in the local geographic area.

IFRS 5 requires assets held for sale to be measured at the lower of their carrying amount, and fair value less costs to sell, and for us to undertake an annual assessment of this measurement.

Following this annual assessment at 31 March 2026 and based on the current available information, the Trust has assessed the fair value as £7.7m and therefore an impairment of £3.2m has been recognised in the SOCIE.

The sale of this asset is highly probable and the asset is no longer required for the operational capacity or service delivery of the Trust

Note 23 Cash and cash equivalents movements

Cash and cash equivalents comprise cash at bank, in hand and cash equivalents. Cash equivalents are readily convertible investments of known value which are subject to an insignificant risk of change in value.

	2025/26	2024/25
	£000	£000
At 1 April	**84,186**	**82,024**
Net change in year	3,882	2,162
At 31 March	**88,068**	**84,186**
Broken down into:		
Cash at commercial banks and in hand	9	7
Cash with the Government Banking Service	88,059	84,179
Total cash and cash equivalents as in SoFP	**88,068**	**84,186**
Total cash and cash equivalents as in SoCF	**88,068**	**84,186**

Note 23.1 Third party assets held by the Trust

University Hospitals of North Midlands NHS Trust held cash and cash equivalents which relate to monies held by the Trust on behalf of patients or other parties and in which the trust has no beneficial interest. This has been excluded from the cash and cash equivalents figure reported in the accounts.

	31 March 2026	31 March 2025
	£000	£000
Bank balances	15	10
Total third party assets	**15**	**10**

DRAFT

Note 24.1 Trade and other payables

	31 March 2026 £000	31 March 2025 £000
Current		
Trade payables	6,906	5,167
Capital payables	17,479	15,045
Accruals	61,201	62,837
Social security costs	18,723	16,099
Pension contributions payable	10,338	9,466
Total current trade and other payables	**114,647**	**108,614**
Of which payables from NHS and DHSC group bodies:		
Current	6,946	6,495

Note 25 Other liabilities

	31 March 2026 £000	31 March 2025 £000
Current		
Deferred income: contract liabilities	20,737	20,801
Total other current liabilities	**20,737**	**20,801**

Note 26.1 Borrowings

	31 March 2026 £000	31 March 2025 £000
Current		
Lease liabilities	5,259	5,213
Obligations under PFI contracts	23,533	15,073
Total current borrowings	**28,792**	**20,286**
Non-current		
Lease liabilities	12,345	13,021
Obligations under PFI contracts	469,903	477,234
Total non-current borrowings	**482,248**	**490,255**

DRAFT

Note 26.2 Reconciliation of liabilities arising from financing activities

	Lease Liabilities	PFI schemes	Total
	£000	£000	£000
Carrying value at 1 April 2025	**18,234**	**492,307**	**510,541**
Cash movements:			
Financing cash flows - payments and receipts of principal	(4,457)	(15,533)	**(19,990)**
Financing cash flows - payments of interest	(528)	(12,909)	**(13,437)**
Non-cash movements:			
Additions	1,816	-	**1,816**
Lease liability remeasurements	2,011	-	**2,011**
Remeasurement of PFI / other service concession liability resulting from change in index or rate	-	16,662	**16,662**
Application of effective interest rate	528	12,909	**13,437**
Carrying value at 31 March 2026	**17,604**	**493,436**	**511,040**

	Lease Liabilities	PFI schemes	Total
	£000	£000	£000
Carrying value at 1 April 2024	**13,183**	**489,589**	**502,772**
Cash movements:			
Financing cash flows - payments and receipts of principal	(4,001)	(21,964)	**(25,965)**
Financing cash flows - payments of interest	(286)	(13,011)	**(13,297)**
Non-cash movements:			
Additions	7,816	2,589	**10,405**
Lease liability remeasurements	1,236	-	**1,236**
Remeasurement of PFI / other service concession liability resulting from change in index or rate	-	22,093	**22,093**
Application of effective interest rate	286	13,011	**13,297**
Carrying value at 31 March 2025	**18,234**	**492,307**	**510,541**

DRAFT

Note 27 Provisions for liabilities and charges analysis

	Pensions: early departure costs	Pensions: injury benefits	Legal claims	Other	Total
	£000	£000	£000	£000	£000
At 1 April 2025	**218**	**1,115**	**449**	**9,470**	**11,252**
Change in the discount rate	(4)	(42)	-	(80)	**(126)**
Arising during the year	39	64	213	743	**1,059**
Utilised during the year	(65)	(34)	(28)	(5,072)	**(5,199)**
Reversed unused	-	-	(40)	(2,592)	**(2,632)**
Unwinding of discount	5	33	-	68	**106**
At 31 March 2026	**194**	**1,136**	**594**	**2,537**	**4,461**
Expected timing of cash flows:					
- not later than one year;	32	74	594	354	**1,054**
- later than one year and not later than five years;	118	176	-	147	**441**
- later than five years.	44	886	-	2,036	**2,966**
Total	**194**	**1,136**	**594**	**2,537**	**4,461**

The Trust has provided £1.330 million (2024/25: £1.333 million) in respect of post employment pension obligations for 18 former employees (2024/25: 18). The Trust has reassessed these provisions and updated the assumptions around the calculation of the provision in line with up to date life expectancy tables. The Trust has also applied the applicable discount rate for 2025/26 of 2.95% (2024/25 2.40%).

The Trust has provided £0.594 million (2024/25 £0.449 million) in respect of legal cases. This includes £0.416 million which relates to current employment legal cases and £0.176 million relating to the insurance excess on public and employer liability cases being administered by the NHS Litigation Authority.

In all these cases the timing and the value of the payments are uncertain and the Trust has provided based on the advice provided by legal advisors and the NHS Litigation Authority.

Other provisions includes £0.323 million in relation to the potential cost of uplifting some band 2 staff to band 3 (2024/25: £7.575 million); lease dilapidations of £1.165 million (2024/25: £0.755 million) and the clinicians' pension reimbursement £1.049 million (2024/25: £1.141 million). Lease dilapidations are the works estimated to be required to put back a property at the end of the lease into the same condition it was when the lease commenced. The clinicians' pension reimbursement provision covers the estimated costs of reimbursing clinicians who face a tax charge in respect of their NHS pension benefits.

Note 27.1 Clinical negligence liabilities

At 31 March 2026, £276.842 million was included in provisions of NHS Resolution in respect of clinical negligence liabilities of University Hospitals of North Midlands NHS Trust (31 March 2025: £280.057 million).

Note 28 Contingent assets and liabilities

	31 March 2026	31 March 2025
	£000	£000
Value of contingent liabilities		
NHS Resolution legal claims	(45)	(53)
Gross value of contingent liabilities	**(45)**	**(53)**
Net value of contingent liabilities	**(45)**	**(53)**

The above relates to the member contingent liability relating to the excess due on clinical negligence cases covered by the NHS Litigation Authority.

Note 29 Contractual capital commitments

	31 March 2026	31 March 2025
	£000	£000
Property, plant and equipment	6,708	32,353
Intangible assets	98	-
Total	**6,806**	**32,353**

Property plant and equipment contractual commitments in 2024/25 included £20.616 million in relation to the Community Diagnostic Centre (CDC) and £9.071 million in relation to the Breast Care Unit. The schemes are now complete.

DRAFT

Note 30 On-SoFP PFI arrangements

The scheme covers the redevelopment of the Royal Stoke (formerly City General) site, facilities management services, PACS equipment, and a managed equipment service.

The Trust retains its existing estate at the Royal Stoke (formerly City General) site in addition to new buildings covered by the PFI scheme.

The main PFI contract ends in August 2044. A monthly unitary payment will be paid up to that point. Historically, bullet payments have been made to reduce the monthly unitary payment. The unitary payment is subject to annual increases in line with RPI. Services are subject to market testing in line with the contract. The arrangement requires the operator to deliver services to the Trust in accordance with the service delivery specification. Non delivery of quality or performance can lead to a reduction in the service charge being paid by the Trust. The Trust retains step in rights should the contractor fail to meet minimum standards as set out within the contract. Under IFRIC 12 the asset is treated as an asset of the Trust. The substance of the contract is that the Trust has a lease and payments comprise 2 elements – imputed lease charges and service charges. Details of the imputed lease charges are included within the table below.

Note 30.1 On-SoFP PFI obligations

The following obligations in respect of the PFI arrangements are recognised in the statement of financial position:

	31 March 2026	31 March 2025
	£000	£000
Gross PFI liabilities	**624,687**	**631,716**
Of which liabilities are due		
- not later than one year;	36,009	27,559
- later than one year and not later than five years;	132,287	130,707
- later than five years.	456,391	473,450
Finance charges allocated to future periods	(131,251)	(139,409)
Net PFI obligation	**493,436**	**492,307**
- not later than one year;	23,533	15,073
- later than one year and not later than five years;	87,950	85,687
- later than five years.	381,953	391,547

Note 30.2 Total on-SoFP PFI arrangement commitments

Total future commitments under these on-SoFP schemes are as follows:

	31 March 2026	31 March 2025
	£000	£000
Total future payments committed in respect of the PFI arrangements	**1,610,703**	**1,614,881**
Of which payments are due:		
- not later than one year;	84,774	80,744
- later than one year and not later than five years;	339,095	322,976
- later than five years.	1,186,834	1,211,161

Note 30.3 Analysis of amounts payable to service concession operator

This note provides an analysis of the unitary payments made to the service concession operator:

	2025/26	2024/25
	£000	£000
Unitary payment payable to service concession operator	**84,265**	**79,947**
Consisting of:		
- Interest charge	12,909	13,011
- Repayment of balance sheet obligation	15,533	21,964
- Service element and other charges to operating expenditure	46,224	41,444
- Capital lifecycle maintenance	6,033	3,351
- Addition to lifecycle prepayment	3,566	177
Total amount paid to service concession operator	**84,265**	**79,947**

DRAFT

Note 31 Financial instruments

Note 31.1 Financial risk management

Financial reporting standard IFRS 7 requires disclosure of the role that financial instruments have had during the period in creating or changing the risks a body faces in undertaking its activities. Because of the continuing service provider relationship that the NHS Trust has with ICBs and the way those ICBs are financed, the NHS Trust is not exposed to the degree of financial risk faced by business entities. Also financial instruments play a much more limited role in creating or changing risk than would be typical of listed companies, to which the financial reporting standards mainly apply. The NHS Trust has limited powers to borrow or invest surplus funds and financial assets and liabilities are generated by day-to-day operational activities rather than being held to change the risks facing the NHS Trust in undertaking its activities.

The Trust's treasury management operations are carried out by the finance department, within parameters defined formally within the Trust's standing financial instructions and policies agreed by the board of directors. Trust treasury activity is subject to review by the Trust's internal auditors.

Currency risk

The Trust is principally a domestic organisation with the great majority of transactions, assets and liabilities being in the UK and sterling based. The Trust has no overseas operations. The Trust therefore has low exposure to currency rate fluctuations.

Interest rate risk

The Trust may borrow from government for revenue financing subject to approval by NHS Improvement at rates set by the Department of Health (the lender).

Credit risk

Because the majority of the Trust's revenue comes from contracts with other public sector bodies, the Trust has low exposure to credit risk. The maximum exposures as at 31 March 2026 are in receivables from customers, as disclosed in the trade and other receivables note.

Liquidity risk

The Trust's operating costs are incurred under contracts with ICBs, which are financed from resources voted annually by Parliament . The Trust funds its capital expenditure from funds obtained within its prudential borrowing limit. The Trust is not, therefore, exposed to significant liquidity risks.

DRAFT

Note 31.2 Carrying values of financial assets

Carrying values of financial assets as at 31 March 2026	Held at amortised cost	Total book value
	£000	£000
Trade and other receivables excluding non financial assets	31,972	**31,972**
Cash and cash equivalents	88,068	**88,068**
Total at 31 March 2026	**120,040**	**120,040**

Carrying values of financial assets as at 31 March 2025	Held at amortised cost	Total book value
	£000	£000
Trade and other receivables excluding non financial assets	26,572	**26,572**
Cash and cash equivalents	84,186	**84,186**
Total at 31 March 2025	**110,758**	**110,758**

Note 31.3 Carrying values of financial liabilities

Carrying values of financial liabilities as at 31 March 2026	Held at amortised cost	Total book value
	£000	£000
Obligations under leases	17,604	**17,604**
Obligations under PFI contracts	493,436	**493,436**
Trade and other payables excluding non financial liabilities	85,586	**85,586**
Total at 31 March 2026	**596,626**	**596,626**

Carrying values of financial liabilities as at 31 March 2025	Held at amortised cost	Total book value
	£000	£000
Obligations under leases	18,234	**18,234**
Obligations under PFI contracts	492,307	**492,307**
Trade and other payables excluding non financial liabilities	74,452	**74,452**
Total at 31 March 2025	**584,993**	**584,993**

DRAFT

Note 31.4 Maturity of financial liabilities

The following maturity profile of financial liabilities is based on the contractual undiscounted cash flows. This differs to the amounts recognised in the statement of financial position which are discounted to present value.

	31 March 2026 £000	31 March 2025 £000
In one year or less	127,370	107,683
In more than one year but not more than five years	141,628	139,779
In more than five years	460,876	479,134
Total	**729,874**	**726,596**

Note 31.5 Fair values of financial assets and liabilities

The Trust has assessed its financial assets and liabilities in line with the requirements of IFRS 7 and for financial assets and liabilities that fall within the scope the Trust has deemed that book value (carrying value) is a reasonable approximation of fair value.

Note 32 Losses and special payments

	2025/26		2024/25	
	Total number of cases Number	Total value of cases £000	Total number of cases Number	Total value of cases £000
Losses				
Cash losses due to overpayment of salaries	59	101	-	-
Claims waived or abandoned (excluding cases between DHSC group bodies)	236	830	613	1,392
Stores losses and damage to property	4	746	6	746
Total losses	**299**	**1,677**	**619**	**2,138**
Special payments				
Ex-gratia payments	39	14	48	38
Special severance payments	1	10	-	-
Total special payments	**40**	**24**	**48**	**38**
Total losses and special payments	**339**	**1,701**	**667**	**2,176**

DRAFT

Note 33 Related parties

UHNM Charity

We are required to disclose the UHNM Charity as a related party under IAS 24 (payments, receipts, income and expenditure).

The Trust received revenue and capital payments from the UHNM Charity during 2025/26, and all of the Trustees are also members of the Trust board. In 2025/26 the total amount received from the UHNM Charity was £4.809 million (2024/25: £3.520 million). At the end of the year £0.717 million (2024/25: £1.244 million) was outstanding and is included within trade and other receivables.

The income received relates mainly to the purchase by the UHNM Charity of equipment that enhances the service provided by the Trust. For practical purposes these purchases are administered via the Trust's established ordering and payment procedures with the UHNM Charity reimbursing the cost to the Trust. The charitable and other contributions to revenue expenditure income disclosed in Note 4 relates to services provided by the Trust to the UHNM Charity, i.e. the running of the Appeals Dept.

Post Graduate Medical Centre (PGMC)

The PGMC is a charity that provides conference, seminar, library and IT facilities for the Trust to enable education of general practitioners, hospital doctors and dentists, medical students and other members of the multi-disciplinary team in Mid and North Staffordshire. The Trust's Chief Financial Officer is also a Trustee of the PGMC. During the year the Trust received £14k from the PGMC for administrative support and paid them £90k for the facilities provided.

Department of Health and Social Care (DHSC)

The Department of Health and Social Care (DHSC) is regarded as a related party as it is our parent department and governing body. During the year the Trust has had a significant number of material transactions with the DHSC and with other entities for which the DHSC is also regarded as the governing body - including NHS England; other NHS Trusts; NHS Foundation Trusts; and Integrated Care Boards (ICBs).

DHSC transactions

The Trust received total NHS income of £1,245.130 million in 2025/26 (2024/25: £1,208.793 million).

The majority of this income was received from Integrated Care Boards (£1,060.753 million) and NHS England, including Health Education England (£143.682 million).

Other government departments

In addition, the Trust has had a number of material transactions with other government departments and other central and local government bodies. The majority of these transactions have been with HM Revenue and Customs (£81,929 million expenditure; £18.723 million payables; £3.818 million VAT receivables); and the NHS Pension scheme (£120.221 million expenditure; £10.383 million payables).

DRAFT

Note 34 Better Payment Practice code

	2025/26	2025/26	2024/25	2024/25
Non-NHS Payables	**Number**	**£000**	**Number**	**£000**
Total non-NHS trade invoices paid in the year	124,713	722,221	129,880	714,550
Total non-NHS trade invoices paid within target	122,554	712,867	127,660	700,695
Percentage of non-NHS trade invoices paid within target	**98.3%**	**98.7%**	**98.3%**	**98.1%**
NHS Payables				
Total NHS trade invoices paid in the year	2,937	48,196	2,756	44,377
Total NHS trade invoices paid within target	2,557	39,400	2,458	38,564
Percentage of NHS trade invoices paid within target	**87.1%**	**81.7%**	**89.2%**	**86.9%**

The Better Payment Practice code requires the NHS body to aim to pay all valid invoices by the due date or within 30 calendar days of receipt of goods or a valid invoice (whichever is later) unless other payment terms have been agreed.

Note 35 Capital Resource Limit

	2025/26	2024/25
	£000	**£000**
Gross capital expenditure	74,839	81,396
Less: Disposals	-	(18)
Less: Donated and granted capital additions	(4,809)	(6,047)
Charge against Capital Resource Limit	**70,030**	**75,331**
Capital Resource Limit	70,530	90,982
Under / (over) spend against CRL	**500**	**15,651**

Note 36 Adjusted financial performance

	2025/26	2024/25
	£000	**£000**
Deficit for the period per SOCI	(13,201)	(11,681)
Remove net impairments not scoring to the departmental expenditure limit	18,183	268
Remove I&E impact of capital grants and donations	(2,756)	(4,293)
IFRIC 12 breakeven adjustment*: Remove I&E impact of IFRIC 12 schemes on an IFRS 16 basis	75,739	75,937
IFRIC 12 breakeven adjustment*: Add back I&E impact of IFRIC 12 schemes on former UK GAAP basis	(82,704)	(78,379)
Remove net impact of DHSC centrally procured inventories	-	92
Adjusted financial performance deficit	**(4,739)**	**(18,056)**

Note 37 Breakeven duty financial performance

	2025/26	2024/25
	£000	**£000**
Adjusted financial performance deficit	(4,739)	(18,056)
*IFRIC 12 breakeven adjustment	6,965	2,442
Breakeven duty financial performance surplus	**2,226**	**(15,614)**

DRAFT

Note 38 Breakeven duty rolling assessment

	1997/98 to 2008/09	2009/10	2010/11	2011/12	2012/13	2013/14	2014/15	2015/16	2016/17
	£000	£000	£000	£000	£000	£000	£000	£000	£000
Breakeven duty in-year financial performance		5,312	4,141	1,050	235	(19,301)	3,782	(26,936)	(27,773)
Breakeven duty cumulative position	(7,625)	(2,313)	1,828	2,878	3,113	(16,188)	(12,406)	(39,342)	(67,115)
Operating income		408,938	418,078	426,319	473,558	475,330	623,835	702,917	739,279
Cumulative breakeven position as a percentage of operating income		**(0.6%)**	**0.4%**	**0.7%**	**0.7%**	**(3.4%)**	**(2.0%)**	**(5.6%)**	**(9.1%)**

	2017/18	2018/19	2019/20	2020/21	2021/22	2022/23	2023/24	2024/25	2025/26
	£000	£000	£000	£000	£000	£000	£000	£000	£000
Breakeven duty in-year financial performance	(69,717)	(63,607)	5,231	7,085	9,126	47	(8,375)	(15,614)	2,226
Breakeven duty cumulative position	(136,832)	(200,439)	(195,208)	(188,123)	(178,997)	(178,950)	(187,325)	(202,939)	(200,713)
Operating income	696,630	713,838	840,636	915,076	980,348	1,064,132	1,151,805	1,292,878	1,380,315
Cumulative breakeven position as a percentage of operating income	**(19.6%)**	**(28.1%)**	**(23.2%)**	**(20.6%)**	**(18.3%)**	**(16.8%)**	**(16.3%)**	**(15.7%)**	**(14.5%)**

The Trust recorded an in-year deficit of £13.201 million against a planned £6.900 surplus. After statutory adjustments, a surplus for breakeven duty purposes was achieved of £2.226 million and the adjusted financial performance deficit was £4.739 million against a breakeven plan. The position was supported by non-recurrent measures, and the Trust recognises the need to strengthen recurrent efficiency and cost control to support long-term financial sustainability.

Due to the continued cumulative deficit and the expectation that expenditure will exceed income for the foreseeable future, the External Auditors issued a Section 30 referral to the Secretary of State for Health on 27 May 2026. This follows earlier referrals made since 2017.

Financial performance in the Trust is subject to regular oversight by the Finance and Business Performance Committee and the Board, supported by established financial policies and a devolved operational structure. Internal Audit concluded reasonable assurance with minor improvements required on key financial systems, and External Audit issued an unqualified opinion on the financial statements.

The Trust continues to work with system partners to address the wider financial sustainability challenges across the local health and care system.

DRAFT

Statement of Comprehensive Income

Heading	2024/25 Total £000	2025/26 Total £000	Variance £000	%	Comments / Explanations and corroborating evidence
Operating income from patient care activities	1,186,037	1,271,227	85,190	7%	See detailed explanations for movement on income notes
Other operating income	106,840	109,088	2,248	2%	See detailed explanations for movement on income notes
Total operating income from continuing operations	**1,292,877**	**1,380,315**			
Operating expenses	(1,271,731)	(1,364,149)	(92,418)	7%	See detailed explanations for movement on operating expenses note
Operating surplus/(deficit) from continuing operations	**21,146**	**16,166**			
Finance income	6,054	5,185	(869)	(14%)	Interest received on cash balances reduced mainly due to lower interest rates
Finance expenses	(35,422)	(30,144)	5,279	(15%)	Reduction in the impact of the remeasurement of the PFI liability from £22m to £16m. This is based on a reduction in RPI increase from 4.5% to 3.4%.
PDC dividends payable	(3,530)	(4,545)	(1,015)	29%	Impact on net assets of the increase in PFI liability due to IFRS16 lease remeasurement, PDC funded capital schemes and the asset valuation of land and buildings (opening and closing balances)
Net finance costs	**(32,898)**	**(29,504)**			
Other gains/losses	70	137	67	96%	
Surplus/(deficit) for the year from continuing operations	**70**	**137**			
Surplus/(deficit) for the year	**(11,682)**	**(13,201)**			
Other comprehensive income					
Revaluations	11,724	6,013	(5,711)	(49%)	Revaluations are not expected to be consistent year on year. Increase in value due to capital works undertaken and building indicies. Significant capital expenditure in 24/25 on AMRAU and Elective Hub and in 25/26 on County Breast Unit which has resulted in a significant impairment to the MEA notional asset.
Impairment	(8,095)	(7,960)	135	100%	
Total comprehensive income/(expense) for the period	**(8,053)**	**(15,148)**			
Adjusted financial performance (control total basis)					
Surplus/deficit for the period	(11,682)	(13,201)	(1,519)	13%	This is an accumulation of the above entries but particularly the movement in finance expenses.
Remove net impairments not scoring to the departmental expenditure limit	268	18,183	17,915	6685%	In 2025/26 the main impairment charged to the I&E was for the valuation of the tenant improvement works at the CDC and also downward valuation of RI/COPD land sites in assets held for sale.
Remove I&E impact of capital grants and donations	(4,293)	(2,756)	1,537	(36%)	Higher capital grants and donations in 24/25 due to PSDS air heat boiler grant and Charity funded expansion of the Holistic Cancer Centre.
Remove impact of IFRS 16 on IFRIC 12 schemes	(2,442)	(6,965)	(4,523)	185%	See explanations under finance income - signficant movement in PFI finance expenses due to the PFI lease remeasurement. Changes in the financial performance measure from 2024/25 to align with DHSC reporting under UK GAAP for PFI schemes.
Remove net impact of inventories received from DHS group bodies for COVID response	92	-	(92)	(100%)	
Adjusted financial performance surplus	**(18,057)**	**(4,739)**			

DRAFT

Income

	2024/25 Total £000	DRAFT 2025/26 Total £000	Variance £m	%	Comments / Explanations
Note 3.1 Income from patient care activities (by nature)					
Income from commissioners under API contracts - variable element*	228,253	255,927	27,674	12%	Cost Uplift Factor / additional growth funding
Income from commissioners under API contracts - fixed element*	819,996	847,581	27,585	3%	Cost Uplift Factor / Deficit Support Funding /
High cost drugs income from commissioners	82,831	110,816	27,985	34%	General uplift year on year of high cost drugs.
Other NHS clinical income	7,236	7,389	153	2%	Increase in Injury Cost Recovery Income off set by reduction in overseas patients income
Private patient income	1,722	1,535	(187)	(11%)	Reduction in activity for private patients
National pay award central funding***	2,352	-	(2,352)	(100%)	Non recurrent funding in 2024/25
Additional pension contribution central funding**	43,647	47,979	4,332	10%	Impact of the pay awards
Total income from activities	**1,186,037**	**1,271,227**			
Note 3.2 Income from patient care activities (by source)					
Income from activities					
NHS England	188,626	191,661	3,034	2%	General uplift year on year of high cost drugs.
Integrated care boards	979,252	1,060,753	81,501	8%	Cost Uplift Factor / Deficit Support Funding / Industrial Action funding / Additional growth funding
NHS trusts	-	239	239	100%	Increase in recharges to NHS Trusts
Department of Health and Social Care	-	55	55	100%	DHSC EHIC incentive income
Non-NHS: private patients	1,722	1,535	(187)	(11%)	Reduction in activity for private patients
Non-NHS: overseas patients (chargeable to patient)	4,342	3,163	(1,179)	(27%)	Reduction in activity for overseas patients
Injury cost recovery scheme	2,842	3,932	1,090	38%	Increased value of claims received in year
Non NHS: other	9,253	9,886	633	7%	Cost Uplift Factor / additional growth funding
Total income from activities	**1,186,037**	**1,271,223**			
Other operating income					
Research and development	3,200	4,175	975	30%	Increase in reasearch income / in year release of deferred income
Education and training	42,052	44,169	2,117	5%	£5.7m due to additonal Madel income due to additional placment and inflation
Non patient care services to other bodies	40,862	40,398	(464)	(1%)	
Non-patient care services to other non WGA bodies	3,047	3,847	800	26%	Increase in activity with Alliance Medical, improved coding of other income
Receipt of capital grants and donations and peppercorn leases	6,047	4,809	(1,238)	(20%)	Higher capital grants and donations in 24/25 due to PSDS air heat boiler grant and Charity funded expansion of the Holistic Cancer Centre.
Charitable and other contributions to expenditure	404	446	42	10%	Increased spend through charity
Revenue from operating leases	901	913	12	1%	
Education and training - notional income from apprenticeship fund	1,715	2,039	324	19%	Increased utilisation of the levy to support apprentice training
Other income	8,613	8,291	(322)	(4%)	
Total other operating income	**106,841**	**109,088**			
Other Income					
Car Parking charges	3,730	4,317	587	16%	Improved income recovery relating to car parking charges
Catering	236	229	(7)	(3%)	
Clinical Excellence Awards	426	432	6	1%	
External contribution to Community Diagnostic Centre landlord works	2,433	-	(2,433)	(100%)	One-off funding in 2024/25
Overseas nurse recruitment	-	-	-		
Pharmacy sales	405	361	(44)	(11%)	
Pharmacy services	794	864	70	9%	
Staff accommodation rental	576	692	116	20%	
Other income not identified above	3,060	1,396	(1,664)	(54%)	Improved coding of other income
	11,660	**8,291**			
Total operating income	**1,292,878**	**1,380,315**			

DRAFT

Operating Expenditure

	2024/25 Total £000	2025/26 Total £000	Variance £m	%	Comments / Explanations
Purchase of healthcare from NHS and DHSC bodies	13,537	13,392	(145)	(1%)	
Purchase of healthcare from non-NHS and non-DHSC bodies	20,675	12,286	(8,389)	(41%)	Gastroenterology and endoscopy outsourcing reduction due to internal investment (£6.1m), Imaging reduced external send away tests and reporting (£0.4m), Neurology insourcing reduction replaced with agency medics (£1.1m), Pathology reduced external send away tests (£0.4m), Ophthalmology reduced insourcing (£0.2m), Spinal reduced insourcing (£0.4m)
Staff and executive directors costs	783,504	842,386	58,882	8%	Impact of the pay award £45.3m includes employer NI cost increases introduced in April 2025, medical bank increases to cover Industrial Action and rota gaps £7.0m, nursing assistant bank increases for enhanced care shifts £2.0m, additional recruitment and investments
Remuneration of non-executive directors	178	179	2	1%	
Supplies and services - clinical (excluding drugs costs)	123,979	134,026	10,047	8%	Funded inflation £4.5m, implants (hip, knee and bone fit) increases £0.6m, Pathology Siemens and Beckman Blood Science Managed Service contract increases £1.6m, renal satellite (Leighton Fresenius contract) price and volume increases £0.6m, impact of additional investments/ inflation above funded levels
Supplies and services - general	9,891	10,078	187	2%	
Drug costs (drugs inventory consumed and purchase of non-inventory drugs)	136,775	142,284	5,510	4%	£5.3m due to pass through drugs offset by an equal and opposite impact on income, impact of inflation £0.3m
Inventories written down	745	746	1	0%	
Consultancy costs	1,206	1,904	698	58%	Costs in 2025/26: Deloitte cost improvement programme £0.5m and PRISM Outpatient productivity £0.5m
Establishment	5,172	6,094	922	18%	Increase in work permits driven by price and international recruitment £0.7m, increase in postage due to price £0.2m
Premises	43,159	43,192	33	0%	
Transport (including patient travel)	6,030	5,970	(61)	(1%)	
Depreciation on property, plant and equipment	34,800	37,193	2,393	7%	Increase in depreciation and amortisation as a result of valuation increased from prior year building valuation and also impact of the 24/25 capital programme and externally PDC funded schemes
Amortisation on intangible assets	4,920	4,578	(342)	(7%)	
Net impairments	268	18,183	17,915	6685%	In 2025/26 the main impairment charged to the I&E was for the valuation of the tenant improvement works at the CDC and also downward valuation of RI/COPD land sites in assets held for sale.
Movement in credit loss allowance: contract receivables/contract assets	4,033	2,633	(1,400)	(35%)	This is a calculation based on the level and ageing of outstanding invoices. In the prior year there were two significant overseas visitors debts (£1m+) raised and provided for which increased the provision in that year
Increase/decrease in other provisions	3,469	1,019	(2,450)	(71%)	Increase in lease dilapidations £420k; band 2 to band 3 provision £323k following full utilisation of prior year provision; £213k increase in legal claims
Change in provisions discount rate(s)	6	(46)	(52)	(867%)	Discount rate has increased from 2.4% to 2.95% between 24/25 and 25/26 leading to a credit following discounting of the provision. In the previous year the discount rate decreased from 2.45% in 2023/24 to 2.4% in 2024/25 leading to a small debit following discounting of the provision
Fees payable to the external auditor: auditor services - statutory audit	198	318	120	61%	Due to increase in the proposed audit fees that include additional and more robust testing (SA (UK) 540) and further assurance around property valuations
Internal audit costs	169	221	52	31%	
Clinical negligence	26,042	28,823	2,781	11%	The cost increase is due to the assessment of claims set out by NHS Resolution
Legal fees	131	127	(5)	(4%)	
Insurance	97	138	41	42%	
Research and development	3,818	3,656	(162)	(4%)	
Education and training	2,796	2,758	(38)	(1%)	
Education and training - notional expenditure funded from apprenticeship fund	1,715	2,039	324	19%	Increased utilisation of the levy to support apprentice training
Expenditure on short term leases	316	475	159	50%	
Charges to operating expenditure for on-SoFP IFRIC 12 Schemes (eg PFI/LIFT)	41,444	46,224	4,780	12%	Increase in operating expenditure due to inflation, increase in service element and revenue lifecycle costs
Car parking & security	833	1,178	346	42%	Increase in car parking management fees and contract variation for additional officers to comply with national standards regarding helicopter landing & take off
Hospitality	138	159	21	15%	
Other services, e.g. external payroll	761	819	58	8%	Increased cost of RWT payroll service due to inflationary factors
Redundancy Costs	-	506	506	100%	Compulsory reducanies and MARS scheme ran in 2025/26
Other	926	610	(316)	(34%)	Improved coding of expenditure
Total	**1,271,731**	**1,364,149**			

DRAFT

Statement of Financial Position

	2024/25 Total £000	DRAFT 2025/26 Total £000	Variance £m	%	Comments / Explanations
Non-current Assets					
Intangible Assets	15,985	14,615	(1,370)	(9%)	Overall reduction of £1.4m due to additions of £3.2m being lower than the amortisation of intangible assets of £4.6m.
Property, Plant and Equipment	715,699	734,232	18,533	3%	Overall increase of £18.3m made up of - - additions £67.8m increase - depreciation £32.8m decrease - revaluation reduction of £16.5m Of which £15.6m related to the CDC tenant improvement works. See detailed PPE note within the accounts and explanation of revaluation and impairment entries within the relevant notes and capital resource limit.
Right of use assets	23,087	22,062	(1,025)	(4%)	Increase in Right of Use assets relating to lease additions and remeasurements of £3.8m including leases relating to Sharman Close, pathology MSC and endoscopy equipment. Depreciation charge of £4.8m, resulting in the overall reduction in carrying value.
Receivables	1,105	1,018	(87)	(8%)	
Total Non-current Assets	**755,876**	**771,928**			
Current Assets					
Assets held for sale	10,900	7,700	(3,200)	(29%)	Assets held for sale are £3.2m lower than 2024/25 as the value of the former Royal Infirmary and COPD sites has been reduced to reflect the latest information available to the Trust as part of the required annual impairment review.
Inventories	19,219	21,429	2,210	11%	Inventories are £2.2m higher than 2024/25. This is mainly due to an increase of £0.1m in Angioplasty, a £0.78m increase in TAVI stock, a £.35m increase in Pacemakers, £0.15m in Haematology stock and a £0.45m increase in theatre stock.
Receivables	43,518	48,703	5,185	12%	Movement in receivables is driven by net increase in NHS and Non NHS accrued income in March. Included in the movement is £5.3m tracker payments from the ICB
Cash and Cash Equivalents	84,186	88,083	3,897	5%	Cash has increased by £3.9m, this can be explained by the movement in working capital in the balance sheet with the increase in both payables and receivables balances at the year end. This offsets the reduction in cash due to the I&E revenue deficit including non-cash movements included in I&E.
Total Current Assets	**157,823**	**165,915**			
Current Liabilities					
Trade and Other Payables	(108,614)	(112,610)	(3,996)	4%	The net increase in trade and other payable is driven an increase in trade payables £2.7m, capital payables £2.4m and accruals £4.0m, driven by timing and cost increases The social security payable has increased by £2.6m due to the increased employer NI costs that came into force from April 2025. The increased payables are partly offset by the release of the annual leave accrual of £8.6m due to enforcement of the Trust policy to not allow annual leave carry forward.
Borrowings	(20,286)	(28,792)	(8,506)	42%	Overall movement in borrowing of £0.5m is not significant. The change in classification between current and non-current is mainly due to the PFI liability and the repayment of liabilty increase in 2026/27 per the PFI accounting model.
Provisions	(8,469)	(1,054)	7,415	(88%)	Provisions are £6.8m lower than 2024/25 which reflects the utilisation of the band 2 to band 3 provision to offset the payments made through revenue in 2025/26 to date, (including those lump sums via instalments) and the release of the unused provision. This is partly offset by an increase to the provision for dilapidations for leased accomodation.
Other Liabilities	(20,801)	(20,737)	64	(0%)	
Total Current Liabilities	**(158,170)**	**(163,193)**			
Non-current Liabilities					
Borrowings	(490,255)	(482,248)	8,007	(2%)	See non-current borrowing above
Provisions	(2,783)	(3,407)	(624)	22%	See current provisions above
Total Long Term Liabilities	**(493,038)**	**(485,655)**			
Total Assets Employed	**262,491**	**288,995**			
Financed By					
Public dividend capital	734,943	775,578	40,635	6%	Increase reflects capital funding in the year of £40.6m including for CDC £18.1m, estates safety £4.8m, additional ICB system support £4m, completion of County Breast unit £3m and constitutional standards funding of £6.35m.
Revaluation reserve	208,297	204,310	(3,987)	(2%)	Decrease due to downward revaluations see SOCI. Revaluations are not expected to be consistent. Significant capital expenditure County Breast unit and a number of other schemes resulted in significant impairment to the MEA notional asset which was partly offset by increases in the value of other assets.
Income and expenditure reserve	(680,749)	(691,911)	(11,162)	2%	Movement reflects the deficit for the year per the SOCI including the impact of impairments. The movement is also due to the transfer of the £2m revaluation reserve balances relating to intangible assets to Retained Earnings. This was required by a change in accounting standards and mandated at month 9 by NHSE.
Total taxpayers' and others' equity	**262,491**	**287,977**			

DRAFT

APPENDIX 3

University Hospitals of North Midlands NHS Trust

Executive Summary

Trust Board | 26th June 2026

Non-consolidation of UHNM Charitable Funds Accounts

Purpose:	**Information**		**Approval**	✓	**Assurance**		**Agenda Item:**	
Author:								
Executive Lead:								

Alignment with our Strategic Priorities		
	Our People We will create an inclusive environment where everyone learns, thrives and makes a positive difference	✓
	Our Patients We will provide timely, innovative and effective services to our patients	✓
	Our Population We will tackle inequality and improve the health of our population	✓

Risk Register Mapping		
ID	Title of Risk [insert or delete rows as appropriate]	Risk Level

DRAFT

Executive Summary

An updated review has been carried out to determine whether the UHNM Charity should be consolidated into the Trust's 2025/26 financial statements following receipt of a one-off £12.1m restricted grant.

Applying IFRS 10 and IAS 1, consolidation is only required where the Trust both controls the Charity and the impact is material to the Trust's financial position. The Charity's funds are legally restricted, cannot support the Trust's general operations, and the £12.1m grant is non-recurring.

A high-level consolidation shows only minor impacts on income, expenditure and net assets, all relating to restricted funds. Including the grant would artificially improve the Trust's deficit and would not provide a more faithful representation of the Trust's financial position.

The assessment concludes that consolidation remains not material and is not required for 2025/26. The position will continue to be monitored.

Key Recommendations

- The Trust Board are asked to approve the recommendation that UHNM Charity accounts is not required for 2025/26

Non-consolidation of UHNM Charitable Fund Accounts

Trust Board 26th June 2026

1. Introduction

NHS Trust accounts are prepared in accordance with International Financial Reporting Standards (IFRS). IFRS 10 - Consolidated Financial Statements requires a parent entity to consolidate entities it controls, where consolidation is necessary to present financial information that is not misleading.

Since 1 April 2013, HM Treasury has required the Department of Health and Social Care to consolidate NHS charities into the Group Resource Account. However, individual NHS bodies must still apply IFRS 10 and IAS 1 independently when determining whether to consolidate their own charitable funds.

In October 2020, the Audit Committee approved the judgement that the UHNM Charity should not be consolidated into the Trust's financial statements, as the Charity was not material in the context of the Trust's accounts.

In March 2026, UHNM Charity received a one-off restricted grant of £12m from the Denise Coates Foundation to support the purchase of two surgical robots to support the delivery of emergency, cardiac and spinal surgery. As this is a significant transaction, an updated assessment of the consolidation judgement is required.

DRAFT

2. Accounting Standards

2.1 IFRS 10 – Control Assessment

IFRS 10 states that an entity controls another when it has:

- Power over the investee
- Exposure, or rights, to variable returns
- The ability to use power to affect those returns

The Trust Board acts as the corporate trustee of UHNM Charity and therefore has power over the Charity's activities. However:

- The Charity's funds are legally restricted and cannot be used for the Trust's general purposes
- The Trust does not receive financial returns or economic benefits from the Charity
- The Trust cannot use its power to influence returns for its own benefit

Accordingly, the Trust does not meet the second and third limbs of the IFRS 10 control test. Nevertheless, for completeness and consistency with sector practice, this paper considers whether consolidation would be required if control were deemed to exist.

2.2 IAS 1 – Materiality

IAS 1 Presentation of Financial Statements requires an entity to provide information that is material to users of the financial statements. Information is material if omitting, misstating or obscuring it could reasonably be expected to influence users' decisions.

Disclosure requirements in individual IFRS Standards need not be applied if the information is not material.

2.3 Interaction of IFRS 10 and IAS 1

Even where control exists, consolidation is required only if it results in financial statements that faithfully represent the entity's financial position and performance. If consolidation would mislead users, IAS 1 requires the information to be excluded.

Therefore, the UHNM Charity should be consolidated only if its inclusion is material to the Trust's financial position, financial performance or cash flows; and the consolidation is not misleading.

3. Material grant received

3.1 Grant details

The Trust has annual expenditure in excess of £1.3 billion and holds £88.1 million in cash balances. The linked NHS charity holds £17.6 million in cash and £19.9m in reserves. In March 2026 the Charity received a £12.1m grant from the Denise Coates Foundation for 2 surgical robots, as shown in the following extract from the Grant Agreement.

1.	**Purpose**
1.1	The purpose of the Grant is to purchase two Da Vinci 5 Surgical Robots and related additional functionality to support emergency cardiac and spinal robotic surgery (including support costs for assistance and servicing over a 5 year period) (the '**Purpose**').
1.2	The Grant shall not be used for any other purpose.

Under IFRS 15 and IAS 20 (as adapted by the GAM), donated income must be recognised immediately in the Statement of Comprehensive Income (SOCI) when:

- the Trust obtains control of the asset or cash,
- it is probable that economic benefits will flow to the Trust, and
- the value can be measured reliably.

Even where donations are ringfenced for specific capital equipment, the income cannot be deferred unless the donor has a legally enforceable right to require repayment if conditions are not met. A commitment or intention to spend the funds in future years does not create a liability.

However, the agreement does include the following clause:

7.	**Return of Grant**
	The Foundation may, in its sole discretion, require the return of some or all of the Grant monies and/or declare this Agreement terminated if:
7.1	The Recipient does not comply in all material respects with this Agreement;
7.2	The Recipient takes any actions which, in the Foundation's reasonable opinion, bring, or are likely to bring, its name or reputation into disrepute or to damage its reputation in any way.

Where income is received under a formal grant agreement with specific performance obligations, the transaction falls under IFRS 15. Income must be deferred until the performance obligation is satisfied.

In this case:

- The requirement to procure two specified robots constitutes a sufficiently specific performance obligation.
- The presence of a clause allowing the donor to require repayment if conditions are not met means the Trust has not yet earned entitlement to the funds.
- The £12 million must therefore be recognised as deferred income until the robots are delivered and control transfers to the Trust.

DRAFT

There are also further reasons why deferral of the income is the appropriate treatment:

- The amount cannot be spent in 2025/26 and therefore can only relate to a future period.
- The expenditure is uncertain – there is business case in the Trust for the robots, and no application in the Charity to spend the amount.

3.2 Impact of grant receipt and deferral

This treatment to defer prevents artificial inflation of the Trust's surplus and ensures compliance with IFRS 15. Deferring the £12.1m conditional grant significantly reduces the impact of consolidation and brings the net impact close to, or below, performance materiality.

Financial Metric	Trust (Parent) (£'000)	Charity (£'000)	Net Impact Value (£'000)	Variance vs. Auditor PM (£'000)	Below PM? (Y/N)	Audit Conclusion / Impact
Annual Operating Spend	1,364,149	7,616	0.56%	(10,384)	Y	Negligible impact on Trust operating performance.
Gross Cash & Cash Equivalents	88,083	17,590	19.97%	(410)	Y	Gross cash impact is £0.4m below Performance Materiality.
Less: Conditional Grant Liability deferred income	0	(12,060)	0	0		Matched liability; deferred under IFRS 15 / IAS 20.
Net Unencumbered Cash Impact	88,083	5,530	6.28%	(12,470)	Y	Net cash impact is £12.5m below Performance Materiality.
Reserves Impact	287,977	7,904	2.74%	(10,096)	Y	Reserves impact is £10.1m below Performance Materiality.
Performance Materiality £18,000						
Materiality £24,000						

DRAFT

4. Analysis

To assess materiality, the Trust has prepared high level consolidated figures using the draft 2025/26 Trust accounts and the draft 2025/26 UHNM Charity accounts, adjusted to include the £12m grant received and deferred in March 2026.

Please see Appendix 1 for detail of the analysis undertaken.

4.1 Statement of Comprehensive Income

Consolidation would result in the following for the Trust:

- £1.569m additional operating income (0.11%)
- £7.616m additional operating expenditure (0.56%)
- Net impact: £6.048m deterioration in the Trust's deficit

The income impact is below 1% and is therefore clearly immaterial.

Importantly, the £12.1m grant is restricted and cannot be used to support the Trust's general operations. Including it would artificially worsen the Trust's deficit, which would be misleading under IAS 1.

4.2 Statement of Financial Position

Consolidation would increase net assets by £7.904m, representing:

- 2.74% of net assets employed

- 0.91% of total non-current assets

The impact on net assets is immaterial. More importantly, the increase relates entirely to restricted charitable funds, which do not enhance the Trust's financial capacity or ability to meet its obligations.

4.3 Qualitative Considerations

Qualitative factors strongly support non consolidation:

- The £12.1m grant is restricted and cannot be used to reduce the Trust's deficit. Charity cash in total is legally ringfenced and cannot be used to support Trust operational liquidity.
- The grant is non-recurring, and therefore lacks predictive value whilst being "one-off" in nature as the amount is expected to be spent during 2026/27.
- Consolidation would increase reported cash to £113m, potentially overstating the Trust's available liquid resources. Consolidation would obscure the Trust's underlying financial position
- The Charity's activities are not integrated with the Trust's operational performance
- Consolidation would distort trend analysis and key financial metrics
- Consolidation does not affect the PDC dividend calculation or underlying financial performance.
- The charity's funds are subject to separate governance, restrictions and regulatory oversight.

These factors support the argument that consolidation may distort, rather than enhance, the presentation of the Trust's financial position under IAS 1.

5. Conclusion

Based on the quantitative and qualitative assessment:

- The impact of consolidation on the Statement of Comprehensive Income is immaterial
- The impact on the Statement of Financial Position, while notable, is within commonly applied sector benchmarks and relates solely to restricted funds
- Consolidation would misrepresent the Trust's financial position by presenting restricted charitable funds as if they were available for general use
- The £12.1m grant is non-recurring, has been deferred to be spent or committed in 2026/27, further reducing any ongoing impact

Therefore, consolidation of the UHNM Charity into the Trust's 2025/26 financial statements is not required under IAS 1.

The Trust will continue to monitor the Charity's financial position. A sustained increase in donations or significant changes in the scale of the Charity's activities would prompt a reassessment.

While the charity's gross cash balance appears quantitatively material, the presence of a £12m conditional grant significantly reduces the net impact on the Trust's group financial position. When combined with the qualitative considerations regarding ringfenced funds and the potential for misleading presentation, we have concluded that we should not consolidate the Charity accounts under the materiality provisions of the DHSC Group Accounting Manual.

6. Recommendations

It is recommended that the Trust and Charity accounts continue to be prepared on a non-consolidated basis, as the Charity's financial impact is not material in the context of the Trust's financial statements and consolidation would not result in a more faithful representation of the Trust's financial position.

DRAFT

NHS
University Hospitals of North Midlands
NHS Trust

24th June 2026

Royal Stoke University Hospital
Executive Suite
Springfield
Newcastle Road
Stoke-on-Trent
Staffordshire
ST4 6QG

Grant Thornton UK LLP
17th Floor
103 Colmore Row
Birmingham
B3 3AG

Dear Grant Thornton UK LLP

University Hospitals of North Midlands NHS Trust - Financial Statements for the year ended 31 March 2026

DRAFT

This representation letter is provided in connection with the audit of the financial statements of University Hospitals of North Midlands NHS Trust (the "Trust") for the year ended 31 March 2026 for the purpose of expressing an opinion as to whether the Trust financial statements give a true and fair view in accordance with International Financial Reporting Standards and the Department of Health and Social Care Group Accounting Manual 2025-26 and applicable law.

We confirm that to the best of our knowledge and belief having made such inquiries as we considered necessary for the purpose of appropriately informing ourselves:

Financial Statements

i. We have fulfilled our responsibilities, as set out in the terms of the audit engagement letter dated 9 January 2026 , for the preparation of the Trust's financial statements in accordance with International Financial Reporting Standards and the Department of Health and Social Care Group Accounting Manual 2025-26 (the "GAM"); in particular the financial statements are fairly presented in accordance therewith.

ii. We have complied with the requirements of all statutory directions affecting the Trust and these matters have been appropriately reflected and disclosed in the financial statements.

iii. The Trust has complied with all aspects of contractual agreements that could have a material effect on the financial statements in the event of non-compliance. There has been no non-compliance with requirements of any regulatory authorities that could have a material effect on the financial statements in the event of non-compliance.

iv. We acknowledge our responsibility for the design, implementation and maintenance of internal control to prevent and detect fraud.

v. Significant assumptions used by us in making accounting estimates, including those measured at fair value, are reasonable. Such accounting estimates include the valuation of land and buildings. We are satisfied that the material judgements used in the preparation of the financial statements are soundly based, in accordance with the GAM and adequately disclosed in the financial statements. We understand our responsibilities includes identifying and considering alternative methods,

assumptions or source data that would be equally valid under the financial reporting framework, and why these alternatives were rejected in favour of the estimate used. We are satisfied that the methods, the data and the significant assumptions used by us in making accounting estimates and their related disclosures are appropriate to achieve recognition, measurement or disclosure that is reasonable in accordance with the GAM and adequately disclosed in the financial statements.

vi. In calculating the amount of income to be recognised in the financial statements from other NHS organisations we have applied judgement, where appropriate, to reflect the appropriate amount of income expected to be derived by the Trust in accordance with International Financial Reporting Standards and the GAM. We are satisfied that the material judgements used in the preparation of the financial statements are soundly based, in accordance with International Financial Reporting Standards and the GAM, and adequately disclosed in the financial statements. There are no other material judgements that need to be disclosed.

vii. We acknowledge our responsibility to participate in the Department of Health and Social Care's agreement of balances exercise and have followed the requisite guidance and directions to do so. We are satisfied that the balances calculated for the Trust ensure the financial statements and consolidation schedules are free from material misstatement, including the impact of any disagreements.

viii. Except as disclosed in the financial statements:
a. there are no unrecorded liabilities, actual or contingent;
b. none of the assets of the Trust has been assigned, pledged or mortgaged; and
c. there are no material prior year charges or credits, nor exceptional or non-recurring items requiring separate disclosure.

ix. Related party relationships and transactions have been appropriately accounted for and disclosed in accordance with the requirements of International Financial Reporting Standards and the GAM.

x. All events subsequent to the date of the financial statements and for which International Financial Reporting Standards and the GAM require adjustment or disclosure have been adjusted or disclosed.

xi. We have considered the unadjusted misstatements schedule included in your Audit Findings Report and attached to this letter. We have not adjusted the financial statements for these misstatements brought to our attention as they are immaterial to the results of the Trust and its financial position at the year-end. The financial statements are free of material misstatements, including omissions.

xii. Actual or possible litigation and claims have been accounted for and disclosed in accordance with the requirements of International Financial Reporting Standards.

xiii. We have no plans or intentions that may materially alter the carrying value or classification of assets and liabilities reflected in the financial statements.

xiv. The Trust's asset register included assets with a nil net book value and are fully depreciated in the asset register. We acknowledge that are three risks in relation to this issue:
- if these assets are no longer operational, the gross cost and accumulated depreciation balance will be overstated in the asset register and Note 15.1 Property, plant and equipment;
- if these assets are operational, there is a risk that the Trust is not assigning appropriate asset lives to its plant and equipment assets; and
- if these assets are operational, the Trust is potentially using assets that are past their prime operational functionality, which could impact on the quality of service provision.

DRAFT

xv. We have updated our going concern assessment. We continue to believe that the Trust's financial statements should be prepared on a going concern basis and have not identified any material uncertainties related to going concern on the grounds that:
   a. the nature of the Trust means that, notwithstanding any intention to cease its operations in their current form, it will continue to be appropriate to adopt the going concern basis of accounting because, in such an event, services it performs can be expected to continue to be delivered by related public authorities and preparing the financial statements on a going concern basis will still provide a faithful representation of the items in the financial statements;
   b. the financial reporting framework permits the Trust to prepare its financial statements on the basis of the presumption set out under a) above; and
   c. the Trust's system of internal control has not identified any events or conditions relevant to going concern.
   - We believe that no further disclosures relating to the Trust's ability to continue as a going concern need to be made in the financial statements.

Information Provided

xvi. We have provided you with:
   a. access to all information of which we are aware that is relevant to the preparation of the Trust's financial statements such as records, documentation and other matters;
   b. additional information that you have requested from us for the purpose of your audit; and
   c. unrestricted access to persons within the Trust from whom you determined it necessary to obtain audit evidence.

xvii. We have communicated to you all deficiencies in internal control of which management is aware.

xviii. All transactions have been recorded in the accounting records and are reflected in the financial statements.

xix. We have disclosed to you the results of our assessment of the risk that the financial statements may be materially misstated as a result of fraud.

xx. We have disclosed to you all information in relation to fraud or suspected fraud that we are aware of and that affects the Trust and involves:
   a. management;
   b. employees who have significant roles in internal control; or
   c. others where the fraud could have a material effect on the financial statements.

xxi. We have disclosed to you all information in relation to allegations of fraud, or suspected fraud, affecting the financial statements communicated by employees, former employees, analysts, regulators or others.

xxii. We have disclosed to you all known instances of non-compliance or suspected non-compliance with laws and regulations whose effects should be considered when preparing financial statements.

xxiii. We have disclosed to you the identity of the Trust's related parties and all the related party relationships and transactions of which we are aware.

xxiv. We have disclosed to you all known actual or possible litigation and claims whose effects should be considered when preparing the financial statements.

DRAFT

Annual Governance Statement

xxv. We are satisfied that the Annual Governance Statement fairly reflects the Trust's risk assurance and governance framework, and we confirm that we are not aware of any significant risks that are not disclosed within the Annual Governance Statement.

Annual Report

xxvi. The disclosures within the Annual Report fairly reflect our understanding of the Trust's financial and operating performance over the period covered by the Trust's financial statements.

Approval

The approval of this letter of representation was minuted by the Trust's Audit Committee at its meeting on 19th June 2026.

Yours faithfully

Name……

Position……

Date……

Name……

Position……

Date……

Signed on behalf of the Trust

DRAFT

Appendix 1

Unadjusted misstatements

Audit adjustments

Impact of unadjusted misstatements

The table below provides details of adjustments identified during the audit which have not been made within the final set of financial statements. The Audit Committee is required to approve management's proposed treatment of all items recorded within the table below.

Detail	Statement of Comprehensive Income £'000	Statement of Financial Position £'000	Impact on net deficit £'000	Reason for not adjusting
Payables and prepayments overstatement				
Excluding items identified above testing of a sample of prepayments identified additional one item where the prepayment had been miscalculated and one other which did not meet the classification of a prepayment.				Projected error
Debit – Trade payables		1,779		
Credit – Receivables		(1,664)		
Credit – Expenditure	(115)		Reduce by 115k	
Annual leave accrual				
The Trust has not included annual leave accrual as at 31 March 2026. This was £8.597m a in prior financial year. No calculations have been provided to support this. Given Trusts staff base remains relatively stable we estimate the Trust expenditure is understated by £8.597m.				Not adjusted as not material. The Trust implemented a strict policy whereby staff are not permitted to carry forward any leave and therefore we have not undertaken a calculation of an estimated annual leave accrual in 2025/26 as any policy breaches would be immaterial
Debit – Employee expenses	8,597			
Credit – Payables		(£8,597)	Increase by 8,597k	
Overall impact	**Increase expenditure 8,482k**	**Decrease net assets (8,482k)**	**Increase deficit by 8,482k**	

© 2026 Grant Thornton UK LLP

DRAFT

Impact of unadjusted misstatements in the prior year

Below is a summary of the unadjusted misstatements identified in the prior year end the impact on the current year financial statements.

Detail	Statement of Comprehensive Income £'000	Statement of Financial Position £'000	Impact on net surplus £'000	Reason for not adjusting in 2024/25	Reason for not adjusting in 2025/26
After date payments testing (completeness) As part of expenditure completeness testing an item was identified where delivery of goods had taken place in March 2025, however the cost had not been accrued into the financial statements. As such the Trusts expenditure and accruals in the prior financial year was understated by £984k. This expenditure has now been accounted for in 2025/26. As such there is no carried forward impact on the Trusts Statement of financial position, Expenditure is however overstated by £984k in 2025/26 as this should have been accounted for in the prior financial year.	Expenditure overstated £984k	Opening reserves overstated £984k Closing reserves – no impact	Overstated £984k	Immaterial	N/A – adjusted as transaction processed
Receivables testing errors As part of receivables testing in the prior year resulting in the misclassification between receivables and payables. Extrapolated over the untested population would suggest receivables are overstated by £659k, payables are overstated by £512k and expenditure is understated by £147k	0	0	0	Projected error	N/A

Impact of unadjusted misstatements in the prior year (continued)

Detail	Statement of Comprehensive Income £'000	Statement of Financial Position £'000	Impact on net surplus £'000	Reason for not adjusting in 2024/25	Reason for not adjusting in 2025/26
Payables accrual error As part of payables testing 1 error was identified in relation to an accrual calculation. This error was an over accrual of £970k as the source report used for the calculation of the accrual was found to be incorrect. Extrapolated over the untested population would suggest payables and expenditure was overstated £1.647m in the prior year. As this expenditure was accounted for in the prior financial year the 2025/26 expenditure is understated by £1.647m. This error has not been carried forward at 31 March 2026 as such there is no continuing impact on reserves	Expenditure understated £1,647k	Opening reserves understated £1,647k Closing reserves – No impact	Understated £1,647k	Projected error	N/A – adjusted as transaction processed
Overall impact	Expenditure understated £663k	Opening reserves understated £663k	Increase deficit £663k		

Statement of the chief executive's responsibilities as the accountable officer of the trust

The Chief Executive of NHS England has designated that the Chief Executive should be the Accountable Officer of the trust. The relevant responsibilities of Accountable Officers are set out in the *NHS Trust Accountable Officer Memorandum.* These include ensuring that:

- there are effective management systems in place to safeguard public funds and assets and assist in the implementation of corporate governance
- value for money is achieved from the resources available to the trust
- the expenditure and income of the trust has been applied to the purposes intended by Parliament and conform to the authorities which govern them
- effective and sound financial management systems are in place and
- annual statutory accounts are prepared in a format directed by the Secretary of State to give a true and fair view of the state of affairs as at the end of the financial year and the income and expenditure, other items of comprehensive income and cash flows for the year.

As far as I am aware, there is no relevant audit information of which the trust's auditors are unaware, and I have taken all the steps that I ought to have taken to make myself aware of any relevant audit information and to establish that the entity's auditors are aware of that information.

To the best of my knowledge and belief, I have properly discharged the responsibilities set out in my letter of appointment as an Accountable Officer.

DRAFT

24th June 2026 ..... Chief Executive

Statement of directors' responsibilities in respect of the accounts

The directors are required under the National Health Service Act 2006 to prepare accounts for each financial year. The Secretary of State, with the approval of HM Treasury, directs that these accounts give a true and fair view of the state of affairs of the trust and of the income and expenditure, other items of comprehensive income and cash flows for the year. In preparing those accounts, the directors are required to:

- apply on a consistent basis accounting policies laid down by the Secretary of State with the approval of the Treasury
- make judgements and estimates which are reasonable and prudent
- state whether applicable accounting standards have been followed, subject to any material departures disclosed and explained in the accounts and
- prepare the financial statements on a going concern basis and disclose any material uncertainties over going concern.

The directors are responsible for keeping proper accounting records which disclose with reasonable accuracy at any time the financial position of the trust and to enable them to ensure that the accounts comply with requirements outlined in the above mentioned direction of the Secretary of State. They are also responsible for safeguarding the assets of the trust and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

The directors confirm to the best of their knowledge and belief they have complied with the above requirements in preparing the accounts.

The directors confirm that the annual report and accounts, taken as a whole, is fair, balanced and understandable and provides the information necessary for patients, regulators and stakeholders to assess the NHS trust's performance, business model and strategy

By order of the Board

24th June 2026 ..... Chief Executive

24th June 2026 ..... Chief Financial Officer

DRAFT

Certificate on summarisation schedules

Trust Accounts Consolidation (TAC) Summarisation Schedules for University Hospitals of North Midlands NHS Trust

Summarisation schedules numbers TAC01 to TAC34 and accompanying WGA sheets for 2025/26 have been completed and this certificate accompanies them.

Finance Director Certificate

1. I certify that the TAC schedules have been compiled and are in accordance with:
    - the financial records maintained by the NHS trust and
    - accounting standards and policies which comply with the *Department of Health and Social Care's Group Accounting Manual* or any deviation from these policies has been explained in the confirmation questions in the TAC schedules (except for any immaterial misstatements reported in the auditor's report to those charged with governance or below their reporting threshold).
2. I certify that the TAC schedules are internally consistent and that there are no validation errors*.
3. I certify that the information in the TAC schedules is consistent with the financial statements of the University Hospitals of North Midlands NHS trust.

DRAFT

……..

Mark Oldham, Chief Financial Officer

24th June 2026

Chief Executive Certificate

1. I acknowledge the accompanying TAC schedules, which have been prepared and certified by the Finance Director, as the TAC schedules which the Trust is required to submit to NHS England.
2. I have reviewed the schedules and agree the statements made by the Director of Finance above.

……

Simon Constable, Chief Executive

24th June 2026

Grant Thornton

Audit Findings for University Hospitals of North Midlands NHS Trust

For the year ended 31 March 2026

16 June 2026

DRAFT

Grant Thornton

University Hospitals of North Midlands NHS Trust

Grant Thornton UK LLP
17th Floor
103 Colmore Row
Birmingham
B3 3AG
T +44 (0)121 212 4000
www.grantthornton.co.uk

DRAFT

16 June 2026

Dear Audit Committee members,

Audit Findings for University Hospitals of North Midlands NHS Trust for the year ended 31 March 2026

This Audit Findings presents the observations arising from the audit that are significant to the responsibility of those charged with governance to oversee the financial reporting process and confirmation of auditor independence, as required by International Standard on Auditing (UK) 260. Its contents have been discussed with management.

As auditor we are responsible for performing the audit, in accordance with International Standards on Auditing (UK), which is directed towards forming and expressing an opinion on the financial statements that have been prepared by management with the oversight of those charged with governance. The audit of the financial statements does not relieve management or those charged with governance of their responsibilities for the preparation of the financial statements.

The contents of this report relate only to those matters which came to our attention during the conduct of our normal audit procedures which are designed for the purpose of expressing our opinion on the financial statements. Our audit is not designed to test all internal controls or identify all areas of control weakness. However, where, as part of our testing, we identify control weaknesses, we will report these to you. In consequence, our work cannot be relied upon to disclose all defalcations or other irregularities, or to include all possible improvements in internal control that a more extensive special examination might identify. This report has been prepared solely for your benefit and should not be quoted in whole or in part without our prior written consent. We do not accept any responsibility for any loss occasioned to any third party acting, or refraining from acting on the basis of the content of this report, as this report was not prepared for, nor intended for, any other purpose.

Chartered Accountants

Grant Thornton UK LLP is a limited liability partnership registered in England and Wales: No.OC307742. Registered office: 8 Finsbury Circus, London, EC2M 7EA. A list of members is available from our registered office. Grant Thornton UK LLP is authorised and regulated by the Financial Conduct Authority. Grant Thornton UK LLP is a member firm of Grant Thornton International Ltd (GTIL). GTIL and the member firms are not a worldwide partnership. Services are delivered by the member firms. GTIL and its member firms are not agents of, and do not obligate, one another and are not liable for one another's acts or omissions.

© 2026 Grant Thornton UK LLP

We encourage you to read our transparency report which sets out how the firm complies with the requirements of the Audit Firm Governance Code and the steps we have taken to manage risk, quality and internal control particularly through our Quality Management Approach. The report includes information on the firm's processes and practices for quality control, for ensuring independence and objectivity, for partner remuneration, our governance, our international network arrangements and our core values, amongst other things. This report is available at: transparency-report-2025.pdf (grantthornton.co.uk)

We would like to take this opportunity to record our appreciation for the kind assistance provided by the finance team and other staff during our audit.

Avtar Sohal
Director
For Grant Thornton UK LLP

DRAFT

Chartered Accountants

Grant Thornton UK LLP is a limited liability partnership registered in England and Wales: No.OC307742. Registered office: 8 Finsbury Circus, London, EC2M 7EA. A list of members is available from our registered office. Grant Thornton UK LLP is authorised and regulated by the Financial Conduct Authority. Grant Thornton UK LLP is a member firm of Grant Thornton International Ltd (GTIL). GTIL and the member firms are not a worldwide partnership. Services are delivered by the member firms. GTIL and its member firms are not agents of, and do not obligate, one another and are not liable for one another's acts or omissions.

© 2026 Grant Thornton UK LLP



Contents

Section	Page
Headlines	5
Our approach to materiality	9
Overview of significant and other audit risks identified	10
Other findings	16
Communication requirements and other responsibilities	22
Audit adjustments	27
Value for Money arrangements	35
Independence considerations	36

Appendices		Page
A.	Communication with those charged with governance	40
B.	Action plan	41
C.	Follow up of prior year recommendations	48
D.	Management letter of representation	55
E.	Proposed changes to valuation of PPE	58
F.	Section 30 referral	59

DRAFT

© 2026 Grant Thornton UK LLP

Headlines

Summary of the key findings and other matters arising from the statutory audit of University Hospitals of North Midlands NHS Trust (the 'Trust') and the preparation of the Trust's financial statements for the year ended 31 March 2026 for those charged with governance.

Financial statements

Under the National Audit Office (NAO) Code of Audit Practice (the 'Code'), we are required to report whether, in our opinion:

- The Trust's financial statements give a true and fair view of the financial position of the Trust and of its income and expenditure for the period; and
- The Trust's financial statements, and the parts of the Remuneration and Staff Report to be audited, have been properly prepared in accordance with the Department of Health and Social Care (DHSC) Group Accounting Manual 2025/26 (GAM).

We are also required to report whether other information published together with the audited financial statements in the Annual Report is materially consistent with the financial statements or our knowledge obtained in the audit or otherwise appears to be materially misstated.

Our findings are summarised on pages 11 to 21. We have identified adjustments to the financial statements which impact your reported deficit for the year. These have not been adjusted and would increase the Trusts deficit by £8.482m. We have also identified several disclosure amendments. These amendments, adjusted and unadjusted are set out on pages 27 to 34. We have also raised recommendations for management as a result of our audit work. These are set out in Appendix B. Our follow up of recommendations from the prior year's audit are detailed in Appendix C.

Our work is ongoing and as yet there are no matters of which we are aware that would require modification of our audit opinion or material changes to the financial statements, subject to satisfactory resolution of the matters on page 8 being cleared.

We have concluded that the other information to be published with the financial statements, is consistent with our knowledge of your organisation and the financial statements we have audited.

Our anticipated audit report opinion will be unmodified. A draft audit opinion is attached to 19 June 2026 Audit Committee as separate agenda item. A draft letter of representation is attached at Appendix D

The Trust's finance team delivered a set of working papers to support its financial statements at the start of the audit process. We experienced delays in certain areas, primarily due to evidence and explanations being provided later than anticipated.

Additional time was also required to assess the non-consolidation of the Trust's charitable funds, as management had not completed this assessment until an audit query was raised. All delays have been escalated promptly, and we continue to work collaboratively with the Trust to address outstanding matters as efficiently as possible.

We note the Trust's Annual Report was received earlier than previous years which is positive.

We value the positive working relationship we have with the Trust and would like to express out thanks, in particular to the Trust's finance team for their support throughout the audit process.

DRAFT

© 2026 Grant Thornton UK LLP

Headlines

Summary of the key findings and other matters arising from the statutory audit of University Hospitals of North Midlands NHS Trust (the 'Trust') and the preparation of the Trust's financial statements for the year ended 31 March 2026 for those charged with governance.

Value for Money (VFM) arrangements

Under the National Audit Office (NAO) Code of Audit Practice ('the Code'), we are required to consider whether the Trust has put in place proper arrangements to secure economy, efficiency and effectiveness in its use of resources. Auditors are required to provide a commentary on the Trust's overall arrangements, and set out our key recommendations on any significant weaknesses in arrangements identified during the audit.

Auditors are required to report their commentary on the Trust's arrangements under the following specified criteria:

- Financial sustainability;
- Governance.; and
- Improving economy, efficiency and effectiveness

A significant weakness in arrangements has been identified in relation to financial sustainability and a key recommendation made relating to short-and medium-term financial planning. We also raise a related improvement recommendation on planning for delivery of recurrent savings.

Further information is set out in the Auditors Annual Report which is presented alongside this report to the 19th June 2026 Audit Committee.

DRAFT

© 2026 Grant Thornton UK LLP

Headlines

Summary of the key findings and other matters arising from the statutory audit of University Hospitals of North Midlands NHS Trust (the 'Trust') and the preparation of the Trust's financial statements for the year ended 31 March 2026 for those charged with governance.

Statutory duties

The Local Audit and Accountability Act 2014 ('the Act') also requires us to:

- report to you if we have applied any of the additional powers and duties ascribed to us under the Act; and
- to certify the closure of the audit.

As in prior years, under our statutory duties as your auditor, we have referred a matter to the Secretary of State under section 30 of the Local Audit and Accountability Act 2014 in relation to the Trust's ongoing breach of its breakeven duty at 31 March 2026. The Trust has set a breakeven budget for 2025/26, however we are still required to make a further referral under section 30(a) where there is no clear plan to achieve cumulative financial balance.

We cannot formally conclude the audit and issue an audit certificate for the Trust for the year ended 31 March 2026 in accordance with the requirements of the Local Audit and Accountability Act 2014 until the National Audit Office has concluded their work in respect of consolidation returns for the year ended 31 March 2026.

We expect to certify the completion of the audit by 31 December 2026.

DRAFT

© 2026 Grant Thornton UK LLP

Headlines

Our work is largely complete and there are currently no matters of which we are aware that would require further modification of our audit opinion, subject to the more significant outstanding matters detailed below.

- Community Diagnostic Centre – direct confirmation of value from Trusts external valuer and finalisation of work regarding reassessed valuation
- Receipt of evidence to support trust complementary controls regarding ESR system and our consideration thereon
- Receipt of query regarding patient care income
- Receipt and review of updated accounts, Annual Report and remuneration report to ensure necessary amendments
- Manager and Engagement review of above following team completion

- Procedures regarding subsequent events
- Finalisation of WGA procedures
- Receipt of letter of representation
- Manager and Engagement review of above following team completion

DRAFT

© 2026 Grant Thornton UK LLP

Our approach to materiality

As communicated in our Audit Plan dated 22 January 2026, we determined materiality at the planning stage as £24m based on approximately 2% of prior year gross operating expenses. On receipt of the draft financial statements, we reconsidered planning materiality based on the 2025/26 figure but, based on the stability of expenditure year-on-year, we did not deem it necessary to alter our thresholds.

Materiality area	Amount (£k)	Qualitative factors considered
Materiality for the financial statements	24,000	This is equivalent to approximately 2% of the operating expenses for the period ended 31 March 2026.
Performance materiality for the financial statements	18,000	Performance materiality has been set at 70% of financial statements materiality. This reflects our risk-assessed knowledge of potential for errors occurring. Performance materiality is used for the purposes of assessing the risks of material misstatement and determining the nature, timing, and extent of further audit procedures. This is the amount we set at less than materiality for the financial statements as a whole, to reduce to an appropriately low level the probability that the aggregate of uncorrected and undetected misstatements exceeds materiality for the financial statements as a whole.
Reporting threshold	1,000	Our audit plan reported a threshold of £1.2m, we have reduced this to £1m as this is the threshold for reporting any errors identified during our work to the National Audit Office for its Whole of Government Accounts (WGA) exercise.
Materiality for specific transactions, balances or disclosures - Remuneration Report	48	Due to the public interest in senior officer remuneration disclosures, we apply specific audit procedures to this work and set a lower materiality level for this area. We design our procedures to detect errors in specific accounts at a lower level of precision which we have determined to be applicable for senior officer remuneration disclosures. We evaluate errors in this disclosure for both quantitative and qualitative factors against this lower level of materiality. We will apply heightened auditor focus on the completeness and clarity of disclosures in this area and will request amendments to be made if any errors exceed the threshold we have set or would alter the bandings reported for any individual.

DRAFT

© 2026 Grant Thornton UK LLP

Overview of significant and other audit risks identified

The below table summarises the significant and other risks discussed in more detail on the subsequent pages.

Significant risks are defined by ISAs (UK) as an identified risk of material misstatement for which the assessment of inherent risk is close to the upper end of the spectrum due to the degree to which risk factors affect the combination of the likelihood of a misstatement occurring and the magnitude of the potential misstatement if that misstatement occurs.

Other risks are, in the auditor's judgment, those where the risk of material misstatement is lower than that for a significant risk, but they are nonetheless an area of focus for our audit.

DRAFT

Risk title	Risk level	Change in risk since Audit Plan	Fraud risk	Level of judgement or estimation uncertainty	Findings
Risk 1 Management override of controls	Significant	↔	✓	Low	🟡
Risk 2 Closing valuation of land and buildings	Significant	↔	✗	High	TBC
Risk 3 non rebuttable risk of fraud in other operating income – non patient care services	Significant	↔	✓	Medium	🟢

Key

↑ Assessed risk increase since Audit Plan

↔ Assessed risk consistent with Audit Plan

↓ Assessed risk decrease since Audit Plan

🟢 No adjustment or change in disclosure required

🟡 Non-material adjustment or change in disclosure required

🔴 Material adjustment or change in disclosure required

© 2026 Grant Thornton UK LLP

Overview of significant risks identified – financial statements


Risk identified in our Audit Plan	Audit procedures performed	Key observations
Management override of controls In accordance with ISA (UK) 240, we have identified a risk of fraud in respect of management override of controls.	We have: • evaluated the design effectiveness of management controls over journals • analysed the journals listing and determined the criteria for selecting high risk unusual journals • challenged management's key judgements and estimates and considering whether these judgements and estimates are individually or cumulatively indicative of management bias • tested unusual journals made during the year and the accounts production stage for appropriateness and corroboration • gained an understanding of the accounting estimates and critical judgements applied by management and considered their reasonableness	**Journals** We identified, through our consideration of IT general controls that there is one generic/default user account with privileged access to E-Financials Application. We have reported on this in prior years (also one account) . Generic accounts have login capability and are not assigned to a specific individual within the Trust. The risk associated with this is that the potential exists to bypass system-enforced internal control mechanisms through inappropriate use of administrative functionality by: • making unauthorized changes to system configuration parameters • creation of unauthorized accounts • making unauthorized updates to their own account's privileges, or • deletion of audit logs or disabling logging mechanisms leading to financial misstatement. The generic user account 'workflow user' relates to the EFIN/EPROC service with the e-mail address strategic.procurement@uhnm.nhs.uk. This user was set up by ELFS and is used to run scripts as part of the system administration. There has been no log in to the user as this isn't a 'sign in' account. We are satisfied that no transactions have been processed under this user which is also consistent with the prior year. The Trust have reviewed this and continue to accept the risk. We will continue to report and tailor our audit response to this risk. The risk pertaining to prior year as reported in Appendix C remains open in this regard.

DRAFT

© 2026 Grant Thornton UK LLP

Overview of significant risks identified – financial statements

Risk identified in our Audit Plan	Audit procedures performed	Key observations
Management override of controls – (continued)	The Trust processed journals comprising in excess of 843,570 (PY 980,616) lines of data in respect of the year ending 31 March 2026, with a total value of £16,450 billion (PY £16,067 billion) as shown in the chart below (where GJ and GR represent manual journals). 5.77% of these by number occur at year end (PY: 5.42%), with the majority linked to a handful of users. While we generally anticipate an increase in activity at year end, auditing standards specifically require us to consider year-end journals.	**Journal authorisation limits** The Trusts journal authorisation limits range from £1m to £10bn. This is deemed excessive given the value of journals currently posted by the Trust. The Trust reviewed these limits in 2025/26 and concluded them to be reasonable. ELFS limits are the highest but given the volume of transactions ELFS post with large values e.g. payroll BACS payments, etc the limits have been considered as reasonable, The limits have been decreased from 100bn in 2024/25 to 10bn in the current year. A recommendation was raised in the prior year regarding this. We have therefore kept this recommendation open to ensure authorisation limits are kept under review. **Journal supporting documentation** As part of journal sample testing we identified one item where the documentation to support the journal did not fully support the values entered and a misposting had been made. A journal relating to employer's national insurance for MARS schemes incorrectly posted £17k to the Statement of Financial Position (SOFP) instead of the Statement of Comprehensive Income (SOCI). Although the Trust's reconciliation processes identified the discrepancy, no corrective journal was processed to amend the error. We have raised a recommendation in relation to this in Appendix B.



DRAFT

© 2026 Grant Thornton UK LLP

Overview of significant risks identified – financial statements

Risk identified in our Audit Plan	Audit procedures performed	Key observations
Management override of controls – (continued)		**Accounting estimates** We identified that year-end expenditure accruals and provisions had decreased across several areas compared with the prior year. While we were satisfied with the rationale for most of these reductions, we were not satisfied that the annual leave accrual has been appropriately recognised. No accrual was recorded by management in 2025/26, compared to an £8.5m accrual in the prior year. We requested an updated estimate from management for 2025/26; however, this has not been provided. We understand that limitations in the underlying systems used to capture leave data across the Trust, including the absence of a centralised system, have contributed to this issue. Notwithstanding these challenges, we do not consider it reasonable for the annual leave accrual to reduce from £8.597m in the prior year to nil. In the absence of alternative evidence and given the relative stability in staff numbers across the Trust, we consider that an accrual of £8.597m remains a reasonable estimate at the current year-end. This matter has been included within unadjusted misstatements and aggregated with other identified differences to inform our assessment of whether the financial statements are materially misstated. Whilst the trust have been overly optimistic in relation to the treatment of its annual leave accrual in 2025/26 we have not identified any instances of management override of controls. Recommendations have been made in Appendix B including follow up of prior year recommendations in Appendix C. **Conclusion - Management override of controls** Our work in this area is complete. We have not identified any issues in relation to management override of controls.

DRAFT

© 2026 Grant Thornton UK LLP

Overview of significant risks identified – financial statements

DRAFT

Risks identified in our Audit Plan	Audit procedures performed	Key observations
Non rebuttable risk of fraud in other operating income – non patient care services	We have rebutted the presumed risk that the education and training element of other operating income may be misstated due to improper recognition. This is due to the low fraud risk in the nature of the underlying transactions. For non-patient care services income, research and development income, and other income, we have assessed these revenue streams as being at greater risk of manipulation and as such we have identified a significant risk of fraud in these revenue streams. We have: • evaluated the Trust's accounting policy for recognition of income for appropriateness and compliance with the DHSC Group Accounting Manual (GAM) 2025/26 • updated our understanding of the Trust's system for accounting for income and evaluated the design of associated controls • tested a sample of other operating income and associated year-end receivables to invoices and cash receipt or other supporting evidence • tested a sample of cash receipts and invoices issued in the period following 31 March 2026 to determine whether income was recognised in the correct accounting period Our audit work has not identified any issues in respect of other operating income recognition.	As identified in prior years our testing of income identified the absence of signed income contracts for associates. It is understood a number of organisations are included as an associate as part of the main ICB contract. The overall contract is signed however this states 'TBC' in terms of total contract value for the associate ICB's. There is also a footnote stating, 'Associate contract values to be confirmed and will be varied into the contract'. We have not seen any signed contract subsequent to this. In addition, in relation to other operating income testing whilst contracts were provided to support income , four contracts were not signed. A recommendation has been raised in relation to this in appendix B. Our work in this area is complete.

© 2026 Grant Thornton UK LLP

Overview of significant risks identified – financial statements

Risks identified in our Audit Plan	Audit procedures performed	Key observations
Closing valuation of land and buildings	The Trust revalues its land and buildings annually to ensure that the carrying value of these assets if not materially difference from the current value as at the financial statements date. The Trust commissioned District Valuer, its valuation expert. We have: • evaluated management's processes and assumptions for the calculation of the estimate, the instructions issued to the valuation expert and the scope of their work • written to the valuer to confirm the basis on which the valuations were carried out • evaluated the competence, capabilities and objectivity of the valuation expert • challenged the information and assumptions used by the valuer to assess completeness and consistency with our understanding, including through use of our auditor's expert • tested a sample of revaluations made during the year to ensure that the valuations made are reasonable and that the accounting entries have been input correctly into the Trust's asset register, revaluation reserve, and Statement of Comprehensive Income	Our work in this area is well progressed. We are currently working through the Trusts reassessment of the Community Diagnostic Centre valuation, including liaison with our valuation experts.

DRAFT

© 2026 Grant Thornton UK LLP

Other findings – key judgements and estimates (continued)

Key judgement or estimate	Summary of management's approach	Auditor commentary	Assessment
Land and building valuations £640.6 m (per draft financial statements)	Land and buildings comprise of specialised assets such as the Trust's hospitals, which are required to be valued at depreciated replacement cost (DRC) at year end on a modern equivalent asset basis. Management has determined the amount of space and location required for ongoing service delivery in the light of their current and projected service needs and have instructed the valuer accordingly. The remainder of land and buildings are not specialised in nature and are required to be valued in existing use (EUV) at year end. The Trust has engaged the District Valuer Property Specialists to complete the valuation of properties as at 31 March 2026.	We have: • deepened our risk assessment procedures performed including understanding processes and controls around the identification and determination of estimates. This included understanding methods, assumptions and data used; • discussed management's determination of accounting estimates with those charged with governance, for example, qualitative considerations, the development and validation of models, data integrity and the selection of inputs; • considered the competence, capabilities and objectivity of the valuation expert used by the Trust. We have not identified any concerns; • considered the data and assumptions used by management to derive the accounting estimate. We have not noted any issues with the completeness and accuracy of this underlying information; • considered the appropriateness of the MEA assumptions used, in particular we have confirmed that none have changed since the prior year; • we have considered the movements in the valuations of individual assets and their consistency with indices provided by our auditor's expert. This work has not raised any issues with the 2025/26 valuations; • confirmed that there have been no changes to the valuation method this year; • Carried out specific procedures in relation to the Community Diagnostic Centre – including consultation with auditors expert; and • assessed the reasonableness of the disclosures related to accounting estimates. See narrative on further pages.	TBC

DRAFT

© 2026 Grant Thornton UK LLP

Other findings – key judgements and estimates (continued)

Key judgement or estimate	Summary of management's approach	Auditor commentary	Assessment
Land and building valuations £640.6 m (per draft financial statements)	The Trust has engaged the DV/VOA in its capacity as a valuation professional to value the Trust's land and buildings as at 31 March 2026. Through our review of the DV/VOA's approach, we identified that the DV/VOA applies a build cost, indexed from an historical industry standard build rate using actual cost data held by the DV/VOA from other NHS building projects that it has been involved in. The DV/VOA refers to this as a 'beacon' approach. We have requested access to the DV/VOA's cost data so we can corroborate the accuracy and relevance of the data it has used. The DV/VOA has been unwilling to provide us access. The NAO, on behalf of auditors, has also commissioned its own valuation expert, Montagu Evans, to provide assurance as to the reasonableness of the DV/VOA approach. We received their report on 31 March 2026. This report does not provide any specific commentary on the 'beacon' approach, however Montagu Evans has instructed auditors to discuss the valuation methodology applied with the DV/VOA and gain our own assurance over the reasonableness of the use of this indexation.	**Existing site assets-** In the absence of being able to corroborate the DV/VOA build cost data, we have completed audit procedures to establish an expectation of appropriate build costs, starting from an appropriate BCIS rate for hospital buildings and using other variables that can be verified. We determined that an appropriate value applying appropriate BCIS index would not give a materially different valuation when compared to the Trusts valuation. The DV/VOA did not provide us with sufficient access or assurance that the build cost data and indexation used in its valuation approach is reasonable. We are satisfied that there is unlikely to be a materially different value if appropriate industry standard BCIS rates were used, however we are unable to corroborate that the DV/VOA applies a reasonable approach to determining a build cost rate. If there was an error in its data or calculations, we have not been provided with the opportunity to identify it. Whilst we are satisfied the value is materially reasonable as at 31 March 2026, in comparison to using an industry standard index, we are unable to give those charged with governance assurance that the estimation process will continue to produce materially accurate valuations in the future.	TBC

DRAFT

© 2026 Grant Thornton UK LLP

Other findings – key judgements and estimates (continued)

Key judgement or estimate	Summary of management's approach	Auditor commentary	Assessment
Land and building valuations £640.6 m (per draft financial statements)		We continue to recommend that management revisit their valuation instructions with the valuer, to ensure that access to source data used by the valuers is made available to auditors, or that the valuer uses an industry standard approach to valuing land and buildings. New asset -Community Diagnostic Centre This asset became operational in 2025/26. As such, capital expenditure incurred by the Trust totalling £30.755m was transferred from Assets Under Construction to relevant operational asset categories when the building opened. This was then revalued as at 31 March 2026 to £15.110m, resulting in an impairment of £15.645m. Our work in this area is well progressed. We are currently working through the Trusts reassessment of the Community Diagnostic Centre valuation, including liaison with our valuation experts.	TBC

DRAFT

© 2026 Grant Thornton UK LLP

Other findings – information technology

This section provides an overview of results from our assessment of information technology (IT) environment and controls which included identifying risks from the use of IT related to business process controls relevant to the financial audit. This includes an overall IT general control (ITGC) rating per IT system and details of the ratings assigned to individual control areas.

DRAFT

IT application	Level of assessment performed	Overall ITGC rating	ITGC control area rating			Related significant or other risks
			Security management	Technology acquisition, development and maintenance	Technology infrastructure	
e-Financials	ITGC assessment (design and implementation effectiveness only)	●	● ** *	●	●	Management override of controls Presumed risk of fraud in revenue recognition
Electronic Staff Record (ESR)	ITGC assessment (design and implementation effectiveness only)	TBC	TBC	TBC	TBC	None identified
RAM	ITGC assessment (design and implementation effectiveness only)	●	●	●	●	Valuation of land and buildings

*generic user account 'workflow user' relating to the EFIN/EPROC service (see page 11 for detail)

** review of user access scheduled to be carried out on a quarterly basis not carried out until month 10 (see page 47 for recommendation raised)

Assessment

- ● Significant deficiencies identified in IT controls relevant to the audit of financial statements
- ● Non-significant deficiencies identified in IT controls relevant to the audit of financial statements/significant deficiencies identified but with sufficient mitigation of relevant risk
- ● IT controls relevant to the audit of financial statements judged to be effective at the level of testing in scope
- ● Not in scope for testing

© 2026 Grant Thornton UK LLP

Other findings

Matter	Commentary	Auditor view
Service Auditor Reports Under ISA 315R, auditors are required to understand and assess relevant internal controls of the systems relevant to the preparation of financial statements. This includes systems provided by service organisations. An independent auditor produces a service auditor report to provide management with assurance over the internal control environment of the system they use and as external auditors we review these service auditor reports when undertaking our work. The following systems used by the Trust are provided by service organisations. The data from these systems are relevant to preparation of financial statements of The Trust. • E-Financials ISAE 3402 TYPE II Report: Finance and accounting services • The Electronic Staff Record Programme (ESR)	**E-Financials ISAE 3402 TYPE II Report: Finance and accounting services** Advanced is currently the primary contractor for the ELFS (E-Financials) Service. As it provides day to day IT Operations, systems support and development for the E-Financials service. The audit team reviewed the ISAE 3402 Audit Type II service auditor report, which assesses the design and operating effectiveness of the controls of finance and accounting systems, Oracle EBS and BI, provided by NHS Shared Business Service Limited for period 1 April 2025 to 31 March 2026. This report noted no significant findings and concluded an unmodified opinion. We reviewed this report as part of our risk assessment and our testing of design and implementation of relevant controls at the entity. Complimentary user entity controls - The processes of ELFS are designed with the assumption that certain controls would be implemented by user entities. One control reviewed was to ascertain whether, upon termination, personnel access to data and systems is disabled in a timely manner upon notification from human resources or other appropriate entity personnel. We were satisfied the staff member tested had been removed from the system, there was however a delay, as their last day of employment was 31 December 2025 and they were not removed until 23 January 2026. We carried out further review to confirm the last logon date for this individual did not extend past their leave date. Our work on the E-Financials system is complete.	Assurance has been gained over the design and implementation over the controls at the service organisations for the below systems: • E-Financials ISAE 3402 TYPE II Report: Finance and accounting services • The Electronic Staff Record Programme (ESR) We have considered the control findings identified and not consider them significant enough to have an impact on our audit opinion. The control findings reported are relevant to controls operating at the third party and not the Trust. We have one query outstanding with the Trust regarding ESR complementary user controls. Once we receive this information we will conclude our testing. Recommendations from findings to date are included in Appendix B.

DRAFT

© 2026 Grant Thornton UK LLP

Other findings

Matter	Commentary	Auditor view
Service Auditor Reports - continued	**NHS Business Services Authority and IBM UK Limited: The Electronic Staff Record Programme** The audit team have reviewed the ISAE 3000 Audit Type II service auditor report which assesses the design and operating effectiveness of controls of the ESR system provided by NHS Business Services Authority for period 1 April 2025 to 31 March 2026. This report noted no significant findings and concluded an unmodified opinion. We reviewed this report as part of our risk assessment and our testing of design and implementation of relevant controls at the entity. Complimentary user entity controls - The processes of NHSBSA and IBM United Kingdom Limited are designed with the assumption that certain controls would be implemented by user entities. We have reviewed the ISAE 3000 Audit Type II report which describes the internal controls that should be in operation at the Trust to complement the internal controls operated by the ESR Programme and considered whether the suggested internal controls are present and operating effectively. One control reviewed was to ascertain whether, upon termination, personnel access to data and systems is disabled in a timely manner upon notification from human resources or other appropriate entity personnel. Our work in this area is not yet complete.	See previous page

DRAFT

© 2026 Grant Thornton UK LLP

Communication requirements

Issue	Commentary
Matters in relation to fraud	We have previously discussed the risk of fraud with the Audit Committee. We have not been made aware of any incidents in the period, and no other issues have been identified during the course of our audit procedure.
Matters in relation to related parties	We are not aware of any related parties or related party transactions which have not been disclosed.
Matters in relation to laws and regulations	You have not made us aware of any significant incidences of non-compliance with relevant laws and regulations and we have not identified any incidences from our audit work.
Written representations	A letter of representation has been requested from the Trust which is included at Appendix D to this report.
Accounting practices	We have evaluated the appropriateness of the Trust's accounting policies, accounting estimates and financial statement disclosures. A number of minor amendments were made to the accounting policies, as noted on page 29.
Confirmation requests from third parties	We requested from management permission to send confirmation requests to the Trust's banking partners. This permission was granted and the requests were sent. Confirmations have been received as part of our final accounts work.
Disclosures	Our review found no material omissions in the financial statements.
Audit evidence and explanations	All information and explanations requested from management were provided.
Significant difficulties	We did not encounter any significant difficulties.

DRAFT

© 2026 Grant Thornton UK LLP

Other responsibilities

Issue	Commentary
Going concern	In performing our work on going concern, we have had reference to Statement of Recommended Practice – Practice Note 10: Audit of financial statements of public sector bodies in the United Kingdom (Revised 2024). The Financial Reporting Council recognises that for particular sectors, it may be necessary to clarify how auditing standards are applied to an entity in a manner that is relevant and provides useful information to the users of financial statements in that sector. Practice Note 10 provides that clarification for audits of public sector bodies. Practice Note 10 sets out the following key principles for the consideration of going concern for public sector entities: • the use of the going concern basis of accounting is not a matter of significant focus of the auditor's time and resources because the applicable financial reporting frameworks envisage that the going concern basis for accounting will apply where the entity's services will continue to be delivered by the public sector. In such cases, a material uncertainty related to going concern is unlikely to exist, and so a straightforward and standardised approach for the consideration of going concern will often be appropriate for public sector entities • for many public sector entities, the financial sustainability of the reporting entity and the services it provides is more likely to be of significant public interest than the application of the going concern basis of accounting. Our consideration of the Trust's financial sustainability is addressed by our value for money work, which is covered elsewhere in this report. Practice Note 10 states that if the financial reporting framework provides for the adoption of the going concern basis of accounting on the basis of the anticipated continuation of the provision of a service in the future, the auditor applies the continued provision of service approach set out in Practice Note 10. The financial reporting framework adopted by the Trust meets this criteria, and so we have applied the continued provision of service approach. In doing so, we have considered and evaluated: • the nature of the Trust and the environment in which it operates • the Trust's financial reporting framework • the Trust's system of internal control for identifying events or conditions relevant to going concern • management's going concern assessment. On the basis of this work, we have obtained sufficient appropriate audit evidence to enable us to conclude that: • a material uncertainty related to going concern has not been identified; and • management's use of the going concern basis of accounting in the preparation of the financial statements is appropriate.

DRAFT

© 2026 Grant Thornton UK LLP

Other statutory powers and duties

Issue	Commentary
Other information	We are required to give an opinion on whether the other information published together with the audited financial statements (including the Annual Report), is materially inconsistent with the financial statements or our knowledge obtained in the audit or otherwise appears to be materially misstated as per ISA720 - The Auditor's Responsibilities Relating to Other Information. Whilst not material, we have identified a small number of variations between operating expenditure values reported within the Trusts financial statements and the Annual Report. The Trust has agreed to make all necessary amendments which we will check once updated accounts are received.
Auditable elements of Remuneration Report and Staff Report	We are required to give an opinion on whether the parts of the Remuneration Report and Staff Report subject to audit have been prepared properly in accordance with the requirements of the Act, directed by the Secretary of State with the consent of the Treasury. We have audited the elements of the Remuneration Report and Staff Report, including the Fair Pay Multiple Disclosures, as required by the DHSC GAM. To date we identified a number of minor amendments, these are summarised below: • Update for one officer date in post and amend salary banding; • Update comparative value for one officer to ensure agree to prior year report; • Round the value of the cash equivalent transfer value at the end of the reporting period to the nearest £1,000 and ensure expenses are rounded to the nearest £100; • The Trust made payments relating to the Mutually Agreed Resignation Scheme (MARS). As per the GAM, entities must provide additional disclosure where payments are not covered by the NHS Pension Scheme, for example ex-gratia payments agreed with the Treasury or exit schemes such as MARS. Relevant narrative needs to be updated. • Pay multiples to be recalculated and updated to include agency staff and exclude non-executive directors • Update amount disclosed regarding capitalised staff costs to correlate to reported value per financial statements. The Trust has agreed to make all necessary amendments which we will check once updated accounts are received.

DRAFT

© 2026 Grant Thornton UK LLP

Other statutory powers and duties

Issue	Commentary
Public interest report	No issues have been identified that would require us to issue a public interest report.
Written recommendations	No issues have been identified that would require us to issue written recommendations.
Referral to Secretary of State and notification to NHS England	A local auditor of the accounts of a health service body must as soon as reasonably practicable refer the matter to the Secretary of State if the auditor believes that the body or an officer of the body: (a) is about to make, or has made, a decision which involves or would involve the body incurring unlawful expenditure, or (b) is about to take or has begun to take a course of action which, if followed to its conclusion, would be unlawful and likely to cause a loss or deficiency. We are making a referral to the Secretary of State in accordance with section 30(b) of the Local Audit and Accountability Act 2014. Paragraph 2(1) of Schedule 5 of the National Health Service Act 2006 provides: *Each NHS trust must ensure that its revenue is not less than sufficient, taking one financial year with another, to meet outgoings properly chargeable to revenue account.* This duty is known as the 'break even duty'. The phrase 'taking one financial year with another' has been interpreted by the Department of Health and Social Care and HM Treasury as meaning that the duty is met if income equals or exceeds expenditure over a three-year rolling period, or exceptionally a five-year rolling period with the agreement of NHS Improvement. On 27 May 2026 we referred a matter to the Secretary of State under section 30 (b) of the Local Audit and Accountability Act 2014 in relation to the Trust's ongoing breach of its break-even duty for the year ending 31 March 2026. In addition, we referred a matter under section 30 (a) as the Trust does not have a formal plan to return to financial balance in the foreseeable future. The wording of this referral is included for the Audit Committee's reference at Appendix F.

DRAFT

© 2026 Grant Thornton UK LLP

Other responsibilities under the Code

Issue	Commentary
Matters on which we report by exception	We are required to report on matters by exception in a number of areas: • the Annual Governance Statement does not comply with guidance issued by NHS England or is misleading or inconsistent with the information of which we are aware from our audit; • the information in the annual report is materially inconsistent with the information in the audited financial statements or is apparently materially incorrect based on, or is materially inconsistent with, our knowledge of the Trust acquired in the course of performing our audit, or otherwise misleading; • if we have applied any of our statutory powers or duties; or • where we are not satisfied in respect of arrangements to secure value for money and have reported significant weaknesses. We have the following to report; • **Arrangements to secure value for money -** We have reported one significant weakness in relation to the Trusts arrangements to secure value for money. This is reported separately in our Auditors Annual Report. • **Statutory powers or duties -**Under our statutory duties as your auditor, we have referred a matter to the Secretary of State under section 30 of the Local Audit and Accountability Act 2014. Further detail is included on the previous page.
Review of accounts consolidation schedules and specified procedures on behalf of the group auditor	We are required to give a separate statement on the Trust accounts consolidation schedules and to carry out specified procedures (on behalf of the NAO) on these schedules under group audit instructions. In the group audit instructions the Trust was not selected as a sampled component. We have nothing to report on these matters.
Certification of the closure of the audit	We cannot formally conclude the audit and issue an audit certificate for the Trust for the year ended 31 March 2026 in accordance with the requirements of the Local Audit and Accountability Act 2014 until the National Audit Office has concluded their work in respect of consolidation returns for the year ended 31 March 2026. We expect to certify the closure of this audit by December 2026.

DRAFT

© 2026 Grant Thornton UK LLP

Audit adjustments

We are required to report all non-trivial misstatements to those charged with governance, whether or not the accounts have been adjusted by management.

Impact of adjusted misstatements

All adjusted misstatements are set out in detail below, along with the impact on the key statements.

DRAFT

Detail	Statement of Comprehensive Income £'000	Statement of Financial Position £'000	Impact on net surplus £'000
Provisions The Trust has treated £2.544m of a provision as utilised rather than as reversed/unused as it is no longer required. This is a presentation adjustment on note 27 'provisions for liabilities and charges analysis' and has the following impact on the SOCI: Debit Employee benefits (note 9) £ 2.544m Credit Increase/Decrease in other provisions (note 7.1) £2.544m	2,544 (2,544)	0	0
Overall impact	0	0	0

© 2026 Grant Thornton UK LLP

Audit adjustments

Impact of adjusted misstatements - continued

Detail	Statement of Comprehensive Income £'000	Statement of Financial Position £'000	Impact on net surplus £'000
Payables and prepayments misclassification			
One item identified in trade payables testing did not meet the definition, relating to prepaid 2026/27 Council Tax with no SOCI impact. The Trust carried out a further review of items processed through this mechanism and found £921k incorrectly recorded as payables (prepayments made to correct SOCI), resulting in a factual overstatement of both payables and receivables of £921k.	0		0
Debit – Trade payables		921	
Credit – Receivables		(921)	
Debit balances within payables			
The working papers provided to support the Trusts accruals balance include £2.973m debtor balances relating to amounts recoverable arising from employee benefit schemes. The balance should be included within receivables.	0		0
Debit – Other receivables		2,973	
Credit – Payables		(2,973)	
Overall impact	0	0	0

DRAFT

© 2026 Grant Thornton UK LLP

Audit adjustments

Misclassification and disclosure changes

The table below provides details of misclassification and disclosure changes identified during the audit which have been made in the final set of financial statements.

Disclosure	Misclassification or change identified	Adjusted?
Throughout	A number of typographical errors have been identified throughout the financial statements, including ensuring values between TAC forms and financial statement fully agree.	TBC
Throughout	A number of immaterial accounting policies and disclosures have been included in the financial statements. These should be removed to avoid obscuring material information within the financial statements. An example of this being note 6.1, operating income.	TBC
Senior officers disclosures, staff report	A number of amendments to the senior officer note have been identified – these are disclosed on page 24.	TBC
Annual report	A small number of amendments have been identified – these are disclosed on page 24.	TBC
Cash flow statement	Cash flow statement refers to "investment property" within PPE movements, this should be removed.	TBC
Note 1.4 – Accounting Policies	Disclosure of significant judgements in determining timing of satisfaction of performance obligations and whether the Trust has applied IFRS 15 practical expedients has been omitted.	TBC
Note 5, fees and charges	Disclosure should include a narrative to explain what service this relates to.	TBC
Note 5.1 – Additional Information on Contract Revenue	Revenue recognised in the reporting period that was included in the opening contract liability balance has not been disclosed as required by IFRS 1. Revenue recognised in the current period of £5.034m relating to performance obligations satisfied in prior periods has not been disclosed.	TBC

DRAFT

© 2026 Grant Thornton UK LLP

Audit adjustments

Misclassification and disclosure changes - continued

Disclosure	Misclassification or change identified	Adjusted?
Note 14.1 intangible assets	Included within the intangible asset register is an asset with a gross book value of £3.2m relates to legacy Mid Staffordshire assets that no longer exist at the Trust. The Trust should remove this from gross cost and accumulated depreciation.	TBC
Note 15.3 & 15.4 Property Plant and Equipment financing	The land value of £15.497m has been omitted from print parameters which mean current disclosed values to not add to the total values of £734.232m and comparative of £715.699m.	TBC
Note 23.1 Third party assets held by the Trust	The financial statements should exclude third party assets. At present £15k of patient monies is included in the cash and cash equivalents figure with opposite entry within payables. The Trust should amend this in the accounts as bank and cash and payables are both overstated by £15k.	TBC
Note 20.1 – Allowances for Credit Losses	The financial statements do not disclose gross carrying amounts by credit risk rating grades or equivalent analysis of credit risk exposure. The financial statements do not include disclosure of gross carrying amounts of financial assets by credit risk rating grades or equivalent analysis of credit risk exposure as required by IFRS 7. The Trust applies a simplified provision matrix; however, additional disclosure (e.g. ageing or credit risk analysis) is required to meet IFRS 7 requirements.	TBC

DRAFT

© 2026 Grant Thornton UK LLP

Audit adjustments

Misclassification and disclosure changes - continued

Disclosure	Misclassification or change identified	Adjusted?
Financial instruments - note 31	• Note 31.4 , The maturity of financial liabilities analysis the financial liabilities due in in one year or less is overstated by £3.538m. £128.841m is disclosed instead of £125.030m, • Disclosure of fee income and expense arising from financial instruments (where applicable) has not been included within the financial statements; • Disclosure of the entity's definition of default, including criteria and assumptions applied in assessing credit risk, has not been included; • The financial statements do not include adequate disclosures in relation to fair value measurements as required by IFRS 13, including, fair value measurements at reporting date, Fair value hierarchy (Levels 1, 2, 3), Valuation techniques and inputs and appropriate disaggregation into classes. Disclosures for financial instruments not measured at fair value	TBC
Note 32 - Losses and special payments	'Bad debts and claims abandoned' is not a valid analysis category per the GAM and should be amended to 'Claims waived or abandoned (excluding cases between DHSC group bodies)'.	TBC
Note 33 - Related party transactions	DHSC has not been disclosed as the parent department within the financial statements, as required by IAS 1 and GAM guidance. In addition, total NHS income should be updated to £1,245.130m.	TBC
Note 35 - Capital Resource Limit	During our testing of Note 36, we identified a discrepancy between the CRL balance disclosed in the financial statements and the amount confirmed externally. The limit referred to in the financial statements is £70.030m whereas the final agreed CRL is £70.530m. Management has explained that the figure included in the financial statements reflects the initial limit prepopulated in the TAC forms, prior to receipt of the final confirmed limit. This should now be updated to actual confirmed value.	TBC

DRAFT

© 2026 Grant Thornton UK LLP

Audit adjustments

Impact of unadjusted misstatements

The table below provides details of adjustments identified during the audit which have not been made within the final set of financial statements. The Audit Committee is required to approve management's proposed treatment of all items recorded within the table below.

Detail	Statement of Comprehensive Income £'000	Statement of Financial Position £'000	Impact on net deficit £'000	Reason for not adjusting
Payables and prepayments overstatement				
Excluding items identified above testing of a sample of prepayments identified additional one item where the prepayment had been miscalculated and one other which did not meet the classification of a prepayment.				Projected error
Debit – Trade payables		1,779		
Credit – Receivables		(1,664)		
Credit – Expenditure	(115)		Reduce by 115k	
Annual leave accrual				
The Trust has not included annual leave accrual as at 31 March 2026. This was £8.597m a in prior financial year. No calculations have been provided to support this. Given Trusts staff base remains relatively stable we estimate the Trust expenditure is understated by £8.597m.				Not adjusted as not material. The Trust implemented a strict policy whereby staff are not permitted to carry forward any leave and therefore we have not undertaken a calculation of an estimated annual leave accrual in 2025/26 as any policy breaches would be immaterial
Debit – Employee expenses	8,597			
Credit – Payables		(£8,597)	Increase by 8,597k	
Overall impact	**Increase expenditure 8,482k**	**Decrease net assets (8,482k)**	**Increase deficit by 8,482k**	

DRAFT

© 2026 Grant Thornton UK LLP

Impact of unadjusted misstatements in the prior year

Below is a summary of the unadjusted misstatements identified in the prior year end the impact on the current year financial statements.

Detail	Statement of Comprehensive Income £'000	Statement of Financial Position £'000	Impact on net surplus £'000	Reason for not adjusting in 2024/25	Reason for not adjusting in 2025/26
After date payments testing (completeness) As part of expenditure completeness testing an item was identified where delivery of goods had taken place in March 2025, however the cost had not been accrued into the financial statements. As such the Trusts expenditure and accruals in the prior financial year was understated by £984k. This expenditure has now been accounted for in 2025/26. As such there is no carried forward impact on the Trusts Statement of financial position, Expenditure is however overstated by £984k in 2025/26 as this should have been accounted for in the prior financial year.	Expenditure overstated £984k	Opening reserves overstated £984k Closing reserves – no impact	Overstated £984k	Immaterial	N/A – adjusted as transaction processed
Receivables testing errors As part of receivables testing in the prior year resulting in the misclassification between receivables and payables. Extrapolated over the untested population would suggest receivables are overstated by £659k, payables are overstated by £512k and expenditure is understated by £147k	0	0	0	Projected error	N/A

DRAFT

© 2026 Grant Thornton UK LLP

Impact of unadjusted misstatements in the prior year (continued)

Detail	Statement of Comprehensive Income £'000	Statement of Financial Position £'000	Impact on net surplus £'000	Reason for not adjusting in 2024/25	Reason for not adjusting in 2025/26
Payables accrual error As part of payables testing 1 error was identified in relation to an accrual calculation. This error was an over accrual of £970k as the source report used for the calculation of the accrual was found to be incorrect. Extrapolated over the untested population would suggest payables and expenditure was overstated £1.647m in the prior year. As this expenditure was accounted for in the prior financial year the 2025/26 expenditure is understated by £1.647m. This error has not been carried forward at 31 March 2026 as such there is no continuing impact on reserves	Expenditure understated £1,647k	Opening reserves understated £1,647k Closing reserves – No impact	Understated £1,647k	Projected error	N/A – adjusted as transaction processed
Overall impact	Expenditure understated £663k	Opening reserves understated £663k	Increase deficit £663k		

DRAFT

© 2026 Grant Thornton UK LLP

Value for Money arrangements

Approach to Value for Money work for the year ended 31 March 2026

The National Audit Office issued its latest Value for Money guidance to auditors in March 2026. The Code requires auditors to consider whether a body has put in place proper arrangements to secure economy, efficiency and effectiveness in its use of resources.

In undertaking our work, we are required to have regard to three specified reporting criteria. These are as set out below.



Financial sustainability

How the body plans and manages its resources to ensure it can continue to deliver its services.



Governance

How the body ensures that it makes informed decisions and properly manages its risks.



Improving economy, efficiency and effectiveness

How the body uses information about its costs and performance to improve the way it manages and delivers its services.

DRAFT

In undertaking this work we have identified significant weaknesses in arrangements. Details are included in our Auditor's Annual Report which accompanies this report to the 19 June 2026 Audit Committee.

© 2026 Grant Thornton UK LLP

Independence considerations

Ethical Standards and ISA (UK) 260 require us to give you timely disclosure of all significant matters that may bear upon the integrity, objectivity and independence of the firm or covered persons (including its partners, senior managers, and managers). In this context, there are no independence matters that we would like to report to you.

We are required to report to you details of any breaches of the requirements of the FRC Ethical Standard, and of any safeguards applied and actions we have taken to address any threats to independence. There are no breaches to report.

We confirm that we have implemented policies and procedures to meet the requirement of the Financial Reporting Council's Ethical Standard.

Further, we have complied with the requirements of the National Audit Office's Auditor Guidance Note 01 issued in February 2025 which sets out supplementary guidance on ethical requirements for auditors of local public bodies.

We confirm that there are no significant facts or matters that impact on our independence as auditors that we are required or wish to draw to your attention and consider that an objective reasonable and informed third party would take the same view. The firm and each covered person (and network firms) have complied with the Financial Reporting Council's Ethical Standard and confirm that we are independent and are able to express an objective opinion on the financial statements.

We have made enquiries of all Grant Thornton UK LLP teams providing services to the Trust. Non-audit services were identified, which have been charged from the beginning of the financial period to the current date. Details of fees charged are set out on page 38.

DRAFT

© 2026 Grant Thornton UK LLP

Independence considerations

As part of our assessment of our independence, we note the following matters:

DRAFT

Matter	Conclusion
Relationships with Grant Thornton	We are not aware of any relationships between Grant Thornton and the Trust that may reasonably be thought to bear on our integrity, independence and objectivity.
Employment of Grant Thornton staff	We are not aware of any former Grant Thornton partners or staff being employed, or holding discussions in respect of employment, by the Trust as a director or in a senior management role covering financial, accounting or control related areas.
Business relationships	We have not identified any business relationships between Grant Thornton and the Trust.
Contingent fees in relation to non-audit services	No contingent fee arrangements are in place for non-audit services provided.
Gifts and hospitality	We have not identified any gifts or hospitality provided to, or received from, a member of the Trust's Board, senior management or staff.

© 2026 Grant Thornton UK LLP

Fees and non-audit services

The following tables below set out the total fees for audit and non-audit services that we have been engaged to provide or charged from the beginning of the financial year to June 2026, as well as the threats to our independence and safeguards have been applied to mitigate these threats.

None of the below services were provided on a contingent fee basis.

For the purposes of our audit, we have made enquiries of all Grant Thornton teams within the Grant Thornton International Limited network member firms providing services to University Hospitals of North Midlands NHS Trust . The table summarises all non-audit services which were identified. We have adequate safeguards in place to mitigate the perceived self-interest threat from these fees.

DRAFT

Audit fees	£
Audit of Trust	265,000
Total	265,000

The above fees are exclusive of VAT and out of pocket expenses.

The fees reconcile to the financial statements as follows:

- fees per financial statements note 7.1 £318,000
- VAT (£53,000)
- total fees per above £265,000
- The Trust has included relevant narrative under note 7.1 operating expenses to clarify that audit fees within the financial statements are inclusive of VAT.

This covers all services provided by us and our network to the Trust, its directors and senior management and its affiliates, that may reasonably be thought to bear on our integrity, objectivity or independence.

© 2026 Grant Thornton UK LLP

Appendices

DRAFT

A. Communication of audit matters with those charged with governance

Our communication plan	Audit Plan	Audit Findings
Respective responsibilities of auditor and management/those charged with governance	●	
Overview of the planned scope and timing of the audit, form, timing and expected general content of communications including significant risks	●	
Confirmation of independence and objectivity	●	●
A statement that we have complied with relevant ethical requirements regarding independence. Relationships and other matters which might be thought to bear on independence. Details of non-audit work performed by Grant Thornton UK LLP and network firms, together with fees charged. Details of safeguards applied to threats to independence	●	●
Significant matters in relation to going concern	●	●
Significant findings from the audit		●
Significant matters and issue arising during the audit and written representations that have been sought		●
Significant difficulties encountered during the audit		●
Significant deficiencies in internal control identified during the audit		●
Significant matters arising in connection with related parties		●
Identification or suspicion of fraud involving management and/or which results in material misstatement of the financial statements		●
Non-compliance with laws and regulations		●
Unadjusted misstatements and material disclosure omissions		●
Expected modifications to the auditor's report, or emphasis of matter		●

ISA (UK) 260, as well as other ISAs (UK), prescribe matters which we are required to communicate with those charged with governance, and which we set out in the table here.

This document, the Audit Findings, outlines those key issues, findings and other matters arising from the audit, which we consider should be communicated in writing rather than orally, together with an explanation as to how these have been resolved.

Respective responsibilities

As auditor we are responsible for performing the audit in accordance with ISAs (UK), which is directed towards forming and expressing an opinion on the financial statements that have been prepared by management with the oversight of those charged with governance.

The audit of the financial statements does not relieve management or those charged with governance of their responsibilities.

Distribution of this Audit Findings report

Whilst we seek to ensure our audit findings are distributed to those individuals charged with governance, as a minimum a requirement exists for our findings to be distributed to those charged with governance and those members of senior management with significant operational and strategic responsibilities. We are grateful for your specific consideration and onward distribution of our report, to those charged with governance.

DRAFT

© 2026 Grant Thornton UK LLP

B. Action plan

We set out here our recommendations for the Trust which we have identified as a result of issues identified during our audit. The matters reported here are limited to those deficiencies that we have identified during the course of our audit and that we have concluded are of sufficient importance to merit being reported to you in accordance with auditing standards.

Assessment	Issue and risk	Recommendations
● High	**Issue – Charitable Funds group consideration** As part of its closedown process the Trust did not undertake an assessment of its charitable fund in relation to group accounting requirements and the need for consolidation. This assessment had not been revisited for a number of years. In 2025/26, the Trust received significant charitable income, resulting in an increase in the value of charitable fund balances. However, the Trust's year-end closedown arrangements did not adequately incorporate consideration of the implications of this increase on group accounting. As a result, there is a risk that the requirement for preparing group accounts may have been overlooked. **Risk** Failure to appropriately assess the charitable fund for consolidation purposes may result in non-compliance with accounting standards and guidance. This could lead to material misstatement in the Trust's financial statements, incomplete group boundary considerations, and reduced transparency over the Trust's financial position.	The Trust should: • undertake a comprehensive and timely assessment of its group boundary, including a detailed review of the size, nature, and activity of its charitable fund, incorporating all transactions up to 31 March; • strengthen its year-end closedown procedures to ensure that charitable fund outturn positions are aligned with the Trust's financial reporting timetable. This will enable informed and timely decisions regarding consolidation requirements and ensure compliance with relevant accounting standards. **Management response** Agreed. We will undertake a review of the Charity's finances across the whole of the 2026/27 financial year and assess whether we can better align the Charity and Trust's financial reporting timetable. **Deputy Director of Finance - Financial Controller** **31 March 2027**

DRAFT

● High – Significant effect on control system and financial statements

● Medium – Effect on control system and financial statements

● Low – Best practice for control systems and financial statements

© 2026 Grant Thornton UK LLP

B. Action plan (continued)

Assessment	Issue and risk	Recommendations
● Medium	**Issue – Journal authorisation limits** The Trust's journal authorisation limits range from £1m to £10bn. This is a high value given the value of journals currently posted by the Trust. Whilst the upper limit has been reduced from £100bn the upper limit of £10bn remains disproportionate to the value and nature of journals currently processed by the Trust. Excessively high approval thresholds reduce the effectiveness of key financial controls and weaken segregation of duties. This increases the risk that inappropriate, erroneous, or potentially fraudulent journal entries could be processed without adequate scrutiny or challenge, leading to material misstatement in the financial statements. **Risk** Excessively high approval thresholds reduce the effectiveness of key financial controls and weaken segregation of duties. This increases the risk that inappropriate, erroneous, or potentially fraudulent journal entries could be processed without adequate scrutiny or challenge, leading to material misstatement in the financial statements.	The Trust should: • review and recalibrate journal authorisation limits to align with the size, complexity, and risk profile of typical journal entries. Limits should be set at more appropriate thresholds, with a tiered approval structure to ensure higher-value or higher-risk journals are subject to more robust review and authorisation. • periodically reassess these limits to ensure they remain appropriate and reflective of operational activity and aligned to risk appetite of the Trust. **Management response** We will review journal limits as we implement a new ledger system. **Deputy Director of Finance - Financial Controller** **31 October 2027**

DRAFT

© 2026 Grant Thornton UK LLP

B. Action plan (continued)

Assessment	Issue and risk	Recommendations
Medium	**Issue – derecognition of replaced assets and review of assets held at Nil NBV** Our testing has identified the following: 1) As part of additions testing one item was selected relating to the purchase of laptops through replacement programme. The assets being replaced however had not been derecognised from the Trust' asset register. 2) Our testing of intangible assets in note 14.1, we identified that an asset with a gross book value of £3.2m relates to legacy Mid Staffordshire assets that no longer exist but remain recorded in the Fixed Asset Register. 3) Management has not performed a comprehensive current-year review to confirm the ongoing existence and use of recorded tangible and intangible assets, in particular those held at nil NBV . This was a recommendation also raised in previous years. As at 31 March 2026 the Trust holds a number of nil NBV assets with gross book value and accumulated depreciation of £48m . Sample testing would indicate this value is overstated by an estimated £6.8m. **Risk** The failure to derecognise replaced assets or update the asset register for assets that no longer exist may result in an overstatement of property, plant and equipment (PPE) and understatement of depreciation expense where assets no longer in use remain capitalised.	Management should implement and enforce controls to ensure that assets replaced as part of structured replacement programmes are promptly identified and derecognised from the fixed asset register. This should include: • Formal linkage between capital additions and disposals for replacement programmes; • Periodic reviews (e.g. Nil NBV or fully depreciated assets reviews) to identify and remove assets no longer in use and consider revisiting its accounting policy relating to useful economic lives of assets and consider extending this if assets are being used for longer than the policy states; and • Management should also consider strengthening cut-off procedures at year end to ensure all disposals relating to replacement activity are appropriately recorded. **Management response** Agreed - we will implement the recommendations suggested **Deputy Director of Finance - Financial Controller** **31 March 2027**

DRAFT

© 2026 Grant Thornton UK LLP

B. Action plan (continued)

Assessment	Issue and risk	Recommendations
Medium	**Issue – Annual leave accrual** The Trust has not performed any formal analysis to support its assessment of a nil annual leave accrual as at 31 March 2026. In addition, existing systems and processes do not appear support the extraction and collation of the information required by the trusts finance team to support this estimate. **Risk** Employee benefits liabilities are not accurately considered for inclusion in the financial statements.	Management should undertake a formal assessment of its annual leave accrual at each reporting date and where appropriate improve systems and processes to ensure accurate and complete recording of employee leave entitlement and usage. Where data limitations remain, management should implement a methodology for estimating the accrual, ensuring assumptions are reasonable, supportable, and documented. **Management response** We will undertake an exercise to estimate the annual leave accrual based, where possible, on existing data and systems **Deputy Director of Finance - Performance and Reporting** **31 March 2027**

DRAFT

© 2026 Grant Thornton UK LLP

B. Action plan (continued)

Assessment	Issue and risk	Recommendations
Medium	**Issue – year end closedown process** The Trust would benefit from reviewing and further enhancing its year-end accounts closedown process. During the audit, a small number of items were identified where improvements to in-year processes or year-end review procedures could help to mitigate similar issues in future periods and reduce audit adjustments. In particular: • A number of misclassifications were identified between receivable and payable balances; • Journal testing identified a journal posted incorrectly. Whilst the control account reconciliation identified this misposting it was not acted upon or corrected; • The Trust has engaged constructively with its valuer regarding the Clinical Diagnostic Centre; however, there may be further opportunity to deepen understanding of the valuation approach and underlying assumptions/data to support effective review and challenge. **Risk** If these areas are not fully embedded within routine processes, there is a risk that misclassifications within financial statements may arise, reconciliation differences may not be fully reflected in reported balances and the level of challenge applied to complex estimates, such as valuations, may be limited.	Management should consider building on its existing processes by: • Introducing a more structured review of SOFP classifications or receivables and payables in particular as part of both in-year monitoring and year-end closedown. • Ensuring that control account reconciliation adjustments are processed in a timely manner. • Continuing to engage with valuers while seeking additional insight into key assumptions and methodologies, to support a well-informed and sufficiently robust review. **Management response** We will review and enhance our existing processes in this area, including the consideration of digital solutions **Head of Financial Services** **31 March 2027**

DRAFT

© 2026 Grant Thornton UK LLP

B. IT Action plan (continued)

Assessment	Issue and risk	Recommendations
Medium	**Issue – Leaver removal delay** We identified through our understanding of IT general controls that there are delays in removing leavers from the ELFS system. This represents a control deficiency, as it increases the risk of unauthorised access to the financial system. Former employees may retain the ability to access sensitive financial data or perform transactions, which may lead to modification of financial transactions	**Recommendation** Management should ensure all leaver accounts are removed or disabled promptly upon termination, and that evidence of removal is retained (e.g. system logs, access tickets). Exceptions (e.g. delayed removal) should be formally approved and documented. **Management response** We will introduce a process and sign off to ensure all leaver accounts are removed or disabled promptly from ELFS system. Key controls will also be introduced as part of the implementation of our new ledger system **Head of Financial Services** **31 March 2027**
Medium	**Issue - User access reviews** There were delays in the performance of user access reviews. The reviews were not conducted on a quarterly basis as required but were only performed from month 10 of the financial year due to internal resource constraints. The risk associated with this is that inappropriate access may remain undetected for extended periods, as well as the risk that dormant or inactive accounts are not promptly identified and removed, thereby weakening overall access control.	**Recommendation** Management should implement a structured and timely user access review process to ensure compliance with the required quarterly review frequency. A formal schedule should be established at the beginning of the financial year, with clear ownership assigned for the completion and oversight of reviews. **Management response** We will review and enhance the process and timetable for user access reviews. Key controls will also be introduced as part of the implementation of our new ledger system **Head of Financial Services** **31 March 2027**

DRAFT

© 2026 Grant Thornton UK LLP

B. IT Action plan (continued)

Assessment	Issue and risk	Recommendations
● Medium	Issue – Generic user accounts As in prior years our IT general controls review identified there is one generic user account 'workflow user' relating to the EFIN/EPROC service with the e-mail address strategic.procurement@uhnm.nhs.uk. This user was set up by ELFS and is used to run scripts as part of the system administration. There has been no log in to the user as this isn't a 'sign in' account and no transactions have been processed under this user which has been confirmed through our review of transactions and users who have posted those transactions. The Trust accept the risk, but we will continue to report and tailor our audit response to this risk.	Recommendation The Trust should continue to review and monitor the use of generic user accounts and any activity undertaken in the period. Management response We will review as part of the implementation of our new ledger system. Head of Financial Services 31 October 2027

DRAFT

© 2026 Grant Thornton UK LLP

C. Follow up of prior year recommendations

We identified the following issues in the audit of the Trust's 2024/25 financial statements, which resulted in 16 recommendations being reported in our 2024/25 Audit Findings Report.

Assessment	Issue and risk previously communicated	Update on actions taken to address the issue
✓	**Manual off ledger adjustments (raised in 24/25 AFR)** During the process of agreeing the year-end closing trial balance to the Statement of Financial Position and the Statement of Comprehensive Income, we identified five discrepancies where the figures did not align. All identified differences resulted from manual off-ledger adjustments made by management post-year-end, which were intended to reclassify amounts to different lines within the financial statements. We recommended that management refrain from making off-ledger adjustments and instead utilise standard journal postings for all necessary adjustments. This approach will ensure that all entries are subject to proper authorization and oversight, thereby enhancing the reliability and accuracy of the financial statements.	**Audit comments** We acknowledge progress has been made in this area, as such the recommendation has been closed.
✓	**Supplier specific automated feed (raised in 24/25 AFR)** Sample testing of after date payments identified one item for £984k which had not been accrued into the financial year. We recommended the Trust carry out a critical path analysis to understand what led to bit the expenditure not being posted and how other 'compensating controls' failed to identify that this expenditure was missing, for example budgetary control.	**Audit comments** Our testing in the current financial year has not identified any reporting points as such this recommendation has been closed.

DRAFT

Assessment

✓ Action completed

X Not yet addressed

© 2026 Grant Thornton UK LLP

C. Follow up of prior year recommendations (continued)

Assessment	Issue and risk previously communicated	Update on actions taken to address the issue
✓	**Bonded orders (raised in 24/25 AFR)** Our testing of asset additions has identified the use of bonded orders. Bonded orders are legal agreements that are intended to transfer legal title ahead of receipt of goods, in exchange for payment in advance. We recommended that management review the use of vesting certificates and ensure they are used in line with Managing Public Money guidance and ensure controls are in place to mitigate the risk of vesting certificates being used inappropriately	**Audit comments** Our testing in the current financial year has not identified any reporting points regarding bonded orders **Management comment** The total value of bonded orders is significantly lower than in the prior year. The finance team were involved in all discussions in relation to the use of vesting certificates as part of the 25/26 accounts closedown to assess the appropriateness and ensure the correct assurances and sign-offs were being obtained.
Superseded	**Nil NBV assets (raised in 24/25 AFR)** Whilst the Trust had made progress in this area at 31 March 2025 the Trust still holds a number of nil NBV assets with gross book value and accumulated depreciation of £56.7m. We recommend the Trust continue to review their Nil net book value assets to ensure these still exist. The Trust should consider revisiting its accounting policy relating to useful economic lives of assets and consider extending this if assets are being used for longer than the policy states.	**Audit comments** This recommendation has not been addressed. No further review of nil NBV assets has been carried out as part of the Trusts audit closedown process. The recommendation has been superseded to encompass other audit findings in the current financial year.
In progress	**Car parking income reconciliation controls (raised in 24/25 AFR)** Our testing of other operating income uncovered a discrepancy in one sample item relating to car parking income. We recommended the Trust should assess its controls concerning the validation of parking income, particularly focusing on how the information provided by the supplier should be reconciled to values eventually banked.	**Management comment** A small discrepancy remains in the car parking income reconciliation this year. The reason for the discrepancy is that there is delay in some credit card payments that are pending at the time the report is issued by APCOA (with payment being captured on the next remittance). We are addressing with APCOA to see if there is a resolution going forward.

DRAFT

© 2026 Grant Thornton UK LLP

C. Follow up of prior year recommendations (continued)

Assessment	Issue and risk previously communicated	Update on actions taken to address the issue
X	**Income contracts (raised in 24/25 AFR)** During the testing of income from Patient care activities, for 4 residual sample items it was identified there was no signed contract in place. It is understood a number of organisations are included as an associate as part of the main ICB contract, which is signed however the signed contract states 'TBC' in terms of total contract value for 5 associate ICB's. There is also a footnote stating, 'Associate contract values to be confirmed and will be varied into the contract'. We have not seen any signed contract subsequent to this. In addition, no signed contract for the funding received from the NHS Greater Manchester ICB has been provided. We recommended the Trust should ensure signed contracts, in particular in relation to associate contracts are in place for all organisations.	**Audit comments** For 2025/26 the contract between UHNM and the lead ICB has been signed however the associated ICB's have not signed the contract. As such the recommendation remains open. **Management comment** Accepted.
Superseded	**Journal authorisation limits -** The Trust's journal authorisation limits range from £1m to £100bn. This is a high value given the value of journals currently posted by the Trust. We recommended the Trust should review journal authorisation limits periodically to ensure they remain appropriate and aligned to risk appetite of the Trust.	**Audit comments** The Trust has reviewed its journal authorisation limits which have been reduced with an upper limit now at £10bn rather than £100bn. As such we have closed this recommendation. We do however assess that this limit is still excessive and as such have raised a new recommendation for 2025/26 financial year. **Management comment** These limits all relate to individuals within the shared financial servicers provider. The high limits are necessary for them to be able to process high value journals for the Trust and for all other organisations they provide services to.

DRAFT

© 2026 Grant Thornton UK LLP

C. Follow up of prior year recommendations (continued)

Assessment	Issue and risk previously communicated	Update on actions taken to address the issue
X	**Expected credit losses (raised in 24/25 AFR)** The Trust's methodology for calculating the expected credit loss is not fully in accordance with IFRS 9 'Financial Instruments'. We recommended the Trust should keep under review its methodology for calculating expected credit losses and ensure this is compliant with IFRS 9 .	**Audit comments** No change has been made on the 2025/26 process. **Management comment** We have undertaken a review and made a decision not to change to process for 2025/26. The only potential area where we could change the process for calculating expected credit losses would be in relation to overseas debt. This would have been a purely mathematical calculation and would not reflect the high risk of non-collection of this category of debt. We are therefore maintaining the current methodology which is prudent but are also planning to gather more information (including data from the national Overseas Cost Improvement Team) and revisit this methodology during 2026/27.
✓	**Annual report (raised in 24/25 AFR)** The Trusts Annual Report was not received until 14 May 2025 . The GAM provides a suggested date of presentation to audit of 6 May. We recommended the Trust should review processes surrounding the preparation of the Annual report to ensure timelines are aligned with the financial statements .	**Audit comments** We acknowledge progress in this area. The 2025/26 draft annual report on which our work commenced was received on 5th May. Recommendation has been closed on that basis.
✓	**Revaluation reserve v ledger(raised in 24/25 AFR)** The Trusts working paper provided to support the revaluation reserve does not agree to the financial statements. We recommended the Trust should seek to amend revaluation reserve working to ensure agrees to financial statements.	**Audit comments** Working papers have been provided to reconcile the revaluation reserve and trial balance. As such this is considered closed.

DRAFT

© 2026 Grant Thornton UK LLP

C. Follow up of prior year recommendations (continued)

Assessment	Issue and risk previously communicated	Update on actions taken to address the issue
X	**Prepayments (raised in 24/25 AFR)** We recommended the Trust should review its procedures regarding prepayments, particularly at year end to ensure they are correctly classified within the accounts.	**Audit comment** Audit testing in 25/26 has identified misclassification between receivables and payables and calculation errors within prepayments recorded. As such recommendation remains relevant. **Management comment** Training on the prepayments process was provided as part of the year end planning session and instructions were issued within the training pack. The relevant control account reconciliations were subject to a senior officer review at the year end.
✓	**Accruals process -** As part of accruals testing an error was identified of £970k. The source of the error was an erroneous report underpinning the calculation of the accrual. We recommended the Trust should review its manual accruals process and the accuracy of any underlying reports supporting the accrual. This should be carried out alongside appropriate training reminders regarding accruals.	**Audit comments** Our testing in the current financial year has not identified any reporting points regarding erroneous reports underpinning accruals calculations **Management comment** Training on the accruals process was provided as part of the year end planning session and instructions were issued within the training pack. The relevant control account reconciliations were subject to a senior officer review at the year end. The issue in 2024/25 was a one-off error caused by the processing of a journal within our shared services provider. Additional checks have been brought in within the shared services provider to ensure the issue does not happen again.

DRAFT

© 2026 Grant Thornton UK LLP

C. Follow up of prior year recommendations (continued)

Assessment	Issue and risk previously communicated	Update on actions taken to address the issue
X	**Evidence to support build costs (raised in 23/24 AFR)** We have been unable to corroborate DV build cost data as part of the audit. We have completed audit procedures to establish what the valuation we would expect, using all the other variables we can verify, using an appropriate BCIS index for hospital buildings. We are satisfied that there is unlikely to be a materially different value if appropriate industry standard BCIS rates were used, however we are unable to corroborate that the DV/VOA applies a reasonable approach to determining a build cost rate. If there was an error in their data or calculations, we have been unable to have the opportunity to identify. Whilst we are satisfied the value is materially reasonable as at 31/3/2024, in comparison to using an industry standard index, we are unable to give those charged with governance assurance that the estimation process will continue to produce materially accurate valuations in the future. We recommend that management revisit their valuation instructions with the valuer, to ensure that access to source data used by the valuers, is made available to auditors or that the valuer uses an industry standard approach to valuing land and buildings.	**Audit comment** No change has been made in arrangements. As such this recommendation remains open. **Management comment** As in previous years the DV will not release this source data to us.
✓	**Related parties (raised in 23/24 AFR)** As per the GAM there is a requirement to disclose a note of the main entities within the public sector with which the body has had dealings but no information needs to be given about these transactions. The Trusts related party note is therefore over disclosing transactions We recommend the Trust review its related party transactions note.	**Audit comment** Recommendation closed

DRAFT

© 2026 Grant Thornton UK LLP

C. Follow up of prior year recommendations (continued)

Assessment	Issue and risk previously communicated	Update on actions taken to address the issue
Superseded	**IT General Controls – Generic Users (raised prior to 23/24)** Our IT general controls review identified 3 generic user accounts which were considered to be key to seamless dataflow/integration in 2022/23. The Trust accepted this risk in relation to this recommendation. We reported we would continue to report this finding and tailor our audit to respond to this risk. Our IT Controls review in 23/24 identified there is now just one generic user account 'workflow user' relating to the EFIN/EPROC service with the e-mail address strategic.procurement@uhnm.nhs.uk. This user was set up by ELFS and is used to run scripts as part of the system administration. There has been no log in to the user as this isn't a 'sign in' account and no transactions have been processed under this user which has been confirmed through our review of transactions and users who have posted those transactions. The Trust accept the risk, but we will continue to report and tailor our audit response to this risk.	**Audit comment** Our IT controls review in 2025/26 confirms the generic user account, strategic.procurement@uhnm.nhs.uk is still in use. This has been transferred to IT recommendation in current year.
✓	**Aged Payables** In 22/23 we identified one item in our testing which related to goods received in the prior year which were still being accrued on the GRNI listing. We recommended the Trust revisit any aged GRNI it is carrying to ensure the related liabilities are still appropriate to hold on the balance sheet. Whilst our testing has not identified any misstatement of GRNI, the Trusts finance team are still required to carry out manual processes to remove old GRNI items from system generated reports. We appreciate the Trust is reviewing this process as such the recommendation remains outstanding.	**Audit comment** We have not identified any issues as part of the 2025/26 audit process. As such recommendation has been closed. **Management comment** The finance team continue to keep this under review and retain manual control over the removal of old GRNI items from system generated reports as a prudent approach to ensure all potential costs are being accrued.

DRAFT

© 2026 Grant Thornton UK LLP

D. Management letter of representation

We have requested a letter of representation from management, a copy of which is replicated below. The letter includes representations on the unadjusted misstatements as included in this audit findings report.

DRAFT

Dear Grant Thornton UK LLP

University Hospitals of North Midlands NHS Trust
Financial Statements for the year ended 31 March 2026

This representation letter is provided in connection with the audit of the financial statements of University Hospitals of North Midlands NHS Trust (the "Trust") for the year ended 31 March 2026 for the purpose of expressing an opinion as to whether the Trust financial statements give a true and fair view in accordance with International Financial Reporting Standards and the Department of Health and Social Care Group Accounting Manual 2025-26 and applicable law.

We confirm that to the best of our knowledge and belief having made such inquiries as we considered necessary for the purpose of appropriately informing ourselves:

Financial Statements

i. We have fulfilled our responsibilities, as set out in the terms of the audit engagement letter dated 9 January 2026 , for the preparation of the Trust's financial statements in accordance with International Financial Reporting Standards and the Department of Health and Social Care Group Accounting Manual 2025-26 (the "GAM"); in particular the financial statements are fairly presented in accordance therewith.

ii. We have complied with the requirements of all statutory directions affecting the Trust and these matters have been appropriately reflected and disclosed in the financial statements.

iii. The Trust has complied with all aspects of contractual agreements that could have a material effect on the financial statements in the event of non-compliance. There has been no non-compliance with requirements of any regulatory authorities that could have a material effect on the financial statements in the event of non-compliance.

iv. We acknowledge our responsibility for the design, implementation and maintenance of internal control to prevent and detect fraud.

v. Significant assumptions used by us in making accounting estimates, including those measured at fair value, are reasonable. Such accounting estimates include the valuation of land and buildings. We are satisfied that the material judgements used in the preparation of the financial statements are soundly based, in accordance with the GAM and adequately disclosed in the financial statements. We understand our responsibilities includes identifying and considering alternative methods, assumptions or source data that would be equally valid under the financial reporting framework, and why these alternatives were rejected in favour of the estimate used. We are satisfied that the methods, the data and the significant assumptions used by us in making accounting estimates and their related disclosures are appropriate to achieve recognition, measurement or disclosure that is reasonable in accordance with the GAM and adequately disclosed in the financial statements.

vi. In calculating the amount of income to be recognised in the financial statements from other NHS organisations we have applied judgement, where appropriate, to reflect the appropriate amount of income expected to be derived by the Trust in accordance with International Financial Reporting Standards and the GAM. We are satisfied that the material judgements used in the preparation of the financial statements are soundly based, in accordance with International Financial Reporting Standards and the GAM, and adequately disclosed in the financial statements. There are no other material judgements that need to be disclosed.

vii. We acknowledge our responsibility to participate in the Department of Health and Social Care's agreement of balances exercise and have followed the requisite guidance and directions to do so. We are satisfied that the balances calculated for the Trust ensure the financial statements and consolidation schedules are free from material misstatement, including the impact of any disagreements.

viii. Except as disclosed in the financial statements:

a) there are no unrecorded liabilities, actual or contingent;

b) none of the assets of the Trust has been assigned, pledged or mortgaged; and

c) there are no material prior year charges or credits, nor exceptional or non-recurring items requiring separate disclosure.

© 2026 Grant Thornton UK LLP

D. Management letter of representation (continued)

ix. Related party relationships and transactions have been appropriately accounted for and disclosed in accordance with the requirements of International Financial Reporting Standards and the GAM.

x. All events subsequent to the date of the financial statements and for which International Financial Reporting Standards and the GAM require adjustment or disclosure have been adjusted or disclosed.

xi. We have considered the unadjusted misstatements schedule included in your Audit Findings Report and attached to this letter. We have not adjusted the financial statements for these misstatements brought to our attention as **[**they are immaterial to the results of the Trust and its financial position at the [**year-end/period end**]/for the reasons noted on the schedule/other reasons**].** The financial statements are free of material misstatements, including omissions.

xii. Actual or possible litigation and claims have been accounted for and disclosed in accordance with the requirements of International Financial Reporting Standards.

xiii. We have no plans or intentions that may materially alter the carrying value or classification of assets and liabilities reflected in the financial statements.

xiv. The Trust's asset register included assets with a nil net book value and are fully depreciated in the asset register. We acknowledge that are three risks in relation to this issue:

- if these assets are no longer operational, the gross cost and accumulated depreciation balance will be overstated in the asset register and Note 15.1 Property, plant and equipment;
- if these assets are operational, there is a risk that the Trust is not assigning appropriate asset lives to its plant and equipment assets; and
- if these assets are operational, the Trust is potentially using assets that are past their prime operational functionality, which could impact on the quality of service provision.

xviii. We have updated our going concern assessment. We continue to believe that the Trust's financial statements should be prepared on a going concern basis and have not identified any material uncertainties related to going concern on the grounds that:

a) the nature of the Trust means that, notwithstanding any intention to cease its operations in their current form, it will continue to be appropriate to adopt the going concern basis of accounting because, in such an event, services it performs can be expected to continue to be delivered by related public authorities and preparing the financial statements on a going concern basis will still provide a faithful representation of the items in the financial statements;

b) the financial reporting framework permits the Trust to prepare its financial statements on the basis of the presumption set out under a) above; and

c) the Trust's system of internal control has not identified any events or conditions relevant to going concern.

xix. We believe that no further disclosures relating to the Trust's ability to continue as a going concern need to be made in the financial statements.

Information Provided

xvi. We have provided you with:

a. access to all information of which we are aware that is relevant to the preparation of the Trust's financial statements such as records, documentation and other matters;

b. additional information that you have requested from us for the purpose of your audit; and

c. unrestricted access to persons within the Trust from whom you determined it necessary to obtain audit evidence.

xvii. We have communicated to you all deficiencies in internal control of which management is aware.

xviii. All transactions have been recorded in the accounting records and are reflected in the financial statements.

xix. We have disclosed to you the results of our assessment of the risk that the financial statements may be materially misstated as a result of fraud.

DRAFT

© 2026 Grant Thornton UK LLP

D. Management letter of representation (continued)

xx. We have disclosed to you all information in relation to fraud or suspected fraud that we are aware of and that affects the Trust and involves:

a. management;

b. employees who have significant roles in internal control; or

c. others where the fraud could have a material effect on the financial statements.

xxi. We have disclosed to you all information in relation to allegations of fraud, or suspected fraud, affecting the financial statements communicated by employees, former employees, analysts, regulators or others.

xxii. We have disclosed to you all known instances of non-compliance or suspected non-compliance with laws and regulations whose effects should be considered when preparing financial statements.

xxiii. We have disclosed to you the identity of the Trust's related parties and all the related party relationships and transactions of which we are aware.

xxiv. We have disclosed to you all known actual or possible litigation and claims whose effects should be considered when preparing the financial statements.

Annual Governance Statement

xxv. We are satisfied that the Annual Governance Statement fairly reflects the Trust's risk assurance and governance framework, and we confirm that we are not aware of any significant risks that are not disclosed within the Annual Governance Statement.

Annual Report

xxvi. The disclosures within the Annual Report fairly reflect our understanding of the Trust's financial and operating performance over the period covered by the Trust's financial statements.

Approval

The approval of this letter of representation was minuted by the Trust's Audit Committee at its meeting on **[**date**]**.

Yours faithfully

Name……

Position……

Date……

Name……

Position……

Date……

Signed on behalf of the Trust

DRAFT

© 2026 Grant Thornton UK LLP

E. Proposed Changes to Valuation of PPE

A sector-wide review of PPE valuation requirements proposes changes to improve consistency, transparency, and robustness of asset valuations across NHS Trusts and Foundation Trusts.

DRAFT

1. Valuation cycles

Changes to the valuation cycle from 2026/27.

An adaptation to the application of IAS 16 Property, plant and equipment to the frequency of revaluations means Trusts should value their property assets either on:

- A 5-yearly revaluation of all assets supplemented by annual indexation in intervening years, or
- A rolling programme of valuations over a 5-year cycle, with annual indexation applied to assets during the four intervening years.

Non-property assets should be revalued using appropriate indices.

In addition, the requirement to revalue an asset when its fair value differs materially from its carrying value has been withdrawn.

Valuations may still be required where there is a potential impairment.

2. Changes to valuation methodologies

Proposal to remove the 'alternative site' assumption from 2028/29.

Valuations will therefore reflect current use and existing site conditions only, rather than a hypothetical optimal or alternative location.

This aligns asset values more closely to service delivery realities within the NHS estate.

Key implications for NHS Trusts

Increased consistency and comparability of property valuations across the NHS.

The carrying values of operational healthcare assets may change significantly in 2028/29. The timetable should provide Trusts with sufficient lead time to incorporate the changes into their valuation strategies and procurement plans. However, early liaison with both valuers and auditors may be needed to ensure smooth transition

© 2026 Grant Thornton UK LLP

F. S30 referral

Grant Thornton

Grant Thornton UK LLP
8 Finsbury Circus
London
EC2M 7EA

T +44 (0)20 7383 5100

The Rt Hon James Murray
Secretary of State
Department of Health and Social Care
39 Victoria Street
London
SW1H 0EU

27 May 2026

Dear Secretary of State

Referral under section 30 of the Local Audit and Accountability Act 2014

We are the auditor appointed to the audit of University Hospitals of North Midlands NHS Trust (the 'Trust') for the year ending 31 March 2026.

Our responsibility

Section 30 of the Local Audit and Accountability Act 2014 states that:

A local auditor of the accounts of a health service body must as soon as reasonably practicable refer the matter to the Secretary of State if the auditor believes that the body or an officer of the body:

(a) is about to make, or has made, a decision which involves or would involve the body incurring unlawful expenditure, or

(b) is about to take or has begun to take a course of action which, if followed to its conclusion, would be unlawful and likely to cause a loss or deficiency.

We are writing to you in accordance with section 30(b) and 30(a) of the Local Audit and Accountability Act 2014.

The duty of the Trust

Paragraph 2(1) of Schedule 5 of the National Health Service Act 2006 states that:

Each NHS trust must ensure that its revenue is not less than sufficient, taking one financial year with another, to meet outgoings properly chargeable to revenue account.

Chartered Accountants. Grant Thornton UK LLP is a limited liability partnership registered in England and Wales: No.OC307742. Registered office: 8 Finsbury Circus, London EC2M 7EA. A list of members is available from our registered office. Grant Thornton UK LLP is authorised and regulated by the Financial Conduct Authority. Grant Thornton UK LLP is a member firm of Grant Thornton International Ltd (GTIL). GTIL and the member firms are not a worldwide partnership. Services are delivered by the member firms. GTIL and its member firms are not agents of, and do not obligate, one another and are not liable for one another's acts or omissions. Please see grantthornton.co.uk for further details.

Commercial in Confidence

This duty is known as the 'breakeven duty'. The phrase 'taking one financial year with another' has been interpreted by the Department of Health and Social Care and HM Treasury as meaning that the duty is met if income equals or exceeds expenditure over a three-year rolling period, or exceptionally a five-year rolling period with the agreement of NHS England.

Reasons for making a referral under section 30 of the Local Audit and Accountability Act 2014

s30(b) referral

Taking into account the 'Statutory breakeven duty: a guide for NHS trusts' guidance issued by NHS Improvement in April 2018, University Hospitals of North Midlands NHS Trust has taken a course of action that has led to a breach of the Trust's breakeven duty for the three-year period ending 31 March 2026.

We made a referral under Section 30 of the Local Audit and Accountability Act 2014 on 28 May 2025, regarding University Hospitals of North Midlands NHS Trust breaching its breakeven duty for the three-year period ending 31 March 2025.

University Hospitals of North Midlands NHS Trust subsequently reported in-year surplus of £2.226 million in 2025/26 resulting in a cumulative deficit of £200.713 million as at 31 March 2026. The referral is in respect of the cumulative deficit position which arose at the Trust prior to 2019/20 and has not yet been addressed. The Trust therefore continues to take a course of action that is unlawful and has caused a loss which gives rise to a duty on us to report to you under section 30(b) of the Local Audit and Accountability Act 2014 in respect of the three-year period ending 31 March 2026.

s30(a) referral

University Hospitals of North Midlands NHS Trust does not have a formal plan to return to in-year financial balance until the foreseeable future. The Trust has set a deficit budget for the year ended 31 March 2027 of £28.6 million. The Trust has no plans to achieve cumulative financial balance over the period of its current medium term financial plan to 2028/29, as demonstrated by its Medium-Term Financial Plan.

The Trust has therefore made a decision, over the period of its current Medium Term Financial Plan, to incur unlawful expenditure which gives rise to a duty on us to report to you under section 30(a) of the Local Audit and Accountability Act 2014.

We understand that this is a matter which is already known to the Secretary of State, hence the brevity of this referral letter. Please do not hesitate to contact us if you need any further information.

Yours sincerely

Grant Thornton UK LLP

Grant Thornton UK LLP, local auditors

DRAFT

© 2026 Grant Thornton UK LLP

DRAFT



© 2026 Grant Thornton. All rights reserved.

'Grant Thornton' refers to the brand under which the Grant Thornton member firms provide assurance, tax and advisory services to their clients and/or refers to one or more member firms, as the context requires. Grant Thornton International Ltd (GTIL) and the member firms are not a worldwide partnership. GTIL and each member firm is a separate legal entity. Services are delivered by the member firms. GTIL does not provide services to clients. GTIL and its member firms are not agents of, and do not obligate, one another and are not liable for one another's acts or omissions.